WorldWideScience

Sample records for testing tritium-labeled radiopharmaceuticals

  1. Synthesis of tritium labeled renin inhibitor ditekiren

    International Nuclear Information System (INIS)

    Hsi, R.S.P.; Stolle, W.T.; Bundy, G.L.

    1994-01-01

    In the search for a radioactive form of the peptidomimetic renin inhibitor, ditekiren, with a metabolically suitable radiolabel for conducting drug disposition studies, we prepared [ 3 H]ditekiren with tritium labels in the N-methyl-histidine moiety and in the leu-val alcohol transition-state insert. [His- 3 H]ditekiren was obtained by first introducing two iodine substituents into the N-methyl-histidine moiety of the parent drug, followed by catalytic hydrodehalogenation with tritium gas. Administration of this labeled drug to monkeys, however, resulted in prolonged retention of radioactivity in the test animals, even though little or no tritiated water was detected in urine. The results, together with similar earlier findings after administration of [ 3 H]ditekiren labeled in the proline moiety of the drug, led us to synthesize [ 3 H]ditekiren labeled in the ''unnatural'' leu-val alcohol (LVA) portion of the molecule. The tritium label in [LVA- 3 H]ditekiren was found to be metabolically suitable for conducting drug disposition studies, with no liability for tritiated water production or prolonged retention of radioactivity in tissues of test animals. (author)

  2. Radiation-induced tritium labelling and product analysis

    Energy Technology Data Exchange (ETDEWEB)

    Peng, C.T. (California Univ., San Francisco, CA (United States). Dept. of Pharmaceutical Chemistry)

    1993-05-01

    By-products formed in radiation-induced tritium labelling are identified by co-chromatography with authentic samples or by structure prediction using a quantitative structure-retention index relationship. The by-products, formed from labelling of steroids, polynuclear aromatic hydrocarbons, 7-membered heterocyclic ring structures, 1,4-benzodiazepines, 1-haloalkanes, etc. with activated tritium and adsorbed tritium, are shown to be specifically labelled and anticipated products from known chemical reactions. From analyses of the by-products, one can conclude that the hydrogen abstraction by tritium atoms and the substitution by tritium ions are the mechanisms of labelling. Classification of the tritium labelling methods, on the basis of the type of tritium reagent, clearly shows the active role played by tritium atoms and ions in radiation-induced methods. (author).

  3. Radiopharmaceutical potential of I-131 labelled diazepam

    International Nuclear Information System (INIS)

    Yurt, F.; Unek, P.; Asikoglu, M.; Baggi, S.; Erener, G.; Ozkilic, H.; Uluc, F.; Tuglular, I.

    1998-01-01

    In this study, diazepam is a derivative of the 1.4 benzodiazepine family that the most widely used drug as anticonvulsant agent has been labeled with I-131, as a new radiopharmaceutical and its radiopharmaceutical potential has been determined. Labeling of diazepam has been performed by iodogen method and optimum labeling conditions have been determined. Optimum reaction conditions are 1 mg for iodogen amount; 1-5 mg for diazepam amount, 15-20 minutes for reaction time and room temperature for reaction temperature. Specific activity of labeled compound was 0,15 Ci/mmol level. N-octanol/water ratio was found 1.9 for 131 IDZ ( 131 I labeled diazepam). In vivo experiments have been carried out to determine radiopharmaceutical potentials of labeled compound. Biodistribution studies on rats showed that 131 IDZ have accumulated in kidneys, liver, lungs and brain tissues. Scintigraphic results taken with gamma camera on rabbits agree with biodistribution results of rats. (author)

  4. Tritium labelled steroids, preparation process and application to synthesis of tritium labelled estrane derivatives

    International Nuclear Information System (INIS)

    1978-01-01

    Process for preparing new steroids labelled with tritium in 6.7 and comprising in 3 a blocked ketonic group as ketal, thioketal or derivatives. Application of these products to the synthesis of tritium labelled estrane derivatives [fr

  5. Experience in the quality control of commercial and self-labelled radiopharmaceuticals

    International Nuclear Information System (INIS)

    Strehlau, E.; Weiland, J.

    1980-01-01

    Different methods of quality control of radiopharmaceuticals checked in the laboratory practice are summarized. Starting from the general organization of quality control in the clinical radiochemical laboratory methods of analysis and working regulations are discussed. The quality tests of sup(99m)Tc-generator eluate, that is the testing for radioactive contaminants and for soluble aluminium as well as the testing of sup(99m)Tc-labelled kits and of different other frequently used radiopharmaceuticals are described in detail. Special conditions of examination and results of chromatography and medium-voltage electrophoresis are also given. Furthermore the routine determination of the output in the labelling of denaturated erythrocytes with sup(99m)Tc is discussed. The clinical practice in the case of preparation deficiencies and of possible incidents following the application of radiopharmaceuticals is outlined. (author)

  6. Increase in the specific radioactivity of tritium-labeled compounds obtained by tritium thermal activation method

    International Nuclear Information System (INIS)

    Badun, G.A.; Chernysheva, M.G.; Ksenofontov, A.L.

    2012-01-01

    A method of tritium introduction into different types of organic molecules that is based on the interaction of atomic tritium with solid organic target is described. Tritium atoms are formed on the hot W-wire, which is heated by the electric current. Such an approach is called 'tritium thermal activation method'. Here we summarize the results of labeling globular proteins (lysozyme, human and bovine serum albumins); derivatives of pantothenic acid and amino acids; ionic surfactants (sodium dodecylsulfate and alkyltrimethylammonium bromides) and nonionic high-molecular weight surfactants - pluronics. For the first time it is observed that if the target-compound is fixed and its radicals are stable the specific radioactivity of the labeled product can be drastically increased (up to 400 times) when the target temperature is ca. 295 K compared with the results obtained at 77 K. The influence of labeling parameters as tritium gas pressure, exposure time and W-wire temperature was tested for each target temperature that results in the optimum labeling conditions with high specific radioactivity and chemical yield of the resulting compound. (orig.)

  7. Tritium labeling of amino acids and peptides with liquid and solid tritium

    International Nuclear Information System (INIS)

    Peng, C.T.; Hua, R.L.; Souers, P.C.; Coronado, P.R.

    1988-01-01

    Amino acids and peptides were labeled with liquid and solid tritium at 21 K and 9 K. At these low temperatures radiation degradation is minimal, and tritium incorporation increases with tritium concentration and exposure time. Ring saturation in L-phenyl-alanine does not occur. Peptide linkage in oligopeptides is stable toward tritium. Deiodination in 3-iodotyrosine and 3,5-diiodotyrosine occurs readily and proceeds in steps by losing one iodine atom at a time. Nickel and noble metal supported catalysts when used as supports for dispersion of the substrate promote tritium labeling at 21 K. Our study shows that both liquid and solid tritium are potentially useful agents for labeling peptides and proteins. 11 refs., 1 fig., 3 tabs

  8. Tritium labeling of amino acids and peptides with liquid and solid tritium

    International Nuclear Information System (INIS)

    Souers, P.C.; Coronado, P.R.; Peng, C.T.; Hua, R.L.

    1988-01-01

    Amino acids and peptides were labeled with liquid and solid tritium at 21/degree/K and 9/degree/K. At these low temperatures radiation degradation is minimal, and tritium incorporation increases with tritium concentration and exposure time. Ring saturation in L-phenylalanine does not occur. Peptide linkage in oligopeptides is stable toward tritium. Deiodination in 3-iodotyrosine and 3,5-diiodotyrosine occurs readily and proceeds in steps by losing one iodine atom at a time. Nickel and noble metal supported catalysts when used as supports for dispersion of the substrate promote tritium labeling at 21 K. Our study shows that both liquid and solid tritiums are potentially useful agents for labeling peptides and proteins

  9. Molecular design of 99Tcm labelled radiopharmaceuticals. Pt.2

    International Nuclear Information System (INIS)

    Wang Xuebin; Chu Jinfeng

    2003-01-01

    The structure-activity relationship of 99 Tc m labelled radiopharmaceuticals and the correlative contents of computer aided drug design are introduced. Of them, quantitative structure-activity relationship and its application to design 99 Tc m labelled radiopharmaceuticals are narrated on emphases

  10. Synthesis of tritium-labeled fosfomycin

    International Nuclear Information System (INIS)

    Mertel, H.E.; Meriwether, H.T.

    1982-01-01

    Tritium gas was used as a labeling agent for the preparation of [1,2- 3 H]fosfomycin. Introduction of tritium into a precursor, the synthesis including resolution of the intermediate racemic 1,2-epoxypropylphosphonic acid, and preparation of both amine and calcium salts of the labeled antibiotic are described. (author)

  11. Tritium labeling for bio-med research

    International Nuclear Information System (INIS)

    Lemmon, R.M.

    1980-01-01

    A very large fraction of what we know about biochemical pathways in the living cell has resulted from the use of radioactively-labeled tracer compounds; the use of tritium-labeled compounds has been particularly important. As research in biochemistry and biology has progressed the need has arisen to label compounds of higher specific activity and of increasing molecular complexity - for example, oligo-nucleotides, polypeptides, hormones, enzymes. Our laboratory has gradually developed special facilities for handling tritium at the kilocurie level. These facilities have already proven extremely valuable in producing labeled compounds that are not available from commercial sources. The principal ways employed for compound labeling are: (1) microwave discharge labeling, (2) catalytic tritio-hydrogenation, (3) catalytic exchange with T 2 O, and (4) replacement of halogen atoms by T. Studies have also been carried out on tritiation by the replacement of halogen atoms with T atoms. These results indicate that carrier-free tritium-labeled products, including biomacromolecules, can be produced in this way

  12. Design and operations at the National Tritium Labelling Facility

    International Nuclear Information System (INIS)

    Morimoto, H.; Williams, P.G.

    1991-09-01

    The National Tritium Labelling Facility (NTLF) is a multipurpose facility engaged in tritium labeling research. It offers to the biomedical research community a fully equipped laboratory for the synthesis and analysis of tritium labeled compounds. The design of the tritiation system, its operations and some labeling techniques are presented

  13. Limulus test for pyrogens and radiometric sterility tests on radiopharmaceuticals. Part of a coordinated programme

    International Nuclear Information System (INIS)

    Gopal, N.G.S.

    1976-10-01

    Sterility testing of radiopharmaceuticals prepared at BARC were carried out using the radiometric technique (Radiometric detection of the metabolic product 14 Co 2 ). Batches of different radiopharmaceuticals were tested for pyrogen using the limulus lysate method and the results were compared with the rabbit method. The results of sterility test on 202 batches of 19 different radiopharmaceuticals show that the radiometric method can be used for sterility testing of radiopharmaceuticals labelled with 35 S, 51 Cr, 57 Co, 59 Fe, 82 Br, 86 Rb, sup(99m)Tc, sup(113m)In, 125 I and 169 Yb. The radiometric test proves to be more rapid than the conventional one for the sterility testing of such radiopharmaceuticals. Detection time is between 6-21 hours. In the case of 131 I-labelled radiopharmaceuticals and in the case of chlormerodrin-Hg-203, it was found an interference due to volatile species (sup(131m)Xe in the case of 131 I and some volatile mercury form in the case of chlormerodrin). In these cases it would be possible to carry out the radiometric sterility test after separation of the microorganisms from the radioactive material (by filtration). The limulus lysate method can be employed for control of various pyrogen-prone raw materials and radiopharmaceuticals. Such method is the only method at present available for detecting the low level pyrogen contamination in intrathecal injections. The limulus test is more rapid than the rabbit test

  14. Basic evaluation of 67Ga labeled digoxin derivative as a metal-labeled bifunctional radiopharmaceutical

    International Nuclear Information System (INIS)

    Fujibayashi, Yasuhisa; Konishi, Junji; Takemura, Yasutaka; Taniuchi, Hideyuki; Iijima, Naoko; Yokoyama, Akira.

    1993-01-01

    To develop metal-labeled digoxin radiopharmaceuticals with affinity with anti-digoxin antibody as well as Na + , K + -ATPase, a digoxin derivative conjugated with deferoxamine was synthesized. The derivative had a high binding affinity with 67 Ga at deferoxamine introduced to the terminal sugar ring of digoxin. The 67 Ga labeled digoxin derivative showed enough in vitro binding affinity and selectivity to anti-digoxin antibody as well as Na + , K + -ATPase. The 67 Ga labeled digoxin derivative is considered to be a potential metal-labeled bifunctional radiopharmaceutical for digoxin RIA as well as myocardial Na + , K + -ATPase imaging. (author)

  15. Tritium labeling of simple 7-membered ring compounds

    International Nuclear Information System (INIS)

    Hiltunen, J.; Peng, C.T.; Yang, Z.C.

    1990-01-01

    Seven-membered ring compounds, from cycloheptane to complex ring structures containing heteroatoms, substituents and fused phenyl rings, were labeled with tritium, using activated and adsorbed tritium. The 7-membered ring structures are generally stable towards reactions with tritium, which allows compounds like 1-benzosuberone, 1-aza-2-methoxy-1-cycloheptane, iminostilbene and clozapine to be labeled to reasonably high specific activities. The best method varies greatly from compound to compound. By optimizing the labeling conditions and use of efficient support exceptionally good results can be obtained. The Pd-on-alumina support gives consistently higher specific activity and less radioimpurity than other supports. Even molecules containing carbon-halogen bond and hydrogen bound to nitrogen can usually be labeled with tritium at stable positions and without dehalogenation. (author)

  16. Use of tritium-labeled PCBs for investigation of PCBs biodegradation by soil bacteria

    International Nuclear Information System (INIS)

    Kim, A.A.; Djuraeva, G.T.; Takhtobiri, K.S.; Yadgarov, H.T.; Zinovev, P. V.; Abdukarimov, A.A.

    2002-01-01

    The method for tritium labelling of polychlorinated biphenyls (PCBs) was developed. The strains of soil bacteria - destructors of chloro organic compounds was studied with the help of test-system based on the using of tritium-labeled PCBs. The strains of bacteria were grown on the agar synthetic medium and then were introduced into the synthetic medium containing tritium-labeled mixture of PCBs (commercial mark - SOVOL) as alone source of carbon. The samples were analysed after one and two months period of incubation. PCBs were extracted by hexane from fraction of bacteria and fraction of cultural medium and radioactivity was measured. The samples were analyzed by thin layer chromatography (TLC) with following radioautography. Additionally samples were analyzed by gas chromatography. It was found that all selected strains survived in the medium with PCBs as alone source of carbon and bacteria accumulated PCBs from cultural medium. Accumulation of PCBs by strains of bacteria was different. The TLC analysis detected additional compounds labeled by tritium, that prove the degradation of PCBs in presence of bacteria. The gas chromatography analysis of cultural medium and bacteria detected redistribution in the system and qualitative changes of PCBs in bacteria. The strains of bacteria also were grown in model condition on the soil with tritium labeled PCBs. We found that some strains effectively destroy PCBs with decreasing level of tritium label in the soil. The using of tritium labeled PCBs' allows to introduce precise quantitative characteristics for study of accumulation and biodegradation PCBs by soil bacteria strains. Developed test-system is very useful tool for selection of new strains of soil bacteria - destructors of PCBs

  17. Methods for the synthesis of tritium labelled steroids

    International Nuclear Information System (INIS)

    Volkova, V.S.; Tatarkina, F.V.; Kaklyushkina, L.N.; Ignat'eva, N.A.; Tupitsyn, I.F.; Efimova, Ts.I.

    1977-01-01

    The catalytic substitution of bromine for tritium in corresponding bromo-derivatives of steroids was used for the preparation of 4 steroids labelled with tritium at position 7. The bromination of the starting steroids was effected with N-bromosuccinimide. Ten steroids labelled with tritium at the positions 1, 2, 6 and 7 were prepared by reduction of the unsaturated derivatives with gaseous tritium in the presence of either the heterogeneous Pd/C catalyst, or the homogeneous chloride of tris(triphenylphosphine)rhodium

  18. Development of method of tritium labeling of pharmacological preparate of drotaverine hydrochloride (NOSPA)

    International Nuclear Information System (INIS)

    Kim, A.A.; Djuraeva, G.T.; Shukurov, B.V.

    2004-01-01

    Full text: The method for tritium labeling of pharmacological preparate of drotaverine hydrochloride (no spa) was developed. Drotaverine hydrochloride was labeled by thermally activated tritium in apparatus for tritium labeling. The optimum regime of labeling was selected. The system of purification of tritium labeled drotaverine hydrochloride by thin layer chromatography (TLC) has been developed. The TLC system of purification of tritium labeled drotaverine hydrochloride was developed. Tritium labeled preparation of drotaverine hydrochloride was purified by TLC on silicagel in system isopropanol: ammonia: water (8:1:1). We found appearance of additional fractions in tritium labeled preparation of drotaverine hydrochloride that testifies to partial transformation of drotaverine hydrochloride during procedure of labeling. Application of TLC for purification of tritium labeled preparation allows to purify completely drotaverine hydrochloride of by-products. The output of purified tritium labeled preparation of drotaverine hydrochloride was about 25 %. The received preparation had specific radioactivity - 3,2 MBq/mg, radiochemical purity of a preparation was 95 %. TLC purification seems inexpensive, fast and suitable for purification of tritium-labeled drotaverine hydrochloride. Thus developed method allows obtain tritium labeled preparation of drotaverine hydrochloride (no - spa), suitable for medical and biologic researches

  19. Basic evaluation of [sup 67]Ga labeled digoxin derivative as a metal-labeled bifunctional radiopharmaceutical

    Energy Technology Data Exchange (ETDEWEB)

    Fujibayashi, Yasuhisa; Konishi, Junji (Kyoto Univ. (Japan). Faculty of Medicine); Takemura, Yasutaka; Taniuchi, Hideyuki; Iijima, Naoko; Yokoyama, Akira

    1993-11-01

    To develop metal-labeled digoxin radiopharmaceuticals with affinity with anti-digoxin antibody as well as Na[sup +], K[sup +]-ATPase, a digoxin derivative conjugated with deferoxamine was synthesized. The derivative had a high binding affinity with [sup 67]Ga at deferoxamine introduced to the terminal sugar ring of digoxin. The [sup 67]Ga labeled digoxin derivative showed enough in vitro binding affinity and selectivity to anti-digoxin antibody as well as Na[sup +], K[sup +]-ATPase. The [sup 67]Ga labeled digoxin derivative is considered to be a potential metal-labeled bifunctional radiopharmaceutical for digoxin RIA as well as myocardial Na[sup +], K[sup +]-ATPase imaging. (author).

  20. Synthesis and pharmacokinetics of thiacoccide labeled with tritium

    International Nuclear Information System (INIS)

    Shestakov, A.D.; Kaminskii, Yu.L.; Nurova, I.M.; Nikitina, V.N.; Zaionts, V.I.; Maksimova, O.V.; Mikhailov, G.A.

    1986-01-01

    To obtain information on the pharmacokinetics of thiacoccide, the authors effect the synthesis of an analog of thiacoccide, viz., the hydrochloride of 2-methyl-N-(2'-n-propyl-4'-aminopyrimid-5'-ylmethyl)pyridinium chloride (I) labeled with tritium. The simplest way to introduce a tritium label into (I) is by isotopic exchange of hydrogen of (I) with H 3 HO. Typical material obtained from isotopic exchange with water labeled with tritium is shown. The dynamics of 3 H distribution in the organism of the chick and the rate of its elimination on single administration of thiacoccide containing isotope in both the methyl group and in the pyridine ring are shown

  1. Enantiospecific tritium labeling of 28-homocastasterone

    Czech Academy of Sciences Publication Activity Database

    Elbert, Tomáš; Patil, Mahadeo Rajshekhar; Marek, Aleš

    2017-01-01

    Roč. 60, č. 3 (2017), s. 176-182 ISSN 0362-4803 R&D Projects: GA AV ČR IAA400550801 Institutional support: RVO:61388963 Keywords : 28-homocastasterone * brassinosteroids * enantiospecific reaction * tritium dehalogenation * tritium labeling Subject RIV: CC - Organic Chemistry OBOR OECD: Organic chemistry Impact factor: 1.745, year: 2016

  2. Preparation of sup(113m)In-labelled compounds of radiopharmaceutical interest. Part of a coordinated programme on radiopharmaceuticals

    International Nuclear Information System (INIS)

    Servian, J.; Robles, A.

    1975-06-01

    Techniques for the preparation and control of already known and new sup(113m)In-radiopharmaceuticals were investigated. New rapid procedures for the control and preparation of a number of radiopharmaceuticals were developed and standardized. After biological distribution studies and clinical tests, new techniques for the preparation of the following indium-113 radiopharmaceuticals were adopted: a) Indium - labelled colloids of: S, Al(OH) 3 , Fe(OH) 3 and AlPO 4 for liver and spleen scintigraphy. b) Indium labelled chelates using the ligands EDTA, DTPA, TTHA (Triethylene-tetramine-hexaacetic acid) and DHPTA (Diamino-hydroxy-propane-tetraacetic acid) for brain scintigraphy. c) Indium labelled Fe(OH) 3 macroaggregates and microspheres for lung scintigraphy. d) Several complexes of sup(113m)In with different ligands (fluoride, tartrate, pyrophosphate, tripolyphosphate, trimetaphosphate, EHDP (or ethane-1-hydroxy-1, 1-diphosphonate), ethylendiamine-pyrophosphate were synthesized and its potential use as bone-scanning agents were evaluated. It was found that the complexes with tartrate, tripolyphosphate and EHDP show appreciable skeletal uptake (bone/muscle ratio are 9.0, 5.5, and 4.7 respectively), although they are inferior to the sup(99m)Tc bone-scanning agents. e) A new simple technique is proposed for the preparation of highly concentrated sup(113m)In solutions. The technique is based on the precipitation of In(OH) 3 , millipore filtration and redissolution in a small volume of 0.05 N HCl

  3. Tritium labelling of two new analgesic drugs

    International Nuclear Information System (INIS)

    Santamaria, J.; Rebollo, D.V.; Rivera, P.; Esteban, M.

    1986-01-01

    The labelling with tritium of two arylpropionic esters was studied. The synthesis between 3 H-Ibuprofen and the two unlabelled alcoholic moieties (Cl-Alkanol and CF 3 -Alkanol) was performed. Assuming that we got ready the acidic moiety, 3 H-Ibuprofen, in our Laboratory, we attempted to label with tritium the alcoholic moiety and then go on to its esterification. Prior to labelling, thermic stability of 2-(4-(3-chlorophenyl)-1-piperazinyl) ethanol (Cl-Alkanol) was studied. As result of this study we had to change the labelling method, so that the Cl-Alkanol was unstable at 70 0 C. Purification was accomplished through thin layer chromatography (TLC) and high performance liquid chromatography (HPLC). Concentration, purity and specific activities of the two labelled compounds were determined by ultraviolet, HPLC and liquid scintillation techniques. (author)

  4. Dual labelling of Lobuprofen with tritium and carbon-14

    International Nuclear Information System (INIS)

    Santamaria, J.; Rivera, P.; Esteban, M.; Martin, J.L.; Carretero, J.M.

    1988-01-01

    Dual labelling of Lobuprofen with tritium and carbon-14 was performed. The synthesis between 2-(4-isobutylphenyl)propionic acid (Ibuprofen), randomly labelled with tritium, and 2-[4-(3-chlorophenyl)-1-piperazinyl]ethanol (Cl-Alkanol) labelled with carbon-14 in the piperazine ring was achieved. Prior to this synthesis, the [ 14 C]Cl-Alkanol was obtained using 2-amino-[2- 14 C]ethanol as a precursor. (author)

  5. A new technique of ion beam tritium labelling

    International Nuclear Information System (INIS)

    Zhang Nianbao; Sheng Shugang; Yao Fuzeng

    1990-01-01

    In this paper a new technique is reported for tritium labelling of proteins, peptides and other nonvolatile organic compounds. A tritium ion beam is accelerated to bombard solid sample target for producing tritium exchange with hydrogen. The tritium labelling method has been applied to tritiated soybean trypsin inhibitor, ribonuclease A, elastin, pachyman and others totalled 11. After purifying by dialysis, ion exchange chromatography and gel filtration, the tritiated proteins and polysaccharide were obtained with specific activity over 37 GBq/mmol, without decomposition and with biological activity well preserved. By amino acid analysis of tritiated protein it was shown that the relative specific radioactivities for His., Tyr. and Phe. residues were higher while those for Val., Ile. and Ser. residues were lower

  6. Adherence of radiopharmaceuticals and labeled cells to intravenous tubing

    International Nuclear Information System (INIS)

    Segall, G.M.; Gurevich, N.; McDougall, I.R.

    1986-01-01

    A survey of 67 nuclear medicine departments revealed no agreement on which radiolabeled agents could be injected through intravenous lines (IVs) and which required direct venipuncture. Labeled cells and several common radiopharmaceuticals were tested for adherence to intravenous tubing. Residual activity remaining in the tubing after an adequate flush was less than 1% of the injected dose in each case. Administration of radiolabeled agents through existing IVs is an acceptable alternative to direct venipuncture in many cases

  7. Tritium-labelled abscisic acid

    International Nuclear Information System (INIS)

    Pluciennik, H.; Michalski, L.

    1991-01-01

    A simple method for the preparation of biologically active abscisic acid (growth inhibiting plant hormone) labelled with tritium is described. The product obtained has a specific radioactivity of 1.12 GBq mmol -1 : the yield is about 60% as compared to the initial amount of the substance used. (author) 7 refs.; 2 figs

  8. Synthesis of tritium-labeled vitamin A and its analogs

    International Nuclear Information System (INIS)

    Rhee, S.W.; Bubb, J.E.

    1985-01-01

    Metabolic and pharmacologic studies of Vitamin A and its analogs related to the prevention of lung cancer and other epithelial cancers required tritium-labeled Vitamin A analogs and β-carotene at high specific activity. Syntheses of some of the isomers were therefore developed in the laboratory, as described in the paper. The advantages of the scheme shown are that : 1. Tritiums are introduced into the molecule by catalytic hydrogenation, thus affording high specific activity. 2. It uses an allylic rearrangement of tritiated vinyl-β-ionol to C 15 -phosphonium salt, which is condensed with C 5 -nitrile to give C 20 -skeleton of retinonitrile. 3. It permits the development of milder methods to convert tritium-labeled retinaldehyde, as a common intermediate, to the other retinoids (i.e., retinoic acid, retinol, and retinyl acetate). Furthermore, tritium-labeled all-trans-β-carotene, an important carotenoid, has been obtained from the retinaldehyde

  9. Preparation of Radiopharmaceuticals Labeled with Metal Radionuclides

    Energy Technology Data Exchange (ETDEWEB)

    Welch, M.J.

    2012-02-16

    The overall goal of this project was to develop methods for the production of metal-based radionuclides, to develop metal-based radiopharmaceuticals and in a limited number of cases, to translate these agents to the clinical situation. Initial work concentrated on the application of the radionuclides of Cu, Cu-60, Cu-61 and Cu-64, as well as application of Ga-68 radiopharmaceuticals. Initially Cu-64 was produced at the Missouri University Research Reactor and experiments carried out at Washington University. A limited number of studies were carried out utilizing Cu-62, a generator produced radionuclide produced by Mallinckrodt Inc. (now Covidien). In these studies, copper-62-labeled pyruvaldehyde Bis(N{sup 4}-methylthiosemicarbazonato)-copper(II) was studied as an agent for cerebral myocardial perfusion. A remote system for the production of this radiopharmaceutical was developed and a limited number of patient studies carried out with this agent. Various other copper radiopharmaceuticals were investigated, these included copper labeled blood imaging agents as well as Cu-64 labeled antibodies. Cu-64 labeled antibodies targeting colon cancer were translated to the human situation. Cu-64 was also used to label peptides (Cu-64 octriatide) and this is one of the first applications of a peptide radiolabeled with a positron emitting metal radionuclide. Investigations were then pursued on the preparation of the copper radionuclides on a small biomedical cyclotron. A system for the production of high specific activity Cu-64 was developed and initially the Cu-64 was utilized to study the hypoxic imaging agent Cu-64 ATSM. Utilizing the same target system, other positron emitting metal radionuclides were produced, these were Y-86 and Ga-66. Radiopharmaceuticals were labeled utilizing both of these radionuclides. Many studies were carried out in animal models on the uptake of Cu-ATSM in hypoxic tissue. The hypothesis is that Cu-ATSM retention in vivo is dependent upon the

  10. The uptake of tritium-labelled carnitine by monolayer cultures of human fetal muscle and its potential as a label in cytotoxicity studies

    International Nuclear Information System (INIS)

    Cambridge, G.; Stern, C.M.M.

    1981-01-01

    As a novel approach to the investigation of immune responses directed against muscle antigens in inflammatory muscle disease, the use of tritium-labelled carnitine as a selective marker for myotubes in monolayer cultures was investigated. Tritium-labelled carnitine was incubated either with monolayer cultures of human fetal muscle or with syngeneic monolayer cultures of human fetal fibroblasts. The rate of uptake and loss of tritium-labelled carnitine by muscle cultures was compared with that shown by fibroblast cultures; values for the ratio Ksub(m)/Vsub(max) were 3.1 for muscle cultures and 0.46 for fibroblast cultures. Freeze-dried radioautographs of muscle monolayers, previously incubated with tritium-labelled carnitine confirmed the specific intra-tubular localization of the label. Fetal muscle monolayers, previously incubated with tritium-labelled carnitine, were used as targets in long-term cytotoxicity experiments into lymphocyte-mediated myotoxicity. Peripheral blood lymphocytes from patients with inflammatory muscle disease were shown to be myotoxic, but lymphocytes from normal individuals or those with non-inflammatory muscle disease were not. Carnitine-based measures of myotoxicity closely followed the clinical activity of the disease in one patient and the test shows considerable potential as a means of assessing myotube killing by lymphocytes on a per-cell basis. (author)

  11. Preparation of pyronaridine labelled with tritium

    International Nuclear Information System (INIS)

    Jiang Shangen; Zhang Liufang; Zheng Dongzhu; Feng Zheng; Wu Zufan

    1987-01-01

    Pyronaridine is a high efficient and low toxic new antimalarial drug. 3 H-pyronaridine was prepared by catalytic isotopic exchange in solution with tritium gas using PdO/BaSO 4 as catalyst. That crude product was purified by extraction. 3 H-NMR spectra of pyronaridine showed that tritium was labelled at the 6-position. Specific activity of 3 H-pyronaridine was 5.5 Ci/mmol and radiochemical purity over 95%

  12. The introduction of tritium label into natural and modified prostaglandins

    International Nuclear Information System (INIS)

    Shevchenko, V.P.; Bezuglov, V.V.; Nagayev, I.Y.; Myasoedov, N.F.

    1989-01-01

    Studies on the role of the nature of both heterogeneous catalysts and the solvent on the reduction selectively of 5,6-double bonds showed that the largest yield could be obtained by using the Lindlar catalyst and ethyl acetate. The use of different isotopes of hydrogen in the protium-deuterium-tritium series markedly decreased the hydrogenation reaction rate, but the selectivity of the process practically remained unaltered. Homogeneous catalysts were also used in the production of natural tritium-labelled prostaglandins and of their fluorine and deoxy analogues. The label was introduced by selective hydrogenation in the presence of (Ph 3 P) 3 RhCl and dioxane as solvent. Different ways have been studied of tritium-label introduction into prostaglandins modified at the carboxyl group. The synthesis of similar preparations was performed either by selective dehalogenation in the presence of heterogeneous catalysts treated with quinoline or triethylamine, or by condensation of prostaglandins at the carboxyl group by tritium-labelled amino acid. (author). 4 refs.; 1 fig

  13. Tritium labelled nucleotides: Heterogeneous metal catalyzed exchange labelling of ATP with tritium gas

    International Nuclear Information System (INIS)

    Jaiswal, D.K.; Morimoto, H.; Williams, P.G.; Wemmer, D.E.

    1991-09-01

    Adenosine 5' triphosphate (ATP) in aqueous solution has been labeled by exchange with tritium gas in the presence of palladium oxide catalyst. Comparison with our experiments using Pd/BaSO 4 as the catalyst shows that we have obtained product with higher specific activity and improved chemical purity. 3 H NMR spectroscopy of the tritiated ATP shows labelling in both the C-8 and C-2 positions, and the integral ratio of these positions was found to vary from 3:1 to 1:1 under different reaction conditions. 5 refs., 1 fig., 2 tabs

  14. Radiopharmaceuticals and other compounds labelled with short-lived radionuclides

    CERN Document Server

    Welch, Michael J

    2013-01-01

    Radiopharmaceuticals and Other Compounds Labelled with Short-Lived Radionuclides covers through both review and contributed articles the potential applications and developments in labeling with short-lived radionuclides whose use is restricted to institutions with accelerators. The book discusses the current and potential use of generator-produced radionuclides as well as other short-lived radionuclides, and the problems of quality control of such labeled compounds. The book is useful to nuclear medicine physicians.

  15. Preparation of pyronaridine labelled with tritium

    Energy Technology Data Exchange (ETDEWEB)

    Shangen, Jiang; Liufang, Zhang; Dongzhu, Zheng; Zheng, Feng; Zufan, Wu

    1987-12-01

    Pyronaridine is a high efficient and low toxic new antimalarial drug. /sup 3/H-pyronaridine was prepared by catalytic isotopic exchange in solution with tritium gas using PdO/BaSO/sub 4/ as catalyst. That crude product was purified by extraction. /sup 3/H-NMR spectra of pyronaridine showed that tritium was labelled at the 6-position. Specific activity of /sup 3/H-pyronaridine was 5.5 Ci/mmol and radiochemical purity over 95%.

  16. Enantiospecific tritium labeling of 28-homocastasterone.

    Science.gov (United States)

    Elbert, Tomáš; Patil, Mahadeo R; Marek, Aleš

    2017-03-01

    A regiospecific and enantiospecific synthesis of tritium-labeled 28-homocastasterone is reported. Appropriate chlorocarbonate, efficiently synthesized from the starting 28-homocastasterone in an overall yield of 46%, undergoes catalytic tritium dechlorination by the T 2 /Pd[0]/Et 3 N system, providing 28-[3β- 3 H]homocastasterone, in a good yield, radiochemical purity (>97%), and with a high specific activity (5.8 Ci/mmol). Copyright © 2016 John Wiley & Sons, Ltd.

  17. Tritium labelling of PACAP-38 using a synthetic diiodinated precursor peptide

    DEFF Research Database (Denmark)

    Pedersen, Martin Holst Friborg; Baun, Michael

    2012-01-01

    In the interest of developing efficient methods for tritium labelling peptides, we here demonstrate the successful labelling of PACAP-38 (pituitary adenylate cyclase-activating polypeptide), a 38-mer peptide, using a synthetic diiodinated PACAP-38 precursor. In this example, we employ standard hy...... hydrogenation chemistry with the use of a heterogeneous palladium catalyst and carrier-free tritium gas on a tritium manifold system....

  18. The radiopharmaceuticals labelled with technetium-99m and the radiopharmacy

    International Nuclear Information System (INIS)

    Bodenant, V.

    1998-01-01

    In less than fifty years, the place of nuclear medicine is become primordial. Among all the radiopharmaceuticals used in nuclear medicine, the technetium-99m is the most used because of its physico-chemical properties and its great availability with the molybdenum-99m - technetium-99m generator. Since 1992, the radiopharmaceuticals, the packages, the generators are included in the pharmaceutic monopole. They are now under the reliability of the radio-pharmacist. This thesis has for object to introduce these different radiopharmaceuticals labelled with technetium-99m and to show the primordial place of the radio-pharmacist in a service of nuclear medicine. (N.C.)

  19. Foot-printing of Protein Interactions by Tritium Labeling

    International Nuclear Information System (INIS)

    Mousseau, Guillaume; Thomas, Olivier P.; Agez, Morgane; Thai, Robert; Cintrat, Jean-Christophe; Rousseau, Bernard; Raffy, Quentin; Renault, Jean Philippe; Pin, Serge; Ochsenbein, Francoise

    2010-01-01

    A new foot-printing method for mapping protein interactions has been developed, using tritium as a radioactive label. As residues involved in an interaction are less labeled when the complex is formed, they can be identified via comparison of the tritium incorporation of each residue of the bound protein with that of the unbound one. Application of this foot-printing method to the complex formed by the histone H3 fragment H3 122-135 and the protein hAsflA 1-156 afforded data in good agreement with NMR results. (authors)

  20. A new technique for ion beam tritium labelling

    International Nuclear Information System (INIS)

    Zhang Nianbao; Sheng Shugang; Yao Fuzeng

    1990-06-01

    An advanced technique, the ion beam tritium labelling method (IBTL), used for labelling proteins, peptides and other nonvolatile organic compounds is introduced. In this method the excited tritium ion beam is accelerated and then bombs a solid sample target in which tritium exchanging for hydrogen is taken place. The IBTL has been used for preparation of tritiated soybean trypsin inhibitor, ribonuclease A, elastin and pachyman etc. After purifing by dialysis, ion exchange chromatography and gel filtration, the tritiated proteins and polysaccharide were obtained with the specific activity over 37 GBq/mmol, the function of tritiated decomposition products was not found. The product was shown to have native biological activity. Amino acid analysis of tritiated protein showed that the relative specific radioactivities were higher for His., Tyr. and Phe. but lower for Val., Ile. and Ser

  1. Synthesis of coenzyme A and nicotineamide-adenine dinucleotide labelled with tritium

    International Nuclear Information System (INIS)

    Sidorov, G.V.; Zverkov, Yu.B.; Myasoedov, N.F.

    1999-01-01

    Isotopic exchange in solution with tritium water and with gaseous tritium and solid-phase reaction of isotopic exchange of NAD with tritium were investigated. For synthesis of labelled with tritium coenzyme A solid-phase reaction of isotopic exchange with gaseous tritium was used. It was determined that 98% of tritium was contained in nicotineamide part of molecule of NAD. In the case of coenzyme A studying of intramolecular distribution of tritium demonstrated that 90% of tritium were localized in adenine fragment [ru

  2. Study on Chinese herbal medicine active ingredients labelled with tritium

    International Nuclear Information System (INIS)

    Dong Mo; Bao Guangliang

    2008-01-01

    Chinese medicinal herb active ingredients was labeled with triteium by using exchange of new synthesized tritiated water or exchange of low-pressure gas-liquid. The active ingredients was Genipin, acetylalkannin and chlorogenic acid .The radiochemical purity of the three labeled compounds were more than 95% after TLC and HPLC purification. The specific activities of tritium labeled-genipin, acetylalkannin and chlorogenic acid were 5.97, 3.24 and 470 GBq/g, respectively. The results indicated that the unstable Chinese medicinal herb active ingredients could be labeled with tritium by the methods of exchange of new synthesized tritiated water and exchange of low-pressure gas-liquid. (authors)

  3. Enhancing radiolytic stability upon concentration of tritium-labeled pharmaceuticals utilizing centrifugal evaporation.

    Science.gov (United States)

    Marques, Rosemary; Helmy, Roy; Waterhouse, David

    2015-05-30

    Tritium radiopharmaceuticals are often used in drug development because of their desirable specific activity. The inherent instability of these radioactive tracers often leads to a requirement to purify prior to use. Purification methodologies such as preparative chromatography and solid/liquid extractions often utilize water as a solvent, which is not suitable for long-term storage and necessitates removal. Rotary evaporation has traditionally been utilized for the removal of this unwanted solvent, however, this method has been shown to lead to decomposition of the tritium species in some cases. Centrifugal evaporation is a milder concentration method which has been demonstrated to effectively remove solvents. In this study, we show that centrifugal evaporation leads to effective concentration of tritium samples without the decomposition typically observed by rotary evaporation. Copyright © 2015 John Wiley & Sons, Ltd.

  4. Investigation of PCBs biodegradation by soil bacteria using tritium-labeled PCBs

    International Nuclear Information System (INIS)

    Kim, A.A.; Djuraeva, G.T.; Takhtobin, K.S.; Kadirova, M.; Yadgarov, H.T.; Zinovev, P.V.; Abdukarimov, A.A.

    2004-01-01

    The method of tritium labeling of polychlorinated biphenyls (PCBs) has been developed. It allows producing of uniformly labeled tritium PCBs. High specific activity permits the tracing all of the tritium labeled PCBs biodegradation products. Radiochemical approach of the investigation of PCBs microbial degradation has been developed and PCB-destructive activity of soil bacteria strains has been studied. It was found that 4 investigated bacteria strains of Bacillus sp. has the ability accumulate and destroy PCBs. Use of developed radiochemical methods in complex with other analytical methods in investigation of PCBs biodegradation provide useful additional information. The radiochemical methods developed can be successfully used for wide screening of microorganisms, destructors of PCBs. (author)

  5. The development of cyclotron radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Yang, Seung Dae; Chun, K. W.; Suh, Y. S.; Lee, J. D.; Ahn, S. H. and others

    1999-03-01

    The purpose of this project is to developthe radiopharmaceuticals and automatic synthetic unit for labelled compounds, and to establish mass production system of radiopharmaceuticals. These will contribute to the early diagnosis of the disease hard to cure. The contents of this project are as follows, the development of the radiopharmaceutical for imaging of cancer, the development of automatic synthesizer for the synthesis of radio-pharmaceuticals, the development of hormone derivatives labelled with {sup 12}'3I, the development of the radiopharmaceuticals for therapy of cancer labelled with cyclotron produced radionuclides, the development of radiopharmaceuticals for therapy of cancer labelled with cyclotron produced radionuclides, the development of radiopharmaceuticals for imaging of myocardial metabolism.

  6. The development of cyclotron radiopharmaceuticals

    International Nuclear Information System (INIS)

    Yang, Seung Dae; Chun, K. W.; Suh, Y. S.; Lee, J. D.; Ahn, S. H. and others

    1999-03-01

    The purpose of this project is to develop the radiopharmaceuticals and automatic synthetic unit for labelled compounds, and to establish mass production system of radiopharmaceuticals. These will contribute to the early diagnosis of the disease hard to cure. The contents of this project are as follows, the development of the radiopharmaceutical for imaging of cancer, the development of automatic synthesizer for the synthesis of radio-pharmaceuticals, the development of hormone derivatives labelled with 12 '3I, the development of the radiopharmaceuticals for therapy of cancer labelled with cyclotron produced radionuclides, the development of radiopharmaceuticals for therapy of cancer labelled with cyclotron produced radionuclides, the development of radiopharmaceuticals for imaging of myocardial metabolism

  7. Analysis and chromatographic purification of eicosanoids multiply labeled by tritium

    International Nuclear Information System (INIS)

    Shevchenko, V.P.; Nagaev, I.Yu.; Myasoedov, N.F.

    1989-01-01

    We show the possibility of analysis and chromatographic purification of eicosanoids triply labeled by tritium. The described methods allow us to isolate chromatographically pure products obtained by selective hydrogenatin, chemical, and enzyme methods, with radiochemical purity at least 95-97%. The following methods are used to analyze the reaction mixtures and to isolate the tritium-labeled eicosanoids: gas-liquid chromatography, high-efficiency liquid chromatography, and thin-layer chromatography on supports impregnated with silver nitrate

  8. The synthesis of a tritium, carbon-14, and stable isotope-labeled cathepsin C inhibitors.

    Science.gov (United States)

    Allen, Paul; Bragg, Ryan A; Caffrey, Moya; Ericsson, Cecilia; Hickey, Michael J; Kingston, Lee P; Elmore, Charles S

    2017-02-01

    As part of a medicinal chemistry program aimed at developing a highly potent and selective cathepsin C inhibitor, tritium, carbon-14, and stable isotope-labeled materials were required. The synthesis of tritium-labeled methanesulfonate 5 was achieved via catalytic tritiolysis of a chloro precursor, albeit at a low radiochemical purity of 67%. Tritium-labeled AZD5248 was prepared via a 3-stage synthesis, utilizing amide-directed hydrogen isotope exchange. Carbon-14 and stable isotope-labeled AZD5248 were successfully prepared through modifications of the medicinal chemistry synthetic route, enabling the use of available labeled intermediates. Copyright © 2016 John Wiley & Sons, Ltd.

  9. Preparation of Radiopharmaceuticals Labeled with Metal Radionuclides. Final Report

    International Nuclear Information System (INIS)

    Welch, M.J.

    2012-01-01

    The overall goal of this project was to develop methods for the production of metal-based radionuclides, to develop metal-based radiopharmaceuticals and in a limited number of cases, to translate these agents to the clinical situation. Initial work concentrated on the application of the radionuclides of Cu, Cu-60, Cu-61 and Cu-64, as well as application of Ga-68 radiopharmaceuticals. Initially Cu-64 was produced at the Missouri University Research Reactor and experiments carried out at Washington University. A limited number of studies were carried out utilizing Cu-62, a generator produced radionuclide produced by Mallinckrodt Inc. (now Covidien). In these studies, copper-62-labeled pyruvaldehyde Bis(N 4 -methylthiosemicarbazonato)-copper(II) was studied as an agent for cerebral myocardial perfusion. A remote system for the production of this radiopharmaceutical was developed and a limited number of patient studies carried out with this agent. Various other copper radiopharmaceuticals were investigated, these included copper labeled blood imaging agents as well as Cu-64 labeled antibodies. Cu-64 labeled antibodies targeting colon cancer were translated to the human situation. Cu-64 was also used to label peptides (Cu-64 octriatide) and this is one of the first applications of a peptide radiolabeled with a positron emitting metal radionuclide. Investigations were then pursued on the preparation of the copper radionuclides on a small biomedical cyclotron. A system for the production of high specific activity Cu-64 was developed and initially the Cu-64 was utilized to study the hypoxic imaging agent Cu-64 ATSM. Utilizing the same target system, other positron emitting metal radionuclides were produced, these were Y-86 and Ga-66. Radiopharmaceuticals were labeled utilizing both of these radionuclides. Many studies were carried out in animal models on the uptake of Cu-ATSM in hypoxic tissue. The hypothesis is that Cu-ATSM retention in vivo is dependent upon the oxygen

  10. The synthesis of tritium-labelled vitamin B-6

    International Nuclear Information System (INIS)

    Babain, V.A.; Kaminskij, Yu.L.; Nagorskij, A.I.; Rozenberg, S.G.

    1992-01-01

    Specimens of pyridoxine (B-6 vitamin) labelled by tritium are obtained due to techniques of liquid-phase and solid-phase heterogeneous isotopic exchange with gaseous tritium over palladium catalysts. [ 3 H] molar activity of the vitamin obtained due to liquid-phase exchange constitutes 925-1295 TBq/mole, due to solid-phase one - 1.85-2.96 PBq/mole. 60 % of tritium are localized in 2-CH 3 -group, 25 % - in 4-C 2 HOH-group, 15 % - in 6H in the vitamin specimen obtained due to liquid-phase exchange, while at solid-phase exchange it is localized respectively as 36, 37 and 25 %

  11. Tritium labelling of testosteron by selective hydrogenation of dihydrotestosteron

    International Nuclear Information System (INIS)

    Postolache, Cristian; Matei, Lidia; Simion, Elena; Barna, Catalina; Condac, Eduard

    2002-01-01

    Elemental tritium is obtained during the decontamination process of the moderator from Cernavoda Nuclear Power Plant. It might be stocked for use in controlled fusion, in a relatively far future, or, it might be immediately used as raw material in the synthesis of labelled compounds with important economic value. Labelling of testosteron with tritium was necessary for the carrying out of radiometric and molecular biology studies concerning androgen dependent diseases. Testosteron was labelled by selective hydrogenation of 1,2 dihydrotestosteron acetate. The forerunner was synthesized in two steps: 1) esterification of testosteron using acetic anhydride, and 2) selective dehydrogenation with 2,6-dichloro-3,5-dicyan-1,4 quinone (DDQ) of the ester formed in the first step. Testosteron acetate was synthesized and purified with yields of 73%, and 80%, respectively. The dehydrogenation process was characterized by yields of 82% for synthesis and 33% for purification. The tritium labelled hormone was obtained in two steps: 1) selective hydrogenation of Δ 1 - testosteron acetate in the presence of T 2 gas, at low pressure, and 2) hydrolysis of the ester at basic pH. The raw product obtained was purified by preparative thin layer chromatography. The physical and chemical characterization of labelled testosteron reveals a radiochemical purity higher than 98% and a specific activity of 53.4 Ci/mmol. (authors)

  12. Developments in radioisotope production and labelling of radiopharmaceuticals

    International Nuclear Information System (INIS)

    Lambrecht, R.M.

    1998-01-01

    Recent developments in both reactor and accelerator production of radioisotopes finding applications in nuclear medicine and in biomedical research are summarised. The priorities for the production of 48 different cyclotron radioisotopes; and for 42 reactor produced radioisotopes finding biomedical applications are identified. Each includes 5 generator systems. The rapid expansion of cyclotron based radioisotope production and automated synthesis of short-lived radiopharmaceuticals with the position-emitting radionuclides continues to gain momentum. Recent feasibility studies of the cyclotron production of 186 Re, 99m Tc and of 99 Mo are cited as examples of motivation to develop accelerator alternatives to use of nuclear reactors for medical radioisotope production. Examples of SPET and PET radiopharmaceuticals labelled with 131 I, 123 I, 124 I, 18 F, and with therapeutic radionuclides are highlighted. (author)

  13. Radiopharmaceuticals generalities

    International Nuclear Information System (INIS)

    Leon Cabana, A.S.

    1994-01-01

    Many applications in nuclear medicine used as diagnostic techniques, images methods with direct and indirect labelled compounds in organs. A brief description about scintillator counters or gamma counters SPECT(single photon emission computed tomography) and PECT (positron emission computed tomography), as well as therapeutic proceedings,radiopharmaceutical classification, labell steps,administration form in the body,physical form and the best radiopharmaceutical ideal classification. Two tables was used contain radiopharmaceuticals more used in diagnostic and more used in therapic uses. Tabs

  14. Frustrated Lewis pairs-assisted tritium labeling

    Czech Academy of Sciences Publication Activity Database

    Marek, Aleš; Široká, Sabina; Elbert, Tomáš

    2016-01-01

    Roč. 14, č. 5 (2016), s. 219 ISSN 2336-7202. [Sjezd českých a slovenských chemických společností /68./. 04.09.2016-07.09.2016, Praha] Institutional support: RVO:61388963 Keywords : frustrated Lewis pairs * one-pot synthesis * tritium -labeling Subject RIV: CC - Organic Chemistry

  15. Automatic isotope gas analysis of tritium labelled organic materials Pt. 1

    International Nuclear Information System (INIS)

    Gacs, I.; Mlinko, S.

    1978-01-01

    A new automatic procedure developed to convert tritium in HTO hydrogen for subsequent on-line gas counting is described. The water containing tritium is introduced into a column prepared from molecular sieve-5A and heated to 550 deg C. The tritium is transferred by isotopic exchange into hydrogen flowing through the column. The radioactive gas is led into an internal detector for radioactivity measurement. The procedure is free of memory effects, provides quantitative recovery with analytical reproducibility better than 0.5% rel. at a preset number of counts. The experimental and analytical results indicate that isotopic exchange between HTO and hydrogen over a column prepared from alumina or molecular sieve-5A can be successfully applied for the quantitative transfer of tritium from HTO into hydrogen for on-line gas countinq. This provides an analytical procedure for the automatic determination of tritium in water with an analytical reproducibility better than 0.5% rel. The exchange process will also be suitable for rapid tritium transfer from water formed during the decomposition of tritium-labelled organic compounds or biological materials. The application of the procedure in automatic isotope gas analysis of organic materials labelled with tritium will be described in subsequent papers (Parts II and III). (T.G.)

  16. Development, preparation and control of sup(99m)Tc or sup(113m)In labelled stannous hydroxide radiopharmaceuticals. Part of a coordinated programme on radiopharmaceuticals

    International Nuclear Information System (INIS)

    Alvarez Cervera, J.

    1975-01-01

    The preparation of different sup(99m)Tc and sup(113m)In radiopharmaceuticals using stannous chloride was investigated. Chemical and radiochemical procedures for the quality control of these preparations were studied. Toxicity and biological controls of the preparation were carried out. Procedures for the preparation and control of the following radiopharmaceuticals have been standardized by the authors; albumin macroaggregates labelled with sup(99m)Tc, sup(113m)In and other isotopes for lung scanning; albumin microspheres labelled with sup(99m)Tc for lung scanning; sup(99m)Tc or sup(113m)In-labelled stannous hydroxide colloid for liver scanning; sup(99m)Tc-stannous phytate for liver scanning; sup(99m)Tc-Sn-dextrose, a new radiopharmaceutical which has been proposed by the authors and is now used in Mexico for renal and cerebral scanning and sup(99m)Tc-Sn pyrophosphate and diphosphonate for bone scanning

  17. Tritium labelling of molecules constrained in microporous catalysts

    International Nuclear Information System (INIS)

    Long, M.A.; Garnett, J.L.; Than, Chit

    1989-01-01

    The use of microporous aluminophosphate catalysts for exchange between tritium gas or tritiated water and organic substrates is described. The results are compared with those of microporous zeolites. Results are interpreted in terms of the influence of the constraints imposed on molecular configuration by the catalyst pore geometry. The use of these porous structures for minimising byproduct formation in radiation induced labelling processes with tritium gas is described. (author). 10 refs.; 3 tabs

  18. Tritium labeling of gonadotropin releasing hormone in its proline and histidine residues

    International Nuclear Information System (INIS)

    Klauschenz, E.; Bienert, M.; Egler, H.; Pleiss, U.; Niedrich, H.; Nikolics, K.

    1981-01-01

    3,4-dehydroproline9-GnRH prepared by solid phase peptide synthesis was tritiated catalytically under various conditions yielding 3H-GnRH with specific radioactivities in the range from 35-60 Ci/mmol and full LH releasing activity in vitro. Using palladium/alumina catalyst, the tritiation of the double bond occurs within ten minutes. Investigation of the tritium distribution between the amino acid residues showed a remarkably high incorporation of tritium into the histidine residue (11 to 37%). On the basis of this observation, the tritium labeling of GnRH and angiotensin I by direct catalytic hydrogen-tritium exchange was found to be useful for the labeling of these peptides at remarkably high specific radioactivity

  19. Radiopharmaceuticals labelled with positron-emitting radioisotopes

    International Nuclear Information System (INIS)

    Comar, D.; Berridge, M.; Maziere, B.; Crouzel, C.

    1982-01-01

    This chapter reviews the preparation of radioisotopes for biochemical and physiological studies and the principal methods for their incorporation into radiopharmaceuticals, while pointing out the problems encountered with their use and considering their medical interest in the following areas: distribution and flow of fluids, metabolic and pharmacokinetic studies. Inorganic and organic radiopharmaceuticals presently in use and most probable to be used in the future are reviewed. It is anticipated that three types of products labelled with 15 O, 13 N, 11 C and 18 F will be developed in the future. The first type includes products which trace general phenomena such as fluid movement or metabolism of sugars, fats and proteins. The compromise between physiological accuracy and imaging technology is discussed in relation to the use of 11 C and 18 F. The second type of product is one to measure more specific parameters such as those of molecular transport kinetics, membrane permeability, cellular pH and receptor-ligand interactions, again with particular reference to 11 C and 18 F. The third type of product discussed is that intended for pharmacology studies, particular reference being made to 68 Ga, 82 Rb. Extensive bibliography. (U.K.)

  20. Synthesis of bradykinin labelled with tritium on the phenylalanine residue in position 5

    International Nuclear Information System (INIS)

    Seproedi, J.; Teplan, I.; Medzihradszky, K.

    1976-01-01

    The polypeptide hormone bradykinine, labelled with tritium in the phenylalanine chain in position 5, has been prepared. The preparation method is described; the tritium atom is incorporated in the last step of the synthesis. The hormone can therefore be labelled immediately before use, which avoids autoradiolysis during storage

  1. Eleventh international symposium on radiopharmaceutical chemistry

    International Nuclear Information System (INIS)

    1995-01-01

    This document contains abstracts of papers which were presented at the Eleventh International Symposium on Radiopharmaceutical Chemistry. Sessions included: radiopharmaceuticals for the dopaminergic system, strategies for the production and use of labelled reactive small molecules, radiopharmaceuticals for measuring metabolism, radiopharmaceuticals for the serotonin and sigma receptor systems, labelled probes for molecular biology applications, radiopharmaceuticals for receptor systems, radiopharmaceuticals utilizing coordination chemistry, radiolabelled antibodies, radiolabelling methods for small molecules, analytical techniques in radiopharmaceutical chemistry, and analytical techniques in radiopharmaceutical chemistry

  2. Eleventh international symposium on radiopharmaceutical chemistry

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1995-12-31

    This document contains abstracts of papers which were presented at the Eleventh International Symposium on Radiopharmaceutical Chemistry. Sessions included: radiopharmaceuticals for the dopaminergic system, strategies for the production and use of labelled reactive small molecules, radiopharmaceuticals for measuring metabolism, radiopharmaceuticals for the serotonin and sigma receptor systems, labelled probes for molecular biology applications, radiopharmaceuticals for receptor systems, radiopharmaceuticals utilizing coordination chemistry, radiolabelled antibodies, radiolabelling methods for small molecules, analytical techniques in radiopharmaceutical chemistry, and analytical techniques in radiopharmaceutical chemistry.

  3. The tritium labelling of ibuprofen by heterogeneous catalytic exchange

    International Nuclear Information System (INIS)

    Santamaria, J.; Rebollo, D.V.; Rivera, P.; Estaban, M.

    1986-01-01

    The tritium labelling of 2-(4-isobutylphenyl) propionic acid (ibuprofen) was performed. The method employed was heterogeneous catalytic exchange between ibuprofen and tritiated water. Prior to labelling, thermic stability of ibuprofen was studied. Purification was accomplished through thin layer chromatography (TLC) and high performance liquid chromatography (HPLC). Concentration, purity and specific activity of the labelled compound were determined by ultraviolet, HPLC and liquid scintillation techniques. (author)

  4. Quality Assurance of technitium-labelled radiopharmaceuticals in the Radiation and Isotopes Centre of Khartoum (RICK)

    International Nuclear Information System (INIS)

    Adlan, A.A.

    2005-09-01

    This descriptive, exploratory study was conducted in the nuclear medicine department at the Radiation and Isotopes Center of Khartoum (RICK) during 2003-2005 the aim of the study was explore and define the dimensions of a problem which was regarded as urgent by the people working in the field of nuclear medicine in Sudan. The problem concerned the quality of technitium-labelled radiopharmaceuticals which are used in more than 90% of the nuclear medicine imaging studies performed in nuclear medicine. Impure 9 ''9''m Tc-labelled radiopharmaceuticals may create problems, and could lead to false diagnosis. These agents must be tested for determination of the levels of radionuclides, radiochemical and chemicals, before administration to patients. They should also be sterile and pyrogen-free. A number of data collection methods, were used by the researcher for adequate exploration of the dimensions of the problem including interviews, questionnaires and close observations to all activities related to the preparation of radiopharmaceuticals in the hot laboratory. Information concerning all the aspects of quality assurance were collected. These aspects were management and organisation of the work, equipment and tools, knowledge and practical experience of the staff members and methods of preparation and administration of the radioactive agents. Data from different sources were then compared with observation results for more validation and finally lead to the following results: All the quality control tests were not normally performed in the department, therefore the levels of impurities in these agents were not exactly determined, moreover these preparations were subject to contamination with microorganisms, due to low level of cleanliness at the work area. The study detected a number of defaults which were likely to be the causes behind these problems. These were, bad management and organisation, in availability of equipment, tools and materials necessary for testing

  5. Preparation of tritium labelled synthanecine A and its bis-N-ethylcarbamate

    International Nuclear Information System (INIS)

    Mattocks, A.R.

    1982-01-01

    A procedure is described for incorporating tritium into the 3-CH 2 side chain of synthanecine A, and preparing the carbamate, 2,3-bis-N-ethylcarbamoyloxymethyl-1-methyl-3-pyrroline, a hepatotoxic pyrrolizidine alkaloid analogue. The pyrrolizidine amino alcohol, retronecine, can be tritium labelled in a similar way. (author)

  6. Preparation of tritium labelled synthanecine A and its bis-N-ethylcarbamate

    Energy Technology Data Exchange (ETDEWEB)

    Mattocks, A.R. (Medical Research Council, Carshalton (UK))

    1982-04-01

    A procedure is described for incorporating tritium into the 3-CH/sub 2/ side chain of synthanecine A, and preparing the carbamate, 2,3-bis-N-ethylcarbamoyloxymethyl-1-methyl-3-pyrroline, a hepatotoxic pyrrolizidine alkaloid analogue. The pyrrolizidine amino alcohol, retronecine, can be tritium labelled in a similar way.

  7. Label Distribution in Tissues of Wheat Seedlings Cultivated with Tritium-Labeled Leonardite Humic Acid

    Science.gov (United States)

    Kulikova, Natalia A.; Abroskin, Dmitry P.; Badun, Gennady A.; Chernysheva, Maria G.; Korobkov, Viktor I.; Beer, Anton S.; Tsvetkova, Eugenia A.; Senik, Svetlana V.; Klein, Olga I.; Perminova, Irina V.

    2016-06-01

    Humic substances (HS) play important roles in the biotic-abiotic interactions of the root plant and soil contributing to plant adaptation to external environments. However, their mode of action on plants remains largely unknown. In this study the HS distribution in tissues of wheat seedlings was examined using tritium-labeled humic acid (HA) derived from leonardite (a variety of lignites) and microautoradiography (MAR). Preferential accumulation of labeled products from tritiated HA was found in the roots as compared to the shoots, and endodermis was shown to be the major control point for radial transport of label into vascular system of plant. Tritium was also found in the stele and xylem tissues indicating that labeled products from tritiated HA could be transported to shoot tissues via the transpiration stream. Treatment with HA lead to an increase in the content of polar lipids of photosynthetic membranes. The observed accumulation of labeled HA products in root endodermis and positive impact on lipid synthesis are consistent with prior reported observations on physiological effects of HS on plants such as enhanced growth and development of lateral roots and improvement/repairs of the photosynthetic status of plants under stress conditions.

  8. Label Distribution in Tissues of Wheat Seedlings Cultivated with Tritium-Labeled Leonardite Humic Acid

    Science.gov (United States)

    Kulikova, Natalia A.; Abroskin, Dmitry P.; Badun, Gennady A.; Chernysheva, Maria G.; Korobkov, Viktor I.; Beer, Anton S.; Tsvetkova, Eugenia A.; Senik, Svetlana V.; Klein, Olga I.; Perminova, Irina V.

    2016-01-01

    Humic substances (HS) play important roles in the biotic-abiotic interactions of the root plant and soil contributing to plant adaptation to external environments. However, their mode of action on plants remains largely unknown. In this study the HS distribution in tissues of wheat seedlings was examined using tritium-labeled humic acid (HA) derived from leonardite (a variety of lignites) and microautoradiography (MAR). Preferential accumulation of labeled products from tritiated HA was found in the roots as compared to the shoots, and endodermis was shown to be the major control point for radial transport of label into vascular system of plant. Tritium was also found in the stele and xylem tissues indicating that labeled products from tritiated HA could be transported to shoot tissues via the transpiration stream. Treatment with HA lead to an increase in the content of polar lipids of photosynthetic membranes. The observed accumulation of labeled HA products in root endodermis and positive impact on lipid synthesis are consistent with prior reported observations on physiological effects of HS on plants such as enhanced growth and development of lateral roots and improvement/repairs of the photosynthetic status of plants under stress conditions. PMID:27350412

  9. Understanding the mechanism of sweet taste: synthesis of tritium labeled guanidineacetic acids

    Energy Technology Data Exchange (ETDEWEB)

    Nagarajan, S.; Kellogg, M.S.; DuBois, G.E. (NutraSweet Company, Mt. Prospect, IL (United States)); Williams, D.S. (Amersham International plc, Cardiff (United Kingdom). Cardiff Labs.); Gresk, C.J.; Markos, C.S. (Searle Research and Development, Skokie, IL (United States))

    1992-08-01

    Syntheses of tritium labeled guanidineacetic acid sweetener and a tritiated photoaffinity labeling reagent via the catalytic hydrogenation of the dibromo intermediates are described. These labeled compounds were required for the investigation of sweet taste mechanism. (author).

  10. Understanding the mechanism of sweet taste: synthesis of tritium labeled guanidineacetic acids

    International Nuclear Information System (INIS)

    Nagarajan, S.; Kellogg, M.S.; DuBois, G.E.; Williams, D.S.

    1992-01-01

    Syntheses of tritium labeled guanidineacetic acid sweetener and a tritiated photoaffinity labeling reagent via the catalytic hydrogenation of the dibromo intermediates are described. These labeled compounds were required for the investigation of sweet taste mechanism. (author)

  11. Click synthesis of PET radiopharmaceuticals

    International Nuclear Information System (INIS)

    Xu Mei; Kuang Chunxiang

    2009-01-01

    Increasing attention has been focused on synthesis radiopharmaceuticals for positron emission tomography (PET). The recent years witnessed applications of click chemistry to PET radiopharmaceutical synthesis,because of its distinctive advantages including high speed,yield and stereospecificity under mild conditions. Synthesis of 18 F-labeled and 11 C-labeled radiopharmaceuticals and intermediates via click chemistry are reviewed. The future trend of click chemistry for the synthesis of PET radiopharmaceutical is prospected. (authors)

  12. labelling and quality control of some 99m Tc-radiopharmaceuticals of expected biological activity

    International Nuclear Information System (INIS)

    Abdallah, A.B.I.

    2009-01-01

    this thesis addresses the labelling and quality control of some 99m Tc-radiopharmaceuticals which could be used for infection imaging. this study focuses on the labelling of sarafloxation, gatifloxation and cefepine with technetium-99m and biological evaluation of these labeled complexes and biodistribution in both normal and inflamed mice. the thesis is organized into two chapters: chapter I :labelling of some antibiotics chapter II :biological evaluation.

  13. Recent Progress toward Microfluidic Quality Control Testing of Radiopharmaceuticals

    Directory of Open Access Journals (Sweden)

    Noel S. Ha

    2017-11-01

    Full Text Available Radiopharmaceuticals labeled with short-lived positron-emitting or gamma-emitting isotopes are injected into patients just prior to performing positron emission tomography (PET or single photon emission tomography (SPECT scans, respectively. These imaging modalities are widely used in clinical care, as well as in the development and evaluation of new therapies in clinical research. Prior to injection, these radiopharmaceuticals (tracers must undergo quality control (QC testing to ensure product purity, identity, and safety for human use. Quality tests can be broadly categorized as (i pharmaceutical tests, needed to ensure molecular identity, physiological compatibility and that no microbiological, pyrogenic, chemical, or particulate contamination is present in the final preparation; and (ii radioactive tests, needed to ensure proper dosing and that there are no radiochemical and radionuclidic impurities that could interfere with the biodistribution or imaging. Performing the required QC tests is cumbersome and time-consuming, and requires an array of expensive analytical chemistry equipment and significant dedicated lab space. Calibrations, day of use tests, and documentation create an additional burden. Furthermore, in contrast to ordinary pharmaceuticals, each batch of short-lived radiopharmaceuticals must be manufactured and tested within a short period of time to avoid significant losses due to radioactive decay. To meet these challenges, several efforts are underway to develop integrated QC testing instruments that automatically perform and document all of the required tests. More recently, microfluidic quality control systems have been gaining increasing attention due to vastly reduced sample and reagent consumption, shorter analysis times, higher detection sensitivity, increased multiplexing, and reduced instrumentation size. In this review, we describe each of the required QC tests and conventional testing methods, followed by a

  14. Exploration of new tritium labelling methods

    International Nuclear Information System (INIS)

    Andres, H.; Jaiswal, D.K.; Morimoto, H.; Saljoughian, M.; Than, C.; Willimas, P.G.; Zippi, E.M.

    1997-01-01

    Full text: A great deal of elegant chemistry is available for hydride transfer reactions, and could be adapted for tritium labelling. Nevertheless, most high level tritiation reactions still involve either hydrogenation (alkene or alkyne precursor) or catalytic dehalogenation. In the last decade we have endeavored to propose and popularize alternative labelling techniques and reagents, including: i) the synthesis of new precursors for the production of methyl iodide; ii) the synthesis of methylene diiodide; iii) the production and use of T 2 O, and solvents made from it, eg. CH 3 COOT, CF 3 COOT; iv) high specific activity hydride reagents, eg. LiAIT 4 , LiEt 3 BT; (Bu n ) 3 SnT, ZrCp 2 CIT, LiT, Li(OCH 3 ) 3 BT, Ph 2 SiT 2 , BT 3 -THF, Li/Na/KBT 4 ; v) reduction with diimide; vi) use of T 2 O in special reactions such as the Shapiro reaction and Brook rearrangement; and vii) developments of a new acetylation reagent. We have also initiated and continued a number of innovative applications of tritium NMR spectroscopy. Many of these projects have grown out of User or Collaborator requirements at the NTLF. We regard this stimulus to develop and refine both tritiation and NMR techniques as healthy and challenging

  15. Synthetic techniques of radiopharmaceuticals production labeled with C-11 for PET in cardiology

    Science.gov (United States)

    Dyubkov, V. S.; Ekaeva, I. V.; Katunina, T. A.; Rumyantsev, A. S.; Silchenkov, A. V.; Tuflina, T. V.

    2017-01-01

    Positron emission tomography (PET) and PET-Computerised Tomography (CT) are unique, non-invasive diagnostic techniques, in which the local, temporal and quantitative distributions of radioactive labelled substances are measured to investigate physiological processes. It is well known that PET centre of Bakulev Scientific Centre for Cardiovascular Surgery is the oldest one in Moscow. During more than fifteen years a large number of patients have received PET scans. Due to main stream of Scientific Centre, emphasis is placed on examining the heart functioning. For the diagnosis innervation of the heart muscle a number of radiopharmaceuticals are used, including PET radiopharmaceuticals such as 11C-CGP 12177, 11C-meta-hydroxyephedrine as well as its synthetic analogues labelled with other PET radionuclides (18F, 68Ga). 11C-meta-hydroxyephedrine is one of the most perspective radiopharmaceutical for an investigation of cardiac receptors function due to required materials availability for a radio synthesis in Russia. The main advantage of proposed 11C-meta-hydroxyephedrine synthesis technique is the use of a catalyst which allows one decrease reaction time from 5 minutes to 30 seconds. Obtained results allow one decrease reaction time of methylation and increase radiochemical and technological yields.

  16. Synthesis of carrier-free tritium-labeled queen bee pheromone

    International Nuclear Information System (INIS)

    Webster, F.X.; Prestwich, G.D.

    1988-01-01

    A short synthesis of [4,5- 3 H 2 ] (E)-9-oxo-2-decenoic acid (ODA), a high-specific-activity tritium-containing isotopomer of the queen bee pheromone, is described. Catalytic tritiation of the ketal of ethyl 9-oxo-4-decenoate introduces tritium into two positions, one of which is completely unactivated. Subsequent transformation by selenation, oxidation, and hydrolysis affords the labeled 9-ODA at >60 Ci/mmol. The material is suitable for biochemical studies of binding and catabolism in ovarian, antennal, and other target tissues

  17. Synthesis of high specific activity tritium labelled [2-3H]-adenosine-5'-triphosphate

    International Nuclear Information System (INIS)

    Jaiswal, D.K.; Morimoto, H.; Trump, E.L.; Williams, P.G.; Wemmer, D.E.

    1996-01-01

    A procedure for high level tritium labelling at the C2-H position of adenosine 5'-triphosphate ([2- 3 H]-ATP, 1), based on the tritiodehalogenation reaction of 2-bromoadenosine 5'-triphosphate (2) has been elaborated. This precursor was prepared in a six-step synthesis from guanosine. The tritiodehalogenation of (2) for three hours over palladium oxide in phosphate buffer yielded tritium labelled ATP with high specific activity, in good chemical yield. (author)

  18. Synthesis of tritium labelled nucleoside triphosphates by enzymatic phosphorylation

    International Nuclear Information System (INIS)

    Shen Decun; Ji Linzhen; Liao Sha

    1986-01-01

    [5- 3 H]UMP, [5- 3 H]CMP, [8- 3 H]AMP and [8- 3 H]GMP were prepared from 5BrUMP 5BrCMP 8BrAMP and 8BrGMP by catalytic halogentritium replacement at the same time. [5- 3 H]UTP, [5- 3 H]CTP, [8- 3 H]ATP and [8- 3 H]GTP were subsequently synthesized from [5- 3 H]UMP, [5- 3 H]CMP, [8- 3 H]AMP and [8- 3 H]GMP by enzymatic phosphorylation with the crude enzyme prepared from brewer's yeasts and purified by paper chromatography simultaneously. In addition, four kinds of tritium labelled nucleoside monophosphates and four kinds of tritium labelled nucleoside diphosphates were obtained as the by-products. The specific activity of these products is between 14-19 Ci/mmol and the radiochemical purity is more than 98%

  19. Determination of residual Kryptofix 2.2.2 levels in [18F]-labeled radiopharmaceuticals for human use

    International Nuclear Information System (INIS)

    Scott, Peter J.H.; Kilbourn, Michael R.

    2007-01-01

    4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane (Kryptofix 2.2.2) is used in the routine preparation of [ 18 F]-labeled tracers employed in positron emission tomography (PET) imaging. Confirming the absence of Kryptofix in radiopharmaceuticals is a quality control criterion required before they can be released for human use. Analysis of Kryptofix levels using the iodoplatinate spot-test can be complicated by false-positive results due to nitrogen containing tracers and/or false-negative results caused by added stabilizers. To overcome this issue, we have developed a universal TLC method for the rapid and reliable determination of Kryptofix levels in the wide range of fluorine-18 radiopharmaceuticals we prepare, including complex multi-component formulations

  20. Internal dosimetry of technetium-99m-labelled radiopharmaceuticals used in clinical nuclear medicine

    Energy Technology Data Exchange (ETDEWEB)

    Roedler, H D [Freie Univ. Berlin (Germany, F.R.). Klinikum Steglitz

    1977-01-01

    For radiopharmaceuticals labelled with /sup 99m/Tc, which is the most common short-lived radionuclide used in nuclear medicine, the possible dose reduction in comparison to other radionuclides for equal administered activities is deduced from the formalism of absorbed dose calculation and compared to the actually achieved decrease of absorbed dose for the most important radiopharmaceuticals. Absorbed doses per ..mu..Ci of administered activity are tabulated for the gonads, red bone marrow, and critical organs of the adult human, the newborn, and the child of 1, 5, 10, and 15 years.

  1. Environmental health-risk assessment for tritium releases from the National Tritium Labeling Facility (NTLF) at Lawrence Berkeley Laboratory

    Energy Technology Data Exchange (ETDEWEB)

    McKone, T.E.; Brand, K.P.

    1994-12-01

    This report is a health risk assessment that addresses continuous releases of tritium to the environment from the National Tritium Labeling Facility (NTLF) at the Lawrence Berkeley Laboratory (LBL). The NTLF contributes approximately 95% of all tritium releases from LBL. Transport and transformation models were used to determine the movement of tritium releases from the NRLF to the air, surface water, soils, and plants and to determine the subsequent doses to humans. These models were calibrated against environmental measurements of tritium levels in the vicinity of the NTLF and in the surrounding community. Risk levels were determined for human populations in each of these zones. Risk levels to both individuals and populations were calculated. In this report population risks and individual risks were calculated for three types of diseases--cancer, heritable genetic effects, and developmental and reproductive effects.

  2. Environmental health-risk assessment for tritium releases from the National Tritium Labeling Facility (NTLF) at Lawrence Berkeley Laboratory

    International Nuclear Information System (INIS)

    McKone, T.E.; Brand, K.P.

    1994-12-01

    This report is a health risk assessment that addresses continuous releases of tritium to the environment from the National Tritium Labeling Facility (NTLF) at the Lawrence Berkeley Laboratory (LBL). The NTLF contributes approximately 95% of all tritium releases from LBL. Transport and transformation models were used to determine the movement of tritium releases from the NRLF to the air, surface water, soils, and plants and to determine the subsequent doses to humans. These models were calibrated against environmental measurements of tritium levels in the vicinity of the NTLF and in the surrounding community. Risk levels were determined for human populations in each of these zones. Risk levels to both individuals and populations were calculated. In this report population risks and individual risks were calculated for three types of diseases--cancer, heritable genetic effects, and developmental and reproductive effects

  3. Quantitation of images from a multiwire camera for autoradiography of tritium-labelled substances

    International Nuclear Information System (INIS)

    Lockett, S.J.; Ramsden, D.B.; Bradwell, A.R.

    1987-01-01

    It has been shown that tritium-labelled substances in two-dimensional systems can be quantitated using a multiwire camera. Its accuracy has now been improved by correcting results for non-uniformity of response over the detection area. Uniformity was assessed by imaging plates of nominally uniform activity. The results were then used to correct images from plates containing tritium-labelled proteins using a computer program. Errors were reduced from 11.3 (+ -6.1) to 7.7 (+ - 2.8)% for standard sources and from 6.2 (+ - 1.8) to 1.9 (+ -0.6)% for a plate containing the labelled proteins. The conducting carbon layer covering the plate absorbed 36 (+ - 3)% of the tritium beta radiation and was estimated to be 85 nm in thickness. Quantitation of the labelled proteins by the camera gave a good correlation with protein content (chi-squared: 30-40%). The activities of the protein samples were measured to an accuracy of 10% by comparison with standard sources. These results indicate useful quantitation of tritiated compounds in two-dimensional media using the multiwire camera. (author)

  4. Tritium transport calculations for the IFMIF Tritium Release Test Module

    Energy Technology Data Exchange (ETDEWEB)

    Freund, Jana, E-mail: jana.freund@kit.edu; Arbeiter, Frederik; Abou-Sena, Ali; Franza, Fabrizio; Kondo, Keitaro

    2014-10-15

    Highlights: • Delivery of material data for the tritium balance in the IFMIF Tritium Release Test Module. • Description of the topological models in TMAP and the adapted fusion-devoted Tritium Permeation Code (FUS-TPC). • Computation of release of tritium from the breeder solid material into the purge gas. • Computation of the loss of tritium over the capsule wall, rig hull, container wall and purge gas return line. - Abstract: The IFMIF Tritium Release Test Module (TRTM) is projected to measure online the tritium release from breeder ceramics and beryllium pebble beds under high energy neutron irradiation. Tritium produced in the pebble bed of TRTM is swept out continuously by a purge gas flow, but can also permeate into the module's metal structures, and can be lost by permeation to the environment. According analyses on the tritium inventory are performed to support IFMIF plant safety studies, and to support the experiment planning. This paper describes the necessary elements for calculation of the tritium transport in the Tritium Release Test Module as follows: (i) applied equations for the tritium balance, (ii) material data from literature and (iii) the topological models and the computation of the five different cases; namely release of tritium from the breeder solid material into the purge gas, loss of tritium over the capsule wall, rig hull, container wall and purge gas return line in detail. The problem of tritium transport in the TRTM has been studied and analyzed by the Tritium Migration Analysis Program (TMAP) and the adapted fusion-devoted Tritium Permeation Code (FUS-TPC). TMAP has been developed at INEEL and now exists in Version 7. FUS-TPC Code was written in MATLAB with the original purpose to study the tritium transport in Helium Cooled Lead Lithium (HCLL) blanket and in a later version the Helium Cooled Pebble Bed (HCPB) blanket by [6] (Franza, 2012). This code has been further modified to be applicable to the TRTM. Results from the

  5. Tritium transport calculations for the IFMIF Tritium Release Test Module

    International Nuclear Information System (INIS)

    Freund, Jana; Arbeiter, Frederik; Abou-Sena, Ali; Franza, Fabrizio; Kondo, Keitaro

    2014-01-01

    Highlights: • Delivery of material data for the tritium balance in the IFMIF Tritium Release Test Module. • Description of the topological models in TMAP and the adapted fusion-devoted Tritium Permeation Code (FUS-TPC). • Computation of release of tritium from the breeder solid material into the purge gas. • Computation of the loss of tritium over the capsule wall, rig hull, container wall and purge gas return line. - Abstract: The IFMIF Tritium Release Test Module (TRTM) is projected to measure online the tritium release from breeder ceramics and beryllium pebble beds under high energy neutron irradiation. Tritium produced in the pebble bed of TRTM is swept out continuously by a purge gas flow, but can also permeate into the module's metal structures, and can be lost by permeation to the environment. According analyses on the tritium inventory are performed to support IFMIF plant safety studies, and to support the experiment planning. This paper describes the necessary elements for calculation of the tritium transport in the Tritium Release Test Module as follows: (i) applied equations for the tritium balance, (ii) material data from literature and (iii) the topological models and the computation of the five different cases; namely release of tritium from the breeder solid material into the purge gas, loss of tritium over the capsule wall, rig hull, container wall and purge gas return line in detail. The problem of tritium transport in the TRTM has been studied and analyzed by the Tritium Migration Analysis Program (TMAP) and the adapted fusion-devoted Tritium Permeation Code (FUS-TPC). TMAP has been developed at INEEL and now exists in Version 7. FUS-TPC Code was written in MATLAB with the original purpose to study the tritium transport in Helium Cooled Lead Lithium (HCLL) blanket and in a later version the Helium Cooled Pebble Bed (HCPB) blanket by [6] (Franza, 2012). This code has been further modified to be applicable to the TRTM. Results from the

  6. Tritium labeling of detonation nanodiamonds.

    Science.gov (United States)

    Girard, Hugues A; El-Kharbachi, Abdelouahab; Garcia-Argote, Sébastien; Petit, Tristan; Bergonzo, Philippe; Rousseau, Bernard; Arnault, Jean-Charles

    2014-03-18

    For the first time, the radioactive labeling of detonation nanodiamonds was efficiently achieved using a tritium microwave plasma. According to our measurements, the total radioactivity reaches 9120 ± 120 μCi mg(-1), with 93% of (3)H atoms tightly bonded to the surface and up to 7% embedded into the diamond core. Such (3)H doping will ensure highly stable radiolabeled nanodiamonds, on which surface functionalization is still allowed. This breakthrough opens the way to biodistribution and pharmacokinetics studies of nanodiamonds, while this approach can be scalable to easily treat bulk quantities of nanodiamonds at low cost.

  7. Inhibition of viability of microorganisms in [18F]-labeled radiopharmaceuticals

    International Nuclear Information System (INIS)

    Jörg, G.; Fosselmann, M.; Leis, W.; Oberdorfer, F.; Fehsenfeld, Ch.

    2017-01-01

    Introduction: Good manufacturing practice (GMP)-compliant production of radiopharmaceuticals for parenteral application requires great efforts in maintenance of clean room infrastructure and equipment in order to reliably guarantee the constant hygienic quality of the product (sterility). Terminal sterilization of the product is not always possible due to short half-life or due to thermal instability of the compound. The typical method for sterilization in these cases is sterile filtration prior to dispensing (distribution of product solution from bulk to patient vials). Therefore, aseptic processing techniques have to be in place in order to ensure sterility. Still, there remains some risk of microbial contamination of the product, and hence a risk for the patient to suffer from infection. Due to the short half-life of the labeling radionuclides, this aspect is aggravated by only retrospectively possible testing for sterility. This work investigated the potential of [ 18 F]-radiation to intrinsically inactivate microorganisms (MO) that might have slipped through the aseptic process. Methods: Defined numbers of viable cells of different bacterial strains and molds were incubated with defined amounts of [ 18 F]-activity. After decay of radiation the number of surviving viable cells was determined, D 10 -values were calculated and evaluated. Results: The MOs tested exhibit a broad range of [ 18 F]-radiation susceptibility, D 10 -values range from a sensitive 114 MBq/mL (46 Gy) to a durable 2,048 MBq/mL (790 Gy). Conclusion: The intrinsic [ 18 F]-radiation in radiopharmaceuticals is no safe measure to generally ensure sterility of the product solution in terms of “autosterilization”, because of dependence on various parameters. Advances in knowledge and implications for patient care: This work presents for the first time experimental data on the influence of [ 18 F]-radiation on MOs. The results suggest, that aseptic processing techniques are essential and that

  8. Kinetic isotope effects in reaction of ferment oxidation of tritium-labelled D-galactosamine

    International Nuclear Information System (INIS)

    Akulov, G.P.; Korsakova, N.A.

    1992-01-01

    Primary, secondary and intramolecular kinetic isotopic effects in reaction of ferment oxidation of D-galactosamine labelled by tritium in position 6, were measured. When comparing values of the effects with previously obtained results for similar reaction D-[6- 3 H]galactose, it was ascertained that the presence of aminogroup in galactopyranosyl mainly affects kinetics of substrate-ferment complex formation stage. The possibility to use kinetic isotope effects for increase in molar activity of D-galactosamine, labelled by tritium in position 6, is shown

  9. Ligand exchange chromatography for analysis and preparative separation of tritium-labelled amino acids

    International Nuclear Information System (INIS)

    Zolotarev, Yu.A.; Zaitsev, D.A.; Penkina, V.I.; Dostavalov, I.N.; Myasoedov, N.F.

    1988-01-01

    Racemic tritium-labelled amino acids were separated into optical isomers by chromatography on a chiral polyacrylamide sorbent filled with copper ions. The polyacrylamide sorbent is synthesized by Mannich's reaction through the action of formaldehyde and L-phenylalanine upon polyacrylamide Biogel P-4 in an alkali phosphate buffer. Tritium-labelled amino acids are eluted by a weak alkali solution of ammonium carbonate. Data are presented on the ligand exchange chromatography of amino acids depending on the degree to which the sorbent is filled with copper ions and on the eluent concentration. Amino acids are isolated from the eluent on short columns filled with sulfonated cation exchanger in the H + form. HPLC on modified silica gel sorbents is also used for the analysis of tritium-labelled optically active amino acids. Amino acids are eluted by a weakly acidic water-methanol solution containing ammonium acetate. UV and scintillation flow type detectors are used. (author) 7 refs.; 8 figs

  10. Results of quality control studies of technetium 99m labelled radiopharmaceuticals prepared from kits

    International Nuclear Information System (INIS)

    McLean, J.R.; Rockwell, L.J.; Welsh, W.J.

    1978-01-01

    This report summarizes the results of quality control studies of Tc 99m labelled normal serum albumin and macro-aggregated albumin radiopharmaceuticals prepared from commercially available kits. It includes all analyses performed since the inception of the program in 1976 until the end of 1977. The results presented herein were obtained through the application of various in vitro tests and animal (mouse) bio-distribution studies. It is hoped that a similar report will be published annually for the benefit of hospital nuclear medicine departments and kit manufacturers. (auth)

  11. Development of tritium technology at the Tritium Systems Test Assembly

    International Nuclear Information System (INIS)

    Anderson, J.L.; Bartlit, J.R.

    1982-01-01

    The Tritium Systems Test Assembly (TSTA) at the Los Alamos National Laboratory is dedicated to the development, demonstration, and interfacing of technologies related to the deuterium-tritium fuel cycle for large scale fusion reactor systems starting with the Fusion Engineering Device (FED) or the International Tokamak Reactor (INTOR). This paper briefly describes the fuel cycle and safety systems at TSTA including the Vacuum Facility, Fuel Cleanup, Isotope Separation, Transfer Pumping, Emergency Tritium Cleanup, Tritium Waste Treatment, Tritium Monitoring, Data Acquisition and Control, Emergency Power and Gas Analysis systems. Discussed in further detail is the experimental program proposed for the startup and testing of these systems

  12. A convenient method to synthesize specifically labelled cholesterol with tritium

    International Nuclear Information System (INIS)

    Malik, S.; Kenny, M.; Ahmad, S.; Washington Univ., Seattle, WA

    1992-01-01

    A simple method is described to label cholesterol with tritium. Cholesterol was first oxidized to 5-cholesten-3-one which was then purified by HPLC. Its structure was established by electron impact (EI) mass spectrometry and 1 H-NMR spectroscopy. The ketone was reduced with NaB 3 H 4 to give specifically labelled cholesterol (C-3 3 H) at low specific activity. (author)

  13. Results of quality control studies of technetium 99m labelled radiopharmaceuticals prepared from kits (1980-81)

    International Nuclear Information System (INIS)

    1983-01-01

    This report summarized the results of quality control studies of Tc 99m labelled human serum albumin, macroaggregated albumin, bone imaging and reticuloendothelial system imaging radiopharmaceuticals prepared from commercially available kits. It includes all analyses performed from January 1980 to December 1981 by the radiopharmaceutical quality control section of the Radiation Protection Bureau. These results were obtained by the application of various in vitro and animal (mouse) biodistribution studies

  14. Results of the quality assurance testing program for radiopharmaceuticals 1995

    Energy Technology Data Exchange (ETDEWEB)

    Baldas, J.; Binnyman, J.; Ivanov, Z.; Lauder, R.

    1996-07-01

    The results of the quality assurance testing conducted by the Australian Radiation Laboratory is summarised. Overall 111 batches of 27 different types of radiopharmaceuticals were tested on samples obtained through normal commercial channels. Failure to meet full specifications was observed in 10 of the 111 batches. All technetium-99m cold kits were reconstituted according to the directions in the package insert using sodium pertechnetate ( {sup 99m}Tc) injection. Radionuclidic purity has been determined at the calibration time, except for Thallous [{sup 201}Tl] Chloride injection where the highest impurity level up to product expiry is quoted. Non-compliance of the vial label was observed in one of the ten batches failing specification and was the sole cause of product failure for this batch. Vial label non-compliance consisted of, absence of volume in the vial. Six batches failed the biodistribution test but in no case did this involve failure of the distribution for the target organs. tabs.

  15. Results of the quality assurance testing program for radiopharmaceuticals 1995

    International Nuclear Information System (INIS)

    Baldas, J.; Binnyman, J.; Ivanov, Z.; Lauder, R.

    1996-07-01

    The results of the quality assurance testing conducted by the Australian Radiation Laboratory is summarised. Overall 111 batches of 27 different types of radiopharmaceuticals were tested on samples obtained through normal commercial channels. Failure to meet full specifications was observed in 10 of the 111 batches. All technetium-99m cold kits were reconstituted according to the directions in the package insert using sodium pertechnetate ( 99m Tc) injection. Radionuclidic purity has been determined at the calibration time, except for Thallous [ 201 Tl] Chloride injection where the highest impurity level up to product expiry is quoted. Non-compliance of the vial label was observed in one of the ten batches failing specification and was the sole cause of product failure for this batch. Vial label non-compliance consisted of, absence of volume in the vial. Six batches failed the biodistribution test but in no case did this involve failure of the distribution for the target organs. tabs

  16. Synthesis of deuterium and tritium labelled tyrosine

    International Nuclear Information System (INIS)

    Kanska, M.; Drabarek, S.

    1980-01-01

    A new method of synthesis of tyrosine labelled with deuterium and tritium in the aromatic ring has been developed. Deuterated and tritiated tyrosine was obtained by isotope exchange between tyrosine and deuterated or tritiated water at elevated temperature in hydrochloric acid medium using K 2 PtCl 4 as a catalyst. For synthesis of tritiated tyrosine 1 Ci HTO was used; the specific activity of the product was 5 mCi/mMol. (author)

  17. Tritium labelling and characterization of the antimalarial drug (+/-)-chloroquine by several methods

    Energy Technology Data Exchange (ETDEWEB)

    Egan, J.A.Judith A.; Laseter, Anne G; Filer, C.N.Crist N. E-mail: crist.filer@perkinelmer.com

    2002-09-01

    To study its mechanism of antimalarial action, a tritium labelled analogue of (+/-)-chloroquine was required at high specific activity. Two synthetic methods were successfully employed. [3-{sup 3}H] (+/-)-Chloroquine 2 was prepared by the catalytic tritium dehalogenation of an iodo precursor and [N-ethyl-{sup 3}H] (+/-)-chloroquine 4 was synthesized by the alkylation of (+/-)-desethylchloroquine with [{sup 3}H] ethyl iodide.

  18. Tritium labelling and characterization of the antimalarial drug (+/-)-chloroquine by several methods

    International Nuclear Information System (INIS)

    Egan, J.A.Judith A.; Laseter, Anne G.; Filer, C.N.Crist N.

    2002-01-01

    To study its mechanism of antimalarial action, a tritium labelled analogue of (+/-)-chloroquine was required at high specific activity. Two synthetic methods were successfully employed. [3- 3 H] (+/-)-Chloroquine 2 was prepared by the catalytic tritium dehalogenation of an iodo precursor and [N-ethyl- 3 H] (+/-)-chloroquine 4 was synthesized by the alkylation of (+/-)-desethylchloroquine with [ 3 H] ethyl iodide

  19. Synthesis of molecules of biological interest labelled with high specific activity tritium

    International Nuclear Information System (INIS)

    Petillot, Yves

    1975-01-01

    Labelled molecules are artificial organic compounds possessing one or several radioactive or steady isotopic atoms. Using tritium to label molecules presents several benefits: a raw material easy to obtain with a high purity and at reasonable cost; synthesised labelled molecules displaying high specific activities very interesting in molecular biology; high resolution of radiographies; relatively simple and quick introduction of tritium atoms in complex molecules. Thus, this report for graduation in organic chemistry addresses the synthesis and study of new labelled molecules which belong to families of organic compounds which have fundamental activities in biology: uridine 3 H-5,6 and thymidine 3 H-methyl which are nucleotides which intervene under the form of phosphates in the synthesis of nucleic acids, oestradiol 3 H-2,4,6,7 which is a powerful estrogenic hormone which naturally secreted by the ovary; and noradrenaline 3 H-1,1' and dopamine 3 H-1,2 which are usually secreted by adrenal medulla and have multiple actions on the nervous system

  20. A new method for tritium labelling of neuraminidase from Vibrio cholerae

    International Nuclear Information System (INIS)

    Keune, D.

    1981-01-01

    This research work related to the radioactive labelling with tritium of the enzyme neuraminidase from Vibrio cholerae by an easily handled method. The reactive compound N-propionyloxysuccinimide, the ester of propionic acid and N-hydroxysuccinimide, offered a suitable labelling reagent. For comparison purposes an already known method of labelling neuraminidase with tritium by the oxidation of hydroxyl groups of the hydrocarbon chain of the enzymal protein and subsequent reduction of the aldehyde groups formed with tritiated sodium borhydride, was also carried out. The advantages and disadvantages of both methods are described in detail, in particular with regard to yields of radioactivity and the influence on enzyme activity. The fact that only 1 mg enzymal protein was available for each modification of the enzyme molecule posed particular problems and, as a consequence, extensive preliminary experiments had to be carried with another protein (beef serum album) in the same concentration range. (orig./MG) [de

  1. Synthesis and labeling 5'-O-(4-4'-dimetoxytrityl) -2,3-anhidrothymidine for preparation of radiopharmaceutical [18F]FLT

    International Nuclear Information System (INIS)

    Purwoko; Maskur; Chaeruman; Sugiarto, Yono

    2013-01-01

    It is has been known that the compound of 3'-deoxy-3,-( 18 F] Fluorothymidine or ( 18 F] FLT is a thymidine derivative radiopharmaceutical used for cancer detection based on DNA metabolism. Synthesis and labeling of 5'-0-(4,4 '-dimetoxytrityl) -2,3' anhidrothymidine precursor for preparation of the radiopharmaceutical [ 18 F]FL T was carried out. The precursor was synthesized in similar manner and procedure literature and it have been obtained a crystalline product with total yield of 32,4 %. The chemical purity of the product which determined by HPLC was found to be more than 95%. Characterization of the product was done by observing the results of the LC / MS and 1 H-NMR test, the resulted data were found to be very closed to those reported in the literature. Labeling of the precursor was done by nucleophilic fluorination reactions using 18 Fluoride at 160 °C for 15 minutes with kryptofix 2.2.2 catalyst followed hydrolysis using HCI at 100 °C for 10 minutes and then neutralized with NaOH. Purification [ 18 F]FLT was performed by single cartridge Alumina-N as a substitute HPLC methods. The results have been obtained a label compound [ 18 F]FLT with high purity as a bulk for preparation of the radiopharmaceutical [ 18 F]FLT. The label compound of [ 18 F]FLT undergone a quality test which included a clarity, pH and a radiochemical purity. The results of quality control on four batches of [ 18 F]FLT showed that these products were colorless clear solution with pH between 6.0-7.5, and radiochemical purity 97.93 ± 1,48% and showed that the label compounds have been obtained [ 18 F]FLT-free particles form a clear solution with a pH between 6,0 - 7,5, radiochemical purity of 97.93 ± 1,48 %, radiochemical yields 8.18 ± 1.54% (decay uncorrected) and processing time 73 ± 4 minutes. (author)

  2. A general method for tritium labelling of benzimidazole carbamates by catalytic exchange in dioxane solutions

    Energy Technology Data Exchange (ETDEWEB)

    Lacey, E [Commonwealth Scientific and Industrial Research Organization, Glebe, NSW (Australia). Div. of Animal Health, McMaster Lab.; Dawson, M [Sydney Univ. (Australia). Dept. of Pharmacy; Long, M A; Than, C [New South Wales Univ., Kensington (Australia). School of Chemistry

    1989-12-01

    Benzimidazole carbamates (BZCs) act as inhibitors of the tubulin-microtubule equilibria in eukaryotic organisms. Recently drug resistance to this class of compounds in helminth parasites has been shown to be due to a reduced ability of resistant tubulin to bind BZCs. In order to quantitate the nature of the tubulin-BZC interaction a general method for the specific tritium labelling of BZCs has been developed. The BZCs: mebendazole, oxfendazole, parbendazole, oxibendazole, albendazole and fenbendazole were labelled by catalytic exchange using palladium on calcium carbonate in pure dioxane at 60{sup 0}C under tritium gas. The position of label incorporation for tritiated albendazole was determined by tritium-NMR as the 4-position of benzimadazole nucleus. The yields for individual BZCs varied from 8 to 68% for a range of specific activity of 0.44 to 13.4 Ci/mmole. (author).

  3. A general method for tritium labelling of benzimidazole carbamates by catalytic exchange in dioxane solutions

    International Nuclear Information System (INIS)

    Lacey, E.; Dawson, M.; Long, M.A.; Than, C.

    1989-01-01

    Benzimidazole carbamates (BZCs) act as inhibitors of the tubulin-microtubule equilibria in eukaryotic organisms. Recently drug resistance to this class of compounds in helminth parasites has been shown to be due to a reduced ability of resistant tubulin to bind BZCs. In order to quantitate the nature of the tubulin-BZC interaction a general method for the specific tritium labelling of BZCs has been developed. The BZCs: mebendazole, oxfendazole, parbendazole, oxibendazole, albendazole and fenbendazole were labelled by catalytic exchange using palladium on calcium carbonate in pure dioxane at 60 0 C under tritium gas. The position of label incorporation for tritiated albendazole was determined by tritium-NMR as the 4-position of benzimadazole nucleus. The yields for individual BZCs varied from 8 to 68% for a range of specific activity of 0.44 to 13.4 Ci/mmole. (author)

  4. Synthesis of two tritium-labeled derivatives of a vasopressin antagonist peptide

    International Nuclear Information System (INIS)

    Landvatter, S.W.; Heys, J.R.

    1986-01-01

    SK and F 101926, a potent vasopressin antagonist, has been tritium labeled in the tyrosine residue via exchange followed by solid phase coupling to a hexapeptide. The peptide thus obtained was subsequently coupled with a PMP residue, cleaved from the resin with HF, oxidized by ferricyanide and purified by HPLC giving the desired cyclic peptide. Alternatively, a labeled PMP residue can be prepared via reduction starting from phenol. Conversion of the labeled cyclohexanone to PMP followed by solid phase coupling to a heptapeptide can then afford PMP labeled peptide. 3 refs

  5. Radiopharmaceutical development

    International Nuclear Information System (INIS)

    Zielinski, F.W.; Robinson, G.D. Jr.; MacDonald, N.S.

    1976-01-01

    Progress is reported in the following areas of research: compact cyclotron production of 123 I iodide for radiopharmaceutical synthesis; synthesis of 123 I-labeled compounds for myocardial imaging and evaluation of kidney and liver functions; 62 Cu: a short-lived, generator-produced, positron emitting radionuclide for radiopharmaceuticals; dry radioaerosols for lung airway imaging; and improved particulate agents for perfusion imaging

  6. Radiopharmaceuticals for thrombus detection

    International Nuclear Information System (INIS)

    Knight, L.C.

    1990-01-01

    Most of the components of the thrombotic and fibrinolytic systems have at some time been evaluated as a means of carrying a radiolabel specifically to thrombi, although very few have been promising enough to emerge from investigational status to routine clinical use. New approaches are being explored, including improved methods of labeling platelets, chemically modified forms of previously tested plasma proteins, and new biomolecules, including monoclonal antibodies specific for fibrin and platelets. The current goal is to find one or more radiotracers that bind specifically and rapidly to thrombi, and that also have a rapid blood disappearance rate, permitting a clear diagnosis within a few hours after injection. Because this test may be needed to assess the course of therapy in an anticoagulated patient, the ideal radiopharmaceutical should be able to locate thrombi without interference by anticoagulants. Until a suitable thrombus-specific radiopharmaceutical becomes generally available, many hospitals will continue to attempt to make a diagnosis with nonspecific radiopharmaceuticals that can at best provide blood pool images to indicate filling defects. Several of the new approaches seem likely to provide the radiopharmaceutical sought, although clinical trials are at an early stage.137 references

  7. Chromatographic analysis and purification of multiply tritium-labelled eicosanoids

    International Nuclear Information System (INIS)

    Shevchenko, V.P.; Nagaev, I.Yu.; Myasoedov, N.F.

    1988-01-01

    A comparative study of different chromatographic techniques (gas-liquid (GLC), thin-layer (TLC), liquid (LC), high-pressure liquid (HPLC) chromatography) is presented. They were applied to the analysis and preparative purification of tritium-labelled eicosanoids with a molar radioactivity of 1.8-8.8 TBq/mmol, obtained by selective hydrogenation and by chemical or enzymic methods. The possibility of analyzing reaction mixtures and isolating individual multiply labelled eicosanoids with a chemical and radiochemical purity of 95-98% was demonstrated. Special features of HPLC for high molar radioactivity eicosanoids are considered. (author) 9 refs.; 6 tabs

  8. Quality assurance of radiopharmaceuticals - specifications and test procedures

    International Nuclear Information System (INIS)

    Baldas, J.; Bonnyman, J.; Colmanet, S.F.; Ivanov, Z.; Lauder, R.A.

    1990-10-01

    The authors report on a Radiopharmaceutical Quality Assurance Test Programme carried out by the Australian Radiation Laboratory in which radiopharmaceuticals used in nuclear medicine in Australia are tested for compliance with specifications. Where the radiopharmaceutical is the subject of a monograph in the British Pharmacopoeia or the European Pharmacopoeia, then the specifications given in the Pharmacopoeia are adopted. In other cases the specifications given have been adopted by this Laboratory and have no legal status. In some cases test procedures described have been taken from various Pharmacopoeias or methods published in the literature. In other cases test methods described have been developed at this Laboratory. It should be noted that, unless stated otherwise, specifications listed apply at all times up until product expire

  9. A study on bacterial endotoxins test of radiopharmaceuticals with limulus agent

    Energy Technology Data Exchange (ETDEWEB)

    Suozhen, Bai; Kai, Luyu; Cheng, Luo [Academia Sinica, Beijing, BJ (China). Inst. of Atomic Energy; Ruiting, Zhang; Zhenmin, Xia [National Inst. for the Control of Pharmaceutical and Biological Products (China)

    1989-08-01

    The feasibility of endotoxins test of radiopharmaceuticals with limulus agent and the approach to take off the inhibition/enhancement effect of radiopharmaceuticals on limulus agent have been studied. Results of the test for 8 radiopharmaceuticals have been given.

  10. Design and test about de tritium system to filling tritium glove box

    International Nuclear Information System (INIS)

    Lei, Jiarong; Du, Yang; Yang, Yong

    2008-01-01

    In order to deal tritium permeated from inflating tritium system at the scene of inflating tritium, dealing waste tritium gas system was designed according to demand and action of dealing waste tritium gas from inflating tritium, and the data of character and volume about appliance of catalyst reaction and drying agent was calculated. Through the test at the scene of inflating tritium, it is result that dealing waste tritium gas system's efficiency reaches above 85% average in circulatory system, so that it can be used in practice extensively. (author)

  11. Radiopharmaceuticals in Czechoslovakia

    International Nuclear Information System (INIS)

    Hron, M.; Kronrad, L.; Svoboda, K.; Melichar, F.

    1986-01-01

    The history is briefly described of the production of radiopharmaceuticals in Czechoslovakia for nuclear medicine purposes. 131 I-labelled orthoiodohippurate and rose Bengal were first produced. Currently, 99m Tc is the most frequently requested radionuclide for radiopharmaceutical labelling. The preparation of 99m Tc is described in detail, a flow chart is shown and the network of 99m Tc distribution to hospitals outlined. In addition of 99m Tc and 131 I, UJV Rez produces other radionuclides for nuclear medicine, such as 113m In, 67 Ga, 35 S, 32 P, 203 Hg, 85 Sr. The methods are being developed of the production of 201 Tl, 125 I and 131 I-labelled bromosulfophthalein. (E.S.)

  12. Preparation of carbon 11-labelled radiopharmaceuticals by the use of HPLC method

    International Nuclear Information System (INIS)

    Berget, G.; Maziere, M.; Godot, J.M.; Sastre, J.; Prenant, C.; Comar, D.

    1982-06-01

    Various medical examinations and metabolic studies are carried out with carbon 11-labelled radiopharmaceuticals. This radioelement offers a number of advantages: it can be introduced into an organic molecule without changing its properties; the radiation dose delivered to the patient is low (T = 20 mn); since the specific activity obtained is high (0.5 to 2 Ci/μ mole) the injected masses are very small; finally, tomographic images of the distribution of the product in the body may be obtained by the use of positron cameras. However in view of the radioactivities handled on a routine basis the preparations must be carried out without manual intervention, in closed shielded hoods. Synthesis methods and special equipment have been developed. In all cases the reaction mixtures are purified by HPLC, a method chosen for its speed, efficiency, ease of automation and adaptation to any product with a suitable choice of column and eluant. The radiopharmaceuticals are obtained in injectable solution (ethanol-physiological serum, buffered physiological serum) or in a mixture of volatile solvents which are evaporated by nitrogen bubbling and finally sterilised by passage over millipore filter. About ten different radiopharmaceuticals are prepared in this way in the laboratory [fr

  13. Investigations with tritium-labelled glycerol of the triglyceride metabolism in patients

    International Nuclear Information System (INIS)

    Leonhardt, W.; Julius, U.; Koch, R.; Schulze, J.

    1980-01-01

    Triglycerides, being components of lipoproteins, are secreted by the liver into the blood and climinated from the blood by adipose and muscle tissue. The kinetics of this metabolic pathway were studied after injection of tritium-labelled glycerol which is incorporated into triglycerides by the liver. The serum triglyceride radioactivity-time curve was analysed with a computer. 99 examinations showed a decrease of the fractional turnover rate and an increase of the turnover rate with the triglyceride level. The test enables to decide whether an increased triglyceride concentration is caued by overproduction or by disturbed climination. (author)

  14. Possible artefacts in thin layer chromatography of tritium-labelled hydrocortisone

    International Nuclear Information System (INIS)

    Sofronie, E.

    1982-12-01

    Artefacts appearing in thin layer chromatography of tritium labelled hydrocortisone are reported. Evidences are presented that these artefacts cause misleading results concerning radiocheemical purity determiniation. Finally, it is reported a rapid and efficient chromatographic technique allowing the elimination of these artefacts and obtaining of an accurate value for radiochemical purity. (author)

  15. Radiopharmaceuticals

    International Nuclear Information System (INIS)

    Kristensen, K.

    1988-01-01

    Different forms of radiopharmaceuticals such as radioactive gases, aerosols and colloids used for diagnostic techniques and radiotherapy and methods of labelling them are discussed. Some reference is made to their documentation, handling and quality control. (U.K.)

  16. The tritium labelling of organic molecules by heterogeneous catalytic exchange

    International Nuclear Information System (INIS)

    Angoso, M.; Kaiser, F.

    1977-01-01

    The influence of the temperature at 65degC and 120degC on the labelling of three organic molecules with tritium was studied. The compounds were: benzoic acid, diphenyl glioxal and 2,3-tetramethylene-4-phenylthien-7-oxodiacetin. The method employed was the heterogeneous catalytic exchange between tritiaded water and the organic compound. The purification was made by thin-layer chromatography and the concentration, purity and specific activity of the products were determined by counting and ultraviolet techniques. The thermal stability and the radiolitic effects on labelled benzoic acid were also considered. (author) [es

  17. Overview of tritium processing development at the tritium systems test assembly

    International Nuclear Information System (INIS)

    Anderson, J.L.

    1986-01-01

    The Tritium Systems Test Assembly (TSTA) at the Los Alamos National Laboratory has been operating with tritium since June 1984. Presently there are some 50 g of tritium in the main processing loop. This 50 g has been sufficient to do a number of experiments involving the cryogenic distillation isotope separation system and to integrate the fuel cleanup system into the main fuel processing loop. In January 1986 two major experiments were conducted. During these experiments the fuel cleanup system was integrated, through the transfer pumping system, with the isotope separation system, thus permitting testing on the integrated fuel processing loop. This integration of these systems leaves only the main vacuum system to be integrated into the TSTA fuel processing loop. In September 1986 another major tritium experiment was performed in which the integrated loop was operated, the tritium inventory increased to 50 g and additional measurements on the performance of the distillation system were taken. In the period June 1984 through September 1986 the TSTA system has processed well over 10 8 Ci of tritium. Total tritium emissions to the environment over this period have been less than 15 Ci. Personnel exposures during this period have totaled less than 100 person-mRem. To date, the development of tritium technology at TSTA has proceeded in progressive and orderly steps. In two years of operation with tritium, no major design flows have been uncovered

  18. Tritium Systems Test Facility. Volume I

    International Nuclear Information System (INIS)

    Anderson, G.W.; Battleson, K.W.; Bauer, W.

    1976-10-01

    Sandia Laboratories proposes to build and operate a Tritium Systems Test Facility (TSTF) in its newly completed Tritium Research Laboratory at Livermore, California (see frontispiece). The facility will demonstrate at a scale factor of 1:200 the tritium fuel cycle systems for an Experimental Power Reactor (EPR). This scale for each of the TSTF subsystems--torus, pumping system, fuel purifier, isotope separator, and tritium store--will allow confident extrapolation to EPR dimensions. Coolant loop and reactor hall cleanup facilities are also reproduced, but to different scales. It is believed that all critical details of an EPR tritium system will be simulated correctly in the facility. Tritium systems necessary for interim devices such as the Ignition Test Reactor (ITR) or The Next Step (TNS) can also be simulated in TSTF at other scale values. The active tritium system will be completely enclosed in an inert atmosphere glove box which will be connected to the existing Gas Purification System (GPS) of the Tritium Research Laboratory. In effect, the GPS will become the scaled environmental control system which otherwise would have to be built especially for the TSTF

  19. CNS active ergot alkaloid dihydro derivatives. Tritium labelling and characterization

    International Nuclear Information System (INIS)

    Egan, J.A.; Nugent, R.P.; Filer, C.N.

    2016-01-01

    The ergot alkaloids are an important class of medicinally useful substances and this report describes the high specific activity tritium labelling of two dihydro derivatives; namely, dihydroergotamine and dihydrobromocriptine. The former was prepared by the direct tritiation of ergotamine itself. However, efforts to perform an analogous direct tritiation on bromocriptine were unsuccessful and a multistep synthesis was required. (author)

  20. Quality assurance of radiopharmaceuticals

    International Nuclear Information System (INIS)

    Frier, M.; Hesslewood, S.R.

    1980-01-01

    A practical guide has been composed for all persons involved in the preparation and use of radiopharmaceuticals on methods used in quality assurance and their applications. These methods include the calibration of ionization chamber assay calibrators, the determination of radionuclide purity, radiochemical purity and chemical purity, particle size analysis and the measurement of pH. Quality assurance procedures are described for products not described in Compendial Monographs, or where the monograph exists, additional useful information is provided; such radiopharmaceuticals include technetium, indium-labelled and iodine-labelled products. (U.K.)

  1. Radiopharmaceuticals for nuclear cardiology

    International Nuclear Information System (INIS)

    Leon Cabana, Alba

    1994-01-01

    One of the diagnostic technique periodically used in Nuclear Medicine is the angiographic studi e, employee for detect cardiovascular diseases. The radiopharmaceutical more used in the angiographic ones is 99mTc. Between thetopics described in the present work it find: myocardial infarction, radiopharmaceuticals classification for cardiac studies, labelled proceedings, cardiovascular diseases

  2. Initial testing of the tritium systems at the Tokamak Fusion Test Reactor

    International Nuclear Information System (INIS)

    Anderson, J.L.; Sissingh, R.A.P.; Gentile, C.A.; Rossmassler, R.L.; Walters, R.T.; Voorhees, D.R.

    1993-01-01

    The Tokamak Fusion Test Reactor (TFTR) at Princeton will start its D-T experiments in late 1993, introducing and operating the tokamak with tritium in order to begin the study of burning plasma physics in D-T. Trace tritium injection experiments, using small amounts of tritium will begin in the fall of 1993. In preparation for these experiments, a series of tests with low concentrations of tritium inn deuterium have been performed as an initial qualification of the tritium systems. These tests began in April 1993. This paper describes the initial testing of the equipment in the TFTR tritium facility

  3. Tritium contaminated waste management at the tritium systems test assembly

    International Nuclear Information System (INIS)

    Jalbert, R.A.; Carlson, R.V.

    1987-01-01

    The Tritium Systems Test Assembly (TSTA) at Los Alamos continues to move toward full operation of an integrated, full-sized, computer-controlled fusion fuel processing loop. Concurrent nonloop experiments further the development of advanced tritium technologies and handling methods. Since tritium operations began in June 1984, tritium contaminated wastes have been produced at TSTA that are roughly typical in kind and amount of those to be produced by tritium fueling operations at fusion reactors. Methods of managing these wastes are described, including information on some methods of decontamination so that equipment can be reused. Data are given on the kinds and amounts of wastes and the general level of contamination. Also included are data on environmental emissions and doses to personnel that have resulted from TSTA operations. Particular problems in waste managements are discussed

  4. Tritium Systems Test Facility

    International Nuclear Information System (INIS)

    Cafasso, F.A.; Maroni, V.A.; Smith, W.H.; Wilkes, W.R.; Wittenberg, L.J.

    1978-01-01

    This TSTF proposal has two principal objectives. The first objective is to provide by mid-FY 1981 a demonstration of the fuel cycle and tritium containment systems which could be used in a Tokamak Experimental Power Reactor for operation in the mid-1980's. The second objective is to provide a capability for further optimization of tritium fuel cycle and environmental control systems beyond that which is required for the EPR. The scale and flow rates in TSTF are close to those which have been projected for a prototype experimental power reactor (PEPR/ITR) and will permit reliable extrapolation to the conditions found in an EPR. The fuel concentrations will be the same as in an EPR. Demonstrations of individual components of the deuterium-tritium fuel cycle and of monitoring, accountability and containment systems and of a maintenance methodology will be achieved at various times in the FY 1979-80 time span. Subsequent to the individual component demonstrations--which will proceed from tests with hydrogen (and/or deuterium) through tracer levels of tritium to full operational concentrations--a complete test and demonstration of the integrated fuel processing and tritium containment facility will be performed. This will occur near the middle of FY 1981. Two options were considered for the TSTF: (1) The modification of an existing building and (2) the construction of a new facility

  5. Chilean experience in production of therapeutic radiopharmaceuticals labelled with 153Sm and 166Ho

    International Nuclear Information System (INIS)

    Chandia, M.; Gil, M.G.; Tomicic, M.; Araya, G.; Olea, E.; Chong, G.

    1998-01-01

    153 Samarium ( 153 Sm) and 166 Holmium ( 166 Ho) were produced at the Nuclear Center of La Reina Research Reactor, Chilean Nuclear Energy Commission. 153 Sm-EDTMP (Ethylenediaminetetramethylene Phosphonate) used for clinical trial of therapy for painful skeletal metastases and labeled particles such as 166 Ho-FHMA (ferric hydroxide macroagregattes) and 153 Sm-HAP (hydroxiapatite particles) used for radiation synevectomy, were labeled. Radionuclide purity of both radionuclides was analyzed by gamma spectrometry using a multichannel gamma spectrometer. Radiochemical labeled reaction parameters of 153 Sm-EDTMP such as: Sm/EDTMP molar ratio, 153 Sm specific activity, labeled pH and temperature, were determined in order to get high radiolabeling yields. Radiochemical Quality Controls of 153 Sm-EDTMP using different chromatographic systems were carried out in order to determine labeling yields. Bodistribution studies were achieved in mice by dissection of animals and by autoradiography of histological slices in rats, after 2h post injection. 153 Sm-HAP and 166 Ho-FHMA labeled particles were prepared using the methods described. Radiochemical purity, in case of radiolabeled particles was carried out by centrifugation, measuring activity in the supernatant and in particles pellet. Physical parameters, such as particle size and range of the radiopharmaceuticals based on particles labeling were evaluated in order to determine the ideal conditions to obtain particles size range between 10 - 40μ. In vitro labeling stability for over seven days and wash out activity by incubation in human synovial fluid after 6 and 24h post labeling, was also studied. 153 Sm-EDTMP was easily labeled with a Radiochemical purity over 99.5% and stable for over 7 days. Biodistribution studies in mice give more than 50% of ID uptake in bone and less than 0,1% in liver this was correlated by autoradiographic image. 153 Sm-HAP and 166 Ho-FHMA were also labeling obtaining radiochemical purity over 95

  6. The tritium labelling of organic molecules by heterogeneous catalytic exchange

    International Nuclear Information System (INIS)

    Angoso Marina, M.; Kaiser Ruiz del Olmo, F.

    1977-01-01

    The influence of the temperature at 65 degree centigree and 120 degree centigree on the labelling of three organic molecules with tritium was studied. The compounds were: benzoic acid, de phenyl glyoxal and 2,3-tetramethylene-4-pantothenyl-7-oxo diacetin.The method employed was the heterogeneous catalytic exchange between tritiated water and the organic compound. The purification was made by thin-layer chromatography and the concentration, purity and specific activity of the products were determined by counting and ultraviolet techniques. The thermal stability and the radiolytic effects on labelled benzoic acid were also considered. (Author) 9 refs

  7. Investigation into chromatographic decomposition of tritium labelled aminoacid racemates

    International Nuclear Information System (INIS)

    Myasoedov, N.F.; Zolotarev, Yu.A.; Penkina, V.I.; Petrenik, O.V.

    1983-01-01

    Results of investigations of ligand-exchange chromatography of amino acids racemates on asymmetric sorbent containing L-oxy-proline groups in polystyrene carcass, and filled with copper ions, are described. Conditions are chosen for ligand-exchange chromatography of amino acids with high specific radioactivity labelled with tritium providing quantitative decomposition of racemates for several hours. Sorbent on polyacryl amide carcass is synthesized, the possibility of its application for the separation of amino acid racemates is studied

  8. Detection of endotoxins in radiopharmaceutical preparations. III. Limulus test assessment using radiopharmaceutical preparations; correlation with the rabbit pyrogen test

    Energy Technology Data Exchange (ETDEWEB)

    Cohen, Y; Bahri, F; Bruneau, J; Dubuis, M; Dubuis, N; Merlin, L; Michaud, T; Peysson, S

    1986-01-01

    Experiments using 17 radiopharmaceuticals containing known amounts of added endotoxin show that none of them inhibits the pyrogenic reaction of the rabbit. Gelation of the Limulus amoebocyte lysate (LAL) is inhibited by 4 of them: colloidal erbium 169Er citrate, colloidal rhenium 186Re sulfide, colloidal technetium /sup 99m/Tc (Re) sulfide for liver scintigraphy and the colloidal technetium /sup 99m/Tc (Re) sulfide for lymphography. This inhibition is cancelled, either by dilution or after neutral pH adjustment. Both controls were performed on 313 batches of various radiopharmaceuticals, 95% of results were identical (93% negative, 2% positive). The remaining 5% correspond to positive LAL tests vs negative rabbit tests on the same batches. No negative LAL test vs positive rabbit test was observed.

  9. Substantiation of rate setting of surface contamination with amino acids, labelled with tritium

    International Nuclear Information System (INIS)

    Zhesko, T.V.

    1987-01-01

    For rate setting of surface contamination with the wide-spread biogenic tritium compounds-protein predecessors-experimental study of skin absorption and skin deposit of amino acids labelled with tritium is carried out on rats. While extrapolating data to people and calculating tolerable skin contamination with 3 H- amino acids, it is supposed that people arm skin, 100-500 cm 2 , has no defects and that the skin surface decontamination after radionuclide contact is carried out with a preparation, efficiency of which is not less than 97%. The value of tolerable skin absorption of tritium amino acids, being 110-550 MBq/year or 4.8 kBq/cm 2 per one working day, is calculated

  10. The introduction of tritium in lactose and saccharose by isotope exchange with gaseous tritium

    International Nuclear Information System (INIS)

    Akulov, G.P.; Snetkova, E.V.; Kaminskij, Yu.L.; Kudelin, B.K.; Efimova, V.L.

    1991-01-01

    Methods for conducting reactions of catalytic protium-tritium isotopic exchange with gaseous tritium were developed in order to synthesize tritium labelled lactose and saccharose. These methods enabled to prepare these labelled disaccharides with high molar activity. The yield was equal to 50-60%, radiochemical purity ∼ 95%

  11. Rapid labelling of radiopharmaceuticals using 11CO2 and 11CH4

    International Nuclear Information System (INIS)

    Crouzel, C.

    1988-07-01

    In the past two decades, much effort has been devoted to the development of new molecules, labelled with β+ emitters usable for Positron Emission Tomography. Gaseous forms of 11 C ( 11 CO 2 or 11 CH 4 ) must be converted to a reactive form known as a ''radioactive precursor'': 11 C-methanol, 11 C-formaldehyde, 11 C-acetone, 11 C-phosgene, 11 C-diazomethane, 11 C-methylamine. These precursors are used to label radiopharmaceuticals. Few examples are given: 11 C-prazosin, 11 C-CGP 12177, 11 C-pindolol. Such synthesis procedures require strong initial activity (1.5 Ci). The processes are therefore remotely controlled or automated, and confined to shielded cells. Small laboratory robots have lately been introduced for this type of production

  12. Drug interaction with radiopharmaceuticals: effect on the labeling of red blood cells with technetium-99m and on the bioavailability of radiopharmaceuticals

    Directory of Open Access Journals (Sweden)

    Maria Luisa Gomes

    2002-09-01

    Full Text Available The evidence that natural and synthetic drugs can affect radiolabeling or bioavailability of radiopharmaceuticals in setting of nuclear medicine clinic is already known. However, this drug interaction with radiopharmaceuticals (DIR is not completely understood. Several authors have described the effect of drugs on the labeling of blood elements with technetium-99m (99mTc and on the biodistribution of radiopharmaceuticals. When the DIR is known, if desirable or undesirable, the natural consequence is a correct diagnosis. However, when it is unknown, it is undesirable and the consequences are the possibility of misdiagnosis and/or the repetition of the examination with an increase of radiation dose to the patient. The possible explanation to the appearance of DIR are (a radiopharmaceutical modification, (b alteration of the labeling efficiency of the radiopharmaceutical, (c modification of the target, (d modification of no target and/or the (e alteration of the binding of the radiopharmaceutical on the blood proteins. The effect of drugs on the labeling of blood elements with 99mTc might be explained by (i a direct inhibition (chelating action of the stannous and pertechnetate ions, (ii damage induced in the plasma membrane, (iii competition of the cited ions for the same binding sites, (iv possible generation of reactive oxygen species that could oxidize the stannous ion and/or (v direct oxidation of the stannous ion. In conclusion, the development of biological models to study the DIR is highly relevant.A evidência de que drogas naturais ou sintéticas podem afetar a radiomarcação ou a biodisponibilidade de radiofármacos nos procedimentos de medicina nuclear já é bem conhecida. Entretanto, essa interação de droga com radiofármacos (IDR não está completamente compreendida. Vários autores têm descrito o efeito de drogas na marcação de elementos sanguíneos com tecnécio-99m (99mTce na biodistribuição de radiofármacos. Quando a

  13. Synthesis of analogues of purine nucleotides selectively labeled by tritium on the C-8 of the purine ring and evaluation of the stability of tritium label

    Czech Academy of Sciences Publication Activity Database

    Elbert, Tomáš

    2010-01-01

    Roč. 53, č. 3 (2010), s. 156-157 ISSN 0362-4803. [Workshop of the International Isotope Society - Central European Division. The Synthesis and applications of Isotopes and Isotopically Labelled Compounds /16./. 01.10.2009-02.10.2009, Bad Soden] Institutional research plan: CEZ:AV0Z40550506 Keywords : acyclic nucleotide analogues * tritium Subject RIV: CC - Organic Chemistry

  14. The ARPANSA quality assurance program for radiopharmaceuticals

    International Nuclear Information System (INIS)

    Baldas, J.; Ivanov, Z.

    2003-01-01

    Full text: The Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) conducts a radiopharmaceutical quality assurance test program in which radiopharmaceuticals used in nuclear medicine in Australia are tested for compliance with specifications. Where the radiopharmaceutical is the subject of a monograph in the British Pharmacopoeia or the European Pharmacopoeia, then the specifications given in these Pharmacopoeias are adopted. Where a monograph is only available in the US Pharmacopoeia, then this specification is generally adopted. In other cases the specifications quoted have been adopted by this Agency. Animal biodistribution testing was discontinued in 1997 due to resource limitation. Samples for testing were obtained through commercial channels. All technetium-99m cold kits were reconstituted according to the directions in the package insert using Sodium Pertechnetate [ 99m Tc] injection. The results of testing conducted by the ARPANSA during 1984-1999 are summarised. A significant cause of failure to meet full specifications has been due to non-compliance of the vial/package labels. Copyright (2003) The Australian and New Zealand Society of Nuclear Medicine Inc

  15. Development of New Tritium Labelling Methods for Peptides & Investigation of Guest-Host Mediated Electrocyclization and Sigma-Tropic Rearrangement Reactions

    DEFF Research Database (Denmark)

    Pedersen, Martin Holst Friborg

    The main parts of the work presented here is Part I; which have involved the installation of a Tritium Chemistry Facility for the synthesis of radiolabelled compounds with tritium, and Part II; the development of new tritium labelling methods for peptides. The intention of Part I is to supply bac...

  16. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.

    Science.gov (United States)

    Vallabhajosula, Shankar

    2007-11-01

    Molecular imaging is the visualization, characterization, and measurement of biological processes at the molecular and cellular levels in a living system. At present, positron emission tomography/computed tomography (PET/CT) is one the most rapidly growing areas of medical imaging, with many applications in the clinical management of patients with cancer. Although [(18)F]fluorodeoxyglucose (FDG)-PET/CT imaging provides high specificity and sensitivity in several kinds of cancer and has many applications, it is important to recognize that FDG is not a "specific" radiotracer for imaging malignant disease. Highly "tumor-specific" and "tumor cell signal-specific" PET radiopharmaceuticals are essential to meet the growing demand of radioisotope-based molecular imaging technology. In the last 15 years, many alternative PET tracers have been proposed and evaluated in preclinical and clinical studies to characterize the tumor biology more appropriately. The potential clinical utility of several (18)F-labeled radiotracers (eg, fluoride, FDOPA, FLT, FMISO, FES, and FCH) is being reviewed by several investigators in this issue. An overview of design and development of (18)F-labeled PET radiopharmaceuticals, radiochemistry, and mechanism(s) of tumor cell uptake and localization of radiotracers are presented here. The approval of clinical indications for FDG-PET in the year 2000 by the Food and Drug Administration, based on a review of literature, was a major breakthrough to the rapid incorporation of PET into nuclear medicine practice, particularly in oncology. Approval of a radiopharmaceutical typically involves submission of a "New Drug Application" by a manufacturer or a company clearly documenting 2 major aspects of the drug: (1) manufacturing of PET drug using current good manufacturing practices and (2) the safety and effectiveness of a drug with specific indications. The potential routine clinical utility of (18)F-labeled PET radiopharmaceuticals depends also on

  17. Radiopharmaceuticals for bone scintillators

    International Nuclear Information System (INIS)

    Rey, A.M.

    1994-01-01

    One of the diagnostic techniques used in nuclear medicine is the bone scintiscanning with labelled compounds for obtain skeletal images. The main sections in this work are: (1) bone composition and anatomy;(2)skeletal radiopharmaceutical development;(3)physical properties of radionuclides;(4)biological behaviour and chemical structures;(5)radiopharmaceuticals production for skeletal scintillation;(6)kits;(7)dosimetry and toxicity.tabs

  18. Synthesis of high specific activity tritium-labelled chloroethylcyclohexylnitrosourea and its application to the study of DNA modification

    International Nuclear Information System (INIS)

    Siew, E.L.; Habraken, Yvette; Ludlum, D.B.

    1991-01-01

    A small-scale synthesis of high specific activity, N-(2-chloro-2-[ 3 H-ethyl)-N'-cyclohexyl-N-nitrosourea ([ 3 H]-CCNU) has been accomplished from tritium-labelled ethanolamine. The product is pure by TLC and HPLC analysis and has been used successfully to modify DNA. The overall yield on radioactivity including losses in HPLC purification is approximately 4 percent. The availability of this tritium-labelled compound makes studies of DNA repair and of cellular resistance to N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea possible. (author)

  19. Use of tritium-labelled water in the study of transfers and exchanges in Helianthus annuus

    International Nuclear Information System (INIS)

    Puard, M.

    1982-01-01

    A labelling method with tritium-labelled water was developed and an experiment was carried out to study the kinetics of water transfer in the plant, to measure the extend of water vapour exchange between the leaves and atmosphere and the migration of this water towards the root systems [fr

  20. Development of radiochemical method of analysis of binding of tritium labeled drotaverine hydrochloride with human blood serum albumin

    International Nuclear Information System (INIS)

    Kim, A.A.; Djuraeva, G.T.; Shukurov, B.V.; Mavlyanov, I.R.

    2004-01-01

    Full text: The albumin, being a basic functional linkage of numerous endogenous and exogenous substances is the most important protein of blood plasma. At the diseases connected to liver disfunction, collected in blood metabolite reduce connecting ability of albumino. The aim of the present research was a development of radiochemical method of determination of ability of albumin to bind the tritium labeled preparation drotaverine hydrochloride (no - spa). We had developed a micromethod of definition of connecting ability of albumin, allowing to analyse 20 mkl of blood serum. The method consists in incubation of tritium labeled drotaverine hydrochloride with blood serum in vitro, the following fractionation of serum proteins by gel - filtration on a microcolumn with Sephadex G-25, and direct measurement of the radioactivity connected to fraction of proteins of blood serum. The method has been tested on a series of blood serum of control group of healthy people and on a series of blood serum of patients with hepatitis B. We received quantitative characteristics of binding of drotaverine hydrochloride with albumin of patients with hepatitis B. It was preliminary established that binding ability of serum albumin of children with various forms of acute virus hepatitis tends to decrease in comparison with group of the control. Advantage of the developed radiochemical method is high precision and the high sensitivity of detection of infringement of binding ability of albumin. Application of tritium labeled drotaverine hydrochloride allows to measure directly levels of binding of a preparation with albumin

  1. Radiopharmaceutical scanning agents

    International Nuclear Information System (INIS)

    1976-01-01

    This invention is directed to dispersions useful in preparing radiopharmaceutical scanning agents, to technetium labelled dispersions, to methods for preparing such dispersions and to their use as scanning agents

  2. Stannous ion quantitation in sup(99m)Tc-radiopharmaceutical kits

    International Nuclear Information System (INIS)

    Chervu, L.R.; Vallabhajosyula, B.; Mani, J.; Chun, S.B.; Blaufox, M.D.

    1982-01-01

    A simple and inexpensive method for the estimation of stannous ion, Sn(II), in radiopharmaceutical kits is described. The method used is a potentiometric titration of Sn(II) in 1 N HCl medium, using potassium iodate as the oxidizing agent in an atmosphere of nitrogen. The apparatus includes a pH meter, a platinum electrode, and a simple titration cell. Several commonly used radiopharmaceutical kits were analyzed for their Sn(II) content using this method. These studies indicate that the procedure can be used, as a routine quantitative test for the Sn(II) content of various sup(99m)Tc-labeled radiopharmaceuticals. (orig.)

  3. Timing tests: automatic valve closure for tritium leaks

    International Nuclear Information System (INIS)

    Hanel, S.

    1976-01-01

    How fast can an automotive valve be closed after a tritium leak occurs in a system. Tests described found that a valve can be closed within fifteen seconds of leakage. In one practical example considered, this delay would limit loss of tritium from a plumbing leak in a tritium system to 1 1 / 4 g. The tests were made in a typical LLL air-flush hood in which a tritium handling system had been installed. Incidental observations suggest that further study be made of a possible leak-actuated recovery system for an entire tritium facility

  4. The radiopharmaceuticals labelled with technetium-99m and the radiopharmacy; Les radiopharmaceutiques marques au technetium-99m et la radiopharmacie

    Energy Technology Data Exchange (ETDEWEB)

    Bodenant, V

    1998-10-01

    In less than fifty years, the place of nuclear medicine is become primordial. Among all the radiopharmaceuticals used in nuclear medicine, the technetium-99m is the most used because of its physico-chemical properties and its great availability with the molybdenum-99m - technetium-99m generator. Since 1992, the radiopharmaceuticals, the packages, the generators are included in the pharmaceutic monopole. They are now under the reliability of the radio-pharmacist. This thesis has for object to introduce these different radiopharmaceuticals labelled with technetium-99m and to show the primordial place of the radio-pharmacist in a service of nuclear medicine. (N.C.)

  5. Synthesis of high specific activity tritium-labelled chloroethylcyclohexylnitrosourea and its application to the study of DNA modification

    Energy Technology Data Exchange (ETDEWEB)

    Siew, E.L. (State Univ. of New York, Albany, NY (USA). Dept. of Chemistry); Habraken, Yvette; Ludlum, D.B. (Massachusetts Univ., Worcester, MA (USA). Medical School)

    1991-02-01

    A small-scale synthesis of high specific activity, N-(2-chloro-2-{sup 3}H-ethyl)-N'-cyclohexyl-N-nitrosourea ({sup 3}H-CCNU) has been accomplished from tritium-labelled ethanolamine. The product is pure by TLC and HPLC analysis and has been used successfully to modify DNA. The overall yield on radioactivity including losses in HPLC purification is approximately 4 percent. The availability of this tritium-labelled compound makes studies of DNA repair and of cellular resistance to N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea possible. (author).

  6. Radiopharmaceuticals for cerebral studies

    International Nuclear Information System (INIS)

    Leon Cabana, Alba

    1994-01-01

    For obtain good brain scintillation images in nuclear medicine must be used several radiopharmaceuticals. Cerebral studies give a tumors visual image as well as brain anomalities detection and are helpful in the diagnostic diseases . Are described in this work: a cerebrum radiopharmaceuticals classification,labelled compounds proceeding and Tc 99m good properties in for your fast caption, post administration and blood purification for renal way

  7. The radiopharmaceutical industry and European Union regulations

    International Nuclear Information System (INIS)

    Fallais, C.J.; Sivewright, S.; Ogle, J.R.

    1997-01-01

    After a brief historical introduction to Council Directives relating to the manufacture of radiopharmaceuticals the work of the Association of Radiopharmaceuticals Producers - Europe (ARPE) is discussed. ARPE has played a significant role as an officially recognized interlocutor with the EEC, influencing decisions on the registration of radiopharmaceuticals and labelling; this role is reviewed and difficulties identified. The future of radiopharmaceuticals is then considered; it is emphasized that harmonization of national laws by the European Council would represent a first step to enabling radiopharmaceutical manufacturers to access the largest possible market for their products. (orig.)

  8. Radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Hunt, F C; Wilson, J G

    1980-03-13

    The claim describes a reducing metal complex of a compound in a suitable form for labelling with technetium-99m for radiopharmaceutical purposes, the compound being a complex derived from an indene heterocycle structure. The indene heterocycle structure is selected from the group consisting of iminodiacetic acid derivates of benzimidazole, benzthiazole and benzoxazole.

  9. Development of radiopharmaceutical for radiosinovectomy

    International Nuclear Information System (INIS)

    Couto, Renata Martinussi

    2009-01-01

    Radiopharmaceuticals prepared with different radionuclides have been used in diagnostic and therapeutic procedures in Nuclear Medicine. The interest in radionuclidic therapy has been increased in last years, with the introduction of new radiopharmaceuticals applied in the destruction of specific cells or to prevent its undesired proliferation. Radiosinovectomy (RSV) is a therapeutic modality that uses radiopharmaceuticals administered in the intra-articular cavity and represents an alternative to the treatment of different arthropaties and, in particular, the arthropaties derived from rheumatoid arthritis and haemophilic. The objective of the present work was to study the labeling of compounds with 90 Y and 177 Lu in order to improve the production conditions and quality control procedures, study the stability of the labeled compounds and preliminary biodistribution studies of the radiopharmaceuticals with potential for RSV applications. The study of the production of 90 Y citrate colloid ( 90 Y-Cit) was based in a labeling procedure using 90 Y Cl 3 solution (37 - 54 MBq) that was previously dried, followed by the addition of yttrium nitrate and sodium citrate in p H 7 at 37 deg C for 30 minutes. The production of hydroxyapatite (HA) labeled with 90 Y was based in a labeling procedure using mono hydrated citric acid, yttrium nitrate and 90 Y Cl 3 solution (37 - 370 MBq). The reaction mixture was incubated for 30 minutes at room temperature and the HA was introduced in aqueous medium and the reaction proceed for 30 minutes under strong stirring. 177 Lu-HA was produced using 177 Lu Cl 3 solution (296 MBq), in presence of lutetium oxide in NaCl medium, p H 7, under continuous stirring for 30 minutes at room temperature. Several reaction parameters were studied for the three radiopharmaceuticals. Labeling yield was determined after particles were centrifuged and washed with NaCl 0,9%. Radiochemical purity was determined by ascending chromatography using different

  10. Detection of sentinel nodes with radiopharmaceuticals

    International Nuclear Information System (INIS)

    Yokoyama, Kunihiko; Michigishi, Takatoshi; Kinuya, Seigo; Konishi, Shota; Nakajima, Kenichi; Tonami, Norihisa

    2000-01-01

    Sentinel lymph nodes have been found to be an indicator of lymph node metastasis in breast cancer. In Japan, the theory and concept of sentinel lymph nodes in breast cancer have begun to be applied to carcinomas of the digestive system. Based on clinical experience in the detection of sentinel lymph nodes with radiopharmaceuticals, differences and similarities between the radiopharmaceuticals, methods, and techniques used to detect sentinel lymph nodes have been assessed in relation to breast cancer and carcinomas of the digestive system (including carcinomas of the esophagus and large intestine). The greatest difference between the methods used for breast and digestive cancers is the site of administration of the radiopharmaceutical. In breast cancer, the radiopharmaceutical is administered into a superficial organ (i.e., the mammary gland), whereas in carcinomas of the digestive system, it is administered into a deep organ (i.e., digestive tract). Another obvious difference is in lymph flow, i.e., the flow of the mammary glands is subcutaneous whereas lymph flow in the digestive tract is submucosal. Two radionuclide diagnostic methods are available to detect sentinel lymph nodes: sentinel lymphoscintigraphy with a gamma camera and a method that involves the use of a gamma probe intraoperatively. Radiopharmaceuticals used to detect sentinel lymph nodes must be smoothly transferred from the site of administration into the lymph, and uptake by the sentinel lymph node must continue for a long time without excessive flowing to lower reaches. The optimal particle size remains a matter of controversy, and no radiopharmaceuticals appropriate for lymphoscintigraphy have ever been approved in Japan. The authors compared the pharmacokinetics of three different radiopharmaceuticals used for sentinel lymphoscintigraphy in breast cancer ( 99m Tc-labeled albumin, 99m Tc-labeled tin colloid, and 99m Tc-labeled phytic acid) and founded that the detection rate was lowest with

  11. Results of quality control studies of technetium 99m labelled radiopharmaceuticals prepared from kits (1978-79)

    International Nuclear Information System (INIS)

    McLean, J.R.; Rockwell, L.J.; Welsh, W.J.

    1982-01-01

    This report summarizes the results of quality control studies of Tc 99m-labelled normal albumin, macroaggregated albumin, and bone imaging radiopharmaceuticals prepared from commercially available kits. It includes all analyses performed from January 1978 to December 1979. The results presented were obtained through the application of various in vitro and animal (mouse) biodistribution studies

  12. Applications and development trend of radiopharmaceuticals

    International Nuclear Information System (INIS)

    Kim, J.R.

    1978-01-01

    Present status of radiopharmaceuticals applications and the trend of the development are extensively reviewed and discussed. The followings are manifested: a) Among the various radionuclides, those of short lived, accelerator produced, and having moderate radiation energies are becoming popular. b) Diagnosis using various labelled molecules are considered to be the most active field in nuclear medicine. c) Development of radiopharmaceuticals for tumor localization studies is one of the trends. d) The use of various convenient kits of both in-vitro radioligand assay, and in-vivo instant labelling is now an enormous domain in nuclear medicine. A great stride is also made in the development of automation technique. Upon it, an urgent development of some new radiopharmaceuticals having local characteristics is proposed. (author)

  13. Use of flow scintillation analyzer combined with amino acid analyzer for measuring low-level radioactivity of tritium-labelled amino acids

    CERN Document Server

    Lukashina, E V; Fedoseev, V M; Ksenofontov, A L; Baratova, L A; Dobrov, E N

    2002-01-01

    Potential application of the Radiomatic 150TR Flow Scintillation Analyzer (Packard Instrument Co., USA) for measuring low radioactivity of tritium-labelled amino acids in eluate from the Amino Acid Analyzer 835 (Hitachi, Japan) was studied. Six scintillating cocktails were tested and the Hionic-Fluor and Ultima-Flo AP cocktails proved the most appropriate for flow measurement of radioactivity. Efficiency of tritium radioactivity recording under various conditions of analysis was determined. Under optimal conditions the lower detection limit for the Hionic-Fluor was 150, while for Ultima-Flo AP-100 decays/min in the peak of amino acid

  14. Investigation of ability of serum albumin to bind the tritium labeled drotaverine hydrochloride at virus hepatitis

    International Nuclear Information System (INIS)

    Kim, A.A.; Mavlyanov, I.R.; Shukurov, B.V.; Djuraeva, G.T.

    2005-01-01

    The most of pathological conditions, and especially liver pathologies, proceeds on the background of intoxication syndromes. One of universal mechanisms of reaction of an organism on increase of concentration of toxic metabolites is removing of metabolites with the help of one of the basic protein of blood plasma - serum albumin. The purpose of the present research was studying of serum albumin ability to bind drotaverine hydrochloride at virus hepatitis in dynamics of traditional therapy. This parameter is rather important for therapy as it is known, that serum albumin is a carrier of pharmaceutical preparations. At intoxication of organism the toxic metabolites can reduce the binding capacity of serum albumin due to competitive binding and by that to reduce efficiency of carry of pharmaceutical preparations. Application of a radiochemical method with use of tritium labeled drotaverine hydrochloride in the given research it is represented to the most effective. The method of tritium labeling of pharmacological preparation of drotaverine hydrochloride was developed. Drotaverine hydrochloride was labeled by thermally activated tritium. The system of purification of tritium labeled drotaverine hydrochloride by thin layer chromatography (TLC) has been developed. Tritium labeled preparation of drotaverine hydrochloride was purified by TLC on silica gel in system isopropanol : ammonia : water (8:1:1). The output of purified tritium labeled preparation of drotaverine hydrochloride was about 25 %. The received preparation had specific radioactivity - 3,2 MBq/mg (37,4 mCi/mmol), radiochemical purity of a preparation was 95 %. We had been developed a micromethod of definition of binding ability of albumin, allowing analyze 20 microliters of blood serum. The method consists in incubation of tritium labeled drotaverine hydrochloride with blood serum in vitro, the following fractionation of serum proteins by gel - filtration on a microcolumn with Sephadex G-25, and direct

  15. In vitro test for pyrogenes in radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Jovanovic, V; Zmbova, B; Bzenic, J [Institut za Nuklearne Nauke Boris Kidric, Belgrade (Yugoslavia); Berkes, J [Institut za Biohemije, Belgrade (Yugoslavia)

    1978-05-01

    Procedure and results of determination of pyrogenic substances in radiopharmaceutical preparations by an in vitro method based on the reaction between bacterial endotoxine and Limulus Amebocyte Lysate are presented. The advantage of this method as compared to the test in experimental animals performed so far has also been analyzed and proved by the fact that it enables avoidance of introduction of radioactive materials in experimental animals and of radiation effects on the results obtained in efficiency studies. The in vitro method is a quick one and requires only small quantities of the radiopharmaceutical preparation to be examined.

  16. On the mechanism of biological activation by tritium.

    Science.gov (United States)

    Rozhko, T V; Badun, G A; Razzhivina, I A; Guseynov, O A; Guseynova, V E; Kudryasheva, N S

    2016-06-01

    The mechanism of biological activation by beta-emitting radionuclide tritium was studied. Luminous marine bacteria were used as a bioassay to monitor the biological effect of tritium with luminescence intensity as the physiological parameter tested. Two different types of tritium sources were used: HTO molecules distributed regularly in the surrounding aqueous medium, and a solid source with tritium atoms fixed on its surface (tritium-labeled films, 0.11, 0.28, 0.91, and 2.36 MBq/cm(2)). When using the tritium-labeled films, tritium penetration into the cells was prevented. The both types of tritium sources revealed similar changes in the bacterial luminescence kinetics: a delay period followed by bioluminescence activation. No monotonic dependences of bioluminescence activation efficiency on specific radioactivities of the films were found. A 15-day exposure to tritiated water (100 MBq/L) did not reveal mutations in bacterial DNA. The results obtained give preference to a "non-genomic" mechanism of bioluminescence activation by tritium. An activation of the intracellular bioluminescence process develops without penetration of tritium atoms into the cells and can be caused by intensification of trans-membrane cellular processes stimulated by ionization and radiolysis of aqueous media. Copyright © 2016 Elsevier Ltd. All rights reserved.

  17. Radiopharmaceutical research: trends and novel concepts

    International Nuclear Information System (INIS)

    Wuest, F.

    2005-01-01

    The efficiency of nuclear medicine in diagnosis, therapy and medicinal research strongly depends on the progress to develop novel suitable radiopharmaceuticals. The selection, preparation, and preclinical evaluation of new radiopharmaceuticals is addressed by the field of radiopharmaceutical chemistry. The rapid developments in the field of biotechnology in the post-genome era combined with the recent advances in the instrumentation of SPECT and PET have directed radiopharmaceutical research into a complex chemical science. Current radiopharmaceutical research comprises novel developments of coordination chemistry with [ 99m Tc]technetium pharmaceuticals, the development of non-standard PET radionuclides and the synthesis of 11 C- and 18 F-labelled radiopharmaceuticals at high specific radioactivity. Further developments deal with an increasing alignment to radiotherapeutics and the implementation of PET into the process of drug development and evaluation. (orig.)

  18. Tritium migration studies at the Nevada Test Site

    International Nuclear Information System (INIS)

    Schulz, R.K.; Weaver, M.O.

    1993-05-01

    Emanation of tritium from waste containers is a commonly known phenomenon. Release of tritium from buried waste packages was anticipated; therefore, a research program was developed to study both the rate of tritium release from buried containers and subsequent migration of tritium through soil. Migration of tritium away from low-level radioactive wastes buried in Area 5 of the Nevada Test Site was studied. Four distinct disposal events were investigated. The oldest burial event studied was a 1976 emplacement of 3.5 million curies of tritium in a shallow land burial trench. In another event, 248 thousand curies of tritium was disposed of in an overpack emplaced 6 m below the floor of a low-level waste disposal pit. Measurement of the emanation rate of tritium out of 55 gallon drums to the overpack was studied, and an annual doubling of the emanation rate over a seven year period, ending in 1990, was found. In a third study, upward tritium migration in the soil, resulting in releases in the atmosphere were observed in a greater confinement disposal test. Releases of tritium to the atmosphere were found to be insignificant. The fourth event consisted of burial of 2.2 million curies of tritium in a greater confinement disposal operation. Emanation of tritium from the buried containers has been increasing since disposal, but no significant migration was found four years following backfilling of the disposal hole

  19. Gastric emptying scintigraphy: choice by in vitro test, of a new 99mTc marker to label solid phase and further analysis with the better radiopharmaceuticals

    International Nuclear Information System (INIS)

    Blanc, F.

    2005-05-01

    The study of gastric emptying by isotopic method occurs regularly in Brest nuclear medicine department. It consists in eating radiolabelled omelette with rhenium sulphide macro-colloid and in drinking radiolabelled water with 111 In-DTPA. The two phases are followed in stomach with gamma-camera. Rhenium sulphide macro-colloid have been taken off the market in january 2004 and no radiopharmaceutical has replaced them. in vitro test permitted us to test solid phase radiolabeling stability with 5 99m Tc-vectors used in nuclear medicine. Two of them are suitable for gastric emptying solid phase labelling: the tin fluoride colloids and the sodium phytate but tin fluoride colloids give better labelling stability than sodium phytate. In order to define solid phase marker properties, studies of medium composition by X fluorescence, size by laser granulometry, structure by NMR (nuclear magnetic resonance), TLC (thin layer chromatography) and by centrifugation are done either with the two vectors or only with sodium phytate. Structural properties of tin fluoride colloids are known. Results of this study indicate that phytates can be colloids. Finally, the good gastric emptying solid phase marker must be a colloid with a size of about 200 nm. (author)

  20. Instant thin layer chromatography (ITLC) - the most true and convenient method for the determination of radiochemical purity of Tc-99m Labeled radiopharmaceuticals

    International Nuclear Information System (INIS)

    Anwar-Ul-Azim, M.; Ansari, M.I.H.

    2007-01-01

    should be 90% to 100% for 99mTc compounds-USP XXI) Conclusion: The findings of the study indicate that routine RCP test of 99mTc-labeled radiopharmaceuticals through ITLC-SG method is a reliable one. Routine RCP measurement by this method not only prevents repeat patient study that results in increased radiation exposure to technologists and patients but also prevent the delay in reporting the study and the additional time and expenses involved. (author)

  1. Investigation into reaction of heterogenous isotopic exchange with gaseoUs tritium in solution for preparation labelled lipid compounds

    International Nuclear Information System (INIS)

    Shevchenko, V.P.; Myasoedov, N.F.

    1983-01-01

    The applicability of the method of heterogeneous catalytic isotopic exchange with gaseous tritium in the solution for the production of labelled lipide preparations is studied. Labelled saturated and unsaturated aliphatic acids, prostaglandins, phospholipides and sphingolipides are prepared

  2. Recent developments in the field of 123I-radiopharmaceuticals

    International Nuclear Information System (INIS)

    Machulla, H.J.; Knust, E.J.

    1984-01-01

    Due to its advantageous nuclear physical properties iodine-123 is an excellent label for radiopharmaceuticals very well suited for measurements by γ-cameras and single-photon emission tomography. The development of 123 I-radiopharmaceuticals should be based on a clear biochemical concept, reliable labelling procedures and careful pharmacokinetic studies in order to evaluate the physiological behaviour of the radioiodinated compounds being analogues of metabolic substrates. The development of 123 I-labelled fatty acids and biogenic amines clearly proved the successful use of 123 I for labelling compounds applied in medical diagnosis. (orig.) [de

  3. Radiochemistry in nuclear medicine. Radiopharmaceuticals

    International Nuclear Information System (INIS)

    Samochocka, K.

    1999-01-01

    Radionuclides and radiopharmaceuticals play a kay role in nuclear medicine, both in diagnostics and therapy. Incorporation of radionuclides into biomolecules, and syntheses of radiolabelled compounds of high biological selectivity are a task for radiochemists working in the multidisciplinary field of radiopharmaceutical chemistry. The most commonly used radionuclide, 99m Tc, owes this popularity to its both nearly ideal nuclear properties in respect to medical imaging, and availability from inexpensive radionuclide generators. Also numerous other radionuclides are widely used for medical imaging and therapy. Labelling of biomolecules with radioiodine and various positron emitters is getting increasingly important. This review describes some chemical and radiochemical problems we meet while synthesizing and using 99m Tc-radiopharmaceuticals and radioiodine-labelled biomolecules. Also represented are the recent developments in the design and use of the second generation radiopharmaceuticals based on bifunctional radiochelates. Several principal routes of fast chemical synthesis concerning incorporation of short-lived positron emitters into biomolecules are outlined as well. The search for chemical structures of high biological selectivity, which would be activated by slow neutrons, is related to the method of Neutron Capture Therapy, an interesting option in nuclear medicine. (author)

  4. Peptide radiopharmaceuticals in nuclear medicine

    International Nuclear Information System (INIS)

    Blok, D.; Vermeij, P.; Feitsma, R.I.J.; Pauwels, E.J.K.

    1999-01-01

    This article reviews the labelling of peptides that are recognised to be of interest for nuclear medicine or are the subject of ongoing nuclear medicine research. Applications and approaches to the labelling of peptide radiopharmaceuticals are discussed, and drawbacks in their development considered. (orig.)

  5. Oesophageal fistula/tritium-labelled water technique for determining dry matter intake and saliva secretion rates of grazing herbivores

    International Nuclear Information System (INIS)

    Luick, J.R.

    1982-01-01

    Seven assumptions on which the use of tritium-labelled water and oesophageal fistula depend, for determining the dry matter intake and saliva secretion rates of grazing herbivores, were tested experimentally. It is concluded that many of the possible sources of error can be ignored, but that a correction is necessary for the saliva dry matter content when calculating the dry matter of ingested food from fistula samples. (author)

  6. Synthesis 1-(5-oxohexyl)-3,7-dimethyl-xanthyne labelled with tritium into 8 position from purinic ring

    International Nuclear Information System (INIS)

    Mihaila, V.; Corol, D.

    1999-01-01

    This paper presents the work on synthesis of 1-(5-oxohexyl)-3,7-dimethyl-xanthyne labelled with tritium into 8 position from purinic ring. The obtaining of tritium labelled compound is realized by initial labelling of theobromine with tritium into 8 position and by coupling the purinic derivative to 1-Br-5-hexanone. Theobromine-8- 3 H was obtained by the bromination of theobromine with elementary bromine and after that the bromine was substituted with tritium i.e.: C 7 H 8 O 2 N 4 theobromine Br 2 /(-HBr) C 7 H 7 O 2 N 4 Br (8-Br-theobromine) ( 3 H 2 /cat)/(-KOH) C 7 H 7 3 HO 2 N 4 (theobromine-8- 3 H). Theobromine-8- 3 H was purified by thin layer chromatography with a solvent system i.e. n-BuOH:AcOH:H 2 O (4:1:1, v/v/v) and characterized radiochemically. It was then diluted by unlabelled theobromine to specific activity of 50 mCi/g. After dilution, theobromine-8- 3 H was coupled to 1-Br-5-hexanone i.e.: C 7 H 7 3 HO 2 N 4 (theobromine-8- 3 H) + Br-(CH 2 ) 4 -CO-CH 3 (1-Br-5-hexanone) (NaOH)/(CH 3 OH) C 13 H 17 3 HO 3 N 4 (1-(5-oxohexyl)- 3,7-dimethyl-xanthine-8- 3 H). The raw compound was purified by recrystallization from 2-propanol and it was characterized radiochemically. (authors)

  7. Study of autoradiolytic processes in tritium labelled polymers by quantum mechanical methods

    International Nuclear Information System (INIS)

    Postolache, Cristian; Fugaru, Viorel

    1999-01-01

    Autoradiolysis is a decomposition process of radionuclide labelled compounds. The process is similar to radiolytic degradation and is due to the autoirradiation following the decay of radioactive elements chemically bound to labelled molecules. In this work, an evaluating model of autoradiolysis behavior of tritium labelled polymers is presented. Polymeric structures of relevance for radioluminescent source industry, namely: polyethyl, polyethyl-phenyl, polypropyl, polypropyl-phenyl siloxanes, hydrogenated (tritiated) polyacetylenes with 1,4-diphenylbutane, 1,4-diphenyl-2-butene and 1,4-diphenylbutadiene structures have been investigated. Modelling of autoradiolytic processes was carried out with HYPERCHEM 4 software and its CHEMPLUS extension. Internal and external primary effects have been analyzed. External primary effects (EPE) were assessed by a procedure used in the study of radiolytic processes of solid polymers. A three step model was proposed for the assessment of internal primary effects (IPE): (a) tritium atom decay inducing a cationic radical in the molecular structure; (b) geometric re-optimization of cationic radical; (c) electron capture from environment and rapid breaking of the chemical bond of LUMO orbital distribution zone. The analysis of autoradiolytic processes in labelled polysiloxanes makes clear the dominant degradation function of EPE. The presence of phenyl groups in the polymeric structure improves the stability to autoradiolysis. The most resistant structures are obtained in the case of ethyl(propyl) and phenyl radicals positioned at different Si atoms. The hydrogenated oligomeric phenylacetylene structures present a high stability to autoradiolysis. In these cases, IPE in benzilic position have a major destructive function in the autoradiolytic process. (authors)

  8. Deuterium- and tritium-labelled compounds. Applications in the life sciences

    International Nuclear Information System (INIS)

    Atzrodt, Jens; Derdau, Volker; Kerr, William J.; Reid, Marc

    2018-01-01

    Hydrogen isotopes are unique tools for identifying and understanding biological and chemical processes. Hydrogen isotope labelling allows for the traceless and direct incorporation of an additional mass or radioactive tag into an organic molecule with almost no changes in its chemical structure, physical properties, or biological activity. Using deuterium-labelled isotopologues to study the unique mass-spectrometric patterns generated from mixtures of biologically relevant molecules drastically simplifies analysis. Such methods are now providing unprecedented levels of insight in a wide and continuously growing range of applications in the life sciences and beyond. Tritium ( 3 H), in particular, has seen an increase in utilization, especially in pharmaceutical drug discovery. The efforts and costs associated with the synthesis of labelled compounds are more than compensated for by the enhanced molecular sensitivity during analysis and the high reliability of the data obtained. In this review, advances in the application of hydrogen isotopes in the life sciences are described. (copyright 2018 Wiley-VCH Verlag GmbH and Co. KGaA, Weinheim)

  9. Stereo and regioselectivity in ''Activated'' tritium reactions

    International Nuclear Information System (INIS)

    Ehrenkaufer, R.L.E.; Hembree, W.C.; Wolf, A.P.

    1988-01-01

    To investigate the stereo and positional selectivity of the microwave discharge activation (MDA) method, the tritium labeling of several amino acids was undertaken. The labeling of L-valine and the diastereomeric pair L-isoleucine and L-alloisoleucine showed less than statistical labeling at the α-amino C-H position mostly with retention of configuration. Labeling predominated at the single β C-H tertiary (methyne) position. The labeling of L-valine and L-proline with and without positive charge on the α-amino group resulted in large increases in specific activity (greater than 10-fold) when positive charge was removed by labeling them as their sodium carboxylate salts. Tritium NMR of L-proline labeled both as its zwitterion and sodium salt showed also large differences in the tritium distribution within the molecule. The distribution preferences in each of the charge states are suggestive of labeling by an electrophilic like tritium species(s). 16 refs., 5 tabs

  10. Operation of the tokamak fusion test reactor tritium systems during initial tritium experiments

    International Nuclear Information System (INIS)

    Anderson, J.L.; Gentile, C.; Kalish, M.; Kamperschroer, J.; Kozub, T.; LaMarche, P.; Murray, H.; Nagy, A.; Raftopoulos, S.; Rossmassler, R.; Sissingh, R.; Swanson, J.; Tulipano, F.; Viola, M.; Voorhees, D.; Walters, R.T.

    1995-01-01

    The high power D-T experiments on the tokamak fusion test reactor (TFTR) at the Princeton Plasma Physics Laboratory commenced in November 1993. During initial operation of the tritium systems a number of start-up problems surfaced and had to be corrected. These were corrected through a series of system modifications and upgrades and by repair of failed or inadequate components. Even as these operational concerns were being addressed, the tritium systems continued to support D-T operations on the tokamak. During the first six months of D-T operations more than 107kCi of tritium were processed successfully by the tritium systems. D-T experiments conducted at TFTR during this period provided significant new data. Fusion power in excess of 9MW was achieved in May 1994. This paper describes some of the early start-up issues, and reports on the operation of the tritium system and the tritium tracking and accounting system during the early phase of TFTR D-T experiments. (orig.)

  11. Radiopharmaceutical drug review process

    International Nuclear Information System (INIS)

    Frankel, R.

    1985-01-01

    To ensure proper radioactive drug use (such as quality, diagnostic improvement, and minimal radioactive exposure), the Food and Drug Administration evaluates new drugs with respect to safety, effectiveness, and accuracy and adequacy of the labeling. The IND or NDA process is used for this purpose. A brief description of the process, including the Chemical Classification System and the therapeutic potential classification, is presented as it applies to radiopharmaceuticals. Also, the status of the IND or NDA review of radiopharmaceuticals is given

  12. Development of nano radiopharmaceutical based on Bevacizumab labelled with Technetium-99m for early diagnosis of gastrointestinal stromal tumor

    International Nuclear Information System (INIS)

    Braga, Thais Ligiero

    2015-01-01

    The development of new radiopharmaceuticals is an essential activity to improve nuclear medicine, and essential for the early and effective diagnosis of oncological diseases. Among the various possibilities current research in the world, the radiopharmaceuticals to chemotherapeutic base may be the most effective in detecting tumors, particularly Gastrointestinal Stromal Tumor (GIST), the Metastatic Renal Cell Carcinoma and neuroendocrine pancreatic tumors. However, difficulties in directing, as well as adhesion of the radiopharmaceutical in the desired location, are currently the main problems in the early detection and treatment of some of these tumors. Advances in the field of nanotechnology, particularly in recent years, indicate significant contribution to overcoming these obstacles, particularly in the implementation of molecular barriers as well as the functionalization of the nanoparticles, thereby improving targeting by the use of surface nucleotides, and the increased adhesion, which facilitates the release of the drug and therefore increases the chances of early diagnosis and more effective treatment. This study aimed to the production, characterization and evaluation of cytotoxicity, as well as in vivo biodistribution test Bevacizumab nanoparticles labeled with Technetium-99m radionuclide for detection of type GIST tumors. Bevacizumab was encapsulated in the form of nanoparticles by the emulsification method using double poly-acetic acid and polyvinyl alcohol polymers (PLA / PVA) at a concentration of 2% of the monoclonal antibody. The characterization of the nanoparticles was performed by the technique of scanning electron microscopy (SEM). The cytotoxicity assessment was performed by XTT assay with various cell lines of solid tumor cells. The labeling with technetium-99m was done by the direct method, and its yield determined by paper chromatography using paper Whatmam 1 as the stationary phase and acetone as mobile phase. In the biodistribution study

  13. Investigations of the metabolic behaviour of lespenephryl with the aid of radiopharmaceutical methods

    International Nuclear Information System (INIS)

    Murisasco, A.; Paulin, A.

    Some phases of the effect mechanisms of the two existing pharmaceutical forms of LESPENEPHRYL (R), were examined applying LESPENEPHRYL (R) labelled with tritium and non-labelled LESPENEPHRYL (R) in order to find out its points of affect with the help of the isotope method. The tests were carried out at rabbits and man, determining 1) the intestinal resorption and the excretion in the urin quantitatively 2) the distribution in the organism after intravenous injection 3) the effects on the renal function with the help of the isotopic-glomerular and tubular clearance-measurement 4) the kinetic distribution of the substance in animal organism in order to explain the metabolic behaviour better. Before starting the tests, problems of labelling, cleansing, and durability of tritium-labelled LESPENEPHRYL (R) were dealt with. (orig./MG) [de

  14. Quality assurance of radiopharmaceuticals-specifications and test procedures

    International Nuclear Information System (INIS)

    Baldas, J.; Bonnyman, J.; Pojer, P.M.

    1981-08-01

    This report is a compilation of test methods used and specifications adopted for the Radiopharmaceutical Quality Assurance Test Programme conducted by the Australian Radiation Laboratory. In some cases test procedures described have been taken from various Pharmacopoeias or methods published in the literature. In other cases test methods have been developed at the ARL

  15. Improvement of organic compounds labelling method with the use of thermally activated tritium gas

    International Nuclear Information System (INIS)

    Nejman, L.A.; Smolyakov, V.S.; Antropova, L.P.

    1982-01-01

    Use of a support (various types of papers) is recommended for organic compounds labelling by tritium gas activated at a hot tungsten filament. This improvement increases chemical and radiochemical yields and makes the experiment simpler and faster. Generally labelled triethyloxonium tetra-fluoroborate, ethyl-p-aminobenzoate, p-aminobenzoic acid (Na-salt), A-factor (a natural regulator of streptomycin biosynthesis), decapeptide angiotensin I, phospholipid 1, 2 - dimyristoyl-sn-glycero-3--phosphocholine and E. coli tRNAs have been prepared by this method. Molar radioactivity of the labelled compounds is in the range of 1-200 GBg/mmole [ru

  16. Five years of tritium handling experience at the Tritium Systems Test Assembly

    International Nuclear Information System (INIS)

    Carlson, R.V.

    1989-01-01

    The Tritium Systems Test Assembly (TSTA) at Los Alamos National Laboratory is a facility designed to develop and demonstrate, in full scale, technologies necessary for safe and efficient operation of tritium systems required for tokamak fusion reactors. TSTA currently consists of systems for evacuating reactor exhaust gas with compound cryopumps; for removing impurities from plasma exhaust gas and recovering the chemically-combined tritium; for separating the isotopes of hydrogen; for transfer pumping; or storage of hydrogen isotopes; for gas analysis; and for assuring safety by the necessary control, monitoring, and tritium removal from effluent streams. TSTA also has several small scale experiments to develop and test new equipment and processes necessary for fusion reactors. In this paper, data on component reliability, failure types and rates, and waste quantities are presented. TSTA has developed a Quality Assurance program for preparing and controlling the documentation of the procedures required for the design, purchase, and operation of the tritium systems. Operational experience under normal, abnormal, and emergency conditions is presented. One unique aspect of operations at TSTA is that the design personnel for the TSTA systems are also part of the operating personnel. This has allowed for the relatively smooth transition from design to operations. TSTA has been operated initially as a research facility. As the system is better defined, operations are proceeding toward production modes. The DOE requirements for the operation of a tritium facility like TSTA include personnel training, emergency preparedness, radiation protection, safety analysis, and preoperational appraisals. The integration of these requirements into TSTA operations is discussed. 4 refs., 3 figs., 3 tabs

  17. Chirality plays important roles in radiopharmaceuticals

    International Nuclear Information System (INIS)

    Shen Yumei

    2006-01-01

    The paper introduces the basic concept of chirality, target specific selectivity and their relationship in radiopharmaceuticals. If the ligands labeled by radionuclides have chiral center, the enantiomers must be separated, or the target specific selectivity will not be good. Chirality is one of the most important factors which must be considered in the study of the structure-activity relationship of radiopharmaceuticals. (authors)

  18. Tritium experience in the Tokamak Fusion Test Reactor

    International Nuclear Information System (INIS)

    Skinner, C.H.; Blanchard, W.; Hosea, J.; Mueller, D.; Nagy, A.; Hogan, J.

    1998-01-01

    Tritium management is a key enabling element in fusion technology. Tritium fuel was used in 3.5 years of successful deuterium-tritium (D-T) operations in the Tokamak Fusion Test Reactor (TFTR) at the Princeton Plasma Physics Laboratory. The D-T campaign enabled TFTR to explore the transport, alpha physics, and MHD stability of a reactor core. It also provided experience with tritium retention and removal that highlighted the importance of these issues in future D-T machines. In this paper, the authors summarize the tritium retention and removal experience in TFTR and its implications for future reactors

  19. Tritium experiments on components for fusion fuel processing at the Tritium Systems Test Assembly

    International Nuclear Information System (INIS)

    Konishi, S.; Yoshida, H.; Naruse, Y.; Carlson, R.V.; Binning, K.E.; Bartlit, J.R.; Anderson, J.L.

    1990-01-01

    Under a collaborative agreement between US and Japan, two tritium processing components, a palladium diffuser and a ceramic electrolysis cell have been tested with tritium for application to a Fuel Cleanup System (FCU) for plasma exhaust processing at the Los Alamos National Laboratory. The fundamental characteristics, compatibility with tritium, impurities effects with tritium, and long-term behavior of the components, were studied over a three year period. Based on these studies, an integrated process loop, ''JAERI Fuel Cleanup System'' equipped with above components was installed at the TSTA for full scale demonstration of the plasma exhaust reprocessing

  20. Radiolabeling of human platelets using four radiopharmaceuticals with Tc-99m

    International Nuclear Information System (INIS)

    Portillo L, M.C.; Godoy, C.

    1991-01-01

    The present investigation work has been done in an evaluation of four different radiopharmaceuticals with Tin II (Glucoheptonate, Pyrophosphate, Citrate and DTPA), with the purpose of determining which one of the four would be obtained a higher rate of radiolabeling of platelets with Tc-99m. In order to evaluate the four radiopharmaceuticals it was procede to the separation and labeling of the human platelets. It was worked with samples of blood from five pacients, and the platelets from each one of them were labeled with the radiopharmaceuticals-Tc-99m. Then was observed a significant difference among the four radiopharmaceuticals studied, with a reliable level of 0.05 being the Glucoheptonate-Tc-99m the best to label platelets, obtaining with the same 50.23% of labeling efficiency, while for DTPA, Pyrophosphate and Citrate, It was obtained 33.42%, 29.82% and |2.62% respectively. Also, it was studied the biodistribution of the labeled platelets, using Glucoheptonate-Tc-99m as a radiopharamceutical. The biodistribution was studied in white mice at different times and it was founded that the place of biodistribution of the labeled platelets is given in greater percentage in the liver, spleen, lungs and kydneis. (Author)

  1. Study of reactions of isotopic exchange of trans-zeatin with tritium

    International Nuclear Information System (INIS)

    Sidorov, G.V.; Myasoedov, N.F.

    2006-01-01

    Reactions of isotopic exchange of trans-zeatin with high-radioactive tritium water, with gaseous tritium in solution and solid-phase catalytic hydrogenation are studied to prepare trans-zeatin and dihydrozeatin labelled with tritium. It is shown that reaction of isotopic exchange of trans-zeatin with gaseous tritium both in solutions and without solvents at 160 Deg C and above leads to practically total hydrogenation of initial compound with formation of dihydrozeatin labelled with tritium. Isotopic exchange with tritium water permits to prepare zeatin labelled with tritium with 67 % yield and specific radioactivity 0.68 PBq/mol. It is determined that in the case of solid-phase isotopic exchange within 150-155 Deg C temperature interval both dihydrozeatin and trans-zeatin labelled with tritium are formed [ru

  2. Experimental nuclear medicine radiopharmaceutical development

    International Nuclear Information System (INIS)

    Harper, P.; Lathrop, K.

    1980-01-01

    This report summarizes progress that has been made on the preparation and biological accumulation of various radiopharmaceuticals including C-hexamethonium, C-cholic acid, Mn-51 and labeled amino acids

  3. Tritium activities in selected wells on the Nevada Test Site

    International Nuclear Information System (INIS)

    Lyles, B.F.

    1993-05-01

    Literature and data were reviewed related to radionuclides in groundwater on and near the Nevada Test Site. No elevated tritium activities have been reported outside of the major testing regions of the Nevada Test Site. Three wells were identified as having water with above-background (>50 pCi/l) tritium activities: UE-15d Water Well; USGS Water Well A; and USGS Test Well B Ex. Although none of these wells have tritium activities greater than the Nevada State Drinking Water standard (20,000 pCi/l), their time-series tritium trends may be indicative to potential on-site radionuclide migration

  4. Radiopharmaceuticals in China. Current status and prospects

    Energy Technology Data Exchange (ETDEWEB)

    Jia, Hong-Mei; Liu, Bo-Li [Beijing Normal Univ. (China). Key Laboratory of Radiopharmaceuticals

    2014-04-01

    The review provides an overview of the current status of radiopharmaceuticals in China for in vivo clinical use and also describes some important advances in the past three decades. Development of the diagnostic and therapeutic radiopharmaceuticals as well as basic research on radiopharmaceutical chemistry are being introduced. The radiotracers developed in China include: (1) Brain perfusion imaging agents and CNS radiotracers for β-amyloid plaques, σ{sub 1} receptors, and dopamine D{sub 2} or D{sub 4} receptors; (2) {sup 99m}Tc- and {sup 18}F-labeled myocardial perfusion imaging agents; (3) tumor imaging agents including integrin-targeting radiotracer, novel sentinel lymph node imaging agents, hypoxia imaging agents, {sup 99m}Tc-labeled glucose derivatives, σ{sub 2} receptor imaging agents, folate receptor imaging agents, and potential radiotracers for imaging of human telomerase reverse transcriptase expression; (4) Potential infection imaging agents; (5) Potential asialoglycoprotein receptor imaging agents; (6) Other imaging agents. Moreover, some prospects of research and development of radiopharmaceuticals in the near future are discussed. (orig.)

  5. A restricted access material for rapid analysis of [11C]-labeled radiopharmaceuticals and their metabolites in plasma

    International Nuclear Information System (INIS)

    Gillings, Nic

    2009-01-01

    Introduction: Analysis of the radioactive components in plasma taken during positron emission tomography (PET) measurements is often vital for the correct quantification of the PET data. The described high-performance liquid chromatography (HPLC) method has been developed to provide a fast, sensitive and robust method for the measurement of plasma samples from PET studies using [ 11 C]-labeled radiopharmaceuticals. Methods: Unadulterated plasma samples were analyzed directly, following a simple filtration, by the use of a small extraction column, containing a restricted access material, combined with a monolithic analysis column in a column-switching HPLC system. Results: Up to 4 ml of plasma was analyzed by this method within 4.5-7 min in a fully automated process. Because of the rapid analysis, a large number of samples could be analyzed during a 90-min PET scan. The extraction column could be used for analysis of up to 500 ml of plasma before replacement was required. Conclusions: The described method is fast and robust and the large sample volumes allow for accurate determination of the radioactive components in plasma even at 90 min after injection of a [ 11 C]-labeled radiopharmaceutical.

  6. A new technique of tritium labelling of neuraminidase from Vibrio cholerae

    International Nuclear Information System (INIS)

    Keune, D.

    1981-01-01

    By acylation of the free amino groups of the enzyme neuraminidase from Vibrio cholerae using N-[(2,3 - 3 H)-propionyloxy]-succinimide it was possible to transfer tritium-labelled propionyl groups to free amino groups of the enzyme glycoprotein. It was established by preliminary trials that a certain minimum concentration of protein was necessary to achieve a satisfactory degree of acylation. After the various processing stages, the acylation of neuraminidase with N-[(2,3 - 3 H)-propionyloxy]-succinimide led to the incorporation of 5.26 μCi radioactivity per mg enzymal protein. Comparison with a known method for neuraminidase labelling showed that the new process is more effective in terms of incorporation of radioactivity. Enzyme activity is inhibited by both methods. (orig./MG) [de

  7. Tritium-gas/water-vapor monitor. Tests and evaluation

    International Nuclear Information System (INIS)

    Jalbert, R.A.

    1982-07-01

    A tritium gas/water-vapor monitor was designed and built by the Health Physics Group at the Los Alamos National Laboratory. In its prototype configuration, the monitor took the shape of two separate instruments: a (total) tritium monitor and a water-vapor monitor. Both instruments were tested and evaluated. The tests of the (total) tritium monitor, basically an improved version of the standard flow-through ion-chamber instrument, are briefly reported here and more completely elsewhere. The tests of the water-vapor monitor indicated that the novel approach used to condense water vapor for scintillation counting has a number of serious drawbacks and that further development of the instrument is unwarranted

  8. Deuterium- and tritium-labelled compounds. Applications in the life sciences

    Energy Technology Data Exchange (ETDEWEB)

    Atzrodt, Jens; Derdau, Volker [Isotope Chemistry and Metabolite Synthesis, Integrated Drug Discovery, Medicinal Chemistry, Frankfurt (Germany); Kerr, William J.; Reid, Marc [Department of Pure and Applied Chemistry, WestCHEM, University of Strathclyde, Glasgow (United Kingdom)

    2018-02-12

    Hydrogen isotopes are unique tools for identifying and understanding biological and chemical processes. Hydrogen isotope labelling allows for the traceless and direct incorporation of an additional mass or radioactive tag into an organic molecule with almost no changes in its chemical structure, physical properties, or biological activity. Using deuterium-labelled isotopologues to study the unique mass-spectrometric patterns generated from mixtures of biologically relevant molecules drastically simplifies analysis. Such methods are now providing unprecedented levels of insight in a wide and continuously growing range of applications in the life sciences and beyond. Tritium ({sup 3}H), in particular, has seen an increase in utilization, especially in pharmaceutical drug discovery. The efforts and costs associated with the synthesis of labelled compounds are more than compensated for by the enhanced molecular sensitivity during analysis and the high reliability of the data obtained. In this review, advances in the application of hydrogen isotopes in the life sciences are described. (copyright 2018 Wiley-VCH Verlag GmbH and Co. KGaA, Weinheim)

  9. Uncertainty sources in radiopharmaceuticals clinical studies

    International Nuclear Information System (INIS)

    Degenhardt, Aemilie Louize; Oliveira, Silvia Maria Velasques de

    2014-01-01

    The radiopharmaceuticals should be approved for consumption by evaluating their quality, safety and efficacy. Clinical studies are designed to verify the pharmacodynamics, pharmacological and clinical effects in humans and are required for assuring safety and efficacy. The Bayesian analysis has been used for clinical studies effectiveness evaluation. This work aims to identify uncertainties associated with the process of production of the radionuclide and radiopharmaceutical labelling as well as the radiopharmaceutical administration and scintigraphy images acquisition and processing. For the development of clinical studies in the country, the metrological chain shall assure the traceability of the surveys performed in all phases. (author)

  10. A rapid kinetic chromogenic method for quantification of bacterial endotoxins in lyophilized reagents for labeling with 99mTc radiopharmaceuticals

    International Nuclear Information System (INIS)

    Fukumori, Neuza T.O.; Campos, Domingos G.; Silva, Laercio; Fernandes, Adriana V.; Mengatti, Jair; Silva, Constancia P.G.; Matsuda, Margareth M.N.

    2009-01-01

    A rapid quantitative kinetic chromogenic test in an automated Portable Test System (PTS) has been developed for determination of bacterial endotoxins in water, in-process and end-products using the Limulus amebocyte lysate (LAL). The aim of this work was to validate the method for lyophilized reagents for labeling with 99m Tc radiopharmaceuticals with no interfering factors. Experiments were performed in three consecutive batches of the lyophilized reagents Methylenediphosphonic Acid (MDP) and Pyrophosphate (PYRO) produced at IPEN-CNEN/ SP using the PTS from Endosafe, Inc. TM , Charleston, SC. The Maximum Valid Dilution (MVD) was calculated to establish the extent of dilution to avoid interfering test conditions (MVD=500). Better results were obtained above 1:20 dilution factor for MDP and 1:100 for PYRO. The parameters of coefficient correlation (R) -0.980, RPPC between 50 - 200% and coefficient variation (CV) of the samples less than 25% were satisfied and the endotoxin concentration was lower than the lowest concentration of the standard curve (0.05 EU mL -1 ), therefore less than the established limit in pharmacopoeias. The PTS is a rapid, simple and accurate technique using the quantitative kinetic chromogenic method for bacterial endotoxin determination. For this reason, it is very practical in the radiopharmaceutical area and it trends to be the method of choice for the pyrogen test. For MDP and PYRO, the validation was successfully performed. (author)

  11. Preparation of pyridostigmine bromide labeled with carbon-14 and tritium

    Energy Technology Data Exchange (ETDEWEB)

    Kepler, J.A.; Twine, C.E.; Austin, R.D. (Research Triangle Inst., Research Triangle Park, NC (United States))

    1992-08-01

    [2-[sup 14]C]Pyridostigmine bromide was prepared in 17.6% radiochemical yield with specific activity of 18 mCi/mmol. The reaction sequence involved preparation of 2-furan[[sup 14]C]carboxylic acid by carbonation of 2-lithiofuran, followed by conversion to 2-amino[[sup 14]C]methylfuran by lithium aluminium hydride reduction of its carboxamide. Oxidative rearrangement of 2-amino[[sup 14]C]methylfuran gave 3-hydroxy[2-[sup 14]C]pyridine which was converted to [2-[sup 14]C]pyridostigmine bromide by reaction with dimethylcarbamyl chloride and quarternization with bromomethane. Pyridostigmine bromide labeled in the methyl group of the carbamate function was prepared in 73% yield with specific activity of 37.6 mCi/mmol by reaction of bis-3-pyridyl carbonate with [[sup 14]C]dimethylamine followed by quarternization with bromomethane. [6-[sup 3]H]-Pyridostigmine bromide with specific activity of 22.5 mCi/mmol was prepared by catalytic halogen-tritium replacement of 2,6-dibromo-3-dimethylcarbamyloxypyridine followed by quarternization with bromomethane and back-exchanging the labile 2-tritium. (author).

  12. Preparation of pyridostigmine bromide labeled with carbon-14 and tritium

    International Nuclear Information System (INIS)

    Kepler, J.A.; Twine, C.E.; Austin, R.D.

    1992-01-01

    [2- 14 C]Pyridostigmine bromide was prepared in 17.6% radiochemical yield with specific activity of 18 mCi/mmol. The reaction sequence involved preparation of 2-furan[ 14 C]carboxylic acid by carbonation of 2-lithiofuran, followed by conversion to 2-amino[ 14 C]methylfuran by lithium aluminium hydride reduction of its carboxamide. Oxidative rearrangement of 2-amino[ 14 C]methylfuran gave 3-hydroxy[2- 14 C]pyridine which was converted to [2- 14 C]pyridostigmine bromide by reaction with dimethylcarbamyl chloride and quarternization with bromomethane. Pyridostigmine bromide labeled in the methyl group of the carbamate function was prepared in 73% yield with specific activity of 37.6 mCi/mmol by reaction of bis-3-pyridyl carbonate with [ 14 C]dimethylamine followed by quarternization with bromomethane. [6- 3 H]-Pyridostigmine bromide with specific activity of 22.5 mCi/mmol was prepared by catalytic halogen-tritium replacement of 2,6-dibromo-3-dimethylcarbamyloxypyridine followed by quarternization with bromomethane and back-exchanging the labile 2-tritium. (author)

  13. Radiopharmaceuticals for diagnosis. Final report

    Energy Technology Data Exchange (ETDEWEB)

    1994-03-01

    In the period 1969-1986, this project was directed to the evolution of target-specific labeled chemicals useful for nuclear medical imaging, especially radioactive indicators suited to tracing adrenal functions and localizing tumors in the neuroendocrine system. Since 1986, this project research has focused on the chemistry of positron emission tomography (PET) ligands. This project has involved the evaluation of methods for radiochemical syntheses with fluorine-18, as well as the development and preliminary evaluation of new radiopharmaceuticals for positron emission tomography. In the radiochemistry area, the ability to predict fluorine-18 labeling yields for aromatic substitution reactions through the use of carbon-13 NMR analysis was studied. Radiochemical yields can be predicted for some structurally analogous aromatic compounds, but this correlation could not be generally applied to aromatic substrates for this reaction, particularly with changes in ring substituents or leaving groups. Importantly, certain aryl ring substituents, particularly methyl groups, appeared to have a negative effect on fluorination reactions. These observations are important in the future design of syntheses of complicated organic radiopharmaceuticals. In the radiopharmaceutical area, this project has supported the development of a new class of radiopharmaceuticals based on the monoamine vesicular uptake systems. The new radioligands, based on the tetrabenazine structure, offer a new approach to the quantification of monoaminergic neurons in the brain. Preliminary primate imaging studies support further development of these radioligands for PET studies in humans. If successful, such radiopharmaceuticals will find application in studies of the causes and treatment of neurodegenerative disorders such as Parkinson`s disease.

  14. Tritium pellet injector for the Tokamak Fusion Test Reactor

    International Nuclear Information System (INIS)

    Gouge, M.J.; Baylor, L.R.; Combs, S.K.; Fisher, P.W.; Foust, C.R.; Milora, S.L.

    1992-01-01

    The tritium pellet injector (TPI) for the Tokamak Fusion Test Reactor (TFTR) will provide a tritium pellet fueling capability with pellet speeds in the 1- to 3-km/s range for the TFTR deuterium-tritium (D-T) plasma phase. An existing deuterium pellet injector (DPI) was modified at Oak Ridge National Laboratory (ORNL) to provide a four-shot, tritium-compatible, pipe-gun configuration with three upgraded single-stage pneumatic guns and a two-stage light gas gun driver. The TPI was designed for frozen pellets ranging in size from 3 to 4 mm in diameter in arbitrarily programmable firing sequences at tritium pellet speeds up to approximately 1.5 km/s for the three single-stage drivers and 2.5 to 3 km/s for the two-stage driver. Injector operation is controlled by a programmable logic controller (PLC). The new pipe-gun injector assembly was installed in the modified DPI guard vacuum box, and modifications were also made to the internals of the DPI vacuum injection line, including a new pellet diagnostics package. Assembly of these modified parts with existing DPI components was then completed and the TPI was tested at ORNL with deuterium pellets. Results of the testing program at ORNL are described. The TPI has been installed and operated on TFTR in support of the CY-92 deuterium plasma run period. In 1993, the tritium pellet injector will be retrofitted with a D-T fuel manifold and tritium gloveboxes and integrated into TFTR tritium processing systems to provide full tritium pellet capability

  15. Tritium

    International Nuclear Information System (INIS)

    Anon.

    1975-01-01

    The role played the large amount supply of tritium and its effects are broadly reviewed. This report is divided into four parts. The introductory part includes the history of tritium research. The second part deals with the physicochemical properties of tritium and the compounds containing tritium such as tritium water and labeled compounds, and with the isotope effects and self radiation effects of tritium. The third part deals with the tritium production by artificial reaction. Attention is directed to the future productivity of tritium from B, Be, N, C, O, etc. by using the beams of high energy protons or neutrons. The problems of the accepting market and the accuracy of estimating manufacturing cost are discussed. The expansion of production may bring upon the reduction of cost but also a large possibility of social impact. The irradiation problem and handling problem in view of environmental preservation are discussed. The fourth part deals with the use of tritium as a target, as a source of radiation or light, and its utilization for geochemistry. The future development of the solid tritium target capable of elongating the life of neutron sources is expected. The rust thickness of the surface of iron can be measured with the X-ray of Ti-T or Zr-T. The tritium can substitute self-light emission paint or lamp. The tritium is suitable for tracing the movement of sea water and land surface water because of its long half life. (Iwakiri, K.)

  16. Preparations for deuterium tritium experiments on the Tokamak Fusion Test Reactor

    International Nuclear Information System (INIS)

    Hawryluk, R.J.; Adler, H.; Alling, P.; Ancher, C.; Anderson, H.; Anderson, J.W.; Arunasalam, V.; Ascione, G.; Ashcroft, D.; Barnes, G.

    1994-04-01

    The final hardware modifications for tritium operation have been completed for the Tokamak Fusion Test Reactor (TFTR). These activities include preparation of the tritium gas handling system, installation of additional neutron shielding, conversion of the toroidal field coil cooling system from water to a Fluorinet trademark system, modification of the vacuum system to handle tritium, preparation and testing of the neutral beam system for tritium operation and a final deuterium-deuterium (D-D) run to simulate expected deuterium-tritium (D-T) operation. Testing of the tritium system with low concentration tritium has successfully begun. Simulation of trace and high power D-T experiments using D-D have been performed. The physics objectives of D-T operation are production of ∼ 10 megawatts (MW) of fusion power, evaluation of confinement and heating in deuterium-tritium plasmas, evaluation of α-particle heating of electrons, and collective effects driven by alpha particles and testing of diagnostics for confined α-particles. Experimental results and theoretical modeling in support of the D-T experiments are reviewed

  17. Preparations for deuterium--tritium experiments on the Tokamak Fusion Test Reactor*

    International Nuclear Information System (INIS)

    Hawryluk, R.J.; Adler, H.; Alling, P.; Ancher, C.; Anderson, H.; Anderson, J.L.; Anderson, J.W.; Arunasalam, V.; Ascione, G.; Aschroft, D.; Barnes, C.W.; Barnes, G.; Batchelor, D.B.; Bateman, G.; Batha, S.; Baylor, L.A.; Beer, M.; Bell, M.G.; Biglow, T.S.; Bitter, M.; Blanchard, W.; Bonoli, P.; Bretz, N.L.; Brunkhorst, C.; Budny, R.; Burgess, T.; Bush, H.; Bush, C.E.; Camp, R.; Caorlin, M.; Carnevale, H.; Chang, Z.; Chen, L.; Cheng, C.Z.; Chrzanowski, J.; Collazo, I.; Collins, J.; Coward, G.; Cowley, S.; Cropper, M.; Darrow, D.S.; Daugert, R.; DeLooper, J.; Duong, H.; Dudek, L.; Durst, R.; Efthimion, P.C.; Ernst, D.; Faunce, J.; Fonck, R.J.; Fredd, E.; Fredrickson, E.; Fromm, N.; Fu, G.Y.; Furth, H.P.; Garzotto, V.; Gentile, C.; Gettelfinger, G.; Gilbert, J.; Gioia, J.; Goldfinger, R.C.; Golian, T.; Gorelenkov, N.; Gouge, M.J.; Grek, B.; Grisham, L.R.; Hammett, G.; Hanson, G.R.; Heidbrink, W.; Hermann, H.W.; Hill, K.W.; Hirshman, S.; Hoffman, D.J.; Hosea, J.; Hulse, R.A.; Hsuan, H.; Jaeger, E.F.; Janos, A.; Jassby, D.L.; Jobes, F.C.; Johnson, D.W.; Johnson, L.C.; Kamperschroer, J.; Kesner, J.; Kugel, H.; Kwon, S.; Labik, G.; Lam, N.T.; LaMarche, P.H.; Laughlin, M.J.; Lawson, E.; LeBlanc, B.; Leonard, M.; Levine, J.; Levinton, F.M.; Loesser, D.; Long, D.; Machuzak, J.; Mansfield, D.E.; Marchlik, M.; Marmar, E.S.; Marsala, R.; Martin, A.; Martin, G.; Mastrocola, V.; Mazzucato, E.; McCarthy, M.P.; Majeski, R.; Mauel, M.; McCormack, B.; McCune, D.C.; McGuire, K.M.; Meade, D.M.; Medley, S.S.; Mikkelsen, D.R.; Milora, S.L.; Monticello, D.; Mueller, D.; Murakami, M.; Murphy, J.A.; Nagy, A.; Navratil, G.A.; Nazikian, R.; Newman, R.; Nishitani, T.; Norris, M.; O'Connor, T.; Oldaker, M.; Ongena, J.; Osakabe, M.; Owens, D.K.; Park, H.; Park, W.; Paul, S.F.; Pavlov, Y.I.; Pearson, G.; Perkins, F.; Perry, E.; Persing, R.; Petrov, M.; Phillips, C.K.; Pitcher, S.; Popovichev, S.; Qualls, A.L.; Raftopoulos, S.; Ramakrishnan, R.; Ramsey, A.; Rasmussen, D.A.; Redi, M.H.

    1994-01-01

    The final hardware modifications for tritium operation have been completed for the Tokamak Fusion Test Reactor (TFTR) [Fusion Technol. 21, 1324 (1992)]. These activities include preparation of the tritium gas handling system, installation of additional neutron shielding, conversion of the toroidal field coil cooling system from water to a Fluorinert TM system, modification of the vacuum system to handle tritium, preparation, and testing of the neutral beam system for tritium operation and a final deuterium--deuterium (D--D) run to simulate expected deuterium--tritium (D--T) operation. Testing of the tritium system with low concentration tritium has successfully begun. Simulation of trace and high power D--T experiments using D--D have been performed. The physics objectives of D--T operation are production of ∼10 MW of fusion power, evaluation of confinement, and heating in deuterium--tritium plasmas, evaluation of α-particle heating of electrons, and collective effects driven by alpha particles and testing of diagnostics for confined α particles. Experimental results and theoretical modeling in support of the D--T experiments are reviewed

  18. Tritium labeling of a powerful methylphosphonate inhibitor of cholinesterase: synthesis and biological applications

    International Nuclear Information System (INIS)

    Balan, A.; Barness, I.; Simon, G.; Levy, D.; Ashani, Y.

    1988-01-01

    7-(Methylethoxy phosphinyloxy)-1-methyl-quinolinium iodide (MEPQ), a powerful anti-cholinesterase methylphosphonate ester, was labeled with tritium (9 Ci/mmol) at the methylphosphonyl moiety (TCH2P(O)(OR)X) by an iodine-tritium replacement reaction. Kinetic measurements of the rate of inhibition of acetylcholinesterase (AChE) by [ 3 H]MEPQ and its rate of hydrolysis in alkaline solution confirmed the identity of [ 3 H]MEPQ with authentic MEPQ, which was prepared by the same reaction sequences. Gel-filtration experiments verified the radiospecificity of [ 3 H]MEPQ. In vitro radiolabeling of both AChE and butyrylcholinesterase along with the whole-body autoradiography of [ 3 H]MEPQ-treated mice suggests that [ 3 H]MEPQ is a convenient marker for studying biological systems containing these esterases

  19. Use of technegas as a radiopharmaceutical for the measurement of gastric emptying

    Energy Technology Data Exchange (ETDEWEB)

    Kwiatek, M.A. [School of Medical Radiation, University of South Australia, Adelaide (Australia); Jones, K.L. [School of Medical Radiation, University of South Australia, Adelaide (Australia)]|[Department of Medicine, Royal Adelaide Hospital, The University of Adelaide, Adelaide (Australia); Burch, W.M. [John Curtin School of Medical Research, Australian National University, Australian Capital Territory (Australia); Horowitz, M. [Department of Medicine, Royal Adelaide Hospital, The University of Adelaide, Adelaide (Australia); Bartholomeusz, F.D.L. [Department of Nuclear Medicine, Royal Adelaide Hospital, Adelaide (Australia)

    1999-08-01

    Many radiopharmaceuticals and test meals that are used to measure gastric emptying are less than optimal. A vegetable-based solid meal, such as rice, labelled with a radiopharmaceutical that also has the capacity to measure gastric emptying of liquids, is likely to be ideal. The role of Technegas as a radioisotopic marker to measure gastric emptying of rice and liquids was evaluated. Technegas-labelled rice was incubated in 0.9% saline, 1 M HCl and simulated gastric fluid (3.2 g/l pepsinogen, pH 2-3) to assess stability of the label. In eight healthy volunteers gastric emptying of two meals - 200 g rice (370 kcal) and 75 g dextrose dissolved in 300 ml water (300 kcal), both labelled with 20 MBq of Technegas - was measured scintigraphically. Over 4 h, the average label stability was 93.7%{+-}0.5% in 0.9% saline, 91.0%{+-}0.4% in 1 M HCl and 93.6%{+-}0.7% in simulated gastric juice. The lag phase was longer for rice than dextrose (25{+-}7 min vs 4{+-}2 min; P<0.05), but there was no difference in the post-lag emptying rate (2.1{+-}0.3 kcal/min vs 1.7{+-}0.2 kcal/min; P=0.2) between the two meals. We conclude that Technegas is a suitable radiopharmaceutical for measurement of gastric emptying of rice and nutrient-containing liquids. (orig.) With 2 figs., 16 refs.

  20. Synthesis and tritium labeling of the food mutagens IQ and methyl-IQ

    International Nuclear Information System (INIS)

    Waterhouse, A.L.; Rapoport, H.

    1985-01-01

    The mutagens found in cooked meat, 2-amino-3-methylimidazo[4,5-f]-quinoline (IQ) and 2-amino-3,4-dimethylimidazo[4,5-f]quinoline (Methyl-IQ), have been synthesized by unambiguous methods that allow for the preparation of sufficient quantities of material for biological studies. These methods avoid difficult separations of regioisomeric mixtures of products and incorporate specific high level tritium labeling, effected by hydrogenolysis of the appropriately substituted 5-bromo precursors. (author)

  1. Synthesis of canrenone and related steroids labelled with tritium, carbon-14, and sulfur-35

    International Nuclear Information System (INIS)

    Markos, C.S.; Dorn, C.R.; Zitzwitz, D.J.

    1988-01-01

    The syntheses of [1- 3 H]canrenone, [1- 3 H]spironolactone, [1- 3 H] potassium canrenoate, [22- 14 C]canrenone, [22- 14 C]spironolactone, [22- 14 C]potassium canrenoate, and [ 35 S]spironolactone are reported. Tritium labelled compounds were obtained by catalytic reduction of a 3-keto-1, 4-diene precursor followed by exchange of enolizable label. Carbon-14 compounds were obtained by reaction of a 17-ethynyl steroid with 14 CO 2 . Sulfur-35 spironolactone was synthesized by the in-situ generation of [ 35 S]thiolacetic acid from [ 35 S]sodium sulfide. (author)

  2. Radiopharmaceutical labeling research

    International Nuclear Information System (INIS)

    Anon.

    1985-01-01

    The objective of this research is to develop methods of attaching radionuclides to monoclonal antibodies and antibody fragments for use in tumor imaging and internal radiation therapy. Monoclonal antibodies and their fragments are of interest because they enable the selective targeting of tumors. The labeled antibodies could be employed as carriers to transport radioisotopes to tumors, thus minimizing total-body radiation dose and radiation damage to normal tissue. Because the time required for labeled antibodies to find the tumor antigen and deliver the dose to the tumor is estimated to be about 1-3 days, radionuclides with a l- to 3-day half-life would be optimum for this purpose. Two of the radionuclides produced at LAMPF, 67 Cu and 77 Br, have the suitable half-life and nuclear-decay properties for use in tumor imaging or therapy with radiolabeled antibodies. These radionuclides and the efforts to prepare radiolabeled antibodies with them are described. We have used three different approaches to meet this objective of labeling antibodies: (1) labeling chelating agents with metal radionuclides, then conjugating the labeled chelating agents to antibodies; (2) conjugating activated chelating agents to antibodies, followed by metalation with metal radionuclides; and (3) radiobrominating small molecules that can be conjugated to antibodies

  3. Radiopharmaceuticals for nuclear cardiology; Radiofarmacos para cardiologica nuclear

    Energy Technology Data Exchange (ETDEWEB)

    Leon Cabana, Alba [Universidad de la Republica, Facultad de Quimica (Uruguay)

    1994-12-31

    One of the diagnostic technique periodically used in Nuclear Medicine is the angiographic studi e, employee for detect cardiovascular diseases. The radiopharmaceutical more used in the angiographic ones is 99mTc. Between thetopics described in the present work it find: myocardial infarction, radiopharmaceuticals classification for cardiac studies, labelled proceedings, cardiovascular diseases.

  4. Radiopharmaceuticals using radioactive compounds in pharmaceutics and medicine

    International Nuclear Information System (INIS)

    Theobald, A.

    1989-01-01

    This review of the latest techniques and developments indicates the importance of radiopharmaceutical techniques in the development of drug compounds. It presents practical demonstrations, offers practical exercises, as well as the underlying theoretical considerations: it will supplement existing (mostly American) texts in this subject, since most industrial pharmaceutical companies have a keen interest in the area and most pharmaceutical courses include the subject at degree level. The authors emphasize the pharmaceutical applications throughout. They review targeting aspects, including cell and protein labelling: and discuss radiotracers in testing dosage forms and formulation studies. Safety and legislation are considered, with reviews of the handling techniques, radiation monitoring, radiochromatography and the use of computer techniques. The latter part of the work discusses standards for radiopharmaceuticals, sterility and pyrogen testing, as well as both radiochromatographic and electrophoretic methods and their importance to quality control. (author)

  5. Method of preparing tritium-labelled thymidine-5'-monophosphates of high specific activity

    International Nuclear Information System (INIS)

    Filip, J.; Vesely, J.; Cihak, A.

    1976-01-01

    A method is described of preparing thymidine-5'-monophosphates labelled with tritium of high specific activity based on enzyme synthesis in vitro. Phosphorylation was carried out using the catalytic effect of an enzyme contained in the supernatant fraction prepared from Yoshida ascites carcinoma in rats. The course of the enzyme reaction can be controlled by the concentration of the individual reaction mixture components. The method described allows obtaining thymidine-5'-monophosphate of radiochemical purity better than 95%. (J.B.)

  6. Tritium test of the tritium processing components under the Annex III US-Japan Collaboration

    International Nuclear Information System (INIS)

    Konishi, Satoshi; Yoshida, Hiroshi; Naruse, Yuji; Binning, K.E.; Carlson, R.V.; Bartlit, J.R.; Anderson, J.L.

    1993-03-01

    The process ready components for Fuel Cleanup System were tested at the TSTA under the US-Japan Collaboration program. Palladium diffuser for tritium purification and Ceramic Electrolysis Cell for decomposition of tritiated water respectively were tested with pure tritium for years. The characteristics of the components with hydrogen isotopes, effects of impurities, and long-term reliability of the components were studied. It was concluded that these components are suitable and attractive for fusion fuel processing systems. (author)

  7. Tritium systems test assembly stabilization

    International Nuclear Information System (INIS)

    Jasen, William G.; Michelotti, Roy A.; Anast, Kurt R.; Tesch, Charles

    2004-01-01

    The Tritium Systems Test Assembly (TSTA) was a facility dedicated to tritium technology Research and Development (R and D) primarily for future fusion power reactors. The facility was conceived in mid 1970's, operations commenced in early 1980's, stabilization and deactivation began in 2000 and were completed in 2003. The facility will remain in a Surveillance and Maintenance (S and M) mode until the Department of Energy (DOE) funds demolition of the facility, tentatively in 2009. A safe and stable end state was achieved by the TSTA Facility Stabilization Project (TFSP) in anticipation of long term S and M. At the start of the stabilization project, with an inventory of approximately 140 grams of tritium, the facility was designated a Hazard Category (HC) 2 Non-Reactor Nuclear facility as defined by US Department of Energy standard DOE-STD-1027-92 (1997). The TSTA facility comprises a laboratory area, supporting rooms, offices and associated laboratory space that included more than 20 major tritium handling systems. The project's focus was to reduce the tritium inventory by removing bulk tritium, tritiated water wastes, and tritium-contaminated high-inventory components. Any equipment that remained in the facility was stabilized in place. All of the gloveboxes and piping were rendered inoperative and vented to atmosphere. All equipment, and inventoried tritium contamination, remaining in the facility was left in a safe-and-stable state. The project used the End Points process as defined by the DOE Office of Environmental Management (web page http://www.em.doe.- gov/deact/epman.htmtlo) document and define the end state required for the stabilization of TSTA Facility. The End Points process added structure that was beneficial through virtually all phases of the project. At completion of the facility stabilization project the residual tritium inventory was approximately 3,000 curies, considerably less than the 1.6-gram threshold for a HC 3 facility. TSTA is now

  8. Necessity for quality assurance tests of tritium gas

    International Nuclear Information System (INIS)

    Bender, L.; Bhat, R.; Guadagno, J.; Sotomayor, R.; Funkhouser, M.; Plasket, E.

    1989-01-01

    For the past 20 years, the U.S. Army has used self-illuminating tritium excited phosphor vials inside the Lensatic compass for night illumination. Tritium was selected as the illuminating mechanism based on calculations from its half-life that projected its field life to be 12 years. Studies conducted by the Radiation Research Group detected deficiencies between the actual luminosity life of the compass and the projected life. Based on this observation, the group conducted subsequent studies to determine if the discrepancy could be attributed to the phosphor or the composition of the tritium contained in the vial. These studies revealed that the composition of tritium gas used in the compass did not match the specifications set for the gas. The group has since incorporated rigorous quality controls in the specifications to avoid future discrepancies. This work has pointed out the need for all tritium vial users to establish specifications and quality control tests for tritium vials

  9. Application of tritium-labeled complex technical mixture of PCB congeners as radiotracer in ecological investigations

    International Nuclear Information System (INIS)

    Kim, A.A.

    2005-01-01

    The quantitative analysis of PCBs (polychlorinated biphenyls) is enough difficult analytical task. According to IUPAC nomenclature it is described more than 200 possible PCB congeners from which about 150 congeners are present at an environment. At the same time in environment PCBs are present as complex technical mixes of congeners (trade names include Apirolio, Aroclor, Clophen, Fenchlor, Kanechlor, Phenoclor, Pyralene, Pyranol, Pyroclor, Santotherm FR, and Sovol). In routine practice of gas chromatography analysis the quantitative measurement of PCB marker congeners is applied. In the most samples containing PCBs, there are often several dozens of different congeners. For practical reasons, all of them are not always measured, but the most important congeners are used as indicators. In Belgian chicken incident, only seven abundant congeners were usually measured: congeners with IUPAC numbers 28, 52, 101, 118, 138, 153, and 180 (2,4,4 '-TriCB, 2,2 ', 5,5 '-TCB, 2,2 ', 4,5,5 '-PeCB, 2,3 ', 4,4 ', 5-PeCB, 2,2 ', 3,4,4 ', 5 '-HxCB, 2,2 ', 4,4 ', 5,5 '-HxCB, 2,2 ', 3,4,4 ', 5,5 '-HpCB, respectively). The seven congeners are estimated to constitute about one third of all PCBs in the contaminated feed. Such measurement can give the big error in a quantitative estimation of PCBs contents in a sample. As alternative method of quantitative measurement PCBs the radiochemical method with use radioactive labeled PCBs as radiotracer can be used. We had been developed a method of synthesis of labeled by thermally activated tritium a complex technical mixture of PCBs congeners - Sovol. We had been showed a basic opportunity of receiving of uniformly tritium labeled mixture of PCBs congeners without structural failure of mixture. The tritium labeled preparation of complex technical mixture of PCBs congeners (Sovol) has been received. On the basis of received tritium labeled preparation of PCBs (Sovol) we had been developed the following quantitative and qualitative radiochemical

  10. Obtaining a metastasis model in vivo for the evaluation of the radiopharmaceuticals sensitivity labeled with 99mTc

    International Nuclear Information System (INIS)

    Gonzalez A, V. M.

    2015-01-01

    Nuclear medicine currently has a wide range of techniques that support the diagnosis of various diseases, including cancer that prevails as the most important. In the present research work was proposed to develop a model that would study the process known as metastasis, because this process is vital because most of the deaths in patients with some form of cancer are caused by metastasis. The objective was to obtain an in vivo model of metastasis induced with AR42J cells for studying the radiopharmaceuticals sensitivity labeled with 99m Tc. To achieve the objective proposed a study model in which it could make a real time evaluation of some radiopharmaceuticals with reported efficiency was development, in order to determine their sensitivity in similar conditions to the metastasis process. This required a mouse model that was used to observe a similar process to metastasis, inducing cells of the AR42J cell line, since these cells have good proliferation and have molecular targets for a minimum of 3 standardized radiopharmaceuticals. Was elected radionuclide 99m Tc, because of its low emission of radiation into the tissues, besides having a half life of 6 hours and provides a good visualization of anatomical structures. On the other hand the stable expression of green fluorescent protein in tumor cells appears to be a suitable tool for the detection of cancer development in early stages and the formation of in vivo micro metastases, so two fluorescence tests were performed and other by electrophoresis. The results showed that both study models can be carried out without increasing complexity and meeting the expectations expected for which they were designed. (Author)

  11. Effect of experimental conditions on the stability of Tc-99m radiopharmaceuticals

    International Nuclear Information System (INIS)

    Vucina, J.

    2002-01-01

    The stability of three 99m Tc radiopharmaceuticals in dependence on the experimental conditions and on the presence of some chemical stabiliser was tested. Examined were dimercapto succinate (DMS), pyrophosphate (PyP) and 2,3-dicarboxypropane-1,1-diphosphonate (DPD). The reliability and applicability of the preparation of the three radiopharmaceuticals from the inactive (technetium-cold) kit solutions were tested. Each kit was dissolved in saline (0.9% NaCl). The storage conditions of the inactive kit solutions before labelling were determined. The main problem is the stability of the reductant stannous ions which is very difficult to predict. Ascorbic or gentisic acid was added in order to stabilise the labelled radiopharmaceuticals and ensure their good quality. The best results were obtained by keeping the samples at -20 deg C. Although either stabiliser can be used, much lower concentrations of ascorbic acid are sufficient for an effective protection. Its concentrations of 12-60 μg/ml of the kit stabilise DMS and PyP for about 7-8 days. The solution of DPD was stable even without any stabiliser, presumably dut to the chemical nature of this complex. In routine practice, however, the procedure requires caution, and the staff should be very experienced in radiopharmacy procedures

  12. Radioactively labelled substances for in vivo and in vitro tests from the time of their production up to their use in nuclear medicine

    International Nuclear Information System (INIS)

    Riccato, M.T.

    1976-01-01

    Most important production steps and control tests applied to radionuclides and radioactive labelled compounds used in nuclear medicine are described. Radiopharmaceutical products are subdivided in products for therapy and for in vivo and in vitro diagnostics tests. (orig./HP) [de

  13. Harvard-MIT research program in short-lived radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Adelstein, S.J.

    1991-01-01

    This report presents research on radiopharmaceuticals. The following topics are discussed: antibody labeling with positron-emitting radionuclides; antibody modification for radioimmune imaging; labeling antibodies; evaluation of technetium acetlyacetonates as potential cerebral blood flow agents; and studies in technetium chemistry. (CBS)

  14. Analysis of Tritium Breeding in the Test Module

    Energy Technology Data Exchange (ETDEWEB)

    Hong, SeongHee; Park, YunSeo; Kim, Myung Hyun [Kyung Hee University, Yongin (Korea, Republic of)

    2015-10-15

    In this paper, neutronic analyses are conducted on redesign of TMs which have high tritium breeding performance based on results of previous study. Calculation model is simplified, there is no effect to cover very complex geometry of fusion reactor for this study. As spent fuel disposal problem is issued in nuclear industry, FFHR is one of the most fascinating candidates for solving this problem through waste transmutation. Our research team also was designed a full core FFHR for waste transmutation. However, in this study, Test Module (TM) as test bed of FFHR for various purposes are analyzed. Analysis of tritium breeding on the TM was conducted as a first phase among TMs having various purposes. Because there are no fissionable materials in the TM for tritium breeding, geometry and neutronic reactions of its simpler compared to TM for waste transmutation and power production. Additionally, it is important database for tritium self-sufficiency as basic design condition of TM. In the previous study, neutronic analyses are conducted on these various TMs: Helium cooled solid breeder (HCSB), water cooled solid breeder (WCSB), Helium cooled dual breeder (HCDB) and molten-salt cooled liquid breeder (MSLB) in order to understand design characteristics. Neutronics calculations are performed with MCNPX 2.6.0 with ENDF/B-VII.0 neutron cross section library and activity and time-dependent tritium production calculations are performed with CINDER'90. In this paper, analysis of tritium breeding on WCHESL and WCHELL as TM is conducted. WCHESL is designed for effective tritium breeding performance and it satisfies design conditions. On the other hand WCHELL is designed for tritium breeding as much as possible and it also satisfies design conditions. However, neutron multiplication performance with these TM is not outstanding. WCHESL consist ceramic Li breeder, its period is 4.15E+08 sec.

  15. In vitro study of proteins surface activity by tritium probe

    International Nuclear Information System (INIS)

    Chernysheva, M.G.; Badun, G.A.

    2010-01-01

    A new technique for in vitro studies of biomacromolecules interactions, their adsorption at aqueous/organic liquid interfaces and distribution in the bulk of liquid/liquid systems was developed. The method includes (1) tritium labeling of biomolecules by tritium thermal activation method and (2) scintillation phase step with organic phase, which can be concerned as a model of cellular membrane. Two globular proteins lysozyme and human serum albumin tested. We have determined the conditions of tritium labeling when labeled by-products can be easy separated by means of dialysis and size-exclusion chromatography. Scintillation phase experiments were conducted for three types of organic liquids. Thus, the influences of the nature of organic phase on proteins adsorption and its distribution in the bulk of aqueous/organic liquid system were determined. It was found that proteins possess high surface activity at aqueous/organic liquid interface. Furthermore, values of hydrophobicity of globular proteins were found by the experiment. (author)

  16. Deficiencies in product labelling instructions and quality control directions for 99mTc radiopharmaceuticals.

    Science.gov (United States)

    Buroni, Federica E; Lodola, Lorenzo; Persico, Marco G; Aprile, Carlo

    2014-02-01

    The aim of the study was to identify deficiencies in product labelling instructions for reconstitution and in the quality control directions detailed in the technical leaflets (TLs) or summary product characteristic (SPC) sheets of commonly used technetium labelling cold kits. The reconstitution and quality control directions in 25 TLs/SPCs were evaluated to identify deficiencies, incompleteness, restrictions, errors, impracticability, and vagueness. In addition, their congruence with the statements given in the relative European Pharmacopoeia (Ph. Eur. VII ed.) monography and diagnostic reference levels of Directive 97/43/EURATOM was evaluated. Deficiencies in information were scored and classified into five categories: 1, absent or incomplete; 2, restrictive; 3, inconsistent or wrong; 4, impractical; and 5, vague. In the 25 documents analyzed a total of 141 deficiencies were found (corresponding to 40.2% of the total scores assigned), and more frequently they pertained to quality control procedures (70.9%), followed by those related to quantitative composition (14.9%), preparation (8.5%), and particle size (5.7%). Nearly 80% of these deficiencies were classified as type 1 - that is, absent or incomplete information. The indications in TLs and SPCs should provide useful information for maintaining the quality and purity of the radiopharmaceutical preparation and ensure the safety level and effectiveness required by law. However, the instructions are often suboptimal or even erroneous, and consequently there are countless failures or difficulties, which represent an impediment to good laboratory practice. We believe that a 'smart' review of radiopharmaceutical documentation would be beneficial in order to align these indications to the real needs of the operators involved in routine in-house nuclear medicine practice.

  17. International symposium on trends in radiopharmaceuticals (ISTR-2005). Book of extended synopses

    International Nuclear Information System (INIS)

    2005-01-01

    Radiopharmaceuticals, along with imaging instrumentation, are the pillars that support the edifice of clinical nuclear medicine and the former is the major driver enabling investigations of molecular phenomena for better understanding of human disease and developing effective treatments. The growth of nuclear medicine has been intimately linked to availability of new radioisotopes and the discovery of new radiopharmaceuticals. The field of radiopharmaceuticals has witnessed continuous evolution thanks to the immense contributions of scientists from diverse disciplines such as radiochemistry, inorganic chemistry, organic chemistry, biochemistry, physiology and pharmacology. Several milestones can be cited in the trajectory of this growth, which include continuing development of a plethora of 99 mTc radiopharmaceuticals, automated synthesis of 18 F labelled compounds, labelled peptides for accurate mapping of metastasis and the advances in radionuclide therapy. The International Symposium on Trends in Radiopharmaceuticals, ISTR-2005, under the auspices of International Atomic Energy Agency, will provide scientists and professionals working in the field of radiopharmaceuticals and related sciences an opportunity to review the exciting developments in the field. The International Atomic Energy Agency has been organizing such Symposia on Radiopharmaceuticals since 1973 and the last one was held in Lisbon, Portugal, in 1998

  18. International symposium on trends in radiopharmaceuticals (ISTR-2005). Book of extended synopses

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    2005-07-01

    Radiopharmaceuticals, along with imaging instrumentation, are the pillars that support the edifice of clinical nuclear medicine and the former is the major driver enabling investigations of molecular phenomena for better understanding of human disease and developing effective treatments. The growth of nuclear medicine has been intimately linked to availability of new radioisotopes and the discovery of new radiopharmaceuticals. The field of radiopharmaceuticals has witnessed continuous evolution thanks to the immense contributions of scientists from diverse disciplines such as radiochemistry, inorganic chemistry, organic chemistry, biochemistry, physiology and pharmacology. Several milestones can be cited in the trajectory of this growth, which include continuing development of a plethora of {sup 99}mTc radiopharmaceuticals, automated synthesis of {sup 18}F labelled compounds, labelled peptides for accurate mapping of metastasis and the advances in radionuclide therapy. The International Symposium on Trends in Radiopharmaceuticals, ISTR-2005, under the auspices of International Atomic Energy Agency, will provide scientists and professionals working in the field of radiopharmaceuticals and related sciences an opportunity to review the exciting developments in the field. The International Atomic Energy Agency has been organizing such Symposia on Radiopharmaceuticals since 1973 and the last one was held in Lisbon, Portugal, in 1998.

  19. Labeled estrogens as mammary tumor probes

    International Nuclear Information System (INIS)

    Feenstra, A.

    1981-01-01

    In this thesis estrogens labeled with a gamma or positron emitting nuclide, called estrogen-receptor binding radiopharmaceuticals are investigated as mammary tumour probes. The requirements for estrogen-receptor binding radiopharmaceuticals are formulated and the literature on estrogens labeled for this purpose is reviewed. The potential of mercury-197/197m and of carbon-11 as label for estrogen-receptor binding radiopharmaceuticals is investigated. The synthesis of 197 Hg-labeled 4-mercury-estradiol and 2-mercury-estradiol and their properties in vitro and in vivo are described. It appears that though basically carbon-11 labeled compounds are very promising as mammary tumour probes, their achievable specific activity has to be increased. (Auth.)

  20. Tritium as an indicator of venues for nuclear tests.

    Science.gov (United States)

    Lyakhova, O N; Lukashenko, S N; Mulgin, S I; Zhdanov, S V

    2013-10-01

    Currently, due to the Treaty on the Non-proliferation of Nuclear Weapons there is a highly topical issue of an accurate verification of nuclear explosion venues. This paper proposes to consider new method for verification by using tritium as an indicator. Detailed studies of the tritium content in the air were carried in the locations of underground nuclear tests - "Balapan" and "Degelen" testing sites located in Semipalatinsk Test Site. The paper presents data on the levels and distribution of tritium in the air where tunnels and boreholes are located - explosion epicentres, wellheads and tunnel portals, as well as in estuarine areas of the venues for the underground nuclear explosions (UNE). Copyright © 2013 Elsevier Ltd. All rights reserved.

  1. Synthesis and characterization of tritium labeled N-((R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-3-sulfamoylbenzamide.

    Science.gov (United States)

    Hong, Yang; Hynes, John; Tian, Yuan; Balasubramanian, Balu; Bonacorsi, Samuel

    2015-08-01

    N-((R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-3-sulfamoylbenzamide is a potent C-C chemokine receptor 1 (CCR1) antagonist. The compound, possessing benzamide functionality, successfully underwent tritium/hydrogen (T/H) exchange with an organoiridium catalyst (Crabtree's catalyst). The labeling pattern in the product was studied with liquid chromatography-mass spectrometry, time-of-flight mass spectrometry, and (3) H-NMR. Overall, multiple labeled species were identified. In addition to the anticipated incorporation of tritium in the benzamide moiety, tritium labeling was observed in the valine portion of the molecule including substitution at its chiral carbon. Using authentic standards, liquid chromatography analysis of the labeled compound showed complete retention of stereochemical configuration. Copyright © 2015 John Wiley & Sons, Ltd.

  2. New blood flow radiopharmaceutical

    International Nuclear Information System (INIS)

    Sargent, T. III; Shulgin, A.T.; Mathis, C.A.; Budinger, T.F.

    1983-01-01

    Our program for research into the causes of mental disorders such as schizophrenia, manic depressive illness and senile dementia has led us to the development of a new radiopharmaceutical agent, IDNNA (4-iodo-2,5-dimethoxy-N,N-dimethylamphetamine). A series of some 15 different 131 I labeled molecules with various substitutions on the amine were synthesized and tested, and the uptake of the 131 I labeled conpounds in rats was measured. The dimethyl amine (IDNNA) had the best brain uptake and brain/blood ratio. When injected into a dog and scanned with a whole-body scanner, the uptake in the brain could be clearly seen and quantified. Plasma sampling at the same time showed that the maximum brain/blood ratio of 8.7 occurred at 8 min after injection, and the concentration in brain remained high for at least 15 min. Labeling is achieved by reacting 131 ICl and the precursor, 2,5-dimethoxy-N,N-dimethyl amphetamine, in glacial acetic acid; the reaction is complete in less than one minute

  3. 'Serial review on clinical PET tracers'. Manufacturing and quality control of positron emitting radiopharmaceuticals produced by in-house cyclotron

    International Nuclear Information System (INIS)

    Saji, Hideo

    2009-01-01

    In order to establish PET diagnosis as a routine clinical tool, manufacture's compliance with regulations under the Good Manufacturing Practice (GMP) principle for PET radiopharmaceuticals is necessary. For this purpose, the Sub-committee on Medical Application of Positron Emitting Radionuclides, Medical Science and Pharmaceutical Committee of Japan Radioisotopes Association has proposed 'Standards for Compounds Labeled with Emitting Radionuclides Approved as Established Techniques for Medical Use'. This guideline includes the general notices, general rules for preparations, general tests for the quality control, quality of each PET agents, guideline for manufacturing environment and manufacturing process at manufacturing facilities of PET agents. Each facility should have a committee and establish an internal system to account for manufacturing compounds labeled with positron emitting radionuclides produced in the facility, and compile standards by referring to the 'Established Standard Techniques of Labeling Compounds with Emitting Radionuclides for use as Radiopharmaceuticals: approved by the Subcommittee on Medical Application of Cyclotron-Produced Radionuclides (revised in 2009)', in order to maintain the quality of radiopharmaceuticals. (author)

  4. Process for preparing radiopharmaceuticals

    International Nuclear Information System (INIS)

    Barak, M.; Winchell, H.S.

    1977-01-01

    A process for the preparation of technetium-99m labeled pharmaceuticals is disclosed. The process comprises initially isolating technetium-99m pertechnetate by adsorption upon an adsorbent packing in a chromatographic column. The technetium-99m is then eluted from the packing with a biological compound to form a radiopharmaceutical

  5. Sixth international symposium on radiopharmaceutical chemistry: Abstracts: Final report

    International Nuclear Information System (INIS)

    1986-01-01

    The 113 abstracts are arranged under the following section headings: alkyl spiperone derivatives labeled with fluorine, synthesis of compounds labeled with positron emitters, technetium compounds, positron emitters (target design and synthesis), indium and gallium, halogens, labeled proteins and antibodies, radiopharmaceuticals for brain and SPECT, general, and receptor radioligands

  6. Tritium Labelling by Means of Uranium Hydride; Marquage au Tritium au Moyen d'Hydrure d'Uranium; 0414 0435 0447 ; Marcacion con Tritio por Medio de Hidruro de Uranio

    Energy Technology Data Exchange (ETDEWEB)

    Felter, R. E.; Currie, L. A. [Pennsylvania State University, University Park, PA (United States)

    1962-02-15

    A new and efficient method for introducing tritium into organic molecules has been observed. Labelling is accomplished by exposure of the organic vapour to heated uranium tritide. In experiments with n-pentane and with ethylene, the principal labelled products were the tritiated parent molecules. The rates of tritium incorporation varied from about 0.2 to 10.0% (of initial tritium) per hour. The mechanism of the reaction has been demonstrated to be not a result of radiation chemistry, but rather a direct reaction of hydrogen atoms from the surface with the hydrocarbon. In addition to the rapid labelling with a significant fraction of the tritium present, the method has another unique advantage : tritium which has not reacted with the organic vapour may be removed from the gas phase simply by cooling the reaction vessel to room temperature. (author) [French] Les auteurs ont mis au point une methode nouvelle et efficace pour introduire le tritium dans les molecules de substances organiques. Le marquage est realise par exposition de la substance organique sous forme de vapeur au tritide Bullet d'uranium chauffe. Dans des experiences avec le n-pe.ntane et l'ethylene, les principaux produits marques ont ete les molecules meres tritiees. Le taux d'incorporation du tritium a varie d'environ 0,2 a 10% (de la quantite initiale de tritium) par heure. On a demontre que le mecanisme de la reaction n'est pas un effet de la chimie des rayonnements, mais plutot une reaction directe des atomes d'hydrogene de la surface avec l'hydrocarbure. Outre qu'une partie importante du tritium utilise reagit rapidement, la methode presente un avantage exceptionnel : on peut aisement separer le tritium qui n'a pas reagi de la substance organique, Bullet en ramenant simplement a la temperature ambiante le recipient dans lequel la reaction a eu lieu. (author) [Spanish] La memoria describe un nuevo procedimiento muy eficaz para introducir tritio en moleculas organicas. La marcacion se consigue

  7. Radiopharmaceuticals for cerebral studies; Radiofarmacos para Estudios Cerebrales

    Energy Technology Data Exchange (ETDEWEB)

    Leon Cabana, Alba [Universidad de la Republica, Facultad de Quimica (Uruguay)

    1994-12-31

    For obtain good brain scintillation images in nuclear medicine must be used several radiopharmaceuticals. Cerebral studies give a tumors visual image as well as brain anomalities detection and are helpful in the diagnostic diseases . Are described in this work: a cerebrum radiopharmaceuticals classification,labelled compounds proceeding and Tc 99m good properties in for your fast caption, post administration and blood purification for renal way.

  8. Enzymatic synthesis of tritium-labelled prostaglandin D2 and its conversion to other prostaglandins

    International Nuclear Information System (INIS)

    Shram, S.I.; Lazurkina, T.Yu.; Shevchenko, V.P.; Nagaev, I.Yu.; Myasoedov, N.F.

    1994-01-01

    The one-stage enzymatic synthesis of tritium-labelled prostaglandin D 2 from labelled arachidonic acid was performed by using the enzyme system PGH-synthetase/PGH-PGD-isomerase. By enzymatic and chemical transformation of [ 3 H]PGD 2 the following compounds were obtained: 15-keto-13,14-dihydro-[ 3 H]PGD 2 , 9α,11β-[ 3 H]PGF 2 , 9-deoxy-Δ 9 -[ 3 H]-PGD 2 ([ 3 H]PGJ 2 ) and Δ 12 -13,14-dihydro-[ 3 H]PGJ 2 . It was found that L-selectride is a more effective reducing agent than sodium borohydride in the synthesis of 9α, 11β-[ 3 H]PGF 2 . (Author)

  9. Preparation of H3-labelled methyl ethers of saturated fatty acids by heterogeneous catalytic isotope exchange in solution with gaseous tritium

    International Nuclear Information System (INIS)

    Shevchenko, V.P.; Myasoedov, N.F.

    1980-01-01

    A simple method of preparing 3 H-labelled methyl ethers of saturated fatty acids in the dioxane solution using the method of isotopic heterogenous catalytic exchange with gaseous tritium, is suggested. 3 H-labelled natural fatty acids (C 12 -C 18 ) are prepared by alkaline hydrolysis [ru

  10. Current operations and experiments at the Tritium Systems Test Assembly

    International Nuclear Information System (INIS)

    Bartlit, J.R.; Anderson, J.L.

    1985-01-01

    The Tritium Systems Test Assembly (TSTA) has continued to move toward operation of a fully-integrated, full-sized, computer-controlled fusion fuel processing loop. Concurrent, nonloop experiments have answered important questions on new components and issues such as palladium diffusion membranes, ceramic electrolysis cells, regenerable tritium getters, laser Raman spectroscopy, unregenerable tritium inventory on molecular sieves, tritium contamination problems and decontamination methods, and operating data on reliability, emissions, doses, and wastes generated. 4 refs., 2 figs

  11. JAERI Fuel Cleanup System (J-FCU) stand-alone tritium test at the TSTA

    International Nuclear Information System (INIS)

    Konishi, Satoshi; Hayashi, Takumi; Inoue, Masahiko

    1993-03-01

    JAERI designed, fabricated, and installed the JAERI Fuel Cleanup System (J-FCU) as a subsystem of simulated fusion fuel loop at the TSTA. The main function of the J-FCU is to purify and to recover hydrogen isotopes from simulated plasma exhaust while exhausting tritium free impurities. After a lot of deuterium tests, a first tritium test of the J-FCU was performed with one gram of tritium at the TSTA on June 1991. Main purpose of this test was to evaluate the total integrity and function of the J-FCU system with a DT mixture. Through this test, the J-FCU was operated well and its function with tritium was demonstrated. This report describes the detail test results of the J-FCU first tritium test and discuss its functions by stand-alone mode. Residual tritium inventory of the J-FCU system was also discussed. (author)

  12. Positron emitting nuclides and their synthetic incorporation in radiopharmaceuticals. [Labeled with /sup 11/C, /sup 13/N, and /sup 18/F

    Energy Technology Data Exchange (ETDEWEB)

    Fowler, J.S.

    1976-01-01

    /sup 11/C, /sup 13/N, and /sup 15/O has potential applicability to the study of metabolism in humans. Problems in the synthesis of radiopharmaceuticals labeled with /sup 11/C, /sup 13/N, and /sup 18/F are described: quality control, radiation exposure, carboxylic acids, glucose, amines, amino acids, nitrosources, fluoroethanol. 54 references. (DLC)

  13. Radioisotope and radiopharmaceutical generators

    International Nuclear Information System (INIS)

    Barak, M.; Winchell, H.W.

    1975-01-01

    A chromatographic column for generating technetium-99m isotopes and technetium-99m labeled pharmaceuticals in a simple two-step process is described. Technetium-99m pertechnetate in a first step is isolated by adsorption upon an adsorbent packing. Then the technetium-99m in a second step is eluted from the packing, either with an immediately labeled biological compound to form a radiopharmaceutical, or by a controlled volume of eluant to produce a 99m-technetium-bearing eluate of a desired specific concentration. (Official Gazette)

  14. The synthesis of tritium, carbon-14 and stable isotope labelled selective estrogen receptor degraders.

    Science.gov (United States)

    Bragg, Ryan A; Bushby, Nick; Ericsson, Cecilia; Kingston, Lee P; Ji, Hailong; Elmore, Charles S

    2016-09-01

    As part of a Medicinal Chemistry program aimed at developing an orally bioavailable selective estrogen receptor degrader, a number of tritium, carbon-14, and stable isotope labelled (E)-3-[4-(2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl]prop-2-enoic acids were required. This paper discusses 5 synthetic approaches to this compound class. Copyright © 2016 John Wiley & Sons, Ltd.

  15. The tritium systems test assembly: Overview and recent results

    International Nuclear Information System (INIS)

    Bartlit, J.R.; Anderson, J.L.

    1988-01-01

    The fusion technology development program for tritium in the US is centered around the Tritium Systems Test Assembly (TSTA) at Los Alamos National Laboratory. The TSTA is a full-scale system of reactor exhaust gas reprocessing for an ITER-sized machine. That is, TSTA has the capacity to process tritium in a closed loop mode at the rate of 1 kg per day, requiring a tritium inventory of about 100 g. The TSTA program also interacts with all other tritium-related fusion technology programs in the US and all major programs abroad. This report summarizes the current status, results and interactions of the TSTA. Special emphasis is given to operations in May/June using large compound cryopumps that completed the fuel loop integration of all TSTA subsystems for the first time. 6 refs., 2 figs

  16. Some radiopharmaceuticals derived from carbon-eleven labelled phosgene

    International Nuclear Information System (INIS)

    Roeda, D.

    1982-01-01

    This thesis deals with some applications of the short lived cyclotron produced radioisotope carbon-11 (half life 20.4 min.) For medical use. Both chemical manipulation of highly radioactive gamma emitting material in order to prepare suitable 11 C-labelled radiopharmaceuticals and two clinical studies are discussed. The first chapter comprises a general introduction concerning the application of the ''tracer principle'' to the short lived positron emitting radionuclides 18 F, 11 C, 13 N and 15 O in medicine. Chapter two deals with the synthesis of 11 COCl 2 . This product is a useful new 11 C-synthon with many potential applications. In chapter three the synthesis of 11 C-urea from 11 C-phosgene for medical use is described. The method uses the reaction of 11 COCl 2 with aqueous ammonia. Chapter four deals with the synthesis of 11 C-barbituric acids and 11 C-hydantoins and presents a clinical study on epilepsy, using 2- 11 C-5,5-diphenylhydantoin ( 11 C-DPH). Patients having intractable epilepsy and patients having no epilepsy were given intravenously a single dose of 11 C-DPH after which the accumulation of the radioactivity in the brain was followed by positron emission tomography. No regional concentration differences could be found near epileptic foci. There was a faint indication that there are some differences in uptake for whole brain between the two categories of patients. (Auth.)

  17. The tokamak fusion test reactor tritium systems test contractor operational readiness review

    International Nuclear Information System (INIS)

    Gentile, C.A.; Levine, J.; Norris, M.; Rehill, F.; Such, C.

    1993-01-01

    In preparation for D-T operations at TFTR, the TFTR project has successfully completed the C-ORR process which has led to the introduction of 200 curies of tritium to the site. Preparations for the C-ORR began approximately 2 years ago. During July 1992 a one-week Site Assistance Review was conducted by the C-ORR , and C-ORR Team consisting of 12 persons, all of whom were outside experts, many of whom were from other facilities within the DOE complex. During the July 1992 Site Assistance Review 201 findings were documented which fell into one of three categories. All of the 109 category one findings which were generated were required to be resolved prior to the introduction of tritium to the TFTR site. On April 5, 1993, the TFTR Tritium System Test C-ORR commenced. The results of the C-ORR as documented in the final report by the C-ORR was that category 1 findings were resolved, and it was the recommendation of the C-ORR Team to the PPPL ES ampersand H Board that TFTR initiate the Tritium Systems Test. DOE (Chicago Operations, Princeton Area Office) concurred with the C-ORR final report and on April 29, 1993, at 12:15 pm tritium was introduced to the TFTR site

  18. Radiation Dose Estimates in Indian Adults in Normal and Pathological Conditions due to 99Tcm-Labelled Radiopharmaceuticals

    International Nuclear Information System (INIS)

    Tyagi, K.; Jain, S.C.; Jain, P.C.

    2001-01-01

    ICRP Publications 53, 62 and 80 give organ dose coefficients and effective doses to ICRP Reference Man and Child from established nuclear medicine procedures. However, an average Indian adult differs significantly from the ICRP Reference Man as regards anatomical, physiological and metabolic characteristics, and is also considered to have different tissue weighting factors (called here risk factors). The masses of total body and most organs are significantly lower for the Indian adult than for his ICRP counterpart (e.g. body mass 52 and 70 kg respectively). Similarly, the risk factors are lower by 20-30% for 8 out of the 13 organs and 30-60% higher for 3 organs. In the present study, available anatomical data of Indians and their risk factors have been utilised to estimate the radiation doses from administration of commonly used 99 Tc m -labelled radiopharmaceuticals under normal and certain pathological conditions. The following pathological conditions have been considered for phosphates/phosphonates - high bone uptake and severely impaired kidney function; IDA - parenchymal liver disease, occlusion of cystic duct, and occlusion of bile duct; DTPA - abnormal renal function; large colloids - early to intermediate diffuse parenchymal liver disease, intermediate to advanced parenchymal liver disease; small colloids - early to intermediate parenchymal liver disease, intermediate to advanced parenchymal liver disease; and MAG3 - abnormal renal function, acute unilateral renal blockage. The estimated 'effective doses' to Indian adults are 14-21% greater than the ICRP value from administration of the same activity of radiopharmaceutical under normal physiological conditions based on anatomical considerations alone, because of the smaller organ masses for the Indian; for some pathological conditions the effective doses are 11-22% more. When tissue risk factors are considered in addition to anatomical considerations, the estimated effective doses are still found to be

  19. Operating experience and procedures at the tritium systems test assembly

    International Nuclear Information System (INIS)

    Carlson, R.V.; Binning, K.E.; Cole, S.P.; Jenkins, E.M.; Wilhelm, R.C.; Cole, S.P.

    1988-01-01

    Operating procedures are important for the safe and efficient operation of the Tritium Systems Test Assembly (TSTA). TSTA has been operating for four years with tritium in a safe and efficient manner. The inventory of tritium in the process loop is 100 grams and several milestone runs have been completed. This paper describes the methods used to operate TSTA. 3 refs., 1 fig

  20. Radioisotope requirements and usage in the radiopharmaceutical industry

    International Nuclear Information System (INIS)

    Langton, M.A.

    1995-01-01

    Radioisotopes are used extensively in many different productive and beneficial human endeavors. Amersham International, a U.K.-based company originating in the British Scientific Civil Service during World War II, has been actively involved in many of these activities for more than 50 yr. Today they are one of the world's largest suppliers of radioactive compounds and scaled radiation sources for use in industrial quality and safety assurance, life science research, and medicine. This paper outlines one of these applications: the use of radioisotopes as radiopharmaceuticals. Radiopharmaceuticals are radioactive nuclides and labeled compounds that have been developed for the diagnosis and treatment of (human) disease. They are manufactured via highly controlled processes and have gone through regulatory scrutiny and approval far in excess of other radioisotopes used in other applications. Radiopharmaceuticals can be conveniently split into two categories. One type is simply an active analog that mimics the physiological behavior of its inactive counterpart in the body. The other involves an actual pharmacological compound that exhibits the desired physiological behavior, which is then labeled with a radionuclide suitable for either imaging or the delivery of a therapeutic radiation dose as appropriate but which plays no part in the mechanism of action of the drug. The latter type, which is the more common of the two, can be supplied either as an active compounded product or as a open-quotes cold kit,close quotes which is then labeled with the appropriate radiopharmaceutical-grade radionuclide to yield the final product

  1. Present status and prospect of copper radiopharmaceuticals

    International Nuclear Information System (INIS)

    Chen Huawei; Li Hongfeng; Liu Boli

    1996-01-01

    In the past decade most of the efforts of copper radiopharmaceuticals research has been focused on bis(thiosemicarbazonato) copper complexes for use in myocardial and brain imaging agents. In the present work, the analogs of bis(thiosemicarbazone) is studied in labeling antibodies and tumors. The retention mechanism of Cu-PTSM is investigated. Other kinds of ligands, BAT (N 2 S 2 ) for example, can be used to prepare neutral copper complexes in order to obtain brain radiopharmaceuticals in future. (60 refs.)

  2. Synthesis, labeling with 99mTc and biokinetics of brains scintigraphy diaminodithiol perfusion radiopharmaceuticals

    International Nuclear Information System (INIS)

    Goncalves, Marcos Moises

    1999-01-01

    The recent tomography status using radiopharmaceuticals have been contributing greatly with the 'age of certainty' in the diagnosis examination of syndromes, pathologies and clinical signs, because they can evidence some phenomena occurring in a molecular manner. The purpose of this work have had the development of new diaminodithiol (DADT) perfusion radiopharmaceuticals to be used in brain diagnosis using S.P.E.T. (Single Photon Emission Tomography). Initially, the rational planning had been performed with the new DADT molecular structures as radiopharmaceutical candidates. Using of Q.S.A.R. (Quantitative Structure Activity Relationship) techniques, the molecular descriptors such as partition coefficient and effective polarizability, have been studied in order to increase the blood brain barrier transport and the brain uptake respectively. Applying the Q.S.P.R. (Quantitative Structure Property Relationship) concepts to perform drug latentiation, based on bio-labile functional groups, the congener DADT derivative has been transformed into a pro-drug that works as a DADT moiety carrier, allowing the increasing of brain radiopharmaceutical uptake. Later on, synthetic routes and chemical purifications have been developed allowing the creation of the proposed chemical structure. Each new DADT derivative has been synthesized and analyzed in terms of elemental analysis, infrared and NMR spectra, in order to confirm its proposed chemical structure. Then, the new derivative has been labeled with 99m Tc, radiochemically purified, intravenously injected in Swiss mice, allowing its biodistribution to evidence its brain transport and uptake. The rational planning studies have been re-evaluated after each biodistribution had been performed, to see what kind of molecular descriptor was responsible for causing a stronger optimization in the brain perfusion characteristics and then, new DADT derivatives have been prepared. Three new DADT derivatives have been obtained by using

  3. In vivo evaluation of a radiogallium-labeled bifunctional radiopharmaceutical, Ga-DOTA-MN2, for hypoxic tumor imaging.

    Science.gov (United States)

    Sano, Kohei; Okada, Mayumi; Hisada, Hayato; Shimokawa, Kenta; Saji, Hideo; Maeda, Minoru; Mukai, Takahiro

    2013-01-01

    On the basis of the findings obtained by X-ray crystallography of Ga-DOTA chelates and the drug design concept of bifunctional radiopharmaceuticals, we previously designed and synthesized a radiogallium-labeled DOTA chelate containing two metronidazole moieties, (67)Ga-DOTA-MN2, for hypoxic tumor imaging. As expected, (67)Ga-DOTA-MN2 exhibited high in vivo stability, although two carboxyl groups in the DOTA skeleton were conjugated with metronidazole moieties. In this study, we evaluated (67/68)Ga-DOTA-MN2 as a nuclear imaging agent for hypoxic tumors. (67)Ga-labeling of DOTA-MN2 with (67)GaCl(3) was achieved with high radiochemical yield (>85%) by 1-min of microwave irradiation (50 W). The pharmacokinetics of (67)Ga-DOTA-MN2 were examined in FM3A tumor-bearing mice, and compared with those of (67)Ga-DOTA-MN1 containing one metronidazole unit and (67)Ga-DOTA. Upon administration, (67)Ga-DOTA-MN2 exhibited higher accumulation in the implanted tumors than (67)Ga-DOTA. Tumor-to-blood ratios of (67)Ga-DOTA-MN2 were about two-fold higher than those of (67)Ga-DOTA-MN1. Autoradiographic analysis showed the heterogeneous localization of (67)Ga-DOTA-MN2 in the tumors, which corresponds to hypoxic regions suggested by well-established hypoxia marker drug, pimonidazole. Furthermore, in positron emission tomography (PET) study, the tumors of mice administered (68)Ga-labeled DOTA-MN2 were clearly imaged by small-animal PET at 1 h after administration. This study demonstrates the potential usefulness of (67/68)Ga-DOTA-MN2 as a nuclear imaging agent for hypoxic tumors and suggests that two functional moieties, such as metronidazole, can be conjugated to radiogallium-DOTA chelate without reducing the complex stability. The present findings provide useful information about the chemical design of radiogallium-labeled radiopharmaceuticals for PET and single photon emission computed tomography (SPECT) studies.

  4. Results of tritium tests performed on Sandia Laboratories decontamination system

    International Nuclear Information System (INIS)

    Gildea, P.D.; Wall, W.R.; Gede, V.P.

    1978-05-01

    The Tritium Research Laboratory (TRL), a facility for performing experiments using gram amounts of tritium, became operational on October 1, 1977. As secondary containment, the TRL employs sealed glove boxes connected on demand to two central decontamination systems, the Gas Purification System and the Vacuum Effluent Recovery System. Performance tests on these systems show the tritium removal systems can achieve concentration reduction factors (ratio of inlet to exhaust concentrations) much in excess of 1000 per pass at inlet concentrations of 1 part per million or less for both tritium and tritiated methane

  5. Development of radiopharmaceutical for radiosinovectomy; Desenvolvimento de radiofarmaco para radiosinovectomia

    Energy Technology Data Exchange (ETDEWEB)

    Couto, Renata Martinussi

    2009-07-01

    Radiopharmaceuticals prepared with different radionuclides have been used in diagnostic and therapeutic procedures in Nuclear Medicine. The interest in radionuclidic therapy has been increased in last years, with the introduction of new radiopharmaceuticals applied in the destruction of specific cells or to prevent its undesired proliferation. Radiosinovectomy (RSV) is a therapeutic modality that uses radiopharmaceuticals administered in the intra-articular cavity and represents an alternative to the treatment of different arthropaties and, in particular, the arthropaties derived from rheumatoid arthritis and haemophilic. The objective of the present work was to study the labeling of compounds with {sup 90}Y and {sup 177}Lu in order to improve the production conditions and quality control procedures, study the stability of the labeled compounds and preliminary biodistribution studies of the radiopharmaceuticals with potential for RSV applications. The study of the production of {sup 90}Y citrate colloid ({sup 90}Y-Cit) was based in a labeling procedure using {sup 90}Y Cl{sub 3} solution (37 - 54 MBq) that was previously dried, followed by the addition of yttrium nitrate and sodium citrate in p H 7 at 37 deg C for 30 minutes. The production of hydroxyapatite (HA) labeled with {sup 90}Y was based in a labeling procedure using mono hydrated citric acid, yttrium nitrate and {sup 90}Y Cl{sub 3} solution (37 - 370 MBq). The reaction mixture was incubated for 30 minutes at room temperature and the HA was introduced in aqueous medium and the reaction proceed for 30 minutes under strong stirring. {sup 177}Lu-HA was produced using {sup 177}Lu Cl{sub 3} solution (296 MBq), in presence of lutetium oxide in NaCl medium, p H 7, under continuous stirring for 30 minutes at room temperature. Several reaction parameters were studied for the three radiopharmaceuticals. Labeling yield was determined after particles were centrifuged and washed with NaCl 0,9%. Radiochemical purity was

  6. Tritium Systems Test Assembly: design for major device fabrication review

    International Nuclear Information System (INIS)

    Anderson, J.L.; Sherman, R.H.

    1977-06-01

    This document has been prepared for the Major Device Fabrication Review for the Tritium Systems Test Assembly (TSTA). The TSTA is dedicated to the development, demonstration, and interfacing of technologies related to the deuterium-tritium fuel cycle for fusion reactor systems. The principal objectives for TSTA are: (a) demonstrate the fuel cycle for fusion reactor systems; (b) develop test and qualify equipment for tritium service in the fusion program; (c) develop and test environmental and personnel protective systems; (d) evaluate long-term reliability of components; (e) demonstrate long-term safe handling of tritium with no major releases or incidents; and (f) investigate and evaluate the response of the fuel cycle and environmental packages to normal, off-normal, and emergency situations. This document presents the current status of a conceptual design and cost estimate for TSTA. The total cost to design, construct, and operate TSTA through FY-1981 is estimated to be approximately $12.2 M

  7. Conceptual design of Tritium Extraction System for the European HCPB Test Blanket Module

    International Nuclear Information System (INIS)

    Ciampichetti, A.; Nitti, F.S.; Aiello, A.; Ricapito, I.; Liger, K.; Demange, D.; Sedano, L.; Moreno, C.; Succi, M.

    2012-01-01

    Highlights: ► HCPB (Helium Cooled Pebble Bed) Test Blanket Module (TBM) to be tested in ITER. ► Tritium extraction by gas purging, removal and transfer to the Tritium Plant. ► Conceptual design of TES and revision of the previous configuration. ► Main components: adsorption column, ZrCo getter beds and PERMCAT reactor. - Abstract: The HCPB (Helium Cooled Pebble Bed) Test Blanket Module (TBM), developed in EU to be tested in ITER, adopts a ceramic containing lithium as breeder material, beryllium as neutron multiplier and helium at 80 bar as primary coolant. In HCPB-TBM the main function of Tritium Extraction System (TES) is to extract tritium from the breeder by gas purging, to remove it from the purge gas and to route it to the ITER Tritium Plant for the final tritium processing. In this paper, starting from a revision of the so far reference process considered for HCPB-TES and considering a new modeling activity aimed to evaluate tritium concentration in purge gas, an updated conceptual design of TES is reported.

  8. The operation of the Tokamak Fusion Test Reactor Tritium Facility

    International Nuclear Information System (INIS)

    Gentile, C.A.; LaMarche, P.H.

    1995-01-01

    The TFTR tritium operations staff has successfully received, stored, handled, and processed over five hundred thousand curies of tritium for the purpose of supporting D-T (Deuterium-Tritium) operations at TFTR. Tritium operations personnel nominally provide continuous round the clock coverage (24 hours/day, 7 days/week) in shift complements consisting of I supervisor and 3 operators. Tritium Shift Supervisors and operators are required to have 5 years of operational experience in either the nuclear or chemical industry and to become certified for their positions. The certification program provides formal instruction, as well as on the job training. The certification process requires 4 to 6 months to complete, which includes an oral board lasting up to 4 hours at which time the candidate is tested on their knowledge of Tritium Technology and TFTR Tritium systems. Once an operator is certified, the training process continues with scheduled training weeks occurring once every 5 weeks. During D-T operations at TFTR the operators must evacuate the tritium area due to direct radiation from TFTR D-T pulses. During '' time operators maintain cognizance over tritium systems via a real time TV camera system. Operators are able to gain access to the Tritium area between TFTR D-T pulses, but have been excluded from die tritium area during D-T pulsing for periods up to 30 minutes. Tritium operators are responsible for delivering tritium gas to TFRR as well as processing plasma exhaust gases which lead to the deposition of tritium oxide on disposable molecular sieve beds (DMSB). Once a DMSB is loaded, the operations staff remove the expended DMSB, and replace it with a new DMSB container. The TFIR tritium system is operated via detailed procedures which require operator sign off for system manipulation. There are >300 procedures controlling the operation of the tritium systems

  9. Experimental study of the tritium uptake in mammal tissues and DNA

    International Nuclear Information System (INIS)

    Lejeune, P.; Lambotte, J.M.; Lafontaine, A.

    1975-01-01

    The authors study the tritium-labelling of ADN in rabbits who receive the tritium as HTO in their drinking water during periods of one to three months. On the basis of the MPC for tritium (according to the belgian legislation, 30 μCi/l in drinking water of occupational workers for 168 h/week exposure) it is stated that for rabbits, this value of continuous impregnation by drinking water must be exceeded by a factor 100 to observe a measurable tritium activity in the ADN, isolated from tissue with fast turnover rate, such as bone marrow. The structural molecules proteins, lipids and carbon hydrates of different organs are labelled with tritium at 5 MPC, th lowest examined concentration. These statements do not evaluate whether the observed phenomenon of tritium labelling is hazardous or not, but rather tend to establish an order of magnitude

  10. Radioisotopes and radiopharmaceuticals catalogue

    International Nuclear Information System (INIS)

    2002-01-01

    The Chilean Nuclear Energy Commission (CCHEN) presents its radioisotopes and radiopharmaceuticals 2002 catalogue. In it we found physical characteristics of 9 different reactor produced radioisotopes ( Tc-99m, I-131, Sm-153, Ir-192, P-32, Na-24, K-42, Cu-64, Rb-86 ), 7 radiopharmaceuticals ( MDP, DTPA, DMSA, Disida, Phitate, S-Coloid, Red Blood Cells In-Vivo, Red Blood Cells In-Vitro) and 4 labelled compounds ( DMSA-Tc99m, DTPA-Tc99m, MIBG-I131, EDTMP-Sm153 ). In the near future the number of items will be increased with new reactor and cyclotron products. Our production system will be certified by ISO 9000 on March 2003. CCHEN is interested in being a national and an international supplier of these products (RS)

  11. Preliminary studies of EDDA-tricine-HYNIC-[Tyr3]octreotide labelled with Technetium-99m: radiopharmaceutical development for the diagnostic of neuroendocrine tumours

    International Nuclear Information System (INIS)

    Melero, Laura T.U.H.; Muramoto, Emiko; Arauho, Elaine Bortoleti de

    2007-01-01

    The use of labelled molecules with high specificity for an organ or receptor in scintigraphy, generate good local images of these specific receptors that are expressed for the biomolecule in question, minimizing the exposition of other organs. Small labelled peptides have showed a big potential for tumors image and other diseases in nuclear medicine. The octreotide was the first somatostatin synthetic analog introduced in clinical use in the localization of tumours with superexpression of somatostatin receptors which is a hundred times over in tumors cells that in normal cells. It did many attempts to development of a somatostatin analog labelled with 99mTc utilizing a variety of chelant systems until development the HYNIC-D-Phe1-Tyr3-octreotide, using tricine and EDDA as coligands, showing maintenance of in vivo affinity and promising of biodistribution in animals with induced tumours. This work involved the development of a 99mTc (technetium-99m) radiopharmaceutical based in a somatostatin peptide derivative (Tyr3-octreotide, TOC), with HYNIC chelating group, to be applied in the diagnostic of neuroendocrine tumors in nuclear medicine. Quality control methodologies to be applied in determination of the radiochemical purity of the labelled compound was also studied as well the biodistribution in normal Swiss mouse. The 99mTc-HYNIC-TOC was obtained in high radiochemical yield. Biodistribution studies suggests the potential of this radiopharmaceutical in the diagnostic of neuroendocrine tumours. (author)

  12. The Tritium Systems Test Assembly applicability to ITER

    International Nuclear Information System (INIS)

    Anderson, J.L.

    1988-01-01

    The Tritium Systems Test Assembly (TSTA), is operated by the Los Alamos National Laboratory (LANL) under the sponsorship of the US Department of Energy (DOE) and the Japan Atomic Energy Research Institute (JAERI). The objectives of the TSTA project are to develop, demonstrate, and evaluate the exhaust gas processing and tritium related safety systems for the magnetic fusion energy program. The applicability of these processes for the ITER Tokamak is discussed

  13. Incorporation and metabolism of tritium in pregnant mice and their offspring after feeding organically labelled tritiated milk powder during pregnancy

    International Nuclear Information System (INIS)

    Bruwaene, R. van; Gerber, G.B.; Kirchmann, R.; Maes, J.; Fagniart, E.

    1982-01-01

    Food mixed from equal amounts of organically labelled tritiated milk powder and normal food pellets was given to mice during pregnancy and lactation. At birth, some new-born were swapped with those from non-exposed mothers to compare separately accumulation and metabolism during pregnancy and lactation. Young mice were sacrificed at different time after birth, and tritium activity in different organs was determined. Tritium activity was also determined in maternal organs at various times during and after the 42 days feeding period. The activity per g in some tissues of the young, particularly in fat, exceeded that of the food given, probably as a result of the high activity and low metabolic dilution of the fats in the food. Young mice contaminated during lactation and pregnancy contained still detectible activity at an age of 2 months. Activity was nearly the same in mice receiving tritium only during lactation as in those receiving it also during pregnancy. Dilution was more marked due to rapid growth when tritium application was discontinued at birth. Tritium water was replaced most rapidly, organic tritium in brain turned over most slowly with and additional metabolic component of a half life in the order of 1 month. Organic tritium in liver displayed an intermediate half life. (author)

  14. Tritium pellet injector design for tokamak fusion test reactor

    International Nuclear Information System (INIS)

    Fisher, P.W.; Baylor, L.R.; Bryan, W.E.

    1985-01-01

    A tritium pellet injector (TPI) system has been designed for the Tokamak Fusion Test Reactor (TFTR) Q approx. 1 phase of operation. The injector gun utilizes a radial design with eight independent barrels and a common extruder to minimize tritium inventory. The injection line contains guide tubes with intermediate vacuum pumping stations and fast valves to minimize propellant leakage to the torus. The vacuum system is designed for tritium compatibility. The entire injector system is contained in a glove box for secondary containment protection against tritium release. Failure modes and effects have been analyzed, and structural analysis has been performed for most intense predicted earthquake conditions. Details of the design and operation of this system are presented in this paper

  15. Radionuclide production and radiopharmaceutical chemistry with BNL cyclotrons

    International Nuclear Information System (INIS)

    Lambrecht, R.M.; Wolf, A.P.

    1985-01-01

    The Brookhaven National Laboratory (BNL) radiopharmaceutical chemistry program focuses on production and utilization of radionuclides having a half-life of > 2 hr. However, a major portion of the BNL program is devoted to short-lived radionuclides, such as 11 C and 18 F. Activities encompassed in the program are classified into seven areas: cyclotron parameters, radiochemistry, design and rapid synthesis of radiopharmaceuticals and labeled compounds, radiotracer evaluation in animals, studies in humans, technology transfer, and several other areas

  16. Quality assessment of radiopharmaceuticals in nuclear medicine services at Northeast states, Brazil

    International Nuclear Information System (INIS)

    Andrade, Wellington Gomes de

    2012-01-01

    The radiopharmaceuticals are used in the field nuclear medicine services (NMS) as tracer in the diagnoses and treatment of many diseases. Radiopharmaceuticals used in nuclear medicine and usually have a minimum of pharmacological effect. The procedures for labelling Radiopharmaceuticals should be observed in order to minimize risks to patients, employees and individuals from the public, and to be administered in humans, must be sterile and free of pyrogens and possess elements all measures of quality controls required a conventional drug. The 'Agencia Nacional de Vigilancia Sanitaria (ANVISA)' in its 'Resolucao de Diretoria Colegiada' (RDC) No. 38 of June 4 th 2008, decided that the NMS must perform quality control in the generators eluate and radiopharmaceuticals according to recommendations of manufacturers and scientific evidence accepted by ANVISA. Thus, this study proposes to evaluate the quality of the generator 99M o- 99m Tc eluate and radiopharmaceuticals labeled with 99m Tc used in most NMS of some states in the Northeast, in relation to radionuclide, chemical, radiochemical purity and pH and promote the inclusion of procedure for quality control of radiopharmaceuticals in routine NMS. The results show that 90% radionuclidic purity, 98.2% purity chemical and radiochemical purity of 46% and 100% of the eluates are in agreement with international pharmacopoeias; already radiopharmaceuticals showed 82.6% purity and all radiochemical pH values are also in accordance with international pharmacopoeias. Even with so many positive results, staff the majority of MNS was not able to perform the quality control of the eluates and radiopharmaceuticals. Showing the importance of implementing of quality control programs of the eluates and radiopharmaceuticals in nuclear medicine. (author)

  17. 18F-Labelled catecholamine type radiopharmaceuticals in the diagnosis of neurodegenerative diseases and neuroendocrine tumours: approaches to synthesis and development prospects

    Science.gov (United States)

    Vatsadze, S. Z.; Eremina, O. E.; Veselova, I. A.; Kalmykov, S. N.; Nenajdenko, V. G.

    2018-04-01

    The pathogenesis of many socially significant diseases such as neurodegenerative dementias and neuroendocrine tumours involves imbalance of neurotransmitters. Among the known neuroimaging methods, positron emission tomography (PET) is the most perfect and informative technique for diagnosing these diseases. The potential of PET is largely determined by the inventory of available radiopharmaceuticals, that is, biologically active molecules containing short-lived nuclides with positron decay. This review gives a systematic account of the application of fluorine-18-labelled catecholamine type radiopharmaceuticals in clinical investigations of the sympathetic and central nervous systems. The methods for the synthesis of these agents and existing problems are considered. The material is arranged according to the mechanisms of reactions that underlie the synthetic approaches: electrophilic, nucleophilic and metal-catalyzed reactions. The bibliography includes 198 references.

  18. Bioassay guideline 2: guidelines for tritium bioassay

    International Nuclear Information System (INIS)

    1983-01-01

    This guideline is one of a series under preparation by the Federal-Provincial Working Group on Bioassay and In Vivo Monitoring Criteria. In this report tritium compounds have been grouped into four categories for the purpose of calculating Annual Limits on Intake and Investigation Levels: tritium gas, tritiated water, tritium-labelled compounds and nucleic acid precursors

  19. [The Qualitative Analysis of the Amide Derivative of HLDF-6 Peptide and Its Metabolites with the Use of Tritium- and Deuterium-Labeled Derivatives].

    Science.gov (United States)

    Zolotarev, A; Dadayan, A K; Kost, N V; Voevodina, M E; Sokolov, O Y; Kozik, V S; Shram, S I; Azev, V N; Bocharov, E V; Bogachouk, A P; Lipkin, V M; Myasoedov, N F

    2015-01-01

    The goal of the study was to elaborate the pharmacokinetics methods of the amide derivative of peptide HLDF-6 (TGENHR-NH2) and its range of nootropic and neuroprotective activity is wide. The hexapeptide 41TGENHR46 is a fragment of the HDLF differentiation factor. It forms the basis for the development of preventive and therapeutic preparations for treating cerebrovascular and neurodegenerative conditions. Pharmacokinetic and molecular mechanisms of the action of the HLDF-6 peptide were studied using tritium- and deuterium-labeled derivatives of this peptide, produced with the use of the high-temperature solid-state catalytic isotope exchange reaction (HSCIE). This reaction was employed to produce the tritium-labeled peptide [3H]TGENHR-NH2 with a molar radioactivity of 230 Ci/mmol and the deuterium-labeled peptide [2H]TGENHR-NH2 with an average deuterium incorporation equal to 10.5 atoms. It was shown by the NMR spectroscopy that the isotope label distribution over the labeled peptide's molecule was uniform, which allowed qualitative analysis ofboth the peptide itself and its fragments in the organism's tissues to be conducted. The newly developed pharmacokinetics method makes it possible to avoid almost completely losses of the peptides under study due to biodegradation during the analysis of tissues. These labeled peptides were used in mice, rats and rabbits to study the pharmacokinetics of the peptide and to calculate the values of its principal pharmacokinetic parameters. Characteristics of its pharmacokinetic profile in the blood were obtained, the hypothesis of pharmacokinetics linearity tested, its metabolism analyzed and its bioavailability value, 34%, calculated. It has been shown that the studied TGENHR-NH2 peptide shows high resistance to hydrolysis in the blood plasma, with dipeptidyl aminopeptidases making the largest contribution to its hydrolysis.

  20. Synthesis of tritium or deuterium labelled 19-nor-3. cap alpha. -hydroxy-5. cap alpha. -androstan-17-one from nortestosterone

    Energy Technology Data Exchange (ETDEWEB)

    Protiva, J; Klinotova, E [Karlova Univ., Prague (Czechoslovakia). Prirodovedecka Fakulta; Filip, J [Ustav pro Vyzkum, Vyrobu a Vyuziti Radioisotopu, Prague (Czechoslovakia); Hampl, R [Research Inst. of Endocrinology, Praha (Czechoslovakia)

    1982-10-20

    Tritium and/or deuterium (5-H) labelled 19-nor-3..cap alpha..-hydroxy-5..cap alpha..-androstan-17-one (norandrosterone) was prepared from nortestosterone in view to use it as a radioligand for radioimmunoassay of the main nortestosterone metabolites. Based upon model experiments using testosterone and deuterium labelling, the following four step procedure was established: nortestosterone was oxidized with pyridine chlorochromate and the resulting 19-nor-4-androsten-3,17-dione was tritiated with tritium gas under catalysis with tris(triphenylphosphine)rhodium chloride to give (4,5..cap alpha..-/sup 3/H)19-nor-5..cap alpha..-androstan-3,17-dione. A selective reduction of the latter compound yielded (5-/sup 3/H)19-nor-3..cap alpha..-hydroxy-5..cap alpha..-androstan-17-one of the molar radioactivity 0.3 TBq (8.15 Ci)/mmol.

  1. Testing of 99mTc labelled sucralfate in induced gastric and duodenal ulcers

    International Nuclear Information System (INIS)

    Pallagi, Katalin; Janoki, Gyoezoe

    1988-01-01

    The conditions of in vitro labelling of sucralfate available in medical practice were established according to literature data including some modifications. Labelling efficiency proved to be 98.1%. The radiopharmaceutical is stable over 6 hours in vitro. 99m Tc-sucralfate accumulates in experimentally induced gastric and duodenal ulcers thus tracing the site of the ulcerous lesion. (author) 14 refs.; 3 tabs

  2. Radiochemical stability of radiopharmaceutical preparations

    International Nuclear Information System (INIS)

    Martins, Patricia de A.; Silva, Jose L. da; Ramos, Marcelo P.S.; Oliveira, Ideli M. de; Felgueiras, Carlos F.; Herrerias, Rosana; Zapparoli Junior, Carlos L.; Mengatti, Jair; Fukumori, Neuza T.O.; Matsuda, Margareth M.N.

    2011-01-01

    The 'in vitro' stability studies of the radiopharmaceutical preparations are an essential requirement for routine practice in nuclear medicine and are an important parameter for evaluating the quality, safety and efficacy required for the sanitary registration of pharmaceutical products. Several countries have published guidelines for the evaluation of pharmaceutical stability. In Brazil, the stability studies should be conducted according to the Guide for Conducting Stability Studies published in the Resolution-RE n. 1, of 29th July 2005. There are also for radiopharmaceutical products, two specific resolutions: RDC-63 regulates the Good Manufacturing Practices for Radiopharmaceuticals and RDC-64 provides the Registration of Radiopharmaceuticals, both published on the 18th December 2009. The radiopharmaceutical stability is defined as the time during which the radioisotope can be safely used for the intended purpose. The radiochemical stability can be affected by a variety of factors, including storage temperature, amount of radioactivity, radioactive concentration, presence or absence of antioxidants or other stabilizing agents. The radiochemical stability studies must be established under controlled conditions determined by the effective use of the product. The aim of this work was to evaluate the radiochemical stability of labeled molecules with 131 I, 123 I, 153 Sm, 18 F, 51 Cr, 177 Lu and 111 In as well as 67 Ga and 201 Tl radiopharmaceuticals. Radiochemical purity was evaluated after production and in the validity period, with the maximum activity and in the recommended storage conditions. The analyses were carried out by thin-layer silica gel plate, paper chromatography and gel chromatography. The experimental results showed to be in accordance with the specified limits for all the analysed products. (author)

  3. A test to enhance the excretion of tritium in man by excessive water intake

    International Nuclear Information System (INIS)

    Takada, K.; Fukuda, H.; Hattori, T.; Akaishi, J.

    1981-01-01

    A worker who accidentally inhaled tritium water vapour at a heavy-water-moderated reactor was recommended to drink an excessive amount of water to enhance the excretion of incorporated tritium. The change in biological half-life of tritium in the body was studied by measuring the tritium in urine, saliva and exhaled water. The results obtained in the present test showed that if the intake of excessive water is performed under no special control the expected shortening of tritium half-life is not necessarily achieved. When severe incorporation of tritium occurs, greater amounts of water than those in the present test must be taken. (U.K.)

  4. Synthesis of carbon-14 and tritium labeled cis-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzamidehydrochloride, an anticonvulsant agent

    International Nuclear Information System (INIS)

    Hsi, R.S.P.; Stolle, W.T.; Ayer, D.E.

    1992-01-01

    The title compound, U-54494A, is an anticonvulsant agent with clinical potential for treating epilepsy and a broad spectrum of seizure disorders. Structurally it is related to kappa opiod agonists and shares their anticonvulsant properties, but appears to be devoid of analgesic, sedative, and diuretic side effects. It also has been shown to inhibit neuronal damage and seizures induced by excitatory amino acids. This report describes the synthesis of the racemic U-54494A labeled with carbon-14 at the carboxamide carbon and with tritium in the pyrrolidine ring at C-3 and C-4. These radioisotope labeled versions of U-54494A were prepared for conducting drug disposition studies of this compound in test animals and human subjects

  5. Application of the Microwave Discharge Modification of the Wilzbach Technique for the Tritium Labelling of some Organics of Biological Interest

    International Nuclear Information System (INIS)

    Gosztonyi, T.

    1969-01-01

    The modification of the Wilzbach technique using microwave discharge has been routinely used in our laboratory for rapid tritium labellings. The applicability of the method and the effects of some of the reaction parameters were studied and published previously. The main advantage of the method is its simplicity and rapidity and the low extent of decomposition of the compound to be labelled during the reaction. Specific activities obtained, however, are not high enough for some investigations. In this paper the labelling of dihydrostreptomycine, tetracycline and antipyrine will be described

  6. Application of the Microwave Discharge Modification of the Wilzbach Technique for the Tritium Labelling of some Organics of Biological Interest

    Energy Technology Data Exchange (ETDEWEB)

    Gosztonyi, T

    1969-01-15

    The modification of the Wilzbach technique using microwave discharge has been routinely used in our laboratory for rapid tritium labellings. The applicability of the method and the effects of some of the reaction parameters were studied and published previously. The main advantage of the method is its simplicity and rapidity and the low extent of decomposition of the compound to be labelled during the reaction. Specific activities obtained, however, are not high enough for some investigations. In this paper the labelling of dihydrostreptomycine, tetracycline and antipyrine will be described.

  7. Exposure of employees engaged on the production and quality control of radiopharmaceuticals labelled with Tc-99m and I-131

    International Nuclear Information System (INIS)

    Trtic, T.; Jovanovic, M.; Vranjes, S.; Vucina, J.; Vuksanovic, Lj.

    1995-01-01

    In this paper, the analysis is presented, of exposure control of employees in the Laboratory for radioisotopes, of the Vinca Institute of nuclear sciences, engaged in the production and quality control of the Tc-99m generator and radiopharmaceuticals labelled with Tc-99m and I-131. Effective doses equivalent (mSv) was measured by personal thermoluminescent dosimeter in the Laboratory for radiation and environmental protection each month. We calculated effective dose equivalents for each year in the period 1986-1990. Thirty one employees were analysed. They were separated into the groups both on the basis of radioisotope which they worked with and the kind of the professional work. The highest average effective doses equivalent were received in the group producing of Tc-99m generator (4-12.5 mSv) and in the group producing I-131 radiopharmaceuticals (3.55-13.73 mSv). (author)

  8. Preliminary study fo the interference of proteic compounds of radiopharmaceuticals in the test of lisadode amebocitos de limulus (LAL)

    International Nuclear Information System (INIS)

    Aldana, Claudia

    1997-01-01

    In this thesis the objective was evaluate the interference of proteic compounds of the radiopharmaceuticals in the test LAL (lisado of amebocitos de limulus) for this, macroagregates of albumina (MAA) was used with metilendifosfonato (MDP) as control that is the radiopharmaceutical more used in the nuclear medicine centers of the country. Initially preliminary test were carried out to assess if some of two radiopharmaceuticals would cause interference with LAL test, after the test was validated and finally routine tests were made. With the preliminary assays was concluded that proteic compounds did not cause interference (albumina with a concentration of 2 md/dl) with the MAA. However with the MDP cause interference with LAL test. The interference was eliminated with a dilution of 1:8 of the sample. Was concluded that the success of LAL test depends on conditions such as temperature, pH, constant incubation (no minimum variations) and that is a good test for quality control of the radiopharmaceuticals

  9. Design of radiopharmaceuticals for monitoring gene transfer therapy

    International Nuclear Information System (INIS)

    Lambrecht, R.M.; Staehler, P.; Kley, J.; Spiegel, M.; Gross, C.; Graepler, F.T.C.; Gregor, M.; Lauer, U.; Oberdorfer, F.

    1998-01-01

    The development of radiopharmaceuticals for monitoring gene transfer therapy with emission tomography is expected to lead to improved management of cancer by the year 2010. There are now only a few examples and approaches to the design of radiopharmaceuticals for gene transfer therapy. This paper introduces a novel concept for the monitoring of gene therapy. We present the optimisation of the labelling of recombinant human β-NGF ligands for in vitro studies prior to using 123 I for SPET and 124 I for PET studies. (author)

  10. Modification and testing of the Sandia Laboratories Livermore tritium decontamination systems

    International Nuclear Information System (INIS)

    Gildea, P.D.; Birnbaum, H.G.; Wall, W.R.

    1978-08-01

    Sandia Laboratories, Livermore, has put into operation a new facility, the Tritium Research Laboratory. The laboratory incorporates containment and cleanup facilities such that any tritium accidentally released is captured rather than vented to the atmosphere. This containment is achieved with hermetically sealed glove boxes that are connected on demand by manifolds to two central decontamination systems called the Gas Purification System (GPS) and the Vacuum Effluent Recovery System (VERS). The primary function of the GPS is to remove tritium and tritiated water vapor from the glove box atmosphere. The primary function of the VERS is to decontaminate the gas exhausted from the glove box pressure control systems and vacuum pumps in the building before venting the gas to the stack. Both of these systems are designed to remove tritium to the few parts per billion range. Acceptance tests at the manufacturer's plant and preoperational testing at Livermore demonstrated that the systems met their design specifications. After preoperational testing the Gas Purification System was modified to enhance the safety of maintanance operations. Both the Gas Purification System and the Vacuum Effluent Recovery System were performance tested with tritium. Results show that concentraion reduction factors (ratio of inlet to exhaust concentrations) much in excess of 1000 per pass have been achieved for both systems at inlet concentrations of 1 ppM or less

  11. Modification and testing of the Sandia Laboratories Livermore tritium decontamination systems

    International Nuclear Information System (INIS)

    Gildea, P.D.; Birnbaum, H.G.; Wall, W.R.

    1979-01-01

    Sandia Laboratories, Livermore, has put into operation a new facility, the Tritium Research Laboratory. The laboratory incorporates containment and cleanup facilities such that any tritium accidentally released is captured rather than vented to the atmosphere. This containment is achieved with hermetically sealed glove boxes that are connected on demand by manifolds to two central decontamination systems called the Gas Purification System (GPS) and the Vacuum Effluent Recovery System (VERS). The primary function of the GPS is to remove tritium and tritiated water vapor from the glove box atmosphere. The primary function of the VERS is to decontaminate the gas exhausted from the glove box pressure control systems and vacuum pumps in the building before venting the gas to the stack. Both of these systems are designed to remove tritium to the few parts per billion range. Acceptance tests at the manufacturer's plant and preoperational testing at Livermore demonstrated that the systems met their design specifications. After preoperational testing the Gas Purification System was modified to enhance the safety of maintanance operations. Both the Gas Purification System and the Vacuum Effluent Recovery System were performance tested with tritium. Results show that concentration reduction factors (ratio of inlet to exhaust concentrations) much in excess of 1000 per pass have been achieved for both systems at inlet concentrations of 1 ppM or less

  12. Radiopharmaceuticals for diagnosis

    International Nuclear Information System (INIS)

    Kuhl, D.E.

    1990-06-01

    During this grant period 1 January 1988--31 December 1990, we have successfully developed a number of new approaches to fluorine-18 labeled compounds, prepared several new radiotracers for both animal studies and eventual clinical trials, and explored the utility of a high-quality industrial robot in radiopharmaceutical applications. The progress during the last grant period is summarized briefly in the following sections. Publications arising from this research are listed below and can be found in Appendix I. 1 fig

  13. Tritium Systems Test Assembly operator training program

    International Nuclear Information System (INIS)

    Kerstiens, F.L.

    1985-01-01

    Proper operator training is needed to help ensure the safe operation of fusion facilities by personnel who are qualified to carry out their assigned responsibilities. Operators control and monitor the Tritium Systems Test Assembly (TSTA) during normal, emergency, and maintenance phases. Their performance is critical both to operational safety, assuring no release of tritium to the atmosphere, and to the successful simulation of the fusion reaction progress. Through proper training we are helping assure that TSTA facility operators perform their assignments in a safe and efficient manner and that the operators maintain high levels of operational proficiency through continuing training, retraining, requalification, and recertification

  14. Enzymatic synthesis of tritium-labelled prostaglandin D[sub 2] and its conversion to other prostaglandins

    Energy Technology Data Exchange (ETDEWEB)

    Shram, S.I.; Lazurkina, T.Yu.; Shevchenko, V.P.; Nagaev, I.Yu.; Myasoedov, N.F. (AN SSSR, Moscow (Russian Federation). Inst. Molekulyarnoj Genetiki)

    1994-04-01

    The one-stage enzymatic synthesis of tritium-labelled prostaglandin D[sub 2] from labelled arachidonic acid was performed by using the enzyme system PGH-synthetase/PGH-PGD-isomerase. By enzymatic and chemical transformation of [[sup 3]H]PGD[sub 2] the following compounds were obtained: 15-keto-13,14-dihydro-[[sup 3]H]PGD[sub 2], 9[alpha],11[beta]-[[sup 3]H]PGF[sub 2], 9-deoxy-[Delta][sup 9]-[[sup 3]H]-PGD[sub 2] ([[sup 3]H]PGJ[sub 2]) and [Delta][sup 12]-13,14-dihydro-[[sup 3]H]PGJ[sub 2]. It was found that L-selectride is a more effective reducing agent than sodium borohydride in the synthesis of 9[alpha], 11[beta]-[[sup 3]H]PGF[sub 2]. (Author).

  15. In-pile test of tritium release from tritium breeding materials (VOM-21H experiment)

    International Nuclear Information System (INIS)

    Kurasawa, Toshimasa; Takeshita, Hidefumi; Watanabe, Hitoshi; Yoshida, Hiroshi.

    1986-10-01

    Material development and blanket design of lithium-based ceramics such as lithium oxide, lithium aluminate, lithium silicate and lithium zirconate have been performed in Japan, United State of America and Europian Communities. Lithium oxide is a most attractive candidate for tritium breeding materials because of its high lithium density, high thermal conductivity and good tritium release performance. This work has been done to clarify the characteristics of tritium release and recovery from Li 2 O by means of in-situ tritium release measurement. The effects of temperature and sweep gas composition on the tritium release were investigated in this VOM-21H Experiment. Good measurement of tritium release was achieved but there were uncertainties in reproduciblity of data. The experimental results show that the role of surface adsorption/desorption makes a significant contribution to the tritium release and tritium inventory. Also, it is necessary to define the rate limiting process either diffusion or surface adsorption/desorption. (author)

  16. Tritium-v. 2

    International Nuclear Information System (INIS)

    1987-01-01

    Several bibliographical references about tritium are shown. The following aspects are presented: properties, analysis, monitoring, dosimetry reactions, labelling, industrial production, radiological protection, applications to science, technology and industry and some processes to obtain the element. (E.G.) [pt

  17. Determination of radiochemistry purity and pH of radiopharmaceutical in Northeast nuclear medicine services

    International Nuclear Information System (INIS)

    Andrade, Wellington; Santos, Poliane; Lima, Fernando de Andrade; Lima, Fabiana Farias de

    2013-01-01

    The radiopharmaceutical is a chemical compound associated with a radionuclide, which is selected so that meets the need cf diagnosis and capable of producing quality images. Drugs labeled with 99m Tc radionuclide kits consist of lyophilized, and be handled by the nuclear medicine services (NMS) must pass tests as the resolution of ANVISA (RDC 38) published in 2008. Among these tests are those of radiochemical purity and pH determination. This study evaluated the radiochemical purity of radiopharmaceuticals and pH SMN manipulated in the Northeast. The radiochemical purity (RCP) was determined by thin layer chromatography, which were used Whatman ® and silica gel, with dimensions of 1 x 10 cm, as stationary phase, and solvents indicated in the inserts of manufacturers. The chromatographic strips were placed in sealed containers so as not to touch the walls thereof. After the chromatographic run, the tape was cut every centimeter and the activities determined in doses of each calibrator NMS. The pH of the radiopharmaceutical was assessed through the use of universal pH paper (Merck®) and obtained staining compared with its color scale. The results showed (hat 82.6% and 100% of the radiopharmaceuticals of the samples were within the limits recommended by international pharmacopoeias for radiochemical purity and pl-l, respectively. There is then the need to include in routine tests indicated SMN by ANVISA. Well, they can detect possible problems in the marking of radiopharmaceuticals administered to the patient and avoid inappropriate material. (author)

  18. Tritium system test assembly control system cost estimate

    International Nuclear Information System (INIS)

    Stutz, R.A.

    1979-01-01

    The principal objectives of the Tritium Systems Test Assembly (TSTA), which includes the development, demonstration and interfacing of technologies related to the deuterium--tritium fuel cycle for fusion reactor systems, are concisely stated. The various integrated subsystems comprising TSTA and their functions are discussed. Each of the four major subdivisions of TSTA, including the main process system, the environmental and safety systems, supporting systems and the physical plant are briefly discussed. An overview of the Master Data Acquisition and Control System, which will control all functional operation of TSTA, is provided

  19. Molecular target in oncology. Opportunity for radiopharmaceuticals development

    International Nuclear Information System (INIS)

    Navarro Marques, Fabio Luiz

    2016-01-01

    Cancer is a cellular multifactorial disease, regulated by changes in phenotype characteristics, such as adhesion, invasion, migration, and tumorigenesis; genotypic status of commonly altered genes (KRAS and p53); microenvironmental conditions, such pH, oxygen and nutrient supply. All these features provide opportunities for radiopharmaceuticals development, both for diagnostic and therapy. For both applications, radiopharmaceuticals molecules can be divided in small synthetic molecules, small peptides (natural or modified), large molecules such as antibody or nanoparticles. The characteristics of those molecules and use will guide the choice of the radionuclide to be used for labeling it. In the presentation, data from literature and research ongoing in the Faculty of Medicine of the University of São Paulo/Brazil will be used for demonstrate the potential for radiopharmaceuticals development. (author)

  20. Labelled molecules, modern research implements

    International Nuclear Information System (INIS)

    Pichat, L.; Langourieux, Y.

    1974-01-01

    Details of the synthesis of carbon 14- and tritium-labelled molecules are examined. Although the methods used are those of classical organic chemistry the preparation of carbon 14-labelled molecules differs in some respects, most noticeably in the use of 14 CO 2 which requires very special handling techniques. For the tritium labelling of organic molecules the methods are somewhat different, very often involving exchange reactions. The following are described in turn: the so-called Wilzbach exchange method; exchange by catalysis in solution; catalytic hydrogenation with tritium; reductions with borotritides. Some applications of labelled molecules in organic chemistry, biochemistry and pharmacology are listed [fr

  1. Auxin Does Not Alter the Permeability of Pea Segments to Tritium-labeled Water.

    Science.gov (United States)

    Dowler, M J; Rayle, D L

    1974-02-01

    The possibility of an auxin effect on the permeability of pea (Pisum sativum L. ev. Alaska) segments to tritium-labeled water has been investigated by three separate laboratories, and the combined results are presented. We were unable to obtain any indication of a rapid effect of indoleacetic acid on the efflux of (3)HHO when pea segments previously "loaded" for 90 minutes with (3)HHO were transferred to unlabeled aqueous medium with indoleacetic acid. We were able to confirm that segments pretreated with (3)HHO plus indoleacetic acid for 60 to 90 minutes can show an enhanced (3)HHO release as compared with minus indoleacetic acid controls. However, this phenomenon appears to be due to an increased uptake of (3)HHO during the prolonged indoleacetic acid pretreatment, and therefore we conclude that auxin does not alter the permeability of pea segments to (3)HHO in either short term or long term tests. We confirm previous reports that the uptake of (3)HHO in pea segments proceeds largely through the cut surfaces, and that the cuticle is a potent barrier to (3)HHO flux.

  2. Radiopharmaceuticals production activities in Egypt

    International Nuclear Information System (INIS)

    Raieh, M.

    1998-01-01

    Applications of radiopharmaceuticals and labelled compounds in the field of nuclear medicine in Egypt have increased so rapidly in the last few years. At present, a large number of hospitals are utilizing these radioisotopic techniques for both diagnosis and treatment. The following production activities are taking place in the Egyptian Radioisotope Production laboratories. By utilizing the research reactor a large number of radioisotopes which find wide applications in nuclear medicine were produced, such as iodine-131, phosphorus-32, sodium-24, potassium-42 and molybdenum-99 / technetium-99m generators. Gallium-67, indium-111 and iodine-123 will be produced locally after installation of the cyclotron at the end of 1998. A large number of Tc-99m based kits for diagnostic medical applications have been produced. Also, many radiopharmaceuticals labelled with iodine-131 were produced. The radioisotope production laboratory is able to supply many hospitals with the radioimmunoassay kits of the thyroid related hormones (T4, T3 and TSH). Research and development activities are taking place in the field of monoclonal antibodies and tumor markers with special consideration of AFP, CEA, PSA and βhCG. (author)

  3. Harvard-MIT research program in short-lived radiopharmaceuticals. Technical progress report, 1991

    Energy Technology Data Exchange (ETDEWEB)

    Adelstein, S.J.

    1991-12-31

    This report presents research on radiopharmaceuticals. The following topics are discussed: antibody labeling with positron-emitting radionuclides; antibody modification for radioimmune imaging; labeling antibodies; evaluation of technetium acetlyacetonates as potential cerebral blood flow agents; and studies in technetium chemistry. (CBS)

  4. Demonstration tests of tritium removal device under the conditions of nuclear fusion reactor. Cooperation test between Japan and USA

    International Nuclear Information System (INIS)

    Hayashi, Takumi; Kobayashi, Kazuhiro; Nishi, Masataka

    2001-01-01

    Performance of oxidation catalysis in emergency tritium removal device was tested in Los Alamos National Laboratory by cooperation between Japan and USA on November 8, 2000. To reduce the effects of tritium on the environment, a plan of the closed space for trapping tritium was made. A tritium removal device using oxidation catalysis and water vapor adsorption removes the tritium in the closed space. The treatment flow rate of the device is about 2,500 m 3 /h, the same as ITER(3,000 to 4,500 m 3 /h). Catalysis is Pt/ alumina. The closed space is 3,000m 2 . The initial concentration of tritium was about 7 Bq/cm 2 , ten times as large as the concentration limit in atmosphere. The concentration of tritium in the test laboratory decreased linearly with time and attained to the limit value after about 200 min. Residue of tritium on the wall had been removed and the significant quantity was not detected after three days. The results proved to satisfy safety of ITER. (S.Y.)

  5. Development of glycoside-bound radiopharmaceuticals; Novel radioiodination method for digoxin

    Energy Technology Data Exchange (ETDEWEB)

    Takemura, Yasutaka; Dote, Nobuhito; Taniuchi, Hideyuki; Iijima, Naoko; Yokoyama, Akira (Kyoto Univ. (Japan). Faculty of Pharmaceutical Science); Fujibayashi, Yasuhisa; Konishi, Junji

    1994-01-01

    We combined 2-hydroxy-3-methylbenzoylhydrazide (HMBH) with glycosides as a novel method for the radioiodination of physiologically active glycosides. This method was tested using digoxin, which is one of the cardiac glycosides. A digoxin-HMBH conjugate was synthesized by periodate cleavage of the third sugar ring, and was readily radiolabelled with Na[[sup 125]I] by the chloramine-T method. [sup 125]I labelled digoxin-HMBH conjugate retained Na[sup +], K[sup +]-ATPase binding in vivo and in vitro, and also retained immunoreactivity to an anti-digoxin antibody. Thus, this [sup 125]I labelled digoxin-HMBH conjugate represents a potential radiopharmaceutical for Na[sup +], K[sup +]-ATPase imaging, as well as for the radioimmunoassay of digoxin. (author).

  6. Radiopharmaceuticals

    International Nuclear Information System (INIS)

    Theobald, A.E.

    1989-01-01

    This book is a review of the latest developments in radiopharmaceuticals. It covers the development of radiopharmaceutical compounds, the theory and practice of their synthesis, and examples of their application. Also covers safe handling of radiopharmaceuticals, legislation affecting their use, radiation monitoring, radiochromatography, and computer techniques

  7. Determination of bacterial endotoxin (pyrogen) in radiopharmaceuticals by the gel clot method. Validation

    International Nuclear Information System (INIS)

    Fukumori, Neuza Taeko Okasaki

    2008-01-01

    Before the Limulus amebocyte lysate (LAL) test, the only available means of pirogenicity testing for parenteral drugs and medical devices was the United States Pharmacopoeia (USP) rabbit pyrogen test. Especially for radiopharmaceuticals, the LAL assay is the elective way to determine bacterial endotoxin. The aim of this work was to validate the gel clot method for some radiopharmaceuticals without measurable interference. The FDA's LALTest guideline defines interference as a condition that causes a significant difference between the endpoints of a positive water control and positive product control series using a standard endotoxin. Experiments were performed in accordance to the USP bacterial endotoxins test in the 131 I- m-iodobenzylguanidine; the radioisotopes Gallium-67 and Thallium-201; the lyophilized reagents DTPA, Phytate, GHA, HSA and Colloidal Tin. The Maximum Valid Dilution (MVD) was calculated for each product based upon the clinical dose of the material and a twofold serial dilution below the MVD was performed in duplicate to detect interferences. The labeled sensitivity of the used LAL reagent was 0.125 EU mL -1 (Endotoxin Units per milliliter). For validation, a dilution series was performed, a twofold dilution of control standard endotoxin (CSE) from 0.5 to 0.03 EU mL -1 , to confirm the labeled sensitivity of the LAL reagent being tested in sterile and non pyrogenic water, in quadruplicate. The same dilution series was performed with the CSE and the product in the 1:100 dilution factor, in three consecutive batches of each radiopharmaceutical. The products 131 I-m-iodobenzylguanidine, Gallium-67, Thallium-201, DTPA, HSA and Colloidal Tin were found compatible with the LAL test at a 1:100 dilution factor. Phytate and GHA showed some interference in the gel clot test. Other techniques to determine endotoxins as the chromogenic (color development) and the turbidimetric test (turbidity development), were also assessed to get valuable quantitative and

  8. Lung radiopharmaceuticals

    International Nuclear Information System (INIS)

    Gonzalez, B.M.

    1994-01-01

    Indication or main clinical use of Lung radiopharmaceuticals is presented and clasification of radiopharmaceuticals as ventilation and perfusion studies. Perfusion radiopharmaceuticals, main controls for administration quality acceptance. Clearence after blood administration and main clinical applications. Ventilation radiopharmaceuticals, gases and aerosols, characteristics of a ideal radioaerosol, techniques of good inhalation procedure, clinical applications. Comparison of several radiopharmaceuticals reflering to retention time as 50% administered dose, percent administered dose at 6 hours post inhalation, blood activity at 30 and 60 minutes post inhalation, initial lung absorbed dose, cumulated activity.Kinetic description of two radiopharmaceuticals, 99mTcDTPA and 99mTc-PYP

  9. Separation and purification of no-carrier-added arsenic from bulk amounts of germanium for use in radiopharmaceutical labelling

    Energy Technology Data Exchange (ETDEWEB)

    Jahn, M.; Radchenko, V.; Roesch, F.; Jennewein, M. [Mainz Univ. (Germany). Inst. of Nuclear Chemsistry; Filosofov, D. [Joint Inst. for Nuclear Research, Dubna (Russian Federation). Lab. of Nuclear Problems; Hauser, H.; Eisenhut, M. [Deutsches Krebsforschungszentrum, Heidelberg (Germany). Radiopharmaceutical Chemistry

    2010-07-01

    Radioarsenic labelled radiopharmaceuticals could add special features to molecular imaging with positron emission tomography (PET). For example the long physical half-lives of {sup 72}As (T{sub 1/2}=26 h) and {sup 74}As (T{sub 1/2}=17.8 d) in conjunction with their high positron branching rates of 88% and 29%, respectively, allow the investigation of slow physiological or metabolical processes, like the enrichment and biodistribution of monoclonal antibodies in tumour tissue or the characterization of stem cell trafficking. A method for separation and purification of no-carrier-added (nca) arsenic from irradiated metallic germanium targets based on distillation and anion exchange is developed. It finally converts the arsenic into an {sup *}As(III) synthon in PBS buffer and pH 7 suitable for labelling of proteins via As-S bond formations. The method delivers radioarsenic in high purity with separation factors of 10{sup 6} from germanium and an overall yield from target to labelling synthon of > 40%. In a proof-of-principle experiment, the monoclonal antibody Bevacizumab, directed against the human VEGF receptor, was labelled with a radiochemical yield > 90% within 1 h at room temperature with nca {sup 72/74/77}As. (orig.)

  10. Regional groundwater flow and tritium transport modeling and risk assessment of the underground test area, Nevada Test Site, Nevada

    Energy Technology Data Exchange (ETDEWEB)

    None

    1997-10-01

    The groundwater flow system of the Nevada Test Site and surrounding region was evaluated to estimate the highest potential current and near-term risk to the public and the environment from groundwater contamination downgradient of the underground nuclear testing areas. The highest, or greatest, potential risk is estimated by assuming that several unusually rapid transport pathways as well as public and environmental exposures all occur simultaneously. These conservative assumptions may cause risks to be significantly overestimated. However, such a deliberate, conservative approach ensures that public health and environmental risks are not underestimated and allows prioritization of future work to minimize potential risks. Historical underground nuclear testing activities, particularly detonations near or below the water table, have contaminated groundwater near testing locations with radioactive and nonradioactive constituents. Tritium was selected as the contaminant of primary concern for this phase of the project because it is abundant, highly mobile, and represents the most significant contributor to the potential radiation dose to humans for the short term. It was also assumed that the predicted risk to human health and the environment from tritium exposure would reasonably represent the risk from other, less mobile radionuclides within the same time frame. Other contaminants will be investigated at a later date. Existing and newly collected hydrogeologic data were compiled for a large area of southern Nevada and California, encompassing the Nevada Test Site regional groundwater flow system. These data were used to develop numerical groundwater flow and tritium transport models for use in the prediction of tritium concentrations at hypothetical human and ecological receptor locations for a 200-year time frame. A numerical, steady-state regional groundwater flow model was developed to serve as the basis for the prediction of the movement of tritium from the

  11. New tritium monitor for the Tokamak Fusion Test Reactor

    International Nuclear Information System (INIS)

    Jalbert, R.A.

    1985-01-01

    At DT-fueled fusion reactors, there will be a need for tritium monitors that can simultaneously measure in real time the concentrations of HTO, HT and the activated air produced by fusion neutrons. Such a monitor has been developed, tested and delivered to the Princeton Plasma Physics Laboratory for use at the Tokamak Fusion Test Reactor (TFTR). It uses semipermeable membranes to achieve the removal of HTO from the sampled air for monitoring and a catalyst to convert the HT to HTO, also for removal and monitoring. The remaining air, devoid of tritium, is routed to a third detector for monitoring the activated air. The sensitivities are those that would be expected from tritium instruments employing conventional flow-through ionization chambers: 1 to 3 μCi/m 3 . Its discriminating ability is approximately 10 -3 for any of the three components (HTO, HT and activated air) in any of the other two channels. For instance, the concentration of HT in the HTO channel is 10 -3 times its original concentration in the sampled air. This will meet the needs of TFTR

  12. Calibration and qualification of equipment in the pharmaceutical industry: emphasis on radiopharmaceuticals production

    International Nuclear Information System (INIS)

    Melero, Laura T.U.H.; Silva, Katia S. da S.; Zanette, Camila; Araujo, Elaine B. de; Mengatti, Jair

    2011-01-01

    The calibration and qualification of equipment are listed items in RDC number 17 of 2010 which refers about the Good Manufacturing Practice (GMP) of medicaments and RDC number 63 of 2009 which refers about GMP of Radiopharmaceuticals. Both are essential requirements since they are involved in process control to attend the regulatory criteria and are a key part of the validation process. The aim of this work is presenting the importance of calibration and qualification, and the routine use of equipment and facilities in industrial scale production of radiopharmaceuticals in the IPEN/CNEN. The radiopharmacy of IPEN is a pharmaceutical industry that produces radiopharmaceuticals for diagnosis and therapy. It was the pioneer institute in production of radioisotopes and radiopharmaceuticals in Brazil. Currently, 38 products are distributed to the nuclear medicine centers, including primary radioisotopes, labeled molecules and lyophilized reagents for labeling with technetium-99m. To fulfill the GMP requirements for quality assurance of products, several factors must be considered including infrastructure, equipment and raw materials beyond, obviously, the whole production process should be controlled until the release of the final product. Therefore, the calibration and verification of equipment, instruments and other appliances used in the production and quality control should be performed. A program of calibration, qualification and requalification of equipment used in production and quality control of radiopharmaceuticals is necessary for the validation of production processes and analytical methods, and should be established for quality assurance of produced radiopharmaceuticals. (author)

  13. Calibration and qualification of equipment in the pharmaceutical industry: emphasis on radiopharmaceuticals production

    Energy Technology Data Exchange (ETDEWEB)

    Melero, Laura T.U.H.; Silva, Katia S. da S.; Zanette, Camila; Araujo, Elaine B. de; Mengatti, Jair [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil)

    2011-07-01

    The calibration and qualification of equipment are listed items in RDC number 17 of 2010 which refers about the Good Manufacturing Practice (GMP) of medicaments and RDC number 63 of 2009 which refers about GMP of Radiopharmaceuticals. Both are essential requirements since they are involved in process control to attend the regulatory criteria and are a key part of the validation process. The aim of this work is presenting the importance of calibration and qualification, and the routine use of equipment and facilities in industrial scale production of radiopharmaceuticals in the IPEN/CNEN. The radiopharmacy of IPEN is a pharmaceutical industry that produces radiopharmaceuticals for diagnosis and therapy. It was the pioneer institute in production of radioisotopes and radiopharmaceuticals in Brazil. Currently, 38 products are distributed to the nuclear medicine centers, including primary radioisotopes, labeled molecules and lyophilized reagents for labeling with technetium-99m. To fulfill the GMP requirements for quality assurance of products, several factors must be considered including infrastructure, equipment and raw materials beyond, obviously, the whole production process should be controlled until the release of the final product. Therefore, the calibration and verification of equipment, instruments and other appliances used in the production and quality control should be performed. A program of calibration, qualification and requalification of equipment used in production and quality control of radiopharmaceuticals is necessary for the validation of production processes and analytical methods, and should be established for quality assurance of produced radiopharmaceuticals. (author)

  14. Radiopharmaceuticals to 99mTc

    International Nuclear Information System (INIS)

    Leon Cabana, Alba

    1994-01-01

    Studies about 99m Tc had demonstrated that have favorable properties for support diagnostic proceedings in nuclear medicine. This physical and chemical properties used for obtain another radiopharmaceuticals have been employed through re actives kits labelled with Tc 99m . A brief description was given about 99m utilities in diagnostic techniques such as endothelium reticular system,renal and hepatic studies,bone scintillators,cardiac diagnostic and cerebral perfusion

  15. Fuel cleanup system for the tritium systems test assembly: design and experiments

    International Nuclear Information System (INIS)

    Kerr, E.C.; Bartlit, J.R.; Sherman, R.H.

    1980-01-01

    A major subsystem of the Tritium Systems Test Assembly is the Fuel Cleanup System (FCU) whose functons are to: (1) remove impurities in the form of argon and tritiated methane, water, and ammonia from the reactor exhaust stream and (2) recover tritium for reuse from the tritiated impurities. To do this, a hybrid cleanup system has been designed which utilizes and will test concurrently two differing technologies - one based on disposable, hot metal (U and Ti) getter beds and a second based on regenerable cryogenic asdorption beds followed by catalytic oxidation of impurities to DTO and stackable gases and freezout of the resultant DTO to recover essentially all tritium for reuse

  16. A novel approach radiolabeling detonation nanodiamonds through the tritium thermal activation method

    Energy Technology Data Exchange (ETDEWEB)

    Badun, Gennadii A.; Chernysheva, Maria G.; Semenenko, Mikhail N.; Lisichkin, Georgii V. [Lomonosov Moscow State Univ. (Russian Federation). Chemistry Dept.; Yakovlev, Ruslan Yu.; Leonidov, Nikolai B. [Pavlov Ryazan State Medical Univ. (Russian Federation)

    2014-07-01

    Tritium labeling was introduced into detonation nanodiamonds (ND) through the tritium thermal activation method. Two target preparation techniques were developed to increase the radioactivity and the specific radioactivity of the labeled product: the desiccation of the waterless solvent suspension and the lyophilization of the hydrosol. The specific radioactivity of the labeled product was shown to correlate with the hydrogen content in the starting material and to achieve 2.6 TBq/g.

  17. A novel approach radiolabeling detonation nanodiamonds through the tritium thermal activation method

    International Nuclear Information System (INIS)

    Badun, Gennadii A.; Chernysheva, Maria G.; Semenenko, Mikhail N.; Lisichkin, Georgii V.

    2014-01-01

    Tritium labeling was introduced into detonation nanodiamonds (ND) through the tritium thermal activation method. Two target preparation techniques were developed to increase the radioactivity and the specific radioactivity of the labeled product: the desiccation of the waterless solvent suspension and the lyophilization of the hydrosol. The specific radioactivity of the labeled product was shown to correlate with the hydrogen content in the starting material and to achieve 2.6 TBq/g.

  18. A perspective on tritium versus carbon-14: ensuring optimal label selection in pharmaceutical research and development.

    Science.gov (United States)

    Krauser, Joel A

    2013-01-01

    Tritium ((3) H) and carbon-14 ((14) C) labels applied in pharmaceutical research and development each offer their own distinctive advantages and disadvantages coupled with benefits and risks. The advantages of (3) H have a higher specific activity, shorter half-life that allows more manageable waste remediation, lower material costs, and often more direct synthetic routes. The advantages of (14) C offer certain analytical benefits and less potential for label loss. Although (3) H labels offer several advantages, they might be overlooked as a viable option because of the concerns about its drawbacks. A main drawback often challenged is metabolic liability. These drawbacks, in some cases, might be overstated leading to underutilization of a perfectly viable option. As a consequence, label selection may automatically default to (14) C, which is a more conservative approach. To challenge this '(14) C-by-default' approach, pharmaceutical agents with strategically selected (3) H-labeling positions based on non-labeled metabolism data have been successfully implemented and evaluated for (3) H loss. From in-house results, the long term success of projects clearly would benefit from a thorough, objective, and balanced assessment regarding label selection ((3) H or (14) C). This assessment should be based on available project information and scientific knowledge. Important considerations are project applicability (preclinical and clinical phases), synthetic feasibility, costs, and timelines. Copyright © 2013 John Wiley & Sons, Ltd.

  19. Analysis of 99mTc-labeled radiopharmaceuticals by high-performance liquid chromatography

    International Nuclear Information System (INIS)

    Muto, Toshio

    1990-01-01

    High-performance liquid chromatography (HPLC) equiped with on line radiometric and optical detectors (i.e. radio-HPLC) have been applied to the radiochemical analysis of commonly-used 99m Tc-radio pharma ceuticals with a view point to check the radiochemical purities of the compounds. Chromatographic conditions were determined by examination of the types of column, mobile phase and pH. An aqueous size-exclusion (Shim-pack Diol-300) and reversed-phase column (Zorbax-ODS) were found to be suitable for 99m Tc-HSA and the other 99m Tc-agents, respectively. The analysis of low molecular weight 99m Tc-agents (e.g. 99m Tc-DTPA, 99m Tc-DMSA, 99m Tc-pyrophosphate, 99m Tc-phytic acid, 99m Tc-MDS, 99m Tc-HMDP) were done by reversed-phaseion pairing chromatography using a optimized mobile phase consisted on a mixture of 50 mM phosphate buffer (pH 7.0) and 2 mM TBA (tetra nbutyl) ammonium hydroxide) in 30 % methanol. The mobile phases for analysis of medium molecular weight 99m Tc-HSA were consisted of a mixture of 50 mM phosphate buffer (ph 7.0) in 30 % methanol, and a mixtures of 1 % SDS (sodium dodecyl sulfonate) in Tris buffer (pH. 7.0), respectively. It was apparent from the radio-chromatograms obtained from these chromatographic conditions, that impurity of 99m TcO 4 was observed in 99m Tc-pyrophosphate, 99m Tc-phytic acid, 99m Tc-MDP, 99m Tc-HMDP, and impurities of 99m Tc-labeled species and 99m TcO 4 , were observed in 99m Tc-HIDA, 99m Tc-HIDA, 99m Tc-HSA. The radiochemical impurities of the 99m Tc-radiopharmaceuticals were ranged between 90 and 100 %. From these results, radio-HPLC has been shown to be suitable method for analysis of 99m Tc-radiopharmaceuticals, with rapidity and excellent precision. (author)

  20. Synthesis of a tritium labeled photolabile analogue of farnesyl diphosphate: (E,E)-[1-3H]-(2-diazo-3-trifluoropropionyloxy)geranyl diphosphate (DATFP-GDP)

    International Nuclear Information System (INIS)

    Liu, J.; Benedict, C.R.

    1996-01-01

    Tritiated (E,E)-(2-diazo-3-trifluoropropionyloxy)geranyl disphosphate (DATFP-GDP) has been used as a photolabile analogue of (E,E)-farnesyl diphosphate (E,E-FDP) for an aid in isolating enzymes utilizing E,E-FDP as a substrate. We now report an alternative method of synthesizing this probe in which the tritium label is introduced in the step just before the introduction of the diphospate group. Thus, DATFP-geranial is oxidized to DATFP-geranial with activated manganese dioxide. The tritium label is introduced by reduction of the aldehyde with NaBT 4 . The DATFP-group successfully withstands both of these steps. The overall yield for these two steps is 69%. Diphosphorylation of the resulting alcohol afforded DATFP-[1- 3 H]-GDP in 8% yield with a specific activity of 48.6 μCi/μmol and radiochemical purity of 94%. (Author)

  1. Transfer of tritium-labeled organic material from grass into cow's milk

    International Nuclear Information System (INIS)

    van den Hoek, J.; ten Have, M.H.J.; Gerber, G.B.; Kirchmann, R.

    1985-01-01

    Two lactating cows were given tritiated hay containing organically bound tritium (OBT) only for about 4 weeks. Tritium activity was determined in milk fat, casein, lactose, milk water, and whole milk. In one cow, milk was sampled for approximately 450 days, covering two lactation periods. At steady state, specific tritium activities in casein, lactose, and milk water were 58, 10, and 11%, respectively, of those in milk fat. Some OBT was converted into THO during catabolism and entered the body water pool. This 3 H source accounted for nearly 40% of tritium in lactose, but in casein and milk fat about 97% of tritium was derived from ingested OBT. Comparison of the specific activity of milk constituents with the specific activity of ingested hay showed the following values: 0.84 for milk fat, 0.49 for casein, 0.05 for lactose, 0.10 for milk water. Decrease of tritium activity with time could be represented by three components with different half-lives for the organic milk constituents. Those for milk fat and casein were quite similar, with a slow component of nearly 3 months

  2. Tritium behaviour in higher plants

    International Nuclear Information System (INIS)

    Guenot, J.

    1984-05-01

    Vine grapes and potato seedlings have been exposed in situ to tritiated water vapor and 14 C labeled carbon dioxide. Leaves sampling was done during and after the exposition. Measurements allowed to distinguish the three forms of tritium in leaves, i.e. tissue free water tritium (TFWT) and organically bound tritium (OBT), in exchangeable position or not. The results lead to a description of the dynamical behaviour of tritium between these three compartments. It has been shown that 20% of organically bound hydrogen is readily exchangeable thus being in permanent isotopic equilibium with tissue free water. Moreover, the activity of nonexchangeable OBT appears to be strongly related to the organic 14 C, which shows that photosynthesis is responsible of tritium incorporation in organic nonexchangeable position, and occurs with a 20% discrimination in favor of protium. In contrast with the other two compartments, this fixation is almost irreversible, which is a fact of importance from a radiological point of view [fr

  3. Current directions in radiopharmaceutical research

    Energy Technology Data Exchange (ETDEWEB)

    Mather, S J [Department of Nuclear Medicine, St. Bartholomew` s Hospital, London (United Kingdom)

    1998-08-01

    Much of current radiopharmaceutical research is directed towards the development of receptor-binding tracers which are targeted towards biochemical processes. These may be extra or intracellular in nature and hold promise for an imaging approach to tissue characterisation in-vivo. Many of these products are based on proteins which range in size from large monoclonal antibodies to small neuropeptides and share a radiolabelling chemistry based on the use of bifunctional chelating agents. Although developed initially for use with indium-111, considerations of cost and isotope availability have continued to direct the efforts of many researchers towards the use of technetium-99m. While polypeptide-based radiopharmaceuticals may be useful for imaging peripheral cell-surface receptors, access to sites of interest within the cell, or in the brain, requires the development of small lipophilic molecules with retained ability to interact with intracellular targets. The design and synthesis of these compounds presents a particular challenge to the radiopharmaceutical chemist which is being met through either a pendant or integrated approach to the use of technetium coordination with particular emphasis on technetium (v) cores. Progress continues to be made in the application of targeted radionuclide therapy particularly in the development of radiopharmaceuticals for the treatment of malignant bone disease. methods for labelling antibodies with a great variety of cytotoxic radionuclides have now been refined and their use for radioimmunotherapy in the treatment of haematological malignancies shows great promise. The major medical areas for application of these new radiopharmaceuticals will be in oncology, neurology and inflammation but the increasingly difficult regulatory climate in which drug development and health-care now operate will make it essential for researchers to direct their products toward specific clinical problems as well as biological targets. (author) 36 refs

  4. Current directions in radiopharmaceutical research

    International Nuclear Information System (INIS)

    Mather, S.J.

    1998-01-01

    Much of current radiopharmaceutical research is directed towards the development of receptor-binding tracers which are targeted towards biochemical processes. These may be extra or intracellular in nature and hold promise for an imaging approach to tissue characterisation in-vivo. Many of these products are based on proteins which range in size from large monoclonal antibodies to small neuropeptides and share a radiolabelling chemistry based on the use of bifunctional chelating agents. Although developed initially for use with indium-111, considerations of cost and isotope availability have continued to direct the efforts of many researchers towards the use of technetium-99m. While polypeptide-based radiopharmaceuticals may be useful for imaging peripheral cell-surface receptors, access to sites of interest within the cell, or in the brain, requires the development of small lipophilic molecules with retained ability to interact with intracellular targets. The design and synthesis of these compounds presents a particular challenge to the radiopharmaceutical chemist which is being met through either a pendant or integrated approach to the use of technetium coordination with particular emphasis on technetium (v) cores. Progress continues to be made in the application of targeted radionuclide therapy particularly in the development of radiopharmaceuticals for the treatment of malignant bone disease. methods for labelling antibodies with a great variety of cytotoxic radionuclides have now been refined and their use for radioimmunotherapy in the treatment of haematological malignancies shows great promise. The major medical areas for application of these new radiopharmaceuticals will be in oncology, neurology and inflammation but the increasingly difficult regulatory climate in which drug development and health-care now operate will make it essential for researchers to direct their products toward specific clinical problems as well as biological targets. (author)

  5. Influence of iron deficiency in the radiopharmaceutical behavior of red blood cells labeled with 99mTc(99mTC-RBC)

    International Nuclear Information System (INIS)

    Calmanovici, G.; Salgueiro, M.J.; Pernas, L.; Collia, N.; Leonardi, N.; Zubillaga, M.

    2005-01-01

    Full text: Red blood cells (RBCs) labeled with 99m Tc are commonly used in the evaluation of cardiac function, gastrointestinal tract bleeding, red blood cell volume or splenic sequestration. Generally stannous ion is used as reducing agent. A proposed mechanism is that once the stannous ion (Sn) and the pertechnetate ( 99m Tc) reach the interior of the RBC, the radionuclide is mainly house in the β-chain of hemoglobin. The aim of this study was to determine if hemoglobin content reduction, an indicator of iron deficiency anemia, could affect the efficiency of RBC labeling and the biological distribution of this radiopharmaceutical. We studied 30 rats fed for 3 weeks after weaning with diets with iron contents of 6.5 ppm (group A), 18 ppm (group B) and 100 ppm (control). For all groups, the labeling yields were always higher than 97%; the percentage of radioactivity was mostly founded in blood with almost negligible radioactivity the rest of the studied organs. We can conclude that the decrease in hemoglobin content, an indicator of iron deficiency anemia, does not interfere neither in the labeling nor in the biodistribution of red blood cells labeled with 99m Tc. (author)

  6. Evaluation and Characterization of The Radiopharmaceutical Lyophilized-Kit of Ciprofloxacin

    International Nuclear Information System (INIS)

    Nurlaila Zainuddin; Eva Maria Widyasari

    2009-01-01

    The 99m Tc-ciprofloxacin radiopharmaceutical is available in the lyophilized-kit which is separately packed in two vials, ciprofloxacin lactate and Sn-tartrate, respectively. Preparation of 99m Tc-ciprofloxacin was performed by adding 99m Tc radionuclide into ciprofloxacin lactate solution, followed by addition of Sn-tartrate solution. The complement information was needed by user in order to assure the successful preparation and utilization of this radiopharmaceutical. Meanwhile, this investigation was performed to obtained the several physicochemical and biological characters of 99m Tc-ciprofloxacin prepared from the radiopharmaceutical lyophilized-kit of ciprofloxacin lactate. The radiochemical purity was determined with instant thin layer chromatography (ITLC-SG) using acetone and solution of dichloromethane : methanol : ammonium hydroxide : acetonitrile : (4:4:2:1) as a mobile phases. The plasma binding protein of 99m Tc-ciprofloxacin was investigated in-vitro by precipitation method using 5% of trichloro acetic acid solution, whereas the lipophilicity (P) was obtained by determination of octanol-water partition. Beside that, studies on the effect of volume of Na 99m TcO4 solution to radiochemical purity of 99m Tc-ciprofloxacin has been carried out. From the experiment, it was obtained that 99m Tc-ciprofloxacin has 95.85 ± 2.10 % of radiochemical purity, the human plasma binding protein of 58.35 ± 2.05 % and the lipophilicity (P) = 0.024 ± 0.005. The volume more than 2 mL of Na 99m TcO4 solution on the labelling of ciprofloxacin gave less than 90 % of radiochemical purity. The labelling efficiency of 44.79 % was obtained after filtration of 99m Tc-ciprofloxacin. The stability test on 99m Tc-ciprofloxacin and ciprofloxacin lyophilized-kit were performed by determining their radiochemical purities. The 99m Tcciprofloxacin was still able to be used until 4 hours after labelling with radiochemical purity of 91.61 ± 1.60 %. The stability determination showed

  7. Study of potential utility of new radiopharmaceuticals based on technetium-99m labeled derivative of glucose

    Science.gov (United States)

    Zeltchan, R.; Medvedeva, A.; Sinilkin, I.; Chernov, V.; Stasyuk, E.; Rogov, A.; Il'ina, E.; Larionova, L.; Skuridin, V.

    2016-08-01

    Purpose: to study the potential utility of 1-thio-D-glucose labeled with 99mTc for cancer imaging in laboratory animals. Materials and method: the study was carried out in cell cultures of normal CHO (Chinese hamster ovary cells CHO) and malignant tissues MCF-7 (human breast adenocarcinoma MCF-7). To evaluate the uptake of 99mTc-1-thio-D-glucose in normal and tumor tissue cells, 25 MBq of 1-thio-D-glucose labeled with 99mTc was added to the vials with 3 million cells and incubated for 30 min at room temperature. After centrifugation of the vials with cells, the supernatant was removed. The radioactivity in vials with normal and tumor cells was then measured. In addition, the study included 40 mice of C57B1/6j lines with tumor lesion of the right femur. For neoplastic lesions, Lewis lung carcinoma model was used. Following anesthesia, mice were injected intravenously with 25 MBq of 99mTc-1-thio-D-glucose. Planar scintigraphy was performed 15 minutes later in a matrix of 512x512 pixels for 5 min. Results: when measuring the radioactivity of normal and malignant cells after incubation with 99mTc-1-thio-D-glucose, it was found that the radioactivity of malignant cells was higher than that of normal cells. The mean values of radioactivity levels in normal and malignant cells were 0.3 ± 0.15 MBq and 1.07 ± 0.6 MBq, respectively. All examined animals had increased accumulation of 99mTc-1-thio-D-glucose at the tumor site. The accumulation of 99mTc-1-thio-D-glucose in the tumor was on average twice as high as compared to the symmetric region. Conclusion: The present study demonstrated that 99mTc-1-thio-D-glucose is a prospective radiopharmaceutical for cancer visualization. In addition, high accumulation of 99mTc-1-thio-D-glucose in the culture of cancer cells and in tumor tissue of animals demonstrates tumor tropism of the radiopharmaceutical.

  8. Experimental study of radiopharmaceuticals based on technetium-99m labeled derivative of glucose for tumor diagnosis

    Science.gov (United States)

    Zeltchan, R.; Medvedeva, A.; Sinilkin, I.; Bragina, O.; Chernov, V.; Stasyuk, E.; Rogov, A.; Il'ina, E.; Larionova, L.; Skuridin, V.; Dergilev, A.

    2016-06-01

    Purpose: to study the potential utility of 1-thio-D-glucose labeled with 99mTc for cancer imaging in laboratory animals. Materials and method: the study was carried out in cell cultures of normal CHO (Chinese hamster ovary cells CHO) and malignant tissues MCF-7 (human breast adenocarcinoma MCF-7). To evaluate the uptake of 99mTc-1-thio-D-glucose in normal and tumor tissue cells, 25 MBq of 1-thio-D-glucose labeled with 99mTc was added to the vials with 3 million cells and incubated for 30 minutes at room temperature. After centrifugation of the vials with cells, the supernatant was removed. Radioactivity in vials with normal and tumor cells was then measured. In addition, the study included 40 mice of C57B 1/6j lines with tumor lesion of the right femur. For neoplastic lesions, Lewis lung carcinoma model was used. Following anesthesia, mice were injected intravenously with 25MBq of 99mTc-1-thio-D-glucose. Planar scintigraphy was performed 15 minutes later in a matrix of 512x512 pixels for 5 minutes. Results: when measuring the radioactivity of normal and malignant cells after incubation with 99mTc-1-thio-D- glucose, it was found that the radioactivity of malignant cells was higher than that of normal cells. The mean values of radioactivity levels in normal and malignant cells were 0.3±0.15MBq and 1.07±0.6MBq, respectively. All examined animals had increased accumulation of 99mTc-1-thio- D-glucose at the tumor site. The accumulation of 99mTc-1-thio-D-glucose in the tumor was on average twice as high as compared to the symmetric region. Conclusion: The present study demonstrated that 99mTc-1-thio-D-glucose is a prospective radiopharmaceutical for cancer visualization. In addition, high accumulation of 99mTc-1-thio-D-glucose in the culture of cancer cells and in tumor tissue of animals demonstrates tumor tropism of the radiopharmaceutical.

  9. Stack and area tritium monitoring systems for the tokamak fusion test reactor (TFTR)

    International Nuclear Information System (INIS)

    Pearson, G.G.; Meixler, L.D.; Sirsingh, R.A.P.

    1992-01-01

    This paper reports on the TFTR Tritium Stack and Area Monitoring Systems which have been developed to provide the required level of reliability in a cost effective manner consistent with the mission of the Tritium Handling System on TFTR. Personnel protection, environmental responsibility, and tritium containing system integrity have been the considerations in system design. During the Deuterium-Tritium (D-T) experiments on TFTR, tritium will be used for the first time as one of the fuels. Area monitors provide surveillance of the air in various rooms at TFTR. Stack monitors monitor the air at the TFTR test site that is exhausted through the HVAC systems, from the room exhaust stacks and the tritium systems process vents. The philosophies for the implementation of the Stack and Area Tritium Monitoring Systems at TFTR are to use hardwired controls wherever personnel protection is involved, and to take advantage of modern intelligent controllers to provide a distributed system to support the functions of tracking, displaying, and archiving concentration levels of tritium for all of the monitored areas and stacks

  10. Tritium. Today's and tomorrow's developments

    International Nuclear Information System (INIS)

    Gazal, S.; Amiard, J.C.; Caussade, Bernard; Chenal, Christian; Hubert, Francoise; Sene, Monique

    2010-01-01

    Radioactive hydrogen isotope, tritium is one of the radionuclides which is the most released in the environment during the normal operation of nuclear facilities. The increase of nuclear activities and the development of future generations of reactors, like the EPR and ITER, would lead to a significant increase of tritium effluents in the atmosphere and in the natural waters, thus raising many worries and questions. Aware about the importance of this question, the national association of local information commissions (ANCLI) wished to make a status of the existing knowledge concerning tritium and organized in 2008 a colloquium at Orsay (France) with an inquiring approach. The scientific committee of the ANCLI, renowned for its expertise skills, mobilized several nuclear specialists to carry out this thought. This book represents a comprehensive synthesis of today's knowledge about tritium, about its management and about its impact on the environment and on human health. Based on recent scientific data and on precise examples, it treats of the overall questions raised by this radionuclide: 1 - tritium properties and different sources (natural and anthropic), 2 - the problem of tritiated wastes management; 3 - the bio-availability and bio-kinetics of the different tritium species; 4 - the tritium labelling of environments; 5 - tritium measurement and modeling of its environmental circulation; 6 - tritium radio-toxicity and its biological and health impacts; 7 - the different French and/or international regulations concerning tritium. (J.S.)

  11. Synthesis of tritium labeled 4-androstenedione, 4-androsten 3α and 3β diols

    International Nuclear Information System (INIS)

    Matei, Lidia; Postolache, C.; Chiper, Diana; Tuta, C.; Bubueanu, G; Tanase, C.

    2009-01-01

    Androgen dependent diseases can appear due to blocking in different stages of biosynthesis of sexual hormones (testosterone, dihydrotestosterone) or to some modification in signalizing pathways through androgen receptor. In the diagnosis of these diseases which appear both in men and women (polycystic ovaries, hirsutism) it is also important the enzymatic activity determination of some key enzymes in steroid genesis steroid 5α-reductase, 3α and 3β-hydroxy-steroid-dehydrogenase, 17β- hydroxy-steroid-dehydrogenase. In this paper, we describe the method of obtaining tritium labeled 4-androstenedione, 4-androsten 3α and 3β diols by biosynthesis and chemical synthesis with testosterone used as substrate. (authors)

  12. Study of isotopic exchange reactions of azidothymidine with tritium

    International Nuclear Information System (INIS)

    Sidorov, G.V.; Zverkov, Yu.B.; Myasoedov, N.F.

    2003-01-01

    Different reactions of isotopic exchange of azidothymidine (3 - azido-3 - desoxythymidine) with tritium, such as solid- and liquid-phase catalytic isotopic exchange with gaseous tritium and isotopic exchange in solution with tritium water, are investigated. It is determined that catalytic reactions of azidothymidine with gaseous tritium in solution lead to practically full reduction of azido group up to amino group. In reactions of solid-phase catalytic hydrogenation this process takes place too and 3 - azido-3 - desoxythymidine yield is from 20 to 70 %. Molar radioactivity of labelled with tritium azidothymidine prepared in reactions of solid-phase catalytic isotopic exchange with gaseous tritium and so by isotopic exchange in solution with tritium water does not exceed 0.5 Cu/mmol [ru

  13. Incorporation of tritium in milk lipids after feeding organically bound tritium to cows

    International Nuclear Information System (INIS)

    Rochalska, M.; Hoek, J. van den

    1982-01-01

    Hay labelled with organically bound tritium was given to two cows for a period of 26 to 28 days. During hay feeding and at different times thereafter, lipids (fatty acids, cholesterol, glycerol, choline phospholipids, other phospholipids, flycolipids and gangliosides) were isolated from milk fat, and their total and specific activities were determined. During tritium administration, fatty acids and cholesterol contained the highest total activity, but the specific activity was highest in cholesterol and choline phospholipids. Activity decreased most rapidly for fatty acids and cholesterol, so that at 56 and 182 days after termination of 3 H feedings, phospholipids and glycolipids made an important contribution to lipid activity in milk. Regression analysis of the values for tritium activity in milk fat samples after stopping tritium administration, showed that three components with different half lives could be distinguished. The differences in metabolic behaviour of the various lipids in milk fat are mainly concerned with their relative participation in these components. (author)

  14. 6. Radiopharmaceuticals

    International Nuclear Information System (INIS)

    Schiller, P.; Havranek, E.; Majer, J.

    1981-01-01

    Radionuclides commonly used in medicine are surveyed and their nuclear characteristics are presented. The methods are given of their preparation, most frequent use and detection. The list is given of radiopharmaceuticals included in the Czechoslovak Pharmacopoeia CsL 3 , ie., sodium chromate( 51 Cr), sodium iodide( 131 I), hippuran( 131 I), sodium phosphate( 32 P), colloidal gold( 198 Au), rose bengal sodium salt( 131 I), and sodium pertechnetate(sup(99m)Tc) injections. Characteristics, chemical preparation, identification tests, packaging, storage, application and dosage are shown for each preparation. Also listed are important unofficial radiopharmaceuticals, their main characteristics and data on their preparation and application. (B.S.)

  15. Hospitable radiopharmaceuticals

    International Nuclear Information System (INIS)

    Gonzalez, M.B.

    1994-01-01

    Two types of hospitalary radiopharmaceutical was given in Nuclear Medicine: the centralized and hospitalary radiopharmaceuticals. The good practice in the use, instrumentation and quality control of radiopharmaceuticals are used in nuclear medicine for diagnostic and therapy diseases

  16. Consequences of radiopharmaceutical extravasation and therapeutic interventions: a systematic review

    Energy Technology Data Exchange (ETDEWEB)

    Pol, Jochem van der; Voeoe, Stefan [Maastricht University Medical Centre (MUMC+), Department of Radiology and Nuclear Medicine, Postbox 5800, Maastricht (Netherlands); Bucerius, Jan; Mottaghy, Felix M. [Maastricht University Medical Centre (MUMC+), Department of Radiology and Nuclear Medicine, Postbox 5800, Maastricht (Netherlands); University Hospital, RWTH Aachen University, Department of Nuclear Medicine, Aachen (Germany)

    2017-07-15

    Radiopharmaceutical extravasation can potentially lead to severe soft tissue damage, but little is known about incidence, medical consequences, possible interventions, and effectiveness of these. The aims of this study are to estimate the incidence of extravasation of diagnostic and therapeutic radiopharmaceuticals, to evaluate medical consequences, and to evaluate medical treatment applied subsequently to those incidents. A sensitive and elaborate literature search was performed in Embase and PubMed using the keywords ''misadministration'', ''extravasation'', ''paravascular infiltration'', combined with ''tracer'', ''radionuclide'', ''radiopharmaceutical'', and a list of keywords referring to clinically used tracers (i.e. ''Technetium-99m'', ''Yttrium-90''). Reported data on radiopharmaceutical extravasation and applied interventions was extracted and summarised. Thirty-seven publications reported 3016 cases of diagnostic radiopharmaceutical extravasation, of which three cases reported symptoms after extravasation. Eight publications reported 10 cases of therapeutic tracer extravasation. The most severe symptom was ulceration. Thirty-four different intervention and prevention strategies were performed or proposed in literature. Extravasation of diagnostic radiopharmaceuticals is common. {sup 99m}Tc, {sup 123}I, {sup 18}F, and {sup 68}Ga labelled tracers do not require specific intervention. Extravasation of therapeutic radiopharmaceuticals can give severe soft tissue lesions. Although not evidence based, surgical intervention should be considered. Furthermore, dispersive intervention, dosimetry and follow up is advised. Pharmaceutical intervention has no place yet in the immediate care of radiopharmaceutical extravasation. (orig.)

  17. Tritium fuel cycle modeling and tritium breeding analysis for CFETR

    Energy Technology Data Exchange (ETDEWEB)

    Chen, Hongli; Pan, Lei; Lv, Zhongliang; Li, Wei; Zeng, Qin, E-mail: zengqin@ustc.edu.cn

    2016-05-15

    Highlights: • A modified tritium fuel cycle model with more detailed subsystems was developed. • The mean residence time method applied to tritium fuel cycle calculation was updated. • Tritium fuel cycle analysis for CFETR was carried out. - Abstract: Attaining tritium self-sufficiency is a critical goal for fusion reactor operated on the D–T fuel cycle. The tritium fuel cycle models were developed to describe the characteristic parameters of the various elements of the tritium cycle as a tool for evaluating the tritium breeding requirements. In this paper, a modified tritium fuel cycle model with more detailed subsystems and an updated mean residence time calculation method was developed based on ITER tritium model. The tritium inventory in fueling system and in plasma, supposed to be important for part of the initial startup tritium inventory, was considered in the updated mean residence time method. Based on the model, the tritium fuel cycle analysis of CFETR (Chinese Fusion Engineering Testing Reactor) was carried out. The most important two parameters, the minimum initial startup tritium inventory (I{sub m}) and the minimum tritium breeding ratio (TBR{sub req}) were calculated. The tritium inventories in steady state and tritium release of subsystems were obtained.

  18. Tritium NMR in the analysis of tritiated compounds

    International Nuclear Information System (INIS)

    Kaspersen, F.M.; Funke, C.W.; Vader, Jan; Wagenaars, G.N.

    1993-01-01

    An overview is given of the possibilities of 3 H NMR in the characterisation of 3 H-labelled compounds. This technique gives information on the identity of the tritiated compounds, the position of the tritium, the distribution of the label and even the radiochemical purity of the labelled products. (author)

  19. Atmospheric tritium 1968-1984. Tritium Laboratory data report No. 14

    International Nuclear Information System (INIS)

    Oestlund, H.G.; Mason, A.S.

    1985-04-01

    Tritium in the form of water, HTO, from the atmospheric testing of nuclear devices in the 60s has now mainly disappeared from the atmosphere and entered the ocean. The additions of such tritium from Chinese and French tests in the 70s were observed but did not make a big impression on the diminishing inventory of atmospheric HTO. Tritium in elemental form, HT, went through a maximum in the mid 70s, apparently primarily as a results of some underground testing of large nuclear devices and releases from civilian and military nuclear industry. The mid 70s maximum was 1.3 kg of tritium in this form, and in 1984 0.5 kg remain. The disappearance is slower than the decay rate of tritium, so sources must still have been present during this time. The global distribution shows, not unexpectedly, smaller inventory in the Southern Hemisphere across the equator and thus southward transport of HT. The chemical lifetime of hydrogen gas in the atmosphere, assuming the elemental tritium being in the form of HT, not T 2 , has been estimated between 6 and 10 years. It is to be expected that increasing activity of nuclear fuel reprocessing would in the near future again increase the global tritium gas inventory. Tritium in the form of light hydrocarbons, primarily methane, has also been measured, and in this form a quantity of 200 g of tritium resided in the global atmosphere 1956 to 1976. By 1982 it had decreased to 50 g. 25 refs., 5 figs., 11 tabs

  20. 188Re(V) Nitrido Radiopharmaceuticals for Radionuclide Therapy.

    Science.gov (United States)

    Boschi, Alessandra; Martini, Petra; Uccelli, Licia

    2017-01-19

    The favorable nuclear properties of rhenium-188 for therapeutic application are described, together with new methods for the preparation of high yield and stable 188 Re radiopharmaceuticals characterized by the presence of the nitride rhenium core in their final chemical structure. 188 Re is readily available from an 188 W/ 188 Re generator system and a parallelism between the general synthetic procedures applied for the preparation of nitride technetium-99m and rhenium-188 theranostics radiopharmaceuticals is reported. Although some differences between the chemical characteristics of the two metallic nitrido fragments are highlighted, it is apparent that the same general procedures developed for the labelling of biologically active molecules with technetium-99m can be applied to rhenium-188 with minor modification. The availability of these chemical strategies, that allow the obtainment, in very high yield and in physiological condition, of 188 Re radiopharmaceuticals, gives a new attractive prospective to employ this radionuclide for therapeutic applications.

  1. 188Re(V) Nitrido Radiopharmaceuticals for Radionuclide Therapy

    Science.gov (United States)

    Boschi, Alessandra; Martini, Petra; Uccelli, Licia

    2017-01-01

    The favorable nuclear properties of rhenium-188 for therapeutic application are described, together with new methods for the preparation of high yield and stable 188Re radiopharmaceuticals characterized by the presence of the nitride rhenium core in their final chemical structure. 188Re is readily available from an 188W/188Re generator system and a parallelism between the general synthetic procedures applied for the preparation of nitride technetium-99m and rhenium-188 theranostics radiopharmaceuticals is reported. Although some differences between the chemical characteristics of the two metallic nitrido fragments are highlighted, it is apparent that the same general procedures developed for the labelling of biologically active molecules with technetium-99m can be applied to rhenium-188 with minor modification. The availability of these chemical strategies, that allow the obtainment, in very high yield and in physiological condition, of 188Re radiopharmaceuticals, gives a new attractive prospective to employ this radionuclide for therapeutic applications. PMID:28106830

  2. Tritium labelling of a cholesterol amphiphile designed for cell membrane anchoring of proteins.

    Science.gov (United States)

    Schäfer, Balázs; Orbán, Erika; Kele, Zoltán; Tömböly, Csaba

    2015-01-01

    Cell membrane association of proteins can be achieved by the addition of lipid moieties to the polypeptide chain, and such lipid-modified proteins have important biological functions. A class of cell surface proteins contains a complex glycosylphosphatidylinositol (GPI) glycolipid at the C-terminus, and they are accumulated in cholesterol-rich membrane microdomains, that is, lipid rafts. Semisynthetic lipoproteins prepared from recombinant proteins and designed lipids are valuable probes and model systems of the membrane-associated proteins. Because GPI-anchored proteins can be reinserted into the cell membrane with the retention of the biological function, they are appropriate candidates for preparing models via reduction of the structural complexity. A synthetic headgroup was added to the 3β-hydroxyl group of cholesterol, an essential lipid component of rafts, and the resulting cholesterol derivative was used as a simplified GPI mimetic. In order to quantitate the membrane integrated GPI mimetic after the exogenous addition to live cells, a tritium labelled cholesterol anchor was prepared. The radioactive label was introduced into the headgroup, and the radiolabelled GPI mimetic anchor was obtained with a specific activity of 1.37 TBq/mmol. The headgroup labelled cholesterol derivative was applied to demonstrate the sensitive detection of the cell membrane association of the anchor under in vivo conditions. Copyright © 2015 John Wiley & Sons, Ltd.

  3. Synthesis of high specific activity tritium labelled 1S,2S-(-)-trans-2-isothiocyanato-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)benzene acetamide, a specific irreversible ligand for kappa opioid receptors

    Energy Technology Data Exchange (ETDEWEB)

    Costa, B.R. de; Thurkauf, A.; Rothman, R.R. (National Inst. of Mental Health, Bethesda, MD (USA)); Jacobson, A.E.; Rice, K.C. (National Inst. of Digestive Diabetes, and Kidney Diseases, Bethesda, MD (USA))

    1990-11-01

    Optically pure tritium labeled 1S,2S-(-)-trans-2-isothiocyanato-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl )benzeneacetamide, an affinity ligand specific for the kappa opioid receptor was synthesized from optically pure 1S,2S-(-)-trans-2-amino-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)benzeneacetamide via the sequence of dibromination (57%) followed by catalytic tritiation of the dibromide. The resulting tritium labelled aniline (14% yield, specific activity 31.2 Ci/mmol) was transformed to the title compound in 13.3% yield and 99+% radiochemical purity by treatment with thiophosgene. (author).

  4. New radiopharmaceuticals

    International Nuclear Information System (INIS)

    Payoux, P.; Esquerre, J.P.; Alonso, M.; Tafani, M.

    2008-01-01

    With the development of positron emission tomography, the significant increase in prescriptions of [ 18 F]F.D.G. has underlined the interest for molecular imaging in many pathologies. Facing the demand of 'new' radiopharmaceuticals (frequently clinically validated in the last century) for more and more specific diagnosis, the nuclear physician is confronted with a sparse offer of the radiopharmaceutical companies and a particularly complicated radiopharmaceutical legislation. This paper briefly reports on the radiopharmaceutical statutes encountered in France nowadays; it emphasizes that is essential to deeply modify the conditions to obtain a marketing authorization for radiopharmaceuticals if we want to propose to our patients the kind of right they have to expect from nuclear medicine. (authors)

  5. Automatic isotope gas analysis of tritium labelled organic materials Pt. 3

    International Nuclear Information System (INIS)

    Gacs, I.; Mlinko, S.; Payer, K.; Otvos, L.; Banfi, D.; Palagyi, T.

    1978-01-01

    An isotope analytical procedure and an automatic instrument developed for the determination of tritium in organic compounds and biological materials by internal gas counting are described. The sample is burnt in a stream of oxygen and the combustion products including water vapour carrying the tritium are led onto a column of molecular sieve-5A heated to 550 deg C. Tritium is retained temporarily on the column, then transferred into a stream of hydrogen by isotope exchange. After addition of butane, the tritiated hydrogen is led into an internal detector and enclosed there for radioactivity measurement. The procedure, providing quantitative recovery, is completed in five minutes. It is free of memory effect and suitable for the determination of tritium in a wide range of organic compounds and samples of biological origin. (author)

  6. [Study on Tritium Content in Soil at Sites of Nuclear Explosions on the Territory of Semipalatinsk Test Site].

    Science.gov (United States)

    Timonova, L V; Lyakhova, O N; Lukashenko, S N; Aidarkhanov, A O

    2015-01-01

    As a result of investigations carried out on the territory of Semipalatinsk Test Site, tritium was found in different environmental objects--surface and ground waters, vegetation, air environment, and snow cover. The analysis of the data obtained has shown that contamination of environmental objects at the Semipalatinsk Test Site with tritium is associated with the places where underground nuclear tests were performed. Since tritium can originate from an activation reaction and be trapped by pock particles during a test, it was decided to examine the soil in the sites where surface and excavation tests took place. It was found that the concentration of tritium in soil correlates with the concentration of europium. Probably, the concentration of tritium in the soil depends on the character and yield of the tests performed. Findings of the study have revealed that tritium can be found in soil in significant amounts not only in sites where underground nuclear tests took place but also in sites where surface and excavation nuclear tests were carried out.

  7. The quality control of technetium-99m radiopharmaceuticals produced at the AAEC Research Establishment

    International Nuclear Information System (INIS)

    Farrington, K.J.

    1983-08-01

    The methods of quality control used for technetium-99m radiopharmaceuticals produced at the AAEC Research Establishment are described for both non-fission and fission derived sources of sodium pertechnetate, technetium-99m labelled radipopharmaceuticals, and reagent kits produced for technetium-99m labelling

  8. SU-E-I-82: PET Radiopharmaceuticals for Prostate Cancer Imaging: A Review

    International Nuclear Information System (INIS)

    Fernandes, F; Silva, D da; Rodrigues, L

    2015-01-01

    Purpose: The aim of this work was to review new and clinical practice PET radiopharmaceuticals for prostate cancer imaging. Methods: PET radiopharmaceuticals were reviewed on the main databases. Availability, dosimetry, accuracy and limitations were considered. Results: The following radioisotopes with respective physical half-life and mean positron energy were found: 18 F (109,7 min, 249,8 keV), 89 Zr (78,4 hs, 395,5 keV), 11 C (20,4 min, 385,7 keV) and 68 Ga (67,8 min, 836 keV). 68 Ga was the only one not produced by cyclotron. Radiopharmaceuticals uptake by glucose metabolism ( 18 F-FDG), lipogenesis ( 11 C-Choline and 11 C-Acetate), amino acid transport (Anti- 18 F-FACBC), bone matrix ( 18 F-NaF), prostatespecific membrane antigen ( 68 Ga-PSMA and 89 Zr-J591), CXCR receptors ( 89 Ga-Pentixafor), adrenal receptors ( 18 F-FDHT) and gastrin release peptide receptor (bombesin analogue). Most of radiopharmaceuticals are urinary excretion, so bladder is the critical organ. 11C-choline (pancreas), Anti- 18 FFACBC (liver) and 18 F-FBDC (stomach wall) are the exception. Higher effective dose was seen 18 F-NaF (27 μSv/MBq) while the lowest was 11 CAcetate (3,5 μSv/MBq). Conclusion: Even though 18 F-FDG has a large availability its high urinary excretion and poor uptake to slow growing disease offers weak results for prostate cancer. Better accuracy is obtained when 18 F-NaF is used for bone metastatic investigation although physicians tend to choose bone scintigraphy probably due to its cost and practice. Many guidelines in oncology consider 11 C or 18 F labeled with Choline the gold standard for biochemical relapse after radical treatment. Local, lymph node and distant metastatic relapse can be evaluated at same time with this radiopharmaceutical. There is no consensus over bigger urinary excretion for 18 F labeling. Anti- 18 F-FACBC, 68 Ga-PSMA and 68 Ga-Pentixafor are demonstrating good results but more researches are needed. While PSMA imaging seems to be

  9. Development of new radiopharmaceuticals

    International Nuclear Information System (INIS)

    1989-12-01

    The possibilities to design and prepare better and more organ-specific radiopharmaceuticals for diagnostic nuclear medicine has increased dramatically in the recent past with a deeper understanding of the relationships between chemical structure and biological activity. Whereas most of the research is performed in well-funded laboratories of industrialized countries, there are several developing countries with adequate resources and expertise as to undertake fruitful research in the field of radiopharmacy. With the aim of promoting advanced research in radiopharmacy by developing new radiodiagnostics agents, in particular, hepatobiliary imaging agents labelled with 99m Tc, and to facilitate exchange of information, the IAEA has established in 1983 the present Research Co-ordination Programme (CRP) with a duration of five years. The report includes detailed results obtained by all participants as well as novel preparation procedures for some of the newest and more promising radiopharmaceuticals developed under the auspices of the CRP. The extensive bibliographic reference listing is considered another important information of particular value for scientists in developing countries who do not always have access to updated scientific information sources. Refs, figs and tabs

  10. The hospital preparation of radiopharmaceuticals

    International Nuclear Information System (INIS)

    The subject is covered in sections: introduction; preparation ((general - sterilization), production areas (laboratories), working methods for injections, working methods for oral preparations and iodination procedures); analytical testing (general, standards common to injections and oral preparations, standards for injections, standards for oral preparations); reliable methods of preparing sup(99m)Tc-radiopharmaceuticals and 51 Cr-red cells; commercial radiopharmaceutical kits. (U.K.)

  11. Present status of irradiation tests on tritium breeding blanket for fusion reactor

    International Nuclear Information System (INIS)

    Futamura, Yoshiaki; Sagawa, Hisashi; Shimakawa, Satoshi; Tsuchiya, Kunihiko; Kuroda, Toshimasa; Kawamura, Hiroshi.

    1994-01-01

    To develop a tritium breeding blanket for a fusion reactor, irradiation tests in fission reactors are indispensable for obtaining data on irradiation effects on materials, and neutronics/thermal characteristics and tritium production/recovery performance of the blanket. Various irradiation tests have been conducted in the world, especially to investigate tritium release characteristics from tritium breeding and neutron multiplier materials, and materials integrity under irradiation. In Japan, VOM experiments at JRR-2 for ceramic breeders and experiments at JMTR for ceramic breeders and beryllium as a neutron multiplier have been performed. Several universities have also investigated ceramic breeders. In the EC, the EXOTIC experiments at HFR in the Netherlands and the SIBELIUS, the LILA, the LISA and the MOZART experiments for ceramic breeders have carried out. In Canada, NRU has been used for the CRITIC experiments. The TRIO experiments at ORR(ORNL), experiments at RTNS-II, FUBR and ATR have been conducted in the USA. The last two are experiments with high neutron fluence aiming at investigating materials integrity under irradiation. The BEATRIX-I and -II experiments have proceeded under international collaboration of Japan, Canada, the EC and the USA. This report shows the present status of these irradiation tests following a review of the blanket design in the ITER CDA(Conceptual Design Activity). (author)

  12. Animal models for the evaluation of radiopharmaceuticals to measure brian blood flow and function

    International Nuclear Information System (INIS)

    Welch, M.J.; Marshall, L.G.I.; Mathias, C.J.

    1987-01-01

    Several techniques have been utilized to carry out initial evaluation of radiopharmaceuticals labeled with technetium-99m and other radionuclides. The simplest technique is to measure the amount of radioactivity in the brain in rats or mice following the intravenous administration of these compounds; brain uptake and washout of radiopharmaceuticals can be estimated. More sophisticated techniques involve measuring the uptake and egress of the radiopharmaceutical following carotid artery administration in rats of primates. The Oldendorf technique compares a tracer with a standard compound e.g. tritiated water, to measure the brain uptake index of various compounds determined by decapiation at short times following administration. Another technique in which consecutive administrations of the compound to be studied and oxygen-15-labeled water are injected via the carotid artery of primates; the brain extraction and washout of the unknown tracer can be evaluated. The blood flow can be varied by altering the pCO 2 of the animal. Examples will be given and techniques compared

  13. Uncertainty sources in radiopharmaceuticals clinical studies; Fontes de incertezas em estudos clinicos com radiofarmacos

    Energy Technology Data Exchange (ETDEWEB)

    Degenhardt, Aemilie Louize; Oliveira, Silvia Maria Velasques de, E-mail: silvia@cnen.gov.br, E-mail: amilie@bolsista.ird.gov.br [Instituto de Radioprotecao e Dosimetria, (IRD/CNEN-RJ), Rio de Janeiro, RJ (Brazil)

    2014-07-01

    The radiopharmaceuticals should be approved for consumption by evaluating their quality, safety and efficacy. Clinical studies are designed to verify the pharmacodynamics, pharmacological and clinical effects in humans and are required for assuring safety and efficacy. The Bayesian analysis has been used for clinical studies effectiveness evaluation. This work aims to identify uncertainties associated with the process of production of the radionuclide and radiopharmaceutical labelling as well as the radiopharmaceutical administration and scintigraphy images acquisition and processing. For the development of clinical studies in the country, the metrological chain shall assure the traceability of the surveys performed in all phases. (author)

  14. Positron emitting nuclides and their synthetic incorporation in radiopharmaceuticals

    International Nuclear Information System (INIS)

    Fowler, J.S.

    1976-01-01

    11 C, 13 N, and 15 O has potential applicability to the study of metabolism in humans. Problems in the synthesis of radiopharmaceuticals labeled with 11 C, 13 N, and 18 F are described: quality control, radiation exposure, carboxylic acids, glucose, amines, amino acids, nitrosources, fluoroethanol. 54 references

  15. Health Physics aspects of the use of tritium

    International Nuclear Information System (INIS)

    Martin, E.B.M.

    1982-01-01

    The health physics aspects of the use of tritium in university laboratories and similar establishments are considered. These aspects include discussion on the behaviour and hazards of tritium in the body, derived limits for contamination, monitoring methods, designation of workers, medical and dosimetric supervision, classification of laboratories, safety precautions, accidents and decontamination, and waste disposal. The radiation hazards from some special uses of tritium, e.g. tritium foil sources, luminous devices, gaseous light sources, are also considered. It was concluded that little harm is likely to come from careful handling of tritium labelled compounds at the millicurie level in a research laboratory. It would, however, be most unwise to be complacent about the use of tritium at the curie level, particularly when high specific activities, organic compounds and chronic exposure over long periods are involved. (U.K.)

  16. Improving radiopharmaceutical supply chain safety by implementing bar code technology.

    Science.gov (United States)

    Matanza, David; Hallouard, François; Rioufol, Catherine; Fessi, Hatem; Fraysse, Marc

    2014-11-01

    The aim of this study was to describe and evaluate an approach for improving radiopharmaceutical supply chain safety by implementing bar code technology. We first evaluated the current situation of our radiopharmaceutical supply chain and, by means of the ALARM protocol, analysed two dispensing errors that occurred in our department. Thereafter, we implemented a bar code system to secure selected key stages of the radiopharmaceutical supply chain. Finally, we evaluated the cost of this implementation, from overtime, to overheads, to additional radiation exposure to workers. An analysis of the events that occurred revealed a lack of identification of prepared or dispensed drugs. Moreover, the evaluation of the current radiopharmaceutical supply chain showed that the dispensation and injection steps needed to be further secured. The bar code system was used to reinforce product identification at three selected key stages: at usable stock entry; at preparation-dispensation; and during administration, allowing to check conformity between the labelling of the delivered product (identity and activity) and the prescription. The extra time needed for all these steps had no impact on the number and successful conduct of examinations. The investment cost was reduced (2600 euros for new material and 30 euros a year for additional supplies) because of pre-existing computing equipment. With regard to the radiation exposure to workers there was an insignificant overexposure for hands with this new organization because of the labelling and scanning processes of radiolabelled preparation vials. Implementation of bar code technology is now an essential part of a global securing approach towards optimum patient management.

  17. Stannous ion determination in99mTc - radiopharmaceutical kits

    International Nuclear Information System (INIS)

    Almeida, M.A.T.M. de; Silva, C.P.G. da.

    1989-10-01

    Two simple and selective methods for determination of stannous ion in radiopharmaceutical kits are proposed. One of this permits the estimation of stannic ion. The first method used is a potentiometric tiration of Sn +2 in HCl medium using KIO 3 solution under nitrogen gas and a redox platinum electrode. The second method consist of a compleximetric tiration of tin (Sn +2 and Sn +4 ) using EDTA standart solution at pH 5.5-5.6 without use of nitrogen gas. The employed procedures indicates that both the methods can be used for routine quantitative determination of tin in most labeled radiopharmaceuticals. (author) [pt

  18. Preparation of phase I of clinical testing of kit for bleomycin labelling with 57Co

    International Nuclear Information System (INIS)

    Brousil, J.; Svihovcova, P.; Seblova, J.; Raban, P.

    1986-01-01

    Experience is described gained in preclinical trials with a kit for bleomycin labelling with 57 Co, of original manufacture. The 57 Co-labelled bleomycin shows a positive tumor imaging potential. As against other labelled bleomycins described in the literature, it best meets the requirements of imaging tumors in the highest possible number of tissues and of good differentiation of tumors from the adjacent tissues. The three-component kit uses a phosphate buffer which makes it more suitable for i.v. administration and significantly increases bleomycin stability. The kit was found to show advantages over previously described radiopharmaceuticals of this type in that that it can quickly be reconstituted immediately prior to the application and that it is significantly cheaper to use, namely 140-fold cheaper than most other similar radiopharmaceuticals. Its disadvantage, i.e., the long half-life is balanced with a short biological half-life; within 24 hours following application 80 to 90% of the applied activity was found to be excreted from the organism. The short biological half-life is also beneficial for the patient in that the radiation load of the patient is 10 times lower than in the application of 67 Ga. (L.O.)

  19. Tritium labeling by thermally generated tritons

    International Nuclear Information System (INIS)

    Morimoto, H.; Williams, P.G.; Saljoughian, M.

    1988-06-01

    The predominant effect of thermal atom irradiation on solid molecules is saturation of their aromatic functions. Only low level of tritium exchange is observed for aliphatic solids. In contrast, liquids whose frozen surface can be rendered somewhat mobile at appropriate temperatures exhibit more exchange than addition. The rank order of effectiveness of several metals in promoting exchange/addition appears similar to the rank order for heterogeneous catalytic hydrogenation. 3 refs., 8 figs

  20. Histotopography of the radiopharmaceuticals 75Se-selenomethionine and 75Se-selenite in critical organs of adult and embryonic mice

    International Nuclear Information System (INIS)

    Khant, S.E.; Norets, T.A.

    1981-01-01

    Adult male and pregnant mice received 75 Se-labelled methionine and selenite, resp. The critical organs and the embryos were examined histoautoradiographically at different time intervals as to the organ distribution of the radiopharmaceuticals. All organs revealed a heterogeneity of the 75 Se distribution with an intensity being unequally organo-specific and depending on the type of the radiopharmaceutical. 75 Se-selenomethionine was deposited mainly in functional areas of kidneys, liver, bone marrow and testes thus causing a long-term retention and an intensive irradiation of these organs. In the embryos 75 Se-seleno-methionine was distributed unequally preferring liver, hematopoietic areas of the bone marrow and the lens

  1. Radiopharmaceuticals

    International Nuclear Information System (INIS)

    Ganatra, R.D.

    1992-01-01

    Today there are an estimated ten million nuclear imaging procedures, performed each year, in just the United States, and the number is still growing. More than 30,000 therapy procedures are performed in the USA each year using radiopharmaceuticals. Moreover, while the numbers continue to grow, so also do the variety of the procedures being employed. A weakness of nuclear medicine is related also to one of its strengths. Unlike other types of imaging where only an instrument and the patient are required (e.g., with ultrasonics); nuclear medicine requires a radiopharmaceutical. At the same time, the variety of radiopharmaceuticals offers the ability to trace one or more particular functions of the human body. This provides nuclear medicine with great variety in detecting specific pathologies. Various nuclear medicine studies are possible because of the localization of radiopharmaceuticals in different organs

  2. Radiolabeling of trastuzumab with {sup 177}Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer

    Energy Technology Data Exchange (ETDEWEB)

    Rasaneh, Samira [Department of Medical Physics, Tarbiat Modares University, Tehran (Iran, Islamic Republic of); Rajabi, Hossein [Department of Medical Physics, Tarbiat Modares University, Tehran (Iran, Islamic Republic of)], E-mail: hrajabi@modares.ac.ir; Babaei, Mohammad Hossein; Daha, Fariba Johari [Department of Radioisotope, Nuclear Science and Technology Research Institute, Tehran (Iran, Islamic Republic of); Salouti, Mojtaba [Department of Biology, School of Sciences, Islamic Azad University - Zanjan Branch, Zanjan (Iran, Islamic Republic of)

    2009-05-15

    Aim: Trastuzumab is a monoclonal antibody that is used in treating breast cancer. We labeled this monoclonal antibody with lutetium-177 and performed in vitro quality control tests as a first step in the production of a new radiopharmaceutical. Material and Methods: Trastuzumab was labeled with lutetium-177 using DOTA as chelator. Radiochemical purity and stability in buffer and human blood serum were determined using thin layer chromatography. Immunoreactivity and toxicity of the complex were tested on MCF7 breast cancer cell line. Results: The radiochemical purity of the complex was 96{+-}0.9%. The stabilities in phosphate buffer and in human blood serum at 96 h postpreparation were 93{+-}1.2% and 85{+-}3.5%, respectively. The immunoreactivity of the complex was 89{+-}1.4%. At a concentration of 1 nM, the complex killed 70{+-}3% of MCF7 cells. At 1.9 nM, 90{+-}5% of the cells were killed. Conclusions: The results showed that the new complex could be considered for further evaluation in animals and possibly in humans as a new radiopharmaceutical for use in radioimmunotherapy against breast cancer.

  3. Radiochemical purity and in vitro stability of Tc-99m radiopharmaceuticals

    International Nuclear Information System (INIS)

    Vucina, J.

    2001-01-01

    The increased contents of long lived 99 Tc, oxygen and cupric ions could affect the labeling yield of eight radiopharmaceuticals. Oxygen and in leaser extend copper were found to affect the radiochemical purity of the preparations. In vitro stability of radiopharmaceuticals, examined on 99m Tc(Sn)-pyrosphoshate solutions, was extended when ascorbic acid was added as the chemical stabilizer. The quantity of 5x10 -7 mol/dm 3 of ascorbic acid was found to be sufficient to keep the content of 99m Tc-pertechnetate below 1 % six hours after labeling even in the cases when 99m Tc was present in high radioactive concentrations (740-814 GBq/dm 3 ). The results led to the development of the kits in which ascorbic or gentisic acid are the standards component in the kit composition (author)

  4. Dispersion for the preparation of an injectable radiopharmaceutical scanning agent

    International Nuclear Information System (INIS)

    Wolfangel, R.G.

    1976-01-01

    The invention deals with the preparation of a dispersion of a tin (II) sulphur colloid in an aqueous solution with additions of a stabilizing agent. Labelled with sup(99m)Tc, the dispersion can be used as an injectable radiopharmaceutical scanning agent. (VJ) [de

  5. Evaluation of Effective Parameters on Labeling of Hydroxyapatite Compound with 90Y and Introducing the Best Method to Produce 90Y-HAp Radiopharmaceutical for Radio synovectomy

    International Nuclear Information System (INIS)

    Davarpanah, M. R.; Khoshhosn, H. A.; Attar Nosrati, S.; Harati, S. M.; Aghamiri, S. M.; Ghannadi Maragheh, M.

    2012-01-01

    Radio synovectomy is a local intra-articular injection of radionuclides in colloidal form for treatment of articular inflammatory in rheumatoid arthritis, hemophilia or orthopedic troubles. β-emitting radionuclides can be used for various joints based on radiation energy. 90 Y is a pure β-emitter with a half-life of 64.1 hours that is used for treatment of the knee joint. β-radiation of this radionuclide possesses maximum energy of 2.281 MeV (99.98%), mean pathway of 3.6 mm in the soft tissue and maximum 11 mm. In this project, hydroxyapatite (HAp) is applied as a colloid maker agent that interacts with 90 Y 3+ ions via ion-dipole bonds and produces 90 Y-HAp. The colloidal pharmaceutical is produced by adding an acidic solution of 90 YCl 3 to an HAp suspension in saline. Effective parameters within which the colloid is applied, such as the volume of diluent, HAp particle size and sonication effect were evaluated and tested. First, these determinative parameters were optimized in the simulated conditions and then examined in the active phase. Finally, the best procedure was determined for the production of the radiopharmaceutical. Radionuclide purity of the radiopharmaceutical according to the primary 90 YCl 3 solution was over 99.9%. Labeling yield and radiochemical purity were obtained over 99% using TLC method in saline solvent up to three days after production of radiopharmaceutical. Radiochemical purity of 90 Y-HAp colloid was also evaluated in human serum albumin solution for three days at room temperature. The amount of released activity was between 0.3 to 2%.

  6. The radioactive labeling of monocytes

    International Nuclear Information System (INIS)

    Ensing, G.J.

    1985-01-01

    With the aim of studying a possible relationship between circulating monocytes and Sternberg-Reed cells investigations were started on the specific labeling of monocytes. In this thesis the literature on the pertinent data has been reviewed and a series of experiments on the monocyte labeling procedure has been described. The principles of cell labeling with radioactive compounds were discussed. 1. Total separation of the particular cell population to be labeled and subsequent labeling with a non-specific radiopharmaceutical. 2. Specific cell labeling in a mixture of cell types based on a well defined affinity of the cell under study for the radiopharmaceutical used. Next the radionuclides that can be used for cell labeling purposes were discussed with special attention for 111 In and its chelates. The principles of radiodosimetry were also discussed shortly. This section was focussed on the radiation dose the labeled cells receive because of the intracellular localized radioactivity. The radiation burden is high in comparison to amounts of radiation known to affect cell viability. A newly developed method for labeling monocytes specifically by phagocytosis of 111 In-Fe-colloid without apparent loss of cells was described in detail. (Auth.)

  7. Innovative complexation strategies for the introduction of short-lived PET isotopes into radiopharmaceuticals

    International Nuclear Information System (INIS)

    Simecek, Jakub

    2013-01-01

    A number of TRAP (Triazacyclononane-triphosphinate) chelators were evaluated for labelling with Gallium-68. Based on the obtained data, a novel bifunctional chelator NOPO was designed, synthesised and employed for preparation of Ga-68 radiopharmaceuticals. Several 68 Ga-labelled NOPO peptidic conjugates showed promising results in preclinical positron emission tomography (PET) imaging studies using the mice models. Moreover, NOPO was found also suitable for labelling with Copper-64.

  8. Experiments on a ceramic electrolysis cell and a palladium diffuser at the tritium systems test assembly

    International Nuclear Information System (INIS)

    Konishi, Satoshi; Yoshida, Hiroshi; Ohno, Hideo; Naruse, Yuji; Coffin, D.O.; Walthers, C.R.; Binning, K.E.

    1985-01-01

    A ceramic electrolysis cell and a palladium diffuser are developed in Japan and is tested with tritium in Tritium Systems Test Assembly (TSTA) of the Los Alamos National Laboratory, in order to confirm the feasibility as possible upgrades for the fuel cleanup system (PCU). The ceramic electrolysis cell made of stabilized zirconia was operated at 630 0 C for an extended period with a mixture of 3% T 2 O in He carrier gas in the circulation system with oxidizing catalyst bed. The palladium diffuser was tested with circulated pure tritium gas at 280 0 C to verify the compatibility of the alloy with tritium, since the 3 He produced in the metal could cause a degradation. The isotopic effects were also measured for both devices

  9. Recent palladium membrane reactor development at the tritium systems test assembly

    International Nuclear Information System (INIS)

    Scott, W.R.; Birdsell, S.A.; Wilhelm, R.C.

    1995-01-01

    The palladium membrane reactor (PMR) is being investigated as a means for recovering hydrogen isotopes (including tritium) from compounds such as water and methane. Previous work with protiated water and methane showed that this device can be used to obtain high hydrogen recovery efficiencies using a single processing pass and with essentially no waste production. With these successful proof-of-principle results completed, recent work has focused on PMR development. This included studies of various geometries and testing with tritium. The results, which are reported here, have led to a better understanding of the PMR and will lead to the ultimate goal of building a production PMR and putting it into practical tritium processing service. 3 refs., 5 figs., 1 tab

  10. Tritium systems test assembly quality assurance program

    International Nuclear Information System (INIS)

    Kerstiens, F.L.; Wilhelm, R.C.

    1986-07-01

    A quality assurance program should establish the planned and systematic actions necessary to provide adequate confidence that fusion facilities and their subsystems will perform satisfactorily in service. The Tritium Systems Test Assembly (TSTA) Quality Assurance Program has been designed to assure that the designs, tests, data, and interpretive reports developed at TSTA are valid, accurate, and consistent with formally specified procedures and reviews. The quality consideration in all TSTA activities is directed toward the early detection of quality problems, coupled with timely and positive disposition and corrective action

  11. Radiation doses to lungs and whole body from use of tritium in luminous paint industry

    International Nuclear Information System (INIS)

    Rudran, K.

    1988-01-01

    The radiation dose to persons exposed to tritium in the luminous paint industry is reported. The biological half-life of labile tritium is observed to be 7 to 10 days. There is evidence of exposure of lung tissue from tritium labelled polystyrene deposited in the pulmonary region and of soft tissue from organically bound tritium. Delayed excretion of labile tritium in urine following removal of the individuals from tritium handling, presence of tritium in organic constituents of blood and urine, and presence of non-volatile tritium in faecal excretion have been verified. From in vitro studies using fresh bovine serum, solubilisation half-life of tritium from the labelled paint is estimated to be 35 to 70 days after the initial fast clearance. Probable annual doses to the whole body, soft tissue and lungs under the prevailing working conditions have been estimated from the urinary and faecal excretion data. It is revealed that the actual values thus estimated are likely to exceed the values estimated by the conventional technique based on urine analysis for tritiated water. (author)

  12. Study of potential utility of new radiopharmaceuticals based on technetium-99m labeled derivative of glucose

    Energy Technology Data Exchange (ETDEWEB)

    Zeltchan, R., E-mail: r.zelchan@yandex.ru; Medvedeva, A.; Sinilkin, I.; Chernov, V. [Tomsk Cancer Research Institute, Tomsk, 634050 (Russian Federation); Tomsk Polytechnic University, Tomsk, 634050 (Russian Federation); Stasyuk, E.; Rogov, A.; Il’ina, E.; Larionova, L.; Skuridin, V. [Tomsk Polytechnic University, Tomsk, 634050 (Russian Federation)

    2016-08-02

    Purpose: to study the potential utility of 1-thio-D-glucose labeled with {sup 99m}Tc for cancer imaging in laboratory animals. Materials and method: the study was carried out in cell cultures of normal CHO (Chinese hamster ovary cells CHO) and malignant tissues MCF-7 (human breast adenocarcinoma MCF-7). To evaluate the uptake of {sup 99m}Tc-1-thio-D-glucose in normal and tumor tissue cells, 25 MBq of 1-thio-D-glucose labeled with {sup 99m}Tc was added to the vials with 3 million cells and incubated for 30 min at room temperature. After centrifugation of the vials with cells, the supernatant was removed. The radioactivity in vials with normal and tumor cells was then measured. In addition, the study included 40 mice of C57B1/6j lines with tumor lesion of the right femur. For neoplastic lesions, Lewis lung carcinoma model was used. Following anesthesia, mice were injected intravenously with 25 MBq of {sup 99m}Tc-1-thio-D-glucose. Planar scintigraphy was performed 15 minutes later in a matrix of 512x512 pixels for 5 min. Results: when measuring the radioactivity of normal and malignant cells after incubation with {sup 99m}Tc-1-thio-D-glucose, it was found that the radioactivity of malignant cells was higher than that of normal cells. The mean values of radioactivity levels in normal and malignant cells were 0.3 ± 0.15 MBq and 1.07 ± 0.6 MBq, respectively. All examined animals had increased accumulation of {sup 99m}Tc-1-thio-D-glucose at the tumor site. The accumulation of {sup 99m}Tc-1-thio-D-glucose in the tumor was on average twice as high as compared to the symmetric region. Conclusion: The present study demonstrated that {sup 99m}Tc-1-thio-D-glucose is a prospective radiopharmaceutical for cancer visualization. In addition, high accumulation of {sup 99m}Tc-1-thio-D-glucose in the culture of cancer cells and in tumor tissue of animals demonstrates tumor tropism of the radiopharmaceutical.

  13. The tritium labelling of organic molecules by heterogeneous catalytic exchange; El marcado de moleculas organicas con tritio por intercambio catalitico heterogeneo

    Energy Technology Data Exchange (ETDEWEB)

    Angoso Marina, M; Kaiser Ruiz del Olmo, F.

    1977-07-01

    The influence of the temperature at 65 degree centigree and 120 degree centigree on the labelling of three organic molecules with tritium was studied. The compounds were: benzoic acid, de phenyl glyoxal and 2,3-tetramethylene-4-pantothenyl-7-oxo diacetin.The method employed was the heterogeneous catalytic exchange between tritiated water and the organic compound. The purification was made by thin-layer chromatography and the concentration, purity and specific activity of the products were determined by counting and ultraviolet techniques. The thermal stability and the radiolytic effects on labelled benzoic acid were also considered. (Author) 9 refs.

  14. Radiopharmaceuticals for hepatobiliary imaging

    International Nuclear Information System (INIS)

    Chervu, L.R.; Nunn, A.D.; Loberg, M.D.

    1982-01-01

    Tests for liver function have by and large centered around clinical laboratory diagnostic procedures for a number of years. Besides these, radiographic imaging procedures, including oral cholecystography and intravenous cholangiography, serve a very useful purpose, but several of them are invasive and involve a certain degree of risk from the administered contrast media as well as discomfort to the patient. The cholescintigraphic procedures, though noninvasive, have not played a significant role in the evaluation of hepatobiliary disorders prior to the introduction of the currently available /sup 99m/Tc-labeled IDAs. These new hepatobiliary agents offer many advantages over the previously utilized radiopharmaceuticals ( 131 I-rose bengal in particular) in terms of the high degree of specificity for localization in the gallbladder with rapid extraction rates by the polygonal cells of the liver and very low excretion via the GU tract. A detailed understanding of the structure distribution relationship of the various groups in the complex enable the design of agents with an improvement in hepatobiliary specificity and other desirable characteristics. In many clinical situations, even in patients with high bilirubin levels, the /sup 99m/Tc-labeled IDAs offer far superior clinical information over the alternative diagnostic imaging modalities. Further, the absorbed radiation dose imparted to the critical organs is far lower than with the older agents. Thus, the introduction of the cholescintigraphic procedures with the /sup 99m/Tc-labeled IDAs have ushered in a new phase in the diagnostic workup of patients with impaired hepatocellular function and other biliary disorders

  15. Harvard-MIT research program in short-lived radiopharmaceuticals. Progress report, March 1, 1983-February 29, 1984

    International Nuclear Information System (INIS)

    Adelstein, S.J.; Brownell, G.L.

    1984-02-01

    This report describes research efforts towards the achievement of a clearer understanding of the solution chemistry of technetium in order to facilitate the design of future clinical agents labeled with Tc-99m, the development of new receptor binding radiopharmaceuticals for the in vivo assessment of insulin receptors and for imaging the adrenal medulla and the brain, the examination of the utility of monoclonal antibodies and liposomes in the design of radiopharmaceuticals for diagnosis and therapy, and the synthesis of short-lived positron-emitting radiopharmaceuticals for transverse imaging of regional physiological processes

  16. Investigation of tritium incorporation by means of excreted metabolites

    International Nuclear Information System (INIS)

    Biro, T.; Szilagyi, M.

    1978-01-01

    The commonly accepted urine analysis by liquid scintillation method was applied for whole body dose estimating. After the separation of metabolite fractions the organically bound tritium in urine could be measured. Urine samples from workers repeatedly exposed to tritium incorporation during the chemical processing of various labeled compounds have been collected and analyzed. The time dependence of tritium activity in certain metabolites was found to be characteristic, significantly differing from the 3 H concentration curve of the native or treated urine sample. (Auth.)

  17. Using tritium as an indicator for development effective radionuclide methods for identification of nuclear testing venues

    Energy Technology Data Exchange (ETDEWEB)

    Lyakhova, O.; Lukashenko, S.; Larionova, N.; Timonova, L. [Institute of radiation safety and ecology (Kazakhstan)

    2014-07-01

    Nuclear explosions cause large amount of tritium, which has long half-life and its natural content in the atmosphere is only a small fraction of the total. On a par with the chemical inert RNG, tritium, as an isotope of hydrogen, effectively incorporates into the air and when creating certain conditions for sampling, can be found in quite small amounts. Inspecting the possibility of using tritium as an indicator was conducted at two test sites 'Degelen' and 'Balapan' located at the Semipalatinsk test site. At 'Degelen' site nuclear tests were conducted in a horizontal tunnels, located inside the rock, with a cross section of from 9 m{sup 2} to 25 m{sup 2} and a depth of 1500 m. The nuclear charge was placed at the end of the tunnel in a specially designed box. At 'Balapan' site nuclear tests were conducted in vertical boreholes depth 500-600 m, partly with casing pipes of various diameters and below the open hole with a diameter of 900 mm. After the nuclear testing, both the boreholes and tunnels have been partially 'conserved' - being constructed special sealing complex, a combination of cement plugs and gravel backfill, the entrance to the tunnel was carefully poured with the rock, borehole head was poured with soil. When studying the tritium content in the atmosphere of 'Degelen' site there was recorded the presence of tritium in air, not only within the tunnels, but also outside, at the tunnel portal and their estuarine areas, even when the tunnels were completely 'conserved'. The tritium content at the outlet of the tunnels ranged from 1 to 300 Bq/m3 at the 'conserved' tunnels and hundreds of Bq/m{sup 3}, and in some cases, thousands of Bq/m{sup 3} - inside tunnels. In the territory of 'Balapan' site when research the level and distribution of tritium in the vicinity of the boreholes there was found that the tritium content in the atmosphere even at a distance from the

  18. Labeling of creatinine with technetium-99m

    Energy Technology Data Exchange (ETDEWEB)

    Yurt Lambrecht, F. [Ege Univ., Bornova, Izmir (Turkey). Dept. of Nuclear Applications, Inst. of Nuclear Sciences; Durkan, K. [Dokuz Eylul Univ., Buca, Izmir (Turkey). Chemistry Technicianship Program, Izmir Vocational School; Soylu, A. [Dokuz Eylul Univ., Narlidere, Izmir (Turkey). Dept. of Pediatrics, Medical Faculty

    2004-07-01

    Creatinine is a clinically important index of renal glomerular filtration rate. Urine creatinine levels can be used as a screening test to evaluate kidney function or can be part of the creatinine clearance test. In case of kidney dysfunction or muscle disorders the creatinine concentration in serum/plasma may rise to a higher value than in healthy body. Technetium- 99m has been used in nuclear medicine and in biomedical research to label molecular and cellular structures employed as radiotracers. {sup 99m}Tc is utilized to label molecules and cells, used as radiopharmaceuticals, and also to label biological species. It presents many desirable characteristics. SnCl{sub 2} method is frequently used as a reducing agent in the {sup 99m}Tc- labeling process. Creatinine metabolism might be investigated by using labeled {sup 99m}Tc- creatinine in healthy or uremic rats. (orig.)

  19. /sup 99m/Tc-labelled hepatobiliary radiopharmaceuticals

    International Nuclear Information System (INIS)

    Galli, G.; Maini, C.L.

    1986-01-01

    During the last 15 years many compounds labelled with /sup 99m/Tc have been proposed for use in cholescintigraphy. A short chronological list includes: toluidine blue, penicillamine, tetracycline, dihydrothioctic acid, mercaptoisubutyric acid, pyridoxals, pyridoxylideneaminates, carboxyl-hydroxyquinoline, substituted acetanilide iminodiacetates (so called IDAs), ethylenediamine-N, N-diacetate derivatives (such as sulfonyl-EDDA and benzoyl-EDDA), and orthoiodohippurate analogues. Among all these compounds the IDAs have been those most extensively used for basic and clinical research. A large series of IDA derivatives has been developed, and the properties of 33 of them have recently been tested

  20. Contamination mechanisms of air basin with tritium in venues of underground nuclear explosions at the former Semipalatinsk test site

    International Nuclear Information System (INIS)

    Lyakhova, O.N.; Lukashenko, S.N.; Larionova, N.V.; Tur, Y.S.

    2012-01-01

    During the period of testing from 1945 to 1962 at the territory of Semipalatinsk test site (STS) within the Degelen Mountains in tunnels, 209 underground nuclear explosions were produced. Many of the tunnels have seasonal water seepage in the form of streams, through which tritium migrates from the underground nuclear explosion (UNE) venues towards the surface. The issue of tritium contamination occupies a special place in the radioactive contamination of the environment. In this paper we assess the level and distribution of tritium in the atmospheric air of ecosystems with water seepage at tunnels № 176 and № 177, located on “Degelen” site. There has been presented general nature of tritium distribution in the atmosphere relative to surface of a watercourse which has been contaminated with tritium. The basic mechanisms were studied for tritium distribution in the air of studied ecosystems, namely, the distribution of tritium in the systems: water–atmosphere, tunnel air–atmosphere, soil water–atmosphere, vegetation–atmosphere. An analytical calculation of tritium concentration in the atmosphere by the concentration of tritium in water has been performed. There has experimentally obtained the dependence for predictive assessment of tritium concentrations in air as a function of tritium concentration in one of the inlet sources such as water, tunnel air, soil water, vegetation, etc.. The paper also describes the general nature of tritium distribution in the air in the area “Degelen”. - Highlights: ► The basic mechanisms for tritium distribution in the air of nuclear testing sites were examined. ► We researched the distribution of tritium in the systems such as water–atmosphere, tunnel air–atmosphere, soil water–atmosphere and vegetation–atmosphere. ► An analytical calculation of tritium concentration in the atmosphere was performed. ► We experimentally obtained the dependence for predictive assessment of tritium concentrations in

  1. General Tritium Labelling of Gentamicin C by catalytic hydrogen exchange Reaction with Tritiated Water

    International Nuclear Information System (INIS)

    Suarez, C.; Diaz, D.; Paz, D.

    1991-01-01

    Gentamicin C was labelled with tritium by means of a PtO2 catalyzed hydrogen exchange reaction. Under the conditions of the exchange (100 mg of gentamicin, basic form, 0,3 ml H2O-3H, and 50 mg of prereduced PtO2) the radiochemical yield was 0,24, 0,38 and 0,48 % at 120 degree celsius, for 8, 16 and 24 hours respectively. Chemical yield for purified gentamicin was about 60 %. Purification was accomplished with a cellulose column eluted with the lower phase of chloroform-methanol 17 % ammonium hydroxide (2:1:1, v/v) . Chemical purity, determined by HPLC, was 96,5 % and radiochemical one was 95. Main exchange degradation products show biological activity. (Author) 12 refs

  2. General Tritium labelling of gentamicin C by catalytic hydrogen exchange reaction with tritiated water

    International Nuclear Information System (INIS)

    Suarez, C.; Diaz, D.

    1991-01-01

    Gentamicin C was labelled with tritium by means of a PtO 2 catalized hydrogen exchange reaction. Under the conditions of the exchange (100 mg of gentamicin, basic form, 0,3 ml H 2 O- 3 H, and 50 mg of prereduced PtO 2 ) the radiochemical yield was 0,24, 0,38 and 0,48 % at 120 o C, for 8, 16 and 24 hours respectively. Chemical yield for purified gentamicin was about 60 %. Purification was accoumplished with a cellulose column eluted with the lower phase of chloroform-methanol 17 % ammonium hydroxide (2:1:1, v/v). Chemical purity, determined by HPLC, was 96,5 % and radiochemical one was 95 % . Main exchange degradation products show biological activity. (Author). 12 refs

  3. Preparation of tritium-labelled dextran and inulin

    International Nuclear Information System (INIS)

    Akulov, G.P.; Kaminski, Ju.L.; Korsakova, N.A.; Kudelin, B.K.

    1992-01-01

    Tritiated dextran and inulin were prepared by both a catalytic solid state and a liquid phase isotropic exchange with gaseous tritium. The liquid phase procedure is convenient for preparation of the polysaccharides with specific activities up to 5 mCi/g, while the solid state procedure allows specific activities up to 700 mCi/g. (Author)

  4. Radiopharmaceuticals

    International Nuclear Information System (INIS)

    1981-01-01

    The catalogue offers a wide-spread product range which meets the requirements of the international trend of in vivo application of radiopharmaceuticals. It includes: (1) conditions of sale and delivery, (2) delivery schedule for radiopharmaceuticals, (3) technical information, (4) product specifications, and (5) the complete delivery programme

  5. Synthesis of tritium labeled Ac-[Nle4, D-Phe7]-α-MSH/sub 4-11/-NH2: a superpotent melanotropin with prolonged biological activity

    International Nuclear Information System (INIS)

    Wilkes, B.D.; Hruby, V.J.; Yamamura, H.I.; Akiyama, K.; Castrucci, A.M. de; Hadley, M.E.; Andrews, J.R.; Wan, Y.P.

    1984-01-01

    Ac-[Nle 4 , D-Phe 7 ]-α-MSH/sub 4-11/-NH 2 an octapeptide, is a melanotropin analogue (Ac-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-NH 2 ), which is a superpotent agonist of frog and lizard skin melanocytes and mouse S 91 (Cloudman) melanoma cells. This melanotropin possesses ultraprolonged activity on melanocytes, both in vitro and in vivo, and the peptide is resistant to inactivation by serum enzymes. The tritium-labeled congener was prepared by direct incorporation of [ 3 H]-labeled norleucine into the peptide. The melanotropic activity of the labeled peptide is identical to the unlabeled analogue. This labeled peptide should be useful for studies on the localization and characterization of melanotropin receptors

  6. Operation of the TSTA (Tritium Systems Test Assembly) with 100 gram tritium

    International Nuclear Information System (INIS)

    Sherman, R.H.; Bartlit, J.R.

    1988-01-01

    In March of 1988 full operation of the 4-column isotope separation system (ISS) was realized in runs that approximated the design load of tritium. Previous operations had been fraught with operating difficulties principally due to external systems. This report will examine the recent highly successful 6-day period of operation. During this time the system was cooled from room temperature, loaded with hydrogen isotopes including 109 grams of tritium, integrated with the transfer pumping, impurity injection, and impurity removal systems, as well as the remote computer control system. At the end of the operation 12 grams of tritium having a measured purity of 99.987% (remainder deuterium) were offloaded from the system. Observed profiles in the columns in general agree with computer models. A Height Equivalent to a Theoretical Plate (HETP) of 5.0 cm is confirmed. 3 refs., 5 figs

  7. Subsystem software for TSTA [Tritium Systems Test Assembly

    International Nuclear Information System (INIS)

    Mann, L.W.; Claborn, G.W.; Nielson, C.W.

    1987-01-01

    The Subsystem Control Software at the Tritium System Test Assembly (TSTA) must control sophisticated chemical processes through the physical operation of valves, motor controllers, gas sampling devices, thermocouples, pressure transducers, and similar devices. Such control software has to be capable of passing stringent quality assurance (QA) criteria to provide for the safe handling of significant amounts of tritium on a routine basis. Since many of the chemical processes and physical components are experimental, the control software has to be flexible enough to allow for trial/error learning curve, but still protect the environment and personnel from exposure to unsafe levels of radiation. The software at TSTA is implemented in several levels as described in a preceding paper in these proceedings. This paper depends on information given in the preceding paper for understanding. The top level is the Subsystem Control level

  8. Use of tritium and sources

    International Nuclear Information System (INIS)

    Noguchi, Hiroshi

    1997-01-01

    There are many kinds of tritium, sources in the environment. The maximum inventory of them is the nuclear tests, although the atmospheric nuclear test has not been carried out since 1981. So that the inventory originated from them will decrease. By the latest data in 1989, the total amount of released tritium was about 24 PBq/yr by the use of atomic energy in the world. The maximum source was the heavy water moderated reactors, for example, CANDU reactor. In the future, large amount of tritium inventory may be the fusion reactor. The test of JET (Joint European Torus) released about 600 GBq of tritium until March in 1992. 80-90% of them were tritium water (HTO). The amount of tritium released from industries and medicine are limited. Although ITER has a large amount of tritium inventory, the amount of release is seemed not to be larger than other nuclear power facility. (S.Y.)

  9. Tritium Systems Test Facility. Volume II. Appendixes

    International Nuclear Information System (INIS)

    Anderson, G.W.; Battleson, K.W.; Bauer, W.

    1976-10-01

    This document includes the following appendices: (1) vacuum pumping, (2) tritium migration into the power cycle, (3) separation of hydrogen isotopes, (4) tritium research laboratory, (5) TSTF containment and cleanup, (6) instrumentation and control, (7) gas heating in torus, and (8) TSTF fuel loop operating procedures

  10. In-pile test of tritium recovery from lithium oxide

    International Nuclear Information System (INIS)

    Kurasawa, Toshimasa; Yoshida, Hiroshi; Watanabe, Hitoshi; Takeshita, Hidefumi; Miyauchi, Takejiro; Matsui, Tomoaki

    1984-05-01

    In-situ tritium recovery experiment with sintered lithium oxide pellets was performed under a high neutron fluence in the JRR-2. The irradiation hole VT-10 is the vertical one in the fuel rods region of the reactor, and the neutron flux is as follows: the thermal neutron flux with the epithermal neutron; 1.12 x 10 14 n/cm 2 . sec, the fast neutron flux; 1.0 x 10 12 n/cm 2 . sec. Irradiation material is the four pellets of cylindrical Li 2 O with the size of 11mm-OD, 1.8mm-ID, 10mm-H, and their total weight is 6.67g(the apparent bulk density 86%TD). A sweep gas capsule with a inner heater was constructed for the present study. Irradiation temperatures were regulated in the high temperature range, 470 -- 760 0 C. Four cycles of irradiation tests were carried out from May to August in 1983, and the effective thermal neutron fluence and the burnup of 6 Li were 5.9 x 10 19 nvt and 0.24% of total lithium(natural abundance of Li), respectively. The amount of generated tritium was calculated to be 31.2Ci by using a value of the depression factor of the thermal neutron flux(0.148) and the effective neutron cross section(543b) for the 6 Li(n, α) 3 H reaction. Present report describes the tritium release behavior in the in-situ tritium recovery apparatus and discuss the effects of the moisture, the hydrogen spiking, the irradiation temperature, etc.. Problems relative to a real time measurement of a comparatively high tritium concentration(10 -1 -- 10 2 μCi/cm 3 ) in the helium gas stream were also investigated. (author)

  11. Audits of radiopharmaceutical formulations

    International Nuclear Information System (INIS)

    Castronovo, F.P. Jr.

    1992-01-01

    A procedure for auditing radiopharmaceutical formulations is described. To meet FDA guidelines regarding the quality of radiopharmaceuticals, institutional radioactive drug research committees perform audits when such drugs are formulated away from an institutional pharmacy. All principal investigators who formulate drugs outside institutional pharmacies must pass these audits before they can obtain a radiopharmaceutical investigation permit. The audit team meets with the individual who performs the formulation at the site of drug preparation to verify that drug formulations meet identity, strength, quality, and purity standards; are uniform and reproducible; and are sterile and pyrogen free. This team must contain an expert knowledgeable in the preparation of radioactive drugs; a radiopharmacist is the most qualified person for this role. Problems that have been identified by audits include lack of sterility and apyrogenicity testing, formulations that are open to the laboratory environment, failure to use pharmaceutical-grade chemicals, inadequate quality control methods or records, inadequate training of the person preparing the drug, and improper unit dose preparation. Investigational radiopharmaceutical formulations, including nonradiolabeled drugs, must be audited before they are administered to humans. A properly trained pharmacist should be a member of the audit team

  12. DPRK's 4"t"h Nuclear Test and its Tritium Production

    International Nuclear Information System (INIS)

    Kim, Min Soo; Lee, Sang Joon; Chang, Sun Young

    2016-01-01

    On January 6, 2016 at 10:30am, the artificial earthquake in the DPRK was detected by multiple international seismic organizations. After 2 hours, the DPRK announced on state TV that 'The first H-bomb test was successfully conducted in the DPRK at 10:00 am on Wednesday, Juche 105(2016), pursuant to the strategic determination of the ruling communist party.' There has been a doubt about the real nature of the DPRK's 4th nuclear test, since 2 months have been passed after its nuclear test. To analyze the nature of the DPRK's nuclear test, it is necessary to check possible options for production of essential materials. The pathways to produce nuclear fusion material (tritium) and to have a relatively high possibility for the DPRK are described in this article. Tritium is key material for H-bomb. And there are two options for the DPRK which are 1) production and 2) illicit trafficking. And this study is focused on production possibility of DPRK. Determination of the nature of DPRK's nuclear test is very hard issue

  13. Tritium transport and control in the FED

    International Nuclear Information System (INIS)

    Rogers, M.L.

    1981-01-01

    The tritium systems for the FED have three primary purposes. The first is to provide tritium and deuterium fuel for the reactor. This fuel can be new tritium or deuterium delivered to the plant site, or recycled DT from the reactor that must be processed before it can be recycled. The second purpose of the FED tritium systems is to provide state-of-the-art tritium handling to limit worker radiation exposure and to minimize tritium losses to the environment. The final major objective of the FED tritium systems is to provide an integrated system test of the tritium handling technology necessary to support the fusion reactor program. Every effort is being made to incorporate available information from the Tritium System Test Assembly (TSTA) at Los Alamos National Laboratory, the Tokamak Fusion Test Reactor (TFTR) tritium systems, and the tritium handling information generated within DOE for the past 20 years

  14. Radioactive labelling of peptidic hormones

    International Nuclear Information System (INIS)

    Fromageot, P.; Pradelles, P.; Morgat, J.L.; Levine, H.

    1976-01-01

    The labelling of peptidic hormones requires stability, specificity and sensitivity of the label. Introduction of a radioactive atome is one way to satisfy these criteria. Several processes have been described to prepare radioactive TRF: synthesis of the peptide with labelled aminoacids or introduction of the label into the hormone. In that approach, tritium can be substituted in the imidazole ring, via precursors activating the proper carbon. Monoiodo TRF leads essentially to tritium labelling of the 5 positions whereas monoazo TRF allows the preparation of 3 H TRF labelled in the 2 positions. Di-substituted TRF leads to labelling into the 2 and 5 carbons. Labelled analogs of TRF can be prepared with labelled iodine; further developments of peptide labelling, will be presented. In particular, the homolytic scission of the C-iodine, bond by photochemical activation. The nascent carbon radical can be stabilized by a tritiated scavenger. This approach eliminates the use of heavy metal catalysts

  15. Analytics of radiochmical impurities in radiopharmaceutics. Pt. 4

    International Nuclear Information System (INIS)

    Heide, L.; Stamm, A.; Boegl, W.

    1981-01-01

    The radiopharmaceutics have been compiled in the present volume in the form of a medicament encyclopaedia. The term radiopharmaceutic has been very broadly covered so that one can find pharmaceutics which are applied in clinical routine as well as for veterinary tests or are being or have been tested. Preparates for radio-immuno assays are also recorded. All analysis methods are considered even if these only slightly differ from one another. Methods described in the literature are given which have resulted in a bad or no separation of the radiopharmaceutics from the impurities. (orig./MG) [de

  16. 99m Tc-labeled dendrimers as a potential radiopharmaceutical for tumor diagnosis process

    International Nuclear Information System (INIS)

    Tassano Hartwich, M.

    2008-01-01

    The present thesis to access the Bachelor of Biological Sciences studies the following: biology, molecular biology, pathology, radiotherapy, radiopharmaceuticals, research techniques and malignant neoplasms

  17. Tritium protective clothing

    International Nuclear Information System (INIS)

    Fuller, T.P.; Easterly, C.E.

    1979-06-01

    Occupational exposures to radiation from tritium received at present nuclear facilities and potential exposures at future fusion reactor facilities demonstrate the need for improved protective clothing. Important areas relating to increased protection factors of tritium protective ventilation suits are discussed. These areas include permeation processes of tritium through materials, various tests of film permeability, selection and availability of suit materials, suit designs, and administrative procedures. The phenomenological nature of film permeability calls for more standardized and universal test methods, which would increase the amount of directly useful information on impermeable materials. Improvements in suit designs could be expedited and better communicated to the health physics community by centralizing devlopmental equipment, manpower, and expertise in the field of tritium protection to one or two authoritative institutions

  18. Tritium protective clothing

    Energy Technology Data Exchange (ETDEWEB)

    Fuller, T. P.; Easterly, C. E.

    1979-06-01

    Occupational exposures to radiation from tritium received at present nuclear facilities and potential exposures at future fusion reactor facilities demonstrate the need for improved protective clothing. Important areas relating to increased protection factors of tritium protective ventilation suits are discussed. These areas include permeation processes of tritium through materials, various tests of film permeability, selection and availability of suit materials, suit designs, and administrative procedures. The phenomenological nature of film permeability calls for more standardized and universal test methods, which would increase the amount of directly useful information on impermeable materials. Improvements in suit designs could be expedited and better communicated to the health physics community by centralizing devlopmental equipment, manpower, and expertise in the field of tritium protection to one or two authoritative institutions.

  19. [Solid state isotope hydrogen exchange for deuterium and tritium in human gene-engineered insulin].

    Science.gov (United States)

    Zolotarev, Yu A; Dadayan, A K; Kozik, V S; Gasanov, E V; Nazimov, I V; Ziganshin, R Kh; Vaskovsky, B V; Murashov, A N; Ksenofontov, A L; Haribin, O N; Nikolaev, E N; Myasoedov, N F

    2014-01-01

    The reaction of high temperature solid state catalytic isotope exchange in peptides and proteins under the action of catalyst-activated spillover hydrogen was studied. The reaction of human gene-engineered insulin with deuterium and tritium was conducted at 120-140° C to produce insulin samples containing 2-6 hydrogen isotope atoms. To determine the distribution of the isotope label over tritium-labeled insulin's amino acid residues, oxidation of the S-S bonds of insulin by performic acid was performed and polypeptide chains isolated; then their acid hydrolysis, amino acid analysis and liquid scintillation counts of tritium in the amino acids were conducted. The isotope label was shown to be incorporated in all amino acids of the protein, with the peptide fragment FVNQHLCGSHLVE of the insulin β-chain showing the largest incorporation. About 45% of the total protein isotope label was incorporated in His5 and His10 of this fragment. For the analysis of isotope label distribution in labeled insulin's peptide fragments, the recovery of the S-S bonds by mercaptoethanol, the enzymatic hydrolysis by glutamyl endopeptidase from Bacillus intermedius and HPLC division of the resulting peptides were carried out. Attribution of the peptide fragments formed due to hydrolysis at the Glu-X bond in the β-chain was accomplished by mass spectrometry. Mass spectrometry analysis data of the deuterium-labeled insulin samples' isotopomeric composition showed that the studied solid state isotope exchange reaction equally involved all the protein molecules. Biological studying of tritium-labeled insulin showed its physiological activity to be completely retained.

  20. Investigation on the distribution of tritium and carbon-14 in the amino acids of labelled green algae (Scenedesmus Quadricauda ssp.)

    International Nuclear Information System (INIS)

    Nuernberger, E.; Clausen, E.; Kistner, G.

    1982-01-01

    Green algae (Scenedesmus quadricauda ssp. subspicatus), labelled twice tritium and carbon-14, showed an incorporation of nuclides into the cell mass of 0.02% and 95%, respectively. The distribution of radioactivity in the individual amino acids was examined in a protein fraction with special emphasis on the essential amino acids in view of their following incorporation into the next link of the aquatic food chain (Daphnia). The highest values were found in glutamine and asparagine acids as well as in the essential amino acids leucine and arginine, which are amino acids with a relatively high amount of non exchangeable H-positions per molecule and, therefore, a relatively high and stable labelling. (author)

  1. SU-E-I-82: PET Radiopharmaceuticals for Prostate Cancer Imaging: A Review

    Energy Technology Data Exchange (ETDEWEB)

    Fernandes, F [Delfin Farmacos e Derivados Ltda, Lauro De Freitas, Bahia (Brazil); Escola Bahiana de Medicina e Saude Publica, Salvador, Bahia (Brazil); Silva, D da [Delfin Farmacos e Derivados Ltda, Lauro De Freitas, Bahia (Brazil); Rodrigues, L [Escola Bahiana de Medicina e Saude Publica, Salvador, Bahia (Brazil)

    2015-06-15

    Purpose: The aim of this work was to review new and clinical practice PET radiopharmaceuticals for prostate cancer imaging. Methods: PET radiopharmaceuticals were reviewed on the main databases. Availability, dosimetry, accuracy and limitations were considered. Results: The following radioisotopes with respective physical half-life and mean positron energy were found: {sup 18}F (109,7 min, 249,8 keV), {sup 89}Zr (78,4 hs, 395,5 keV), {sup 11}C (20,4 min, 385,7 keV) and {sup 68}Ga (67,8 min, 836 keV). {sup 68}Ga was the only one not produced by cyclotron. Radiopharmaceuticals uptake by glucose metabolism ({sup 18}F-FDG), lipogenesis ({sup 11}C-Choline and {sup 11}C-Acetate), amino acid transport (Anti-{sup 18}F-FACBC), bone matrix ({sup 18}F-NaF), prostatespecific membrane antigen ({sup 68}Ga-PSMA and {sup 89}Zr-J591), CXCR receptors ({sup 89}Ga-Pentixafor), adrenal receptors ({sup 18}F-FDHT) and gastrin release peptide receptor (bombesin analogue). Most of radiopharmaceuticals are urinary excretion, so bladder is the critical organ. 11C-choline (pancreas), Anti-{sup 18}FFACBC (liver) and {sup 18}F-FBDC (stomach wall) are the exception. Higher effective dose was seen {sup 18}F-NaF (27 μSv/MBq) while the lowest was {sup 11}CAcetate (3,5 μSv/MBq). Conclusion: Even though {sup 18}F-FDG has a large availability its high urinary excretion and poor uptake to slow growing disease offers weak results for prostate cancer. Better accuracy is obtained when {sup 18}F-NaF is used for bone metastatic investigation although physicians tend to choose bone scintigraphy probably due to its cost and practice. Many guidelines in oncology consider {sup 11}C or {sup 18}F labeled with Choline the gold standard for biochemical relapse after radical treatment. Local, lymph node and distant metastatic relapse can be evaluated at same time with this radiopharmaceutical. There is no consensus over bigger urinary excretion for {sup 18}F labeling. Anti-{sup 18}F-FACBC, {sup 68}Ga-PSMA and {sup

  2. Lung radiopharmaceuticals; Radioformacos pulmonares

    Energy Technology Data Exchange (ETDEWEB)

    Gonzalez, B M [Instituto Nacional de Pediatroa (Mexico)

    1994-12-31

    Indication or main clinical use of Lung radiopharmaceuticals is presented and clasification of radiopharmaceuticals as ventilation and perfusion studies. Perfusion radiopharmaceuticals, main controls for administration quality acceptance. Clearence after blood administration and main clinical applications. Ventilation radiopharmaceuticals, gases and aerosols, characteristics of a ideal radioaerosol, techniques of good inhalation procedure, clinical applications. Comparison of several radiopharmaceuticals reflering to retention time as 50% administered dose, percent administered dose at 6 hours post inhalation, blood activity at 30 and 60 minutes post inhalation, initial lung absorbed dose, cumulated activity.Kinetic description of two radiopharmaceuticals, 99mTcDTPA and 99mTc-PYP.

  3. Preparation of labelled antituberculotics for clarifying specific problems in therapy optimization. 1. Preparation of tritiated isoniazid and injectable solutions, investigation of the stability of labelling

    Energy Technology Data Exchange (ETDEWEB)

    Winsel, K.; Iwainsky, H. (Forschungsinstitut fuer Lungenkrankheiten und Tuberkulose, Berlin-Buch (German Democratic Republic)); Mittag, E.; Kiessling, M. (Zentralinstitut fuer Kernforschung, Rossendorf bei Dresden (German Democratic Republic)); Koehler, H. (Zentralklinik fuer Herz- und Lungenkrankheiten, Bad Berka (German Democratic Republic))

    1985-09-01

    The preparation of tritium labelled isoniazid according to the Wilzbach method and by catalytic exchange is described. The purified labelled isoniazid is adjusted to an activity of 37 MBq/300 mg isoniazid. It meets the requirements for an injectable pharmaceutical. The tritium labelling is stable under in vitro conditions and in the macroorganism.

  4. Method for preparing 99mTc-labelled radiopharmaceuticals for myocardial scintigraphy

    International Nuclear Information System (INIS)

    Seifert, S.; Syhre, R.; Muenze, R.

    1987-01-01

    Radiopharmaceuticals which preferably concentrate in myocardial tissue are prepared, in particular technetium compounds with the reducing ligand molecule DMPE. A method is introduced to convert pertechnetate in one step into the proposed compound by means of a saline, slow-oxidizing and lyophilized form of the reducing ligand DMPE, preferably DMPE x 2HCl

  5. Evaluation of Radioisotope Production Process of 153Sm and 153Sm-EDTMP Radiopharmaceuticals

    International Nuclear Information System (INIS)

    Kadarisman; Sri Hastini; Yayan Tahyan; Abidin; Dadang Hafid; Enny Lestari

    2007-01-01

    Experiments on the process of 153 Sm radioisotope and labeling of 153 Sm-EDTMP radiopharmaceuticals were carried out. This experiments included preparation of Sm 2 O 3 target, dissolution of post irradiation, determination of radioactivity concentration of 153 Sm radioisotope, radionuclide purity, EDTMP labeling, determination of radiochemical purity and pH. In these experiments the total radioactivity 153 Sm product is round about 2845.83 mCi to 36963.31 mCi, or with the radioactivity concentration between 474 mCi/ml to 6160.55 mCi/ml in the SmCl 3 solution form, each its volume is 6.0 ml, and the samarium content is 5.76 mg/ml, and the radionuclide purity of 153 Sm is 100 %. All of the 153 Sm- EDTMP radiopharmaceuticals product are fulfilled requirements the radioactivity concentration, Sm content, radiochemical purity and pH. The radioactivity concentration of 153 Sm-EDTMP radiopharmaceuticals is 37.50 mCi/ml (minimum) to 283.50 mCi/ml (highest). The pH 7.5 were 8 products, and the rest are pH 8.5. Radiochemical purity of 153 Sm-EDTMP are round about 90.00 % to 99.44 %. (author)

  6. Nuclear medicine and imaging research: quantitative studies in radiopharmaceutical science. Comprehensive progress report, January 1, 1980-December 31, 1982

    International Nuclear Information System (INIS)

    Beck, R.N.; Cooper, M.C.

    1982-06-01

    This 3-y report cites progress in the following areas of radiopharmaceutical research: cyclotron operations; 51 Mn for myocardial localization; 82 Rb for heart imaging; 15 O-labelled H 2 O and molecular oxygen; studies on 11 C-2-deoxyglucose localization; 13 NH 3 measurements of myocardial perfusion; 130 Cs myocardial imaging; heart motion studies; labelled amino acids for pancreatic imaging; 11 C-hexamethonium for cartilage imaging; 11 C-cholic acid pharmacology; blood element labelling with /sup 115m/In; 75 Br studies; extrapolation of animal data to humans; in vivo quantification of radioactivity; fetal and neonatal radiation effects from radiopharmaceuticals administered to pregnant and lactating mice; and verification of MIRD absorbed dose calculations for some organ-incorporated radionuclides

  7. Clinical applications of cells labelling

    International Nuclear Information System (INIS)

    Gonzalez, B.M.

    1994-01-01

    Blood cells labelled with radionuclides are reviewed and main applications are described. Red blood cell labelling by both random and specific principle. A table with most important clinical uses, 99mTc labelling of RBC are described pre tinning and in vivo reduction of Tc, in vitro labelling and administration of labelled RBC and in vivo modified technique. Labelled leucocytes with several 99mTc-complex radiopharmaceuticals by in vitro technique and specific monoclonal s for white cells(neutrofiles). Labelled platelets for clinical use and research by in vitro technique and in vivo labelling

  8. Tritium in the Physical and Biological Sciences. Vol. II. Proceedings of the Symposium on the Detection and Use of Tritium in the Physical and Biological Sciences

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1962-02-15

    The use of tritium for research in physics, chemistry, biology and hydrology has in recent years become increasingly important. It was for this reason that the first international conference to discuss the progress of new developments was organized by the IAEA in conjunction with the Joint Commission on Applied Radioactivity and held from 3 - 10 May 1961, in Vienna. The first five sessions of the Symposium were devoted to the use of tritium in hydrology, physics and chemistry. Special emphasis was laid on the role of tritium as a tracer in hydrology, especially in the study of water movement. The establishment and improvement of counting and detection techniques to facilitate the application of tritium as a tracer was another aspect discussed in this part of the proceedings. Papers were read on the preparation of tritiated compounds and it was generally agreed that further clarification of the mechanism of various techniques, and of the Wilzbach gas exposure technique in particular, would lead to further developments in the synthesis of a number of tritium compounds important in biology. Other papers were concerned with tritium applications to studies of the mechanism of some chemical reactions together with the effects of tritium isotopes. During the second part of the Symposium the biological applications of tritium and tritiated compounds were discussed. These included general problems connected with the biological uses of tritium and the radiation effects of tritium on living organisms such as viruses, bacteria and cancer cells. The value of tritium in biological studies became apparent because of the ease with which a large number of metabolically active compounds such as hormones, vitamins and other important constituents in the body can be labelled with tritium. Tritium is also a weak beta-emitter and autoradiographs of tissues and single cells containing tritium-labelled compounds allow an excellent localization of the tracer. The Symposium was attended by

  9. Tritium in the Physical and Biological Sciences. Vol. II. Proceedings of the Symposium on the Detection and Use of Tritium in the Physical and Biological Sciences

    International Nuclear Information System (INIS)

    1962-01-01

    The use of tritium for research in physics, chemistry, biology and hydrology has in recent years become increasingly important. It was for this reason that the first international conference to discuss the progress of new developments was organized by the IAEA in conjunction with the Joint Commission on Applied Radioactivity and held from 3 — 10 May 1961, in Vienna. The first five sessions of the Symposium were devoted to the use of tritium in hydrology, physics and chemistry. Special emphasis was laid on the role of tritium as a tracer in hydrology, especially in the study of water movement. The establishment and improvement of counting and detection techniques to facilitate the application of tritium as a tracer was another aspect discussed in this part of the proceedings. Papers were read on the preparation of tritiated compounds and it was generally agreed that further clarification of the mechanism of various techniques, and of the Wilzbach gas exposure technique in particular, would lead to further developments in the synthesis of a number of tritium compounds important in biology. Other papers were concerned with tritium applications to studies of the mechanism of some chemical reactions together with the effects of tritium isotopes. During the second part of the Symposium the biological applications of tritium and tritiated compounds were discussed. These included general problems connected with the biological uses of tritium and the radiation effects of tritium on living organisms such as viruses, bacteria and cancer cells. The value of tritium in biological studies became apparent because of the ease with which a large number of metabolically active compounds such as hormones, vitamins and other important constituents in the body can be labelled with tritium. Tritium is also a weak beta-emitter and autoradiographs of tissues and single cells containing tritium-labelled compounds allow an excellent localization of the tracer. The Symposium was attended

  10. Differential labelling of retinal neurones by 3H-2-deoxyglucose

    International Nuclear Information System (INIS)

    Basinger, S.F.; Gordon, W.C.; Lam, D.M.K.

    1979-01-01

    The use of tritium-labelled 2-deoxyglucose in combination with plastic embedding is reported to produce stimulus dependent labelling at cellular level in the isolated goldfish retina. The results suggest that the use of tritium in place of the more usual 14 C labelled tracer is advantageous in studying the physiology and functional connections of retinal neurones. (U.K.)

  11. Recent progress in fluorine-18 labelled peptide radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Okarvi, S.M. [Cyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital and Research Centre, Riyadh (Saudi Arabia)

    2001-07-01

    The application of biologically active peptides labelled with positron-emitting nuclides has emerged as a useful and interesting field in nuclear medicine. Small synthetic receptor-binding peptides are currently the preferred agents over proteins and antibodies for diagnostic imaging of various tumours. Due to the smaller size of peptides, both higher target-to-background ratios and rapid blood clearance can often be achieved with radiolabelled peptides. Hence, short-lived positron emission tomography (PET) isotopes are potential candidates for labelling peptides. Among a number of positron-emitting nuclides, fluorine-18 appears to be the best candidate for labelling bioactive peptides by virtue of its favourable physical and nuclear characteristics. The major disadvantage of labelling peptides with {sup 18}F is the laborious and time-consuming preparation of the {sup 18}F labelling agents. In recent years, various techniques have been developed which allow efficient labelling of peptides with {sup 18}F without affecting their receptor-binding properties. Moreover, the development of a variety of prosthetic groups has facilitated the efficient and site-specific labelling of peptides with {sup 18}F. The {sup 18}F-labelled peptides hold enormous clinical potential owing to their ability to quantitatively detect and characterise a wide variety of human diseases when using PET. Recently, a number of {sup 18}F-labelled bioactive peptides have shown great promise as diagnostic imaging agents. This review presents the recent developments in {sup 18}F-labelled biologically active peptides used in PET. (orig.)

  12. Recent progress in fluorine-18 labelled peptide radiopharmaceuticals

    International Nuclear Information System (INIS)

    Okarvi, S.M.

    2001-01-01

    The application of biologically active peptides labelled with positron-emitting nuclides has emerged as a useful and interesting field in nuclear medicine. Small synthetic receptor-binding peptides are currently the preferred agents over proteins and antibodies for diagnostic imaging of various tumours. Due to the smaller size of peptides, both higher target-to-background ratios and rapid blood clearance can often be achieved with radiolabelled peptides. Hence, short-lived positron emission tomography (PET) isotopes are potential candidates for labelling peptides. Among a number of positron-emitting nuclides, fluorine-18 appears to be the best candidate for labelling bioactive peptides by virtue of its favourable physical and nuclear characteristics. The major disadvantage of labelling peptides with 18 F is the laborious and time-consuming preparation of the 18 F labelling agents. In recent years, various techniques have been developed which allow efficient labelling of peptides with 18 F without affecting their receptor-binding properties. Moreover, the development of a variety of prosthetic groups has facilitated the efficient and site-specific labelling of peptides with 18 F. The 18 F-labelled peptides hold enormous clinical potential owing to their ability to quantitatively detect and characterise a wide variety of human diseases when using PET. Recently, a number of 18 F-labelled bioactive peptides have shown great promise as diagnostic imaging agents. This review presents the recent developments in 18 F-labelled biologically active peptides used in PET. (orig.)

  13. Preparation of radiopharmaceuticals labelled with bromine positron emitting isotopes for the study of dopaminergic receptors of the central nervous system using positron emission tomography

    International Nuclear Information System (INIS)

    Loc'h, C.

    1988-04-01

    The in vivo study of dopaminergic receptors of the central nervous system using positron emission tomography requires the preparation of radiopharmaceuticals labelled with β + emitting isotopes. The chemical and pharmacological properties of these ligands are evaluated. Cyclotron produced 75 and 76 bromine β + emitting isotopes are incorporated into dopaminergic ligands by electrophilic substitution using peracetic acid in a no-carrier added form. Purity, lipophilicity and specific activity are analyzed. Pharmacological criteria (specificity, saturability, displacement, localization) required for ligand-receptor binding studies are evaluated in vitro on striatal membranes and in vivo in the rat. Positron emission tomographic studies show that the study of dopaminergic D2 receptors is possible using 75 and 76 bromine labelled bromospiperone and bromolisuride. These ligands are used in physiological and pharmacological studies of the central nervous system [fr

  14. Radiopharmaceuticals - pattern and development and utilisation in India

    International Nuclear Information System (INIS)

    Iya, V.K.; Mani, R.S.

    1990-01-01

    The availability of research reactors at an early stage of India's Atomic Energy Programme led to developemental efforts in the field of radiopharmaceuticals. The use of several 125 I-labelled compounds like Rose-Bengal, hippuran, etc. for imaging has been replaced over the years by 99m Tc compounds; the final formulations are prepared at the hospital using generators and cold kits supplied by the Board of Radioisotope Technology. Parallel with the development of short-lived generators in radiopharmaceuticals came advances in imaging and instrumentation techniques, the scanners being replaced by sophisticated gamma cameras, with capabilities for tomography and computerisation. About 40 centres in India have the modern instrumentation and equipment needed for carrying out nuclear medicine procedures. Further growth of nuclear medicine centres in the country has, however, been limited by the need to import such advanced high cost instumentation not currently available from indigeneous sources. Regarding in-vitro radiopharmaceuticals, some RIA and IRMA kits and procedures have been developed. These include assay of T 3 , T 4 and TSH in the thyroid group of hormones. There are over a hundred and fifty medical laboratories carrying out RIA procedures. (author)

  15. Development of fluorine 18 labelled MPPF, radiopharmaceutical tracer for serotoninergic system exploration

    International Nuclear Information System (INIS)

    Le Bars, D.; Tochon-Danguy, H.

    2002-01-01

    Full text: Positron Emission Tomography (PET) is a non-invasive method for exploration, in man and animals, of metabolism with radiopharmaceutical tracers labelled with positron emitters such as carbon 11 and fluorine 18 obtained with a cyclotron. Among the ever increasing number of tracers focussed at the CNS neurotransmission, the discovery of a new family of serotoninergic 5HT 1A antagonists (WAY 100635) has led to the first in vivo imaging of 5HT 1A receptors in man, located in cerebral structures such as cortex and hippocampus. Exploration of serotonine parthway is particulaly interesting in normal or diseased state, as this neurotransmitter is involved in the control of mood, sleep and is probably altered in psychiatric disorders. CERMEP, in collaboration with other PET centres has developped a new 5HT 1A antagonist, MPPF, labelled with fluorine 18. [ 18 F]MPPF has the advantadge of fluorine 18 labelling, with a longer half-life (110 min vs 20 min for carbon 11) and easier radiosynthesis automation. Moreover, MPPF affinity for 5HT 1A is close to serotonin itself, thus enabling displacement of MPPF by endogenous serotonin during pharmacological challenges. Automated radiosynthesis of MPPF is achieved via a classical [ 18 F]F - fluoro for nitro displacement, activated by a catalyst, on a nitro precursor prepared in four steps. A final HPLC purification ensures the production of [ 18 F]MPPF with a high purity and a high specific activity. Ex vivo autoradiographies and PET studies in animals (rat, cat) have shown the excellent specificity of MPPF for the 5HT 1A receptor. Experiments with intracerebral β probe have evidenced the displacement of [ 18 F]MPPF by endogenous serotonin after fenfluramine injection. [ 18 F]MPPF is now used in man for non-invasive PET studies of serotoninergic system. Normal volunteers matched for age and sex have been screened as a database and to compute a mathematical model of the tracer kinetic describing 5HT 1A receptor affinity and

  16. Radiation dose calculations for orally administered radio-pharmaceuticals in upper gastrointestinal disease

    International Nuclear Information System (INIS)

    Wu, R.K.; Malmud, L.S.; Knight, L.C.; Siegel, J.A.; Stern, H.; Zelac, R.

    1983-01-01

    Radiation burden estimates for upper gastrointestinal function studies employing the following orally administered radiopharmaceuticals are reported. Technetium 99m sulfur colloid (Tc-99m-SC) in water, Indium-111-DTPA in water, Tc-99m-DTPA in water, Indium-113m DTPA in water, Tc-99m Ovalbumin, Tc-99m sulfur colloid in a cooked egg, Tc-99m sulfur colloid in vivo labeled chicken liver, and Indium-111 colloid in vivo labeled chicken liver. Orally administered radiopharmaceuticals for upper gastrointestinal studies afford clinician and investigator valuable clinical and physiologic information not previously obtainable using other techniques. The radiation burden to the patient from single or sequential studies is acceptable in comparison to fluoroscopy which results in approximately 5000 millirem per minute of exposure. The variety of preparations listed above should make these types of studies available in any routinely equipped nuclear medicine radiopharmacy laboratory

  17. Radiopharmaceuticals in Radiosynoviorthesis

    International Nuclear Information System (INIS)

    Cruz Arencibia, Jorge; Morin Zorrilla, Jose; Garcia Rodriguez, Enrique; Sagarra Veranes, Marta

    2010-01-01

    The Radiosynoviorthesis is a procedure of Metabolic Radiotherapy, consisting in the intraarticular injection of a radiopharmaceutical with a beta emitting radionuclide for the treatment of chronic synovitis, frequently present in rheumatoid arthritis, haemophilia and other systemic diseases. As this is a safe, effective and a relatively low-cost procedure, It is ordinarily used in Europe, USA and in some Latin American countries . The existing commercial products are based on 90 Y, 169 Er, 186 Re and 32 P, although research is carried out on the use of 188 Re, 166 Ho, among others radionuclides. In Cuba a suspension of Chromium Phosphate (III) labeled with 32 P, is on trial. The above-mentioned suspension has enough characteristics to become an efficient and safe product in practice. (Author)

  18. Laboratory methods to evaluate therapeutic radiopharmaceuticals

    International Nuclear Information System (INIS)

    Arteaga de Murphy, C.; Rodriguez-Cortes, J.; Pedraza-Lopez, M.; Ramirez-Iglesias, MT.; Ferro-Flores, G.

    2007-01-01

    The overall aim of this coordinated research project was to develop in vivo and in vitro laboratory methods to evaluate therapeutic radiopharmaceuticals. Towards this end, the laboratory methods used in this study are described in detail. Two peptides - an 8 amino acid minigastrin analogue and octreotate - were labelled with 177 Lu. Bombesin was labelled with 99 mTc, and its diagnostic utility was proven. For comparison, 99 mTc-TOC was used. The cell lines used in this study were AR42J cells, which overexpress somatostatin receptors found in neuroendocrine cancers, and PC3 cells, which overexpress gastric releasing peptide receptors (GRP-r) found in human prostate and breast cancers. The animal model chosen was athymic mice with implanted dorsal tumours of pathologically confirmed cell cancers. The methodology described for labelling, quality control, and in vitro and in vivo assays can be easily used with other radionuclides and other peptides of interest. (author)

  19. Preparation of Tritium from irradiated lithium compounds (study)

    International Nuclear Information System (INIS)

    1989-01-01

    The aim of the present study is the selection of a certain scheme for release, collection, measurement and analysis of Tritium as produced in Lithium compounds (Li 2 O, LiOH, Li 2 CO 3 LiF and some Lithium alloys) in accordance with the 6 Li(n, α)T reaction. Tritium technology is of vital concern to power reactor programmes as well as to fusion technology. Meanwhile the fields of activity include, tritium generation and mangement in fission and fusion reactors; enviromental studies, release modeling HT/HTO conversion and dose assessments, absorption/ deabsorption, monitoring and plant design; research and development, labeling, compatibility and physical chemical properties

  20. Preparation of Tritium from irradiated lithium compounds (study)

    Energy Technology Data Exchange (ETDEWEB)

    1989-01-01

    The aim of the present study is the selection of a certain scheme for release, collection, measurement and analysis of Tritium as produced in Lithium compounds (Li[sub 2]O, LiOH, Li[sub 2]CO[sub 3] LiF and some Lithium alloys) in accordance with the [sup 6]Li(n, [alpha])T reaction. Tritium technology is of vital concern to power reactor programmes as well as to fusion technology. Meanwhile the fields of activity include, tritium generation and mangement in fission and fusion reactors; enviromental studies, release modeling HT/HTO conversion and dose assessments, absorption/ deabsorption, monitoring and plant design; research and development, labeling, compatibility and physical chemical properties.

  1. Evaluation of the quality of the radiopharmaceutical 99mTc-MIBI and its influence on image quality in myocardial perfusion scintigraphy

    International Nuclear Information System (INIS)

    Santos, Poliane Angelo de Lucena

    2013-01-01

    This study evaluated the quality of the 99m Tc-MIBI radiopharmaceutical from different manufacturers, used in three nuclear medicine services (NMS) in Recife-PE, through labeling procedure of each service. It was observed their biodistribution by quantifying the activity present in the organs of interest (heart / liver), the influence and interference in image quality and in myocardial scintigraphy diagnosis exam. In these NMS (A, B and C) were done quality controls in the eluates of 99 Mo/ 99m Tc generators (radionuclidic, chemical and radiochemical purity and pH) and of the 99m Tc-MIBI radiopharmaceutical (radiochemical purity and pH) used in myocardial scintigraphy exam. In the case of radiochemical purity (RCP), was used the thin layer chromatography technique; after the chromatographic ran on, the plates were analyzed both in the dose calibrator, and in scintillation camera of each NMS. The radiopharmaceutical biodistribution was evaluated through the activities present in the heart and liver images in 60 patients, using the technique of combined images counting. Five nuclear physicians analyzed 24 images through myocardial perfusion visual interpretation during stress, it was verified the agreement degree among them. The results of the quality control showed that all eluate samples were in agreement with the manufacturers in relation to radionuclidic purity and pH. In relation to chemical purity, 10% of the services samples B and C showed Al +3 values above 10 ppm. In the RCP, it was observed that using the scintillation camera, only 22% of the samples would be discarded, while with dose calibrator would be 78%, indicating that the scintillation camera is more sensitive in chromatographic pale analysis. For the labeled radiopharmaceutical, the services B and C presented respectively one and three samples with RCP percentage below 90%. However, C service presented the lowest medium to liver/heart proportions, showing that this factor does not depends on the

  2. TFTR tritium operations lessons learned

    International Nuclear Information System (INIS)

    Gentile, C.A.; Raftopoulos, S.; LaMarche, P.

    1996-01-01

    The Tokamak Fusion Test Reactor which is the progenitor for full D-T operating tokamaks has successfully processed > 81 grams of tritium in a safe and efficient fashion. Many of the fundamental operational techniques associated with the safe movement of tritium through the TFTR facility were developed over the course of many years of DOE tritium facilities (LANL, LLNL, SRS, Mound). In the mid 1980's The Tritium Systems Test Assembly (TSTA) at LANL began reporting operational techniques for the safe handling of tritium, and became a major conduit for the transfer of safe tritium handling technology from DOE weapons laboratories to non-weapon facilities. TFTR has built on many of the TSTA operational techniques and has had the opportunity of performing and enhancing these techniques at America's first operational D-T fusion reactor. This paper will discuss negative pressure employing 'elephant trunks' in the control and mitigation of tritium contamination at the TFTR facility, and the interaction between contaminated line operations and Δ pressure control. In addition the strategy employed in managing the movement of tritium through TFTR while maintaining an active tritium inventory of < 50,000 Ci will be discussed. 5 refs

  3. Quality control protocols for radiodiagnosis agents and radiopharmaceuticals

    International Nuclear Information System (INIS)

    Robles, A.; Condor, M.; Caballero, J.; Morote, M.; Garcia, C.; Benites, M.

    1997-01-01

    Based on the compilation of pharmacopoeia methods, literature, manuals and other information developed in our laboratory, protocols have been prepared to carry out quality controls for radiodiagnosis agents (RDA), better known as kits and RDA labelled with Tc99m. Quality control protocols cover physicochemical and biological controls. Physicochemical controls described for RDA include physical characteristics, particle size and number, pH, chemical identification, humidity, tin II; whereas biological controls include sterility, acute toxicity and bacterial endotoxin determination (LAL). Physicochemical controls described for radiopharmaceuticals labelled with Tc99m are pH and radiochemical purity; while biological distribution is described as a biological control

  4. The quality of 99mTc-radiopharmaceuticals - a basic requirement in the diagnostic nuclear medicine

    International Nuclear Information System (INIS)

    Ivanova, S.; Popsavova, H.; Kostadinova, I.

    2011-01-01

    Development and application of new high quality radiopharmaceuticals (RP) are of a great significance for the development in nuclear medicine. The high quality of the radiopharmaceuticals has a major influence on the accuracy of nuclear medical examinations. Therefore, a good knowledge and application if various control methods, is essential. Radiochemical impurities affect the quality of RP most significantly and they can appear at every stage of the preparation. The aim of this review is to present the literature information concerning the quality of the most commonly used radiopharmaceuticals, labeled with 99m Tc, and all requirements for them, i.e. radiochemical, radionuclide and chemical purity. This is well-known fact that metastable isotope of Technetium is golden standard for diagnostics in nuclear medicine. Research shows that about 80% of approx. 25 million nuclear medical studies a year are performed with this radionuclide. According to the European Pharmacopoeia and to the leaflets provided with the kits, radiochemical purity must exceed 95%. The main radiochemical impurities in 99m Tc-radiopharmaceuticals are free pertechnetate ( 99m TcO 4 - ), whose presence causes accumulation of RP in the thyroid gland, stomach, gastrointestinal tract, or the salivary glands, leading to a wrong diagnosis, and reduced hydrolyzed technetium, which causes visualization of the reticulo-endothelial system. This paper contains information about the authors' experience with analyses of the radiochemical purity of the two most commonly used radiopharmaceuticals in Bulgaria - for bone and renal scintigraphy (MDA and DTPA). An Instant Thin-Layer Chromatography (ITLC) is used for this purpose. It is concluded that the high quality of the applied 99m Tc-radiopharmaceuticals can be guaranteed only with both selection of renowned manufactures, recognized by EU, and a routine daily control of the labeling and generator eluate, meeting all requirements of the manufacturer and

  5. Tritium handling experience in vacuum systems at TSTA [Tritium Systems Test Assembly

    International Nuclear Information System (INIS)

    Anderson, J.L.; Jenkins, E.M.; Walthers, C.R.; Yoshida, H.; Fukui, H.; Naruse, Y.

    1989-01-01

    Compound cryopumps have been added to the Tritium Systems Test Assembly (TSTA) integrated fusion fuel loop. Operations have been performed which closely simulate an actual fusion reactor pumping scenario. In addition, performance data have been taken that support the concept of using coconut charcoal as a sorbent at 4K for pumping helium. Later tests show that coconut charcoal may be used to co-pump D,T and He mixtures on a single 4K panel. Rotary spiral pumps have been used successfully in several applications at TSTA and have acquired more than 9000 hours of maintenance-free operation. Metal bellows pumps have been used to back the spiral pumps and have been relatively trouble free in loop operations. Bellows pumps also have more than 9000 hours of maintenance-free operation. 5 refs., 6 figs

  6. Formulation of an inhibitor radiopharmaceutical of prostatic antigen of 177Lu-Glu-Nh-CO-Nh-Lys membrane

    International Nuclear Information System (INIS)

    Ortega S, D.

    2015-01-01

    The prostate specific membrane antigen (PSMA) is a zinc metalloenzyme that is expressed on the cell membrane and highly expressed in prostate cancer. Recently, it has been demonstrated that the peptide sequence Glu-Nh-CO-Nh-Lys inhibit PSMA activity through an electrostatic interaction with the Zn. Several theragnostic radiopharmaceuticals with base in 177 Lu have been developed for radiotherapy of specific molecular targets because gamma and beta emissions of the radionuclide (β = 0.498 MeV and γ= 0.133 MeV). However, there is currently no label a formulation for preparing a radiopharmaceutical of 177 Lu-Glu-Nh-CO-Nh-Lys useful treatment of prostate cancer. The aim of this research was to optimize and document the process of production of the radiopharmaceutical 177 Lu-Glu-Nh-CO-Nh-Lys for sanitary registration application before the Comision Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS). The optimization of the production process was assessed a factorial design of three variables with mixed levels (3 x 3 x 2) where the dependent variable is the radiochemical purity, the analytical method was validated by UV-Vis spectrophotometry. Next, process validation was carried out by labeling 3 lots of the optimized formulation of the radiopharmaceutical (5.55 GBq (2.16 μg) of 177 LuCl 3 , 90 mg peptide PSMA, 50 mg ascorbic acid and 150 μL of acetate buffer 1 M ph 5), long-term stability was performed by high resolution liquid chromatography) to determine its useful shelf life. 3 validation batches were prepared under protocols of Good Manufacturing Practice (GMP) in the Production Plant of Radiopharmaceuticals of the Instituto Nacional de Investigaciones Nucleares (ININ), meet specifications preset by obtaining a sterile and free development of bacterial endotoxin yields of labeled 100% and which retains its quality characteristics radiochemical purity greater than 90% for at least 15 days. (Author)

  7. Tritium conference days; Journees tritium

    Energy Technology Data Exchange (ETDEWEB)

    Garnier-Laplace, J.; Lebaron-Jacobs, L.; Sene, M.; Devin, P.; Chretien, V.; Le Guen, B.; Guetat, Ph.; Baglan, N.; Ansoborlo, E.; Boyer, C.; Masson, M.; Bailly-Du-Bois, P.; Jenkinson, St.; Wakeford, R.; Saintigny, Y.; Romeo, P.H.; Thompson, P.; Leterq, D.; Chastagner, F.; Cortes, P.; Philippe, M.; Paquet, F.; Fournier, M.

    2009-07-01

    This document gathers the slides of the available presentations given during this conference day. Twenty presentations out of 21 are assembled in the document and deal with: 1 - tritium in the environment (J. Garnier-Laplace); 2 - status of knowledge about tritium impact on health (L. Lebaron-Jacobs); 3 - tritium, discrete but present everywhere (M. Sene); 4 - management of tritium effluents from Areva NC La Hague site - related impact and monitoring (P. Devin); 5 - tritium effluents and impact in the vicinity of EDF's power plants (V. Chretien and B. Le Guen); 6 - contribution of CEA-Valduc centre monitoring to the knowledge of atmospheric tritiated water transfers to the different compartments of the environment (P. Guetat); 7 - tritium analysis in environment samples: constraints and means (N. Baglan); 8 - organically-linked tritium: the analyst view (E. Ansoborlo); 9 - study of tritium transfers to plants via OBT/HTO{sub air} and OBT/HTO{sub free} (C. Boyer); 10 - tritium in the British Channel (M. Masson and P. Bailly-Du-Bois); 11 - tritium in British coastal waters (S. Jenkinson); 12 - recent results from epidemiology (R. Wakeford); 13 - effects of tritiated thymidine on hematopoietic stem cells (P.H. Romeo); 14 - tritium management issue in Canada: the point of view from authorities (P. Thompson); 15 - experience feedback of the detritiation process of Valduc centre (D. Leterq); 16 - difficulties linked with tritiated wastes confinement (F. Chastagner); 17 - optimisation of tritium management in the ITER project (P. Cortes); 18 - elements of thought about the management of tritium generated by nuclear facilities (M. Philippe); 19 - CIPR's position about the calculation of doses and risks linked with tritium exposure (F. Paquet); 20 - tritium think tanks (M. Fournier). (J.S.)

  8. The data collection system for failure/maintenance at the Tritium Systems Test Assembly

    International Nuclear Information System (INIS)

    Casey, M.A.; Gruetzmacher, K.M.; Bartlit, J.R.; Cadwallader, L.C.

    1988-01-01

    A data collection system for obtaining information which can be used to help determine the reliability and vailability of future fusion power plants has been installed at the Los Alamos National Laboratory's Tritium Systems Test Assembly (TSTA). Failure and maintenance data on components of TSTA's tritium systems have been collected since 1984. The focus of the data collection has been TSTA's Tritium Waste Tratment System (TWT), which has maintained high availability since it became operation in 1982. Data collection is still in progress and a total of 291 failure reports are in the data collection system at this time, 47 of which are from the TWT. 6 refs., 2 figs., 2 tabs

  9. Preparation of gallium-68 radiopharmaceuticals for positron tomography. Progress report, November 1, 1980-December 31, 1981

    International Nuclear Information System (INIS)

    Welch, M.J.

    1981-06-01

    Although the germanium-68 → gallium-68 generator is probably the only source of positron-emitting radionuclides that could enable the widespread application of positron tomography, the commercially available 68 Ga/ 68 Ge generator system suffers from several major disadvantages. The most important of these is that the generator is eluted with EDTA, which forms a very strong chelate with gallium. In order to produce radiopharmaceuticals other than 68 Ga-EDTA, it is first necessary to break the stable EDTA complex and remove all traces of EDTA. This procedure adds several steps and a significant amount of time to procedures for preparing 68 Ga-radiopharmaceuticals. Several years ago, we developed a new generator using a solvent extraction system which produces 68 Ga-oxine (8-hydroxyquinoline), a weak chelate. We have also carried out studies to compare generator systems which produce 68 Ga in an ionic form. Using the gallium-68 eluted from these various generator systems, several 68 Ga-labeled radiopharmaceuticals have been synthesized and tested in vitro and in vivo. In addition, attempts have been made to design and synthesize a lipophilic ligand for gallium-68. The stability of radiogallium complexed with a series of potentially lipophilic complexing agents has been studied using chromatographic techniques and in vivo distribution data. The potential of these complexing agents for altering the biodistribution of gallium radiopharmaceuticals has also been investigated

  10. Complete Biological Evaluation of Therapeutical Radiopharmaceuticals in Rodents, Laboratory Beagles and Veterinary Patients - Preclinical Distribution-, Kinetic-, Excretion-, Internal Dosimetry-, Radiotoxicological-, Radiation Safety- and Efficacy Data

    International Nuclear Information System (INIS)

    Balogh, L.; Domokos, M.; Polyak, A.; Thuroczy, J.; Janoki, G.

    2009-01-01

    The research and development of various novel therapeutical radiopharmaceuticals is a huge demand in many laboratories world-wide. Beside of multiple bone metastases pain-palliation and radiosynovectomy agents a number of specific radiopharmaceutical applicants mainly for oncological applications are in the pipeline. Numerous in vitro methods are available in the first line to test the radiolabelling efficiency, the possible radioactive and non-labelled impurities, the stability of the label at different conditions and mediums, and some specific characteristics of radiopharmaceutical applicants eg.: receptor binding assays, antigen-antibody assays. But, still before human clinical trials there are several questions to be solved in regards of toxicology, radiotoxicology, radiation safety and maybe most importantly the efficacy tasks. All these issues cannot be answered without animal tests. Several decades back animal tests in radiopharmacy meant only standard bioassays in a large number of healthy rodents. Later on pathological models eg.: human tumor xenografts in immunodeficient animals came-out and through them radiopharmaceutical tumor-uptake by the targets were available to evaluate in vivo as well. Xenografts are still popular and widely used models in the field but instead of wide-scaled bioassays nowadays repeated scintiscans or hybrid images (SPECT/CT, PET/CT) are more and more often used to answer kinetic-, excretion-, tumor uptake, internal dosimetry (Minimum Effective Dose, Maximum Tolerable Dose, critical organ doses, tumor doses) questions. Greater animals like laboratory Beagles are more closely in size, clinical and metabolic parameters to the human objects so playing a more perfect role of human medical doctor and especially veterinary patients. Easy to understand that many of the spontaneously occurring companion animal diseases are a good model of human pathological diseases. The need of a better diagnosis and treatment of that animals meets with

  11. Contamination mechanisms of air basin with tritium in venues of underground nuclear explosions at the former Semipalatinsk test site.

    Science.gov (United States)

    Lyakhova, O N; Lukashenko, S N; Larionova, N V; Tur, Y S

    2012-11-01

    During the period of testing from 1945 to 1962 at the territory of Semipalatinsk test site (STS) within the Degelen Mountains in tunnels, 209 underground nuclear explosions were produced. Many of the tunnels have seasonal water seepage in the form of streams, through which tritium migrates from the underground nuclear explosion (UNE) venues towards the surface. The issue of tritium contamination occupies a special place in the radioactive contamination of the environment. In this paper we assess the level and distribution of tritium in the atmospheric air of ecosystems with water seepage at tunnels № 176 and № 177, located on "Degelen" site. There has been presented general nature of tritium distribution in the atmosphere relative to surface of a watercourse which has been contaminated with tritium. The basic mechanisms were studied for tritium distribution in the air of studied ecosystems, namely, the distribution of tritium in the systems: water-atmosphere, tunnel air-atmosphere, soil water-atmosphere, vegetation-atmosphere. An analytical calculation of tritium concentration in the atmosphere by the concentration of tritium in water has been performed. There has experimentally obtained the dependence for predictive assessment of tritium concentrations in air as a function of tritium concentration in one of the inlet sources such as water, tunnel air, soil water, vegetation, etc.. The paper also describes the general nature of tritium distribution in the air in the area "Degelen". Copyright © 2012 Elsevier Ltd. All rights reserved.

  12. Detection of the pyrogen in the radiopharmaceuticals using Limulus test and inhibitory factors in the gelation reaction

    International Nuclear Information System (INIS)

    Murata, Hajime; Iio, Masahiro; Yamada, Hideo; Chiba, Kazuo; Kobayashi, Masayoshi.

    1975-01-01

    To examine the sensitivities of the Limulus test and the inhibitory factors in radiopharmaceuticals, the following procedures were employed. Twenty commonly used radiopharmaceuticals were examined by Limulus Lysate (Pre-gel). In order to detect the inhibitory factors, several doses of endotoxin (E. coli) were added to the radiopharmaceuticals before the Limulus test was made and the results were compared with control results using saline solution of endotoxin. When the pH of the reaction solution lay out of a suitable range (6.0-7.5), the pH was adjusted by Tris-HCl buffer before the reaction. The sensitivity of the Limulus test control using Pre-gel was positive at a concentration of 10 -3 μg/ml of endotoxin. The Limulus test was sensitive and without inhibitory reactions for sup(99m)TcO 4 -, sup(99m)Tc-albumin, sup(99m)Tc-MAA, sup(99m)Tc-Sn-colloid, 131 I-hippurate, Na 131 I, Na 2 51 CrO 4 , 67 Ga-citrate and 57 Co-bleomycin as they were supplied. 111 In-DTPA, sup(99m)Tc-phytate, sup(99m)Tc-pyrophosphate, sup(99m)Tc-DTPA, 131 I-PVP, 59 FeCl 3 , Na-phosphate ( 32 P), 198 Au-colloid and 75 Se-selenomethionine needed to have their pH adjusted to avoid inhibition. Benzyl alcohol in the radiopharmaceutical showed an inhibitory effect at a concentration greater than 1%. Commonly used 169 Yb-DTPA which was evaluated by this test had a sensitivity of 2.5 x 10 -3 μg/ml due to addition of a small amount of benzyl alcohol. 131 I-BSP showed intense inhibition in gelation reaction. Contaminations of endotoxin were detected in sup(99m)Tc-albumin, sup(99m)Tc-Sn-colloid, 131 I-hippurate, Na 131 I, Na 2 51 CrO 4 , 198 Au-colloid, 57 Co-bleomycin and 75 Se-selenomethionine. (auth.)

  13. Synthesis and in vitro/in vivo evaluation of novel mono- and trivalent technetium-99m labeled ghrelin peptide complexes as potential diagnostic radiopharmaceuticals

    International Nuclear Information System (INIS)

    Koźmiński, Przemysław; Gniazdowska, Ewa

    2015-01-01

    Introduction: Ghrelin is an endogenous hormone present in blood. It is released from the oxyntic cells (X/A-like cells) of the stomach and fundus and can exist in two forms: as an acylated and des-acylated ghrelin. Ghrelin is an endogenous ligand of the growth hormone receptor (growth hormone secretagogue receptor, GHS-R). Overexpression of GHS-R1a receptor was identified in cells of different types of tumors (e.g. pituitary adenoma, neuroendocrine tumors of the thyroid, lung, breast, gonads, prostate, stomach, colorectal, endocrine and non-endocrine pancreatic tumors). This fact suggests that gamma radionuclide labeled ghrelin peptide may be considered as a potential diagnostic radiopharmaceutical. Methods: Ghrelin peptide labeled with mono- and trivalent technetium-99m complexes, 99m Tc-Lys-GHR, has been prepared on the n.c.a. scale. The physicochemical (stability, charge, shape, lipophilicity) and biological (receptor affinity, biodistribution) properties of the conjugates have been studied relevant to use the conjugates as receptor-based diagnostic radiopharmaceuticals. Results: The obtained conjugates [ 99m Tc(CO) 3 L N,O (CN-Lys-GHR)] + , 99m Tc(CO) 3 L S,O (CN-Lys-GHR) and 99m Tc(NS 3 )(CN-Lys-GHR) show different shape, charge, lipophilicity and two of them, 99m Tc(CO) 3 L S,O (CN-Lys-GHR) and 99m Tc(NS 3 )(CN-Lys-GHR), high stability in neutral aqueous solutions, even in the presence of excess concentration of histidine/cysteine competitive standard ligands or human serum. The in vitro binding affinity of 99m Tc-Lys-GHR conjugates with respect to growth hormone secretagogue receptor (GHS-R1a) present on DU-145 cells was in the range of IC 50 from 45 to 54 nM. The conjugate 99m Tc(CO) 3 L S,O (CN-Lys-GHR) exhibited excretion route by the liver and kidney in comparable degree, while the more lipophilic conjugate 99m Tc(NS 3 )(CN-Lys-GHR)—mainly by the liver. Conclusions: Basing on the results concerning physicochemical and biochemical properties, the

  14. Summary of the Mol electrolysis cell test program in the CRL tritium laboratory

    International Nuclear Information System (INIS)

    Miller, J.M.; Keyes, R.J.

    1996-01-01

    The development of electrolysis technology for highly tritiated water at the Studiecentrum voor Kernenergie/Centre d'Etude de l'Energie Nucleaire (SCK/CEN), Mol, Belgium, focused on A Low Inventory Capillary Electrolyser (ALICE). The key characteristic of ALICE is its low liquid inventory, a key feature for the radio-toxicity of tritiated water. A program to test this electrolytic cell design with highly tritiated water in the Chalk River Tritium Laboratory was initiated in 1988 and extended through to early 1995. The activities conducted at CRL and associated with the experimental program-design, installation, licensing and commissioning activities- are described in this report along with the results of the test program conducted on the experimental system with non-tritiated heavy water. The installation in the CRL Tritium Laboratory consisted of three main sections: the electrolysis section, the tritium storage and supply section, and the recombination section. 16 figs., 2 tabs., 10 refs

  15. Report on the evaluation of the tritium producing burnable absorber rod lead test assembly. Revision 1

    International Nuclear Information System (INIS)

    1997-03-01

    This report describes the design and fabrication requirements for a tritium-producing burnable absorber rod lead test assembly and evaluates the safety issues associated with tritium-producing burnable absorber rod irradiation on the operation of a commercial light water reactor. The report provides an evaluation of the tritium-producing burnable absorber rod design and concludes that irradiation can be performed within U.S. Nuclear Regulatory Commission regulations applicable to a commercial pressurized light water reactor

  16. Tritium control in fusion reactor materials: A model for Tritium Extracting System

    International Nuclear Information System (INIS)

    Zucchetti, Massimo; Utili, Marco; Nicolotti, Iuri; Ying, Alice; Franza, Fabrizio; Abdou, Mohamed

    2015-01-01

    Highlights: • A modeling work has been performed to address these issues in view of its utilization for the TES (Tritium Extraction System), in the case of the HCPB TBM and for a Molecular sieve as adsorbent material. • A computational model has been setup and tested in this paper. • The results of experimental measurement of fundamental parameters such as mass transfer coefficients have been implemented in the model. • It turns out the capability to model the extraction process of gaseous tritium compounds and to estimate the breakthrough curves of the two main tritium gaseous species (H2 and HT). - Abstract: In fusion reactors, tritium is bred by lithium isotopes inside the blanket and then extracted. However, tritium can contaminate the reactor structures, and can be eventually released into the environment. Tritium in reactor components should therefore be kept under close control throughout the fusion reactor lifetime, bearing in mind the risk of accidents, the need for maintenance and the detritiation of dismantled reactor components before their re-use or disposal. A modeling work has been performed to address these issues in view of its utilization for the TES (Tritium Extraction System), in the case of the HCPB TBM and for a molecular sieve as adsorbent material. A computational model has been setup and tested. The results of experimental measurement of fundamental parameters such as mass transfer coefficients have been implemented in the model. It turns out the capability of the model to describe the extraction process of gaseous tritium compounds and to estimate the breakthrough curves of the two main tritium gaseous species (H2 and HT).

  17. Tritium control in fusion reactor materials: A model for Tritium Extracting System

    Energy Technology Data Exchange (ETDEWEB)

    Zucchetti, Massimo [DENERG, Politecnico di Torino (Italy); Utili, Marco, E-mail: marco.utili@enea.it [ENEA UTIS – C.R. Brasimone, Bacino del Brasimone, Camugnano, BO (Italy); Nicolotti, Iuri [DENERG, Politecnico di Torino (Italy); Ying, Alice [University of California Los Angeles (UCLA), Los Angeles, CA (United States); Franza, Fabrizio [Karlsruhe Institute of Technology, Karlsruhe (Germany); Abdou, Mohamed [University of California Los Angeles (UCLA), Los Angeles, CA (United States)

    2015-10-15

    Highlights: • A modeling work has been performed to address these issues in view of its utilization for the TES (Tritium Extraction System), in the case of the HCPB TBM and for a Molecular sieve as adsorbent material. • A computational model has been setup and tested in this paper. • The results of experimental measurement of fundamental parameters such as mass transfer coefficients have been implemented in the model. • It turns out the capability to model the extraction process of gaseous tritium compounds and to estimate the breakthrough curves of the two main tritium gaseous species (H2 and HT). - Abstract: In fusion reactors, tritium is bred by lithium isotopes inside the blanket and then extracted. However, tritium can contaminate the reactor structures, and can be eventually released into the environment. Tritium in reactor components should therefore be kept under close control throughout the fusion reactor lifetime, bearing in mind the risk of accidents, the need for maintenance and the detritiation of dismantled reactor components before their re-use or disposal. A modeling work has been performed to address these issues in view of its utilization for the TES (Tritium Extraction System), in the case of the HCPB TBM and for a molecular sieve as adsorbent material. A computational model has been setup and tested. The results of experimental measurement of fundamental parameters such as mass transfer coefficients have been implemented in the model. It turns out the capability of the model to describe the extraction process of gaseous tritium compounds and to estimate the breakthrough curves of the two main tritium gaseous species (H2 and HT).

  18. Preliminary analysis of the safety and environmental impact of the Tritium Systems Test Assembly

    International Nuclear Information System (INIS)

    Carlson, R.V.; Jalbert, R.A.

    1980-01-01

    The Tritium Systems Test Assembly (TSTA) is a facility dedicated to the development of technologies associated with the D-T fuel cycle of future fusion reactors while demonstrating that TSTA can be operated safely with no significant losses to the environment. During the initial design stage of TSTA, a safety analysis was performed which investigated the effects of major subsystem component failure, the meteorology and seismicity of the site and their possible effect on the facility, and accident scenarios which result in tritium releases. Major releases of tritium to the environment are considered highly improbable since they require a compound failure of primary and secondary containment, along with either a breach of the building or a failure of the Emergency Tritium Cleanup system. Accidental releases caused by natural phenomena (earthquake, tornado, etc.) are considered highly improbable

  19. Biological effects of tritium releases from fusion power plants

    International Nuclear Information System (INIS)

    Strand, J.A.; Thompson, R.C.

    1976-09-01

    Tritium released as tritium oxide is a much more significant potential hazard to the environment than is elemental tritium. Although most biochemical reactions discriminate against the incorporation of tritium in favor of hydrogen, the possibility of some concentration should not be overlooked. A fraction of tritium accumulated as tritiated water becomes organically bound, that is, exchanges with hydrogen bound in organic molecules. The rate and extent of incorporation are dependent upon metabolic activity of the organism. On this basis, the highest concentration of organically-bound tritium would be expected in tissues and population segments which are in formative or growth stages at the time of exposure. Furthermore, as exposure duration increases from acute to chronic situations, tritium concentrations are shown to approach equilibrium levels with a single tritium-to-hydrogen ratio common to all parts of the hydrogen pool. Organic binding would not be expected to result in significant bioaccumulation of tritium from tritiated water. Tritium loss, both from tissue-free water and the tissue-bound fraction, depends upon metabolic activity. Processes that allow accumulation and incorporation of tritium also assist its elimination. Tritium which is organically bound demonstrates a longer half-time, but it would appear to constitute a small fraction of the total tritium label. The radiation exposure of all living organisms by environmentally dispersed tritium, in whatever form, is essentially a whole body exposure. Uncertainties in the individual parameters, involved in converting measured intake to estimated dose equivalent are probably no larger than a factor of three or four. If fusion reactors hold tritium releases with ICRP standards, no significant adverse impact to the environment from those releases are expected

  20. Cyclotron produced radiopharmaceuticals

    International Nuclear Information System (INIS)

    Kopicka, K.; Fiser, M.; Hradilek, P.; Hanc, P.; Lebeda, O.

    2003-01-01

    Some of the cyclotron-produced radionuclides may serve as important materials for the production of radiopharmaceuticals. This lecture deals with basic information relating to various aspects of these compounds. In comparison with radionuclides /compounds used for non-medical purposes, radiopharmaceuticals are subject to a broader scale of regulations, both from the safety and efficacy point of view; besides that, there are both radioactive and medical aspects that must be taken into account for any radiopharmaceutical. According to the regulations and in compliance with general rules of work with radioactivity, radiopharmaceuticals should only be prepared/manufactured under special conditions, using special areas and special equipment and applying special procedures (e.g. sterilisation, disinfection, aseptic work). Also, there are special procedures for cleaning and maintenance. Sometimes the requirements for the product safety clash with those for the safety of the personnel; several examples of solutions pertaining to these cases are given in the lecture. Also, the specific role of cyclotron radiopharmaceuticals is discussed. (author)

  1. Subsystem cost data for the tritium systems test assembly

    International Nuclear Information System (INIS)

    Bartlit, J.R.; Anderson, J.L.; Rexroth, V.G.

    1983-01-01

    Details of subsystem costs are among the questions most frequently asked about the $14.4 million Tritium Systems Test Assembly (TSTA) at Los Alamos National Laboratory. This paper presents a breakdown of cost components for each of the 20 major subsystems of TSTA. Also included are details to aid in adjusting the costs to other years, contracting conditions, or system sizes

  2. Preparation of labelled antituberculotics for clarifying specific problems in therapy optimization. 1

    International Nuclear Information System (INIS)

    Winsel, K.; Iwainsky, H.; Mittag, E.; Kiessling, M.; Koehler, H.

    1985-01-01

    The preparation of tritium labelled isoniazid according to the Wilzbach method and by catalytic exchange is described. The purified labelled isoniazid is adjusted to an activity of 37 MBq/300 mg isoniazid. It meets the requirements for an injectable pharmaceutical. The tritium labelling is stable under in vitro conditions and in the macroorganism. (author)

  3. Tritium ( 3 H) Retention In Mice: Administered As HTO, DTO or as 3 H-Labeled Amino-Acids.

    Science.gov (United States)

    Priest, Nicholas D; Blimkie, Melinda S J; Wyatt, Heather; Bugden, Michelle; Bannister, Laura A; Gueguen, Yann; Jourdain, Jean-Rene; Klokov, Dmitry

    2017-05-01

    The objective of this study was to compare the biokinetics of injected H-labeled light (HTO) and heavy (DTO) water in CBA/CaJ mice and to compare the organ distribution and/or body content of H administered by chronic ingestion for 1 mo to C57Bl/6J mice, as either H-labeled water or H-labeled amino acids (glycine, alanine and proline). HTO and DTO were administered to CBA/CaJ mice by single intraperitoneal injection and body retention was determined for up to 384 h post-injection. Tritium-labeled water or H-labeled amino acids were given to C57Bl/6J mice ad libitum for 30 d in drinking water. Body content and organ distribution of H during the period of administration and subsequent to administration was determined by liquid scintillation counting. No differences were found between the biokinetics of HTO and DTO, indicating that data generated using HTO can be used to help assess the consequences of H releases from heavy water reactors. The results for H-water showed that the concentration of radionuclide in the mice reached a peak after about 10 d and dropped rapidly after the cessation of H administration. The maximum concentration reached was only 50% of that in the water consumed, indicating that mice receive a significant fraction of their water from respiration. Contrary to the findings of others, the pattern of H retention following the administration of a cocktail of the labeled amino acids was very little different from that found for the water. This is consistent with the suggestion that most of the ingested amino acids were rapidly metabolized, releasing water and carbon dioxide.

  4. Radioactive labelled orgotein

    International Nuclear Information System (INIS)

    1980-01-01

    The preparation and use of radioactively labelled orgotein, i.e. water-soluble protein congeners in pure, injectable form, is described. This radiopharmaceutical is useful in scintigraphy, especially for visualization of the kidneys where the orgotein is rapidly concentrated. Details of the processes for labelling bovine orgotein with sup(99m)Tc, 60 Co, 125 I or 131 I are specified. The pharmaceutical preparation of the labelled orgotein for intravenous and parenteral administration is also described. Examples using either sup(99m)TC or 125 I-orgotein in scintiscanning dogs' kidneys are given. (UK)

  5. Synthesis and formulation of 99m Tc-ECD radiopharmaceutical

    International Nuclear Information System (INIS)

    Ocampo G, B.E.

    1998-01-01

    Nuclear medicine is a medical specialty which uses radioactive compounds (radionuclides) for diagnostic and therapeutic purposes. 99m Tc is the more common radionuclide used in many studies in nuclear medicine because its advantages: it has a photopeak of 140 KeV and a half-life of 6 hours; it can be eluted from a Molybdenum 99 generator, so radiopharmaceuticals can be prepared on site. Ethyl cysteine dimer (ECD) labelled with reduced Technetium 99m has been purposed recently as a promising radiopharmaceutical for brain perfusion imaging 99m Tc-ECD is a lipophilic neutral complex which cross the brain blood barrier and show high brain uptake. The objective of this work was synthesize and to design a freeze dried formulation for the instant preparation of 99m Tc-ECD complex useful for brain perfusion imaging. We obtained a freeze dried stable formulation for the preparation of 99m Tc-ECD kit with a radiochemical purity higher than 90 %, which fulfills with the quality control of radiopharmaceuticals. Furthermore, we developed analytic techniques for the determination of the different chemical compounds into the lyophilized kit. (Author)

  6. Environmental Testing of Tritium-Phosphor Glass Vials for Use in Long-Life Radioisotope Power Conversion Units

    Science.gov (United States)

    Zemcov, Michael; Cardona, Pedro; Parkus, James; Patru, Dorin; Yost, Valerie

    2017-01-01

    Power generation in extreme environments, such as the outer solar system, the night side of planets, or other low-illumination environments, currently presents a technology gap that challenges NASA's ambitious scientific goals. We are developing a radioisotope power cell (RPC) that utilizes commercially available tritium light sources and standard 1.85 eV InGaP2 photovoltaic cells to convert beta particle energy to electric energy. In the test program described here, we perform environmental tests on commercially available borosilicate glass vials internally coated with a ZnS luminescent phosphor that are designed to contain gaseous tritium in our proposed power source. Such testing is necessary to ensure that the glass containing the radioactive tritium is capable of withstanding the extreme environments of launch and space for extended periods of time.

  7. Tritium in plants

    International Nuclear Information System (INIS)

    Vichot, L.; Losset, Y.

    2009-01-01

    The presence of tritium in the environment stems from its natural production by cosmic rays, from the fallout of the nuclear weapon tests between 1953 and 1964, and locally from nuclear industry activities. A part of the tritiated water contained in the foliage of plants is turned into organically bound tritium (OBT) by photosynthesis. The tritium of OBT, that is not exchangeable and then piles up in the plant, can be used as a marker of the past. It has been shown that the quantity of OBT contained in the age-rings of an oak that grew near the CEA center of Valduc was directly correlated with the tritium releases of the center. (A.C.)

  8. Estimation of Uptake of Humic Substances from Different Sources by Escherichia coli Cells under Optimum and Salt Stress Conditions by Use of Tritium-Labeled Humic Materials▿

    Science.gov (United States)

    Kulikova, Natalia A.; Perminova, Irina V.; Badun, Gennady A.; Chernysheva, Maria G.; Koroleva, Olga V.; Tsvetkova, Eugenia A.

    2010-01-01

    The primary goal of this paper is to demonstrate potential strengths of the use of tritium-labeled humic substances (HS) to quantify their interaction with living cells under various conditions. A novel approach was taken to study the interaction between a model microorganism and the labeled humic material. The bacterium Escherichia coli was used as a model microorganism. Salt stress was used to study interactions of HS with living cells under nonoptimum conditions. Six tritium-labeled samples of HS originating from coal, peat, and soil were examined. To quantify their interaction with E. coli cells, bioconcentration factors (BCF) were calculated and the amount of HS that penetrated into the cell interior was determined, and the liquid scintillation counting technique was used as well. The BCF values under optimum conditions varied from 0.9 to 13.1 liters kg−1 of cell biomass, whereas under salt stress conditions the range of corresponding values increased substantially and accounted for 0.2 to 130 liters kg−1. The measured amounts of HS that penetrated into the cells were 23 to 167 mg and 25 to 465 mg HS per kg of cell biomass under optimum and salt stress conditions, respectively. This finding indicated increased penetration of HS into E. coli cells under salt stress. PMID:20639375

  9. Preparation of paraherquamide labeled with deueterium or tritium

    Energy Technology Data Exchange (ETDEWEB)

    Blizzard, T.A.; Rosegay, A.; Mrozik, H.; Fisher, M.H. (Merck Sharp and Dohme Research Labs., Rahway, NJ (United States))

    1990-04-01

    Deprotonation of paraherquamide (1a) at C-24 and subsequent deuteration (or tritiation) is described. The procedure afforded 24-[sup 2]H-paraherquamide (1b) with 66% deuterium incorporation at C-24. Modification of the deuteration procedure to allow the introduction of tritium resulted in the preparation of 24-[sup 3]H-paraherquamide (1c) with specific activity 3.7Ci/mmol. (author).

  10. Radiopharmacokinetic data for 99mTc-ABP - A new radiopharmaceutical for bone scanning: Comparison with 99mTc-MDP

    International Nuclear Information System (INIS)

    Murphy, Consuelo Arteaga de; Melendez-Alafort, Laura; Montoya-Molina, Carlos E.; Sepulveda-Mendez, Jesus

    1997-01-01

    Technetium-99m-labeled alendronate is a new radiopharmaceutical for bone scanning developed under strict quality control at the INNSZ. The purpose of this work was to compare the radiopharmacokinetic data and the dosimetry of 99m Tc-ABP and 99m Tc-MDP in 10 volunteers, after it was tested in laboratory animals. 99m Tc-ABP has shorter mean residence time (MRT) and t (1(2)) β; is less protein bound; has a higher renal clearance; smaller Vdss, and similar bone uptake at 1 and 2 h. 99m Tc-ABP gives less radiation exposure to the patient with a 740 MBq dose, and the quality of the bone scan is excellent. 99m Tc-ABP is a better radiopharmaceutical than 99m Tc-MDP for bone scanning

  11. Recent palladium membrane reactor development at the tritium systems test assembly

    International Nuclear Information System (INIS)

    Willms, R.S.; Birdsell, S.A.; Wilhelm, R.C.

    1995-01-01

    The palladium membrane reactor (PMR) is proving to be a simple and effective means for recovering hydrogen isotopes from fusion fuel impurities such as methane and water. This device directly combines two techniques which have long been utilized for hydrogen processing, namely catalytic shift reactions and palladium/silver permeators. A proof-of-principle (PMR) has been constructed and tested at the Tritium Systems Test Assembly of Los Alamos National Laboratory. The first tests with this device showed that is was effective for the proposed purpose. Initial work concluded that a nickel catalyst was an appropriate choice for use in a PMR. More detailed testing of the PMR with such a catalyst was performed and reported in other works. It was shown that a nickel catalyst-packed PMR did, indeed, recover hydrogen from water and methane with efficiencies approaching 100% in a single processing pass. These experiments were conducted over an extended period of time and no failure or need for regeneration was encountered. These positive results have prompted further PMR development. Topics addressed include alternate PMR geometries and initial testing of the PMR with tritium. These are the subjects of this paper

  12. Tritium in plants; Le tritium dans la matiere organique des vegetaux

    Energy Technology Data Exchange (ETDEWEB)

    Vichot, L.; Losset, Y. [CEA Valduc, 21 - Is-sur-Tille (France)

    2009-07-01

    The presence of tritium in the environment stems from its natural production by cosmic rays, from the fallout of the nuclear weapon tests between 1953 and 1964, and locally from nuclear industry activities. A part of the tritiated water contained in the foliage of plants is turned into organically bound tritium (OBT) by photosynthesis. The tritium of OBT, that is not exchangeable and then piles up in the plant, can be used as a marker of the past. It has been shown that the quantity of OBT contained in the age-rings of an oak that grew near the CEA center of Valduc was directly correlated with the tritium releases of the center. (A.C.)

  13. TFTR tritium handling concepts

    International Nuclear Information System (INIS)

    Garber, H.J.

    1976-01-01

    The Tokamak Fusion Test Reactor, to be located on the Princeton Forrestal Campus, is expected to operate with 1 to 2.5 MA tritium--deuterium plasmas, with the pulses involving injection of 50 to 150 Ci (5 to 16 mg) of tritium. Attainment of fusion conditions is based on generation of an approximately 1 keV tritium plasma by ohmic heating and conversion to a moderately hot tritium--deuterium ion plasma by injection of a ''preheating'' deuterium neutral beam (40 to 80 keV), followed by injection of a ''reacting'' beam of high energy neutral deuterium (120 to 150 keV). Additionally, compressions accompany the beam injections. Environmental, safety and cost considerations led to the decision to limit the amount of tritium gas on-site to that required for an experiment, maintaining all other tritium in ''solidified'' form. The form of the tritium supply is as uranium tritide, while the spent tritium and other hydrogen isotopes are getter-trapped by zirconium--aluminum alloy. The issues treated include: (1) design concepts for the tritium generator and its purification, dispensing, replenishment, containment, and containment--cleanup systems; (2) features of the spent plasma trapping system, particularly the regenerable absorption cartridges, their integration into the vacuum system, and the handling of non-getterables; (3) tritium permeation through the equipment and the anticipated releases to the environment; (4) overview of the tritium related ventilation systems; and (5) design bases for the facility's tritium clean-up systems

  14. Development of a tritium monitor combined with an electrochemical tritium pump using a proton conducting oxide

    Energy Technology Data Exchange (ETDEWEB)

    Tanaka, M. [National Institute for Fusion Science, Toki, Gifu (Japan); Sugiyama, T. [Nagoya University, Fro-cho, Chikusa-ku, Nagoya (Japan)

    2015-03-15

    The detection of low level tritium is one of the key issues for tritium management in tritium handling facilities. Such a detection can be performed by tritium monitors based on proton conducting oxide technique. We tested a tritium monitoring system composed of a commercial proportional counter combined with an electrochemical hydrogen pump equipped with CaZr{sub 0.9}In{sub 0.1}O{sub 3-α} as proton conducting oxide. The hydrogen pump operated at 973 K under electrolysis conditions using tritiated water vapor (HTO). The proton conducting oxide extracts tritium molecules (HT) from HTO and tritium concentration is measured by the proportional counter. The advantage of the proposed tritium monitoring system is that it is able to convert HTO into molecular hydrogen.

  15. Studies in rats on octreotide labelled with Ga-67: A potential radiopharmaceutical agent for the treatment of somatostatin receptor-positive tumours

    International Nuclear Information System (INIS)

    Lazniekova, A.; Laznieek, M.; Trejtnar, F.; Maecke, H.R.

    2001-01-01

    The paper presents the preparation, biodistribution and analysis of elimination mechanisms of 67 Ga-[DFO]-octreotide in rats. For labelling of the ligand with 67 Ga, desferrioxamine B (DFO) coupled to octreotide via the succinyl linker has been shown to form a stable chelating agent for binding of 67 Ga. The radiopharmaceutical was prepared by direct chelating of 67 Ga 3+ with [DFO]-octreotide in a slightly acidic reaction medium with high radiochemical purity. Pharmacokinetics of 67 Ga-[DFO]-octreotide of radioactivity in rats has shown relatively rapid elimination of the compound from the body with a long-term retention in the kidney and organs with high somatostatin receptor density. The agent was eliminated mostly by urine predominantly by the mechanism of glomerular filtration. (author)

  16. Modification of the labelling autologous erythrocytes with Tc-99m to scintigraphic evaluation of deep vein system

    International Nuclear Information System (INIS)

    Quintero, C.M.; Freire, D.Y.

    1993-01-01

    The purpose of this was the modification of labelled autologous red blood cells in vivo/in vitro. Evaluation consisted in different combinations of Tc-99m radiopharmaceuticals as pyrophosphate (PYP) and stannous chloride (SnCl2), anticoagulants as heparin and acid-citrate-dextrose (ACD), and oxidant agents as hydrogen peroxide (H2O2) and sodium hypochlorite (NaClO); factorial block design was carried out to determinate which one brings a better yield of labelling, and more advantages of availability. Results showed that all tested combinations were above 90% labelled; variance analysis indicated significant difference between the two radiopharmaceuticals (P<0.05), being higher percent of labelling with PYP than SnCl2, and PYP-ACD-NaClO the best combination. It was demonstrated that the procedure is safe because hemocultives realized during the labelling process were all negative, evidencing no bacterial contamination. There were significant erythrocyte-shape modifications, too. Due to low costs and good availability of H2O2 as oxidant agent there were no statistic significant differences between the use of H2O2 or NaClO, the modification PYP-ACD-H2O2 will be used as scintigraphic test for deep vein thrombosis

  17. Radiopharmaceutical licensing

    International Nuclear Information System (INIS)

    Mather, S.J.

    1992-01-01

    Recent health service legislation, and especially the loss of crown immunity has once again focussed attention on the arrangements for licensing of radiopharmaceuticals. The aim of the article is to describe in general terms the UK licensing system and in particular to provide guidance to those responsible for the supply of radiopharmaceuticals in hospitals. (author)

  18. Aptamer-based radiopharmaceuticals for diagnostic imaging and targeted radiotherapy of epithelial tumors

    International Nuclear Information System (INIS)

    Missailidis, Sotiris; Perkins, Alan; Santos-Filho, Sebastiao David; Fonseca, Adenilson de Souza da; Bernardo-Filho, Mario

    2008-01-01

    In the continuous search for earlier diagnosis and improved therapeutic modalities against cancer, based on our constantly increasing knowledge of cancer biology, aptamers hold the promise to expand on current antibody success, but overcoming some of the problems faced with antibodies as therapeutic or delivery agents in cancer. However, as the first aptamer reached the market as an inhibitor against angiogenesis for the treatment of macular degeneration, aptamers have found only limited applications or interest in oncology, and even less as radiopharmaceuticals for diagnostic imaging and targeted radiotherapy of tumours. Yet, the chemistry for the labelling of aptamers and the options to alter their pharmacokinetic properties, to make them suitable for use as radiopharmaceuticals is now available and recent advances in their development can demonstrate that these molecules would make them ideal delivery vehicles for the development of targeted radiopharmaceuticals that could deliver their radiation load with accuracy to the tumour site, offering improved therapeutic properties and reduced side effects. (author)

  19. Aptamer-based radiopharmaceuticals for diagnostic imaging and targeted radiotherapy of epithelial tumors

    Energy Technology Data Exchange (ETDEWEB)

    Missailidis, Sotiris [The Open University, Milton Keynes (United Kingdom). Dept. of Chemistry and Analytical Sciences]. E-mail: s.missailidis@open.ac.uk; Perkins, Alan [University of Nottingham (United Kingdom). Dept. of Medical Physics; Santos-Filho, Sebastiao David; Fonseca, Adenilson de Souza da; Bernardo-Filho, Mario [Universidade do Estado do Rio de Janeiro (UERJ), RJ (Brazil). Inst. de Biologia Roberto Alcantara Gomes. Dept. de Biofisica e Biometria

    2008-12-15

    In the continuous search for earlier diagnosis and improved therapeutic modalities against cancer, based on our constantly increasing knowledge of cancer biology, aptamers hold the promise to expand on current antibody success, but overcoming some of the problems faced with antibodies as therapeutic or delivery agents in cancer. However, as the first aptamer reached the market as an inhibitor against angiogenesis for the treatment of macular degeneration, aptamers have found only limited applications or interest in oncology, and even less as radiopharmaceuticals for diagnostic imaging and targeted radiotherapy of tumours. Yet, the chemistry for the labelling of aptamers and the options to alter their pharmacokinetic properties, to make them suitable for use as radiopharmaceuticals is now available and recent advances in their development can demonstrate that these molecules would make them ideal delivery vehicles for the development of targeted radiopharmaceuticals that could deliver their radiation load with accuracy to the tumour site, offering improved therapeutic properties and reduced side effects. (author)

  20. Tritium pellet injector for TFTR

    International Nuclear Information System (INIS)

    Gouge, M.J.; Baylor, L.R.; Cole, M.J.; Combs, S.K.; Dyer, G.R.; Fehling, D.T.; Fisher, P.W.; Foust, C.R.; Langley, R.A.; Milora, S.L.; Qualls, A.L.; Wilgen, J.B.; Schmidt, G.L.; Barnes, G.W.; Persing, R.G.

    1992-01-01

    The tritium pellet injector (TPI) for the Tokamak Fusion Test Reactor (TFTR) will provide a tritium pellet fueling capability with pellet speeds in the 1- to 3-km/s range for the TFTR deuterium-tritium (D-T) phase. The existing TFTR deuterium pellet injector (DPI) has been modified at Oak Ridge National Laboratory (ORNL) to provide a four-shot, tritium-compatible, pipe-gun configuration with three upgraded single-stage pneumatic guns and a two-stage light gas gun driver. The TPI was designed to provide pellets ranging from 3.3 to 4.5 mm in diameter in arbitrarily programmable firing sequences at speeds up to approximately 1.5 km/s for the three single-stage drivers and 2.5 to 3 km/s for the two-stage driver. Injector operation is controlled by a programmable logic controller. The new pipe-gun injector assembly was installed in the modified DPI guard vacuum box, and modifications were made to the internals of the DPI vacuum injection line, including a new pellet diagnostics package. Assembly of these modified parts with existing DPI components was then completed, and the TPI was tested at ORNL with deuterium pellet. Results of the limited testing program at ORNL are described. The TPI is being installed on TFTR to support the D-D run period in 1992. In 1993, the tritium pellet injector will be retrofitted with a D-T fuel manifold and secondary tritium containment systems and integrated into TFTR tritium processing systems to provide full tritium pellet capability

  1. Determination of stannous tin in radiopharmaceutical cold kits

    International Nuclear Information System (INIS)

    Farrant, A.J.

    1979-01-01

    Two methods for determining stannous tin in 'cold kits', used for the preparation of Tc-99m labelled radiopharmaceuticals, have been developed. Both are based on the direct titration of the Sn2 in solution. In the first method titration is with N-bromosuccinimide. Of the materials commonly used as cold kits only albumin has been found to interfere with the determination. The second method is a standard iodometric titration in which starch is used as indicator. None of the materials tested interfere with this procedure. The N-bromosuccinimide method is the method of choice as the re-agent, a solid, can be used without prior standardization. Iodine solution must be standardized daily. The paper describes in detail the methods used and gives examples of kits in which the Sn2 levels have been determined using the described procedures

  2. Tritium processing tests for the validation of upgraded PERMCAT mechanical design

    Energy Technology Data Exchange (ETDEWEB)

    Demange, D.; Glugla, M.; Guenther, K.; Le, T. L.; Simon, K. H.; Wagner, R.; Welte, S. [Forschungszentrum Karlsruhe GmbH, Institue for Technical Physics, Tritium Laboratory Karlsruhe, P.O Box 36 40, D-76021 Karlsruhe (Germany)

    2008-07-15

    The PERMCAT process, chosen for the final clean-up stage of the Tritium Exhaust Processing system in ITER, directly combines a Pd/Ag membrane and a catalyst bed for the detritiation of gaseous mixtures containing molecular and chemically bound tritium. Upgraded PERMCAT mechanical designs have been proposed to both increase the robustness and simplify the design of the reactor. One uses a special corrugated Pd/Ag membrane able to withstand change in length of the membrane during both normal operation and in the case of off-normal events. Based on this design, an upgraded PERMCAT reactor has been produced at FZK and successfully tested at TLK with ITER relevant tritiated gaseous mixtures using the CAPER facility. (authors)

  3. Tritium processing tests for the validation of upgraded PERMCAT mechanical design

    International Nuclear Information System (INIS)

    Demange, D.; Glugla, M.; Guenther, K.; Le, T. L.; Simon, K. H.; Wagner, R.; Welte, S.

    2008-01-01

    The PERMCAT process, chosen for the final clean-up stage of the Tritium Exhaust Processing system in ITER, directly combines a Pd/Ag membrane and a catalyst bed for the detritiation of gaseous mixtures containing molecular and chemically bound tritium. Upgraded PERMCAT mechanical designs have been proposed to both increase the robustness and simplify the design of the reactor. One uses a special corrugated Pd/Ag membrane able to withstand change in length of the membrane during both normal operation and in the case of off-normal events. Based on this design, an upgraded PERMCAT reactor has been produced at FZK and successfully tested at TLK with ITER relevant tritiated gaseous mixtures using the CAPER facility. (authors)

  4. Determination of radiochemical yield of 99mTc radiopharmaceutical preparations using gamma counter and linear radiochromatography scanner

    International Nuclear Information System (INIS)

    Martins, Patricia de A.; Moura, Rebeca G.; Shiki, Andressa M.; Fukumori, Neuza T.O.; Matsuda, Margareth M.N.

    2013-01-01

    The radiochemical purity (RCP) evaluation is a prerequisite for radiopharmaceuticals before the administration in patients. RCP is defined as the proportion of the total radioactivity in the product that is present in the specified chemical form. The most widely used techniques for RCP determination in radiopharmaceutical preparations are thin layer chromatography (TLC-Al), instant thin layer chromatography (ITLC-SG) and paper chromatography (PC). These techniques combined with radioactivity detection are one of the most important tools in the RCP of the radiopharmaceutical compounds. Several methods are used for the determination of the spatial distribution of radioactivity on the strips. The aim of this study was to compare two methods for radioactivity measurement in the determination of RCP in 99m Tc radiopharmaceuticals using gamma counter and linear radiochromatography scanner. Lyophilized radiopharmaceuticals were labeled with 99m Tc. The analysis was carried out using TLC-Al and high performance thin layer chromatography (HPTLC-Cellulose) sheets, ITLC-SG and 3MM Whatman PC. The radioactivity distribution was determined by counting each strip during 1 minute in a radiochromatography TLC scanner. For comparison, the strips were cut into small pieces and each one was separately measured in a gamma-counter during 0.20 minutes in 70-210 KeV 99m Tc window. USP 36 and FDA specify that not less than 90% of the total radioactivity must be in the spot corresponding to 99m Tc labeled compound. In conclusion, the procedure for RCP determination of ALBUMINA-TEC, DEX500-TEC, ECD-TEC, MACRO-TEC and MIBI-TEC can be faster using radiochromatography. (author)

  5. Organic radiopharmaceuticals: recent advances

    International Nuclear Information System (INIS)

    Wolf, A.P.; Fowler, J.S.

    1979-01-01

    Organic radiopharmaceuticals are considered in light of accelerator and nuclide production requirements, special problems relating to the carrier-free state, including terminology, of the special technology required to prepare and manipulate these compounds and new trends in compound design and synthesis. The emphasis is on medical cyclotrons and the positron-emitting radionuclides, carbon-11, nitrogen-13, oxygen-15, and fluorine-18. New routes to synthetic precursors and organic compounds of high specific activity labeled with carbon-11, fluorine-18, and iodine-123 including monosaccharides, aromatic amines, neuroleptics, fatty acids, steroids, and other classes of compounds are discussed. Some compounds are considered in terms of the development and evaluation of structure-activity relationships and including some newer concepts such as metabolic trapping. 67 references

  6. Detection of the pyrogen in the radiopharmaceuticals using Limulus test and inhibitory factors in the gelation reaction

    Energy Technology Data Exchange (ETDEWEB)

    Murata, H; Iio, M; Yamada, H; Chiba, K [Tokyo Metropolitan Geriatric Medical Center (Japan); Kobayashi, M

    1975-08-01

    To examine the sensitivities of the Limulus test and the inhibitory factors in radiopharmaceuticals, the following procedures were employed. Twenty commonly used radiopharmaceuticals were examined by Limulus Lysate (Pre-gel). In order to detect the inhibitory factors, several doses of endotoxin (E. coli) were added to the radiopharmaceuticals before the Limulus test was made and the results were compared with control results using saline solution of endotoxin. When the pH of the reaction solution lay out of a suitable range (6.0-7.5), the pH was adjusted by Tris-HCl buffer before the reaction. The sensitivity of the Limulus test control using Pre-gel was positive at a concentration of 10/sup -3/ ..mu..g/ml of endotoxin. The Limulus test was sensitive and without inhibitory reactions for sup(99m)TcO/sub 4/-, sup(99m)Tc-albumin, sup(99m)Tc-MAA, sup(99m)Tc-Sn-colloid, /sup 131/I-hippurate, Na/sup 131/I, Na/sub 2//sup 51/CrO/sub 4/, /sup 67/Ga-citrate and /sup 57/Co-bleomycin as they were supplied. /sup 111/In-DTPA, sup(99m)Tc-phytate, sup(99m)Tc-pyrophosphate, sup(99m)Tc-DTPA, /sup 131/I-PVP, /sup 59/FeCl/sub 3/, Na-phosphate (/sup 32/P), /sup 198/Au-colloid and /sup 75/Se-selenomethionine needed to have their pH adjusted to avoid inhibition. Benzyl alcohol in the radiopharmaceutical showed an inhibitory effect at a concentration greater than 1%. Commonly used /sup 169/Yb-DTPA which was evaluated by this test had a sensitivity of 2.5 x 10/sup -3/ ..mu..g/ml due to addition of a small amount of benzyl alcohol. /sup 131/I-BSP showed intense inhibition in gelation reaction. Contaminations of endotoxin were detected in sup(99m)Tc-albumin, sup(99m)Tc-Sn-colloid, /sup 131/I-hippurate, Na/sup 131/I, Na/sub 2//sup 51/CrO/sub 4/, /sup 198/Au-colloid, /sup 57/Co-bleomycin and /sup 75/Se-selenomethionine.

  7. Tritium in the Physical and Biological Sciences. V. 1. Proceedings of a Symposium

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1962-01-15

    The use of tritium for research in physics, chemistry, biology and hydrology has in recent years become increasingly important. It was for this reason that the first international conference to discuss the progress of new developments was organized by the IAEA in conjunction with the Joint Commission on Applied Radioactivity and held from 3-10 May 1961, in Vienna. The first five sessions of the Symposium were devoted to the use of tritium in hydrology, physics and chemistry. Special emphasis was laid on the role of tritium as a tracer in hydrology, especially in the study of water movement. The establishment and improvement of counting and detection techniques to facilitate the application of tritium as a tracer was another aspect discussed in this part of the proceedings. Papers were read on the preparation of tritiated compounds and it was generally agreed that further clarification of the mechanism of various techniques, and of the Wilzbach gas exposure technique in particular, would lead to further developments in the synthesis of a number of tritium compounds important in biology. Other papers were concerned with tritium applications to studies of the mechanism of some chemical reactions together with the effects of tritium isotopes. During the second part of the Symposium the biological applications of tritium and tritiated compounds were discussed. These included general problems connected with the biological uses of tritium and the radiation effects of tritium on living organisms such as viruses, bacteria and cancer cells. The value of tritium in biological studies became apparent because of the ease with which a large number of metabolically active compounds such as hormones, vitamins and other important constituents in the body can be labelled with tritium. Tritium is also a weak beta-emitter and autoradiographie s of tissues and single cells containing tritium-labelled compounds allow an excellent localization of the tracer. The Symposium was attended by

  8. Wind tunnel investigations on tritium reemission from soil

    International Nuclear Information System (INIS)

    Taeschner, M.; Bunnenberg, C.

    1993-01-01

    Future fusion plants and tritium handling facilities will contain large amounts of tritium. Following chronical or accidental releases to the atmosphere a secondary HTO source is established in the downwind sector of the tritium release point as a result of deposition processes. To investigate HTO reemission rates, experiments were performed with a special wind tunnel, in which the air flows across the surface of soil columns under controlled conditions. In order to measure the HTO content of an air sample that was experimentally contaminated by reemission of HTO from a labeled soil column, a fast method is used. The air sample is bubbled through a flask filled with a definite volume of low-tritium water. At the end of the sampling period, the volume and the specific activity of the flask water are measured. With the help of a simple mathematical formula, that is presented in this report, the HTO activity of the air sample can be calculated. (orig.) [de

  9. An improved method for preparing tritium labeled fluoxetine

    International Nuclear Information System (INIS)

    Hsi, R.S.P.; Stolle, W.T.

    1996-01-01

    Palladium-on-charcoal catalyzed reduction of N-methyl-3-(3-bromo) phenyl-3-(4-trifluoromethyl)phenoxypropylamine (1) with tritium gas produces a mixture of the debrominated product [ 3 H]fluoxetine (2) and N-methyl-3-[3- 3 H]phenylpropylamine (3), which results from cleavage of the benzylic carbon-oxygen bond. Carrying out this reaction in the presence of pyridine eliminates hydrogenolysis and produces [ 3 H]fluoxetine as the sole product. (author)

  10. Radiopharmaceuticals used in nuclear cardiology

    International Nuclear Information System (INIS)

    Costa, H.

    1985-01-01

    During the last years, since short physical mean life radionuclides have started to be used, radionuclide scanning has been experienced with remarkable culmination. There are detector devices, which jointly with computation equipments, allow to obtain multiple images per second as properly rapid gammagraphic series, in order to obtain whole hemodynamic data or to generate functional images no representing an anatomical structure but reporting about cardiac dynamics at regional level. In these techniques, employed in Nuclear Cardiology, the following radionuclides and radiopharmaceuticals are used: radiolabeled albumin 99m Tc red blood cells, 113m In-transferrin, very short physical mean life radionuclides, such as 195m Au, 178 Ta, 191 Ir. In addition, 113 Xe for coronary flow measurements; radiolabeled microspheres and macroparticles for angiogammagraphy; 129 Cs, 43 K, 81 Rb, 82 Rb and 201 Ti, the most largerly used, for myocardial gammagraphy. It is pointed out that fatty acids are the newest, basically if are radioiodate, and some 99m Tc labeled long chain hydrocarbons. It is expressed that 99m Tc-Sn-pyrophosphate has been used for myocardial infarction. Working on the development of new radiopharmaceuticals, basically fatty acids and 99m Tc chelating agents, for the improvement of these techniques is carried out. (author)

  11. Tritium Assay and Dispensing of KEPRI Tritium Lab

    International Nuclear Information System (INIS)

    Sohn, S. H.; Song, K. M.; Lee, S. K.; Lee, K.W.; Ko, B. W.

    2009-01-01

    The Wolsong Tritium Removal Facility(WTRF) has been constructed to reduce tritium levels in the heavy water systems and environmental emissions at the site. The WTRF was designed to process 100 kg/h of heavy water with the overall tritium extraction efficiency of 97% per single pass and to produce ∼700 g of tritium as T2 per year at the feed concentration of 0.37 TBq/kg. The high purity tritium greater than 99% is immobilized as a metal hydride to secure its long term storage. The recovered tritium will be made available for industrial uses and some research applications in the future. Then KEPRI is constructing the tritium lab. to build-up infrastructure to support tritium research activities and to support tritium control and accountability systems for tritium export. This paper describes the initial phases of the tritium application program including the laboratory infrastructure to support the tritium related R and D activities and the tritium controls in Korea

  12. Radiolabeling of Ceftriaxone with 99mTc as a Targeting Radiopharmaceutical for Staphylococcus Aureus Detection in Mouse Model

    International Nuclear Information System (INIS)

    Fazli, A.; Saluti, M.; Ahmadi, Gh.; Mirshojaei, F.; Mazidi, M.; Heydari, Z.

    2012-01-01

    Bacterial infection is one of the major causes of morbidity and mortality especially in developing countries. Nuclear medicine has an important role in helping the diagnosis of deep-seated infections by developing more specific radiopharmaceuticals. The aim of this study was to evaluate 99mTc-labeling ceftriaxone as a new radiopharmaceutical for Staphylococcus aureus infection imaging in nuclear medicine. Radiolabeling of ceftriaxone was carried out by adding 370 MBq of 99mTc to 10 mg of ceftriaxone in the presence of 50 μg of SnCl 2 .2H 2 O at pH=5. The radiochemical purity and stability tests at room temperature and human blood serum were evaluated with ITLC. Intramuscular infection was induced by injection of Staphylococcus aureus into the left thigh muscle of the mice. The biodistribution of 99mTc-ceftriaxone was studied in normal and infected mice at various times post-injection. Radiochemical purity of the product was 94.5±5.4% with a good stability at room temperature and human serum, 80.6% and 71.2% after 24 h, respectively. The biodistribution studies showed the localization of 99mTc-ceftriaxone at the site of infection with high sensitivity without any significant accumulation in vital organs. Due to the ease of 99mTc-ceftriaxone conjugation method, high labeling efficiency, and high uptake in the infected muscle, it may provide a promising candidate as a targeting radiopharmaceutical for imaging infectious foci due to Staphylococcus aureus in nuclear medicine.

  13. Formulation of DOTATATE Cold Kit for Preparation of Ga-68 Radiopharmaceutical

    International Nuclear Information System (INIS)

    Sriwiang, W.; Duangta, T.; Kaeopookum, P.; Wongsanit, S.

    2014-01-01

    Radiolabeled somatostatin analogs of peptide receptors targeting tumor cells have become a common practice in the diagnosis and treatment of certain types of cancer. The aim of this research was to develop the cold kit to be label with Ga-68 radionuclide for neuroendocrine tumor imaging. DOTATATE peptide for somatostatin receptor was formulated with NaOAc and ascorbic acid into lyophilized form. Radiochemical purity (RCP) of 68 Ga-DOTATATE labeled complex prepared from the cold kit was determined during storage period of 5 months and evaluated before clinical application to EANM guideline. The %RCP of the labeled peptide was more than 95% throughout period of storage with Ge-68 breakthrough less than 0.001%. The peptide content calculated from peak area of standard DOTATATE calibration curve using HPLC at uv 220 nm was found to be 15.3±4.62 μg. The specific activity of 68 Ga-DOTATATE, which depended on activities eluted from generator, was 34.7 - 52 MBq/nmol-peptide. The pH of the Ga-68 radiopharmaceutical kit after dilution with phosphate-buffered saline was 5.0 - 5.3. These results demonstrated that preparing of 68 Ga-DOTATATE radiopharmaceutical from lyophilized kit presented in this study was suitable and convenient method obtaining high radiochemical purity of short half-life Ga-68 radionuclide.

  14. Development of nano radiopharmaceutical based on Bevacizumab labelled with Technetium-99m for early diagnosis of gastrointestinal stromal tumor; Desenvolvimento de nanorradiofarmaco a base de Bevacizumabe marcado com tecnecio-99m para diagnostico precoce do tumor estromal gastrointestinal

    Energy Technology Data Exchange (ETDEWEB)

    Braga, Thais Ligiero

    2015-06-01

    The development of new radiopharmaceuticals is an essential activity to improve nuclear medicine, and essential for the early and effective diagnosis of oncological diseases. Among the various possibilities current research in the world, the radiopharmaceuticals to chemotherapeutic base may be the most effective in detecting tumors, particularly Gastrointestinal Stromal Tumor (GIST), the Metastatic Renal Cell Carcinoma and neuroendocrine pancreatic tumors. However, difficulties in directing, as well as adhesion of the radiopharmaceutical in the desired location, are currently the main problems in the early detection and treatment of some of these tumors. Advances in the field of nanotechnology, particularly in recent years, indicate significant contribution to overcoming these obstacles, particularly in the implementation of molecular barriers as well as the functionalization of the nanoparticles, thereby improving targeting by the use of surface nucleotides, and the increased adhesion, which facilitates the release of the drug and therefore increases the chances of early diagnosis and more effective treatment. This study aimed to the production, characterization and evaluation of cytotoxicity, as well as in vivo biodistribution test Bevacizumab nanoparticles labeled with Technetium-99m radionuclide for detection of type GIST tumors. Bevacizumab was encapsulated in the form of nanoparticles by the emulsification method using double poly-acetic acid and polyvinyl alcohol polymers (PLA / PVA) at a concentration of 2% of the monoclonal antibody. The characterization of the nanoparticles was performed by the technique of scanning electron microscopy (SEM). The cytotoxicity assessment was performed by XTT assay with various cell lines of solid tumor cells. The labeling with technetium-99m was done by the direct method, and its yield determined by paper chromatography using paper Whatmam 1 as the stationary phase and acetone as mobile phase. In the biodistribution study

  15. Irradiaiton facilities for testing solid and liquid blanket breeder materials with in-situ tritium release measurements in the HFR Petten

    International Nuclear Information System (INIS)

    Conrad, R.; Debarberis, L.

    1991-01-01

    Lithium-based tritium breeder materials for solid and liquid fusion reactor blanket concepts are being tested in the High Flux Reactor (HFR) Petten with in-situ tritium release measurements since 1985, within the European Fusion Technology Programme and the BEATRIX-I programme. Ceramic breeder materials are being tested in the EXOTIC and COMPLIMENT experimental programmes and the liquid breeder material, Pb-17Li, is being tested in the LIBRETTO experimental programme. The in-pile experiments are performed with irradiation facilities developed by the Joint Research Centre (JRC) Petten. The irradiation vehicles are multi-channel rigs. The sample holders consist of independent, fully instrumented and triple contained capsules. The out-of-pile experimental equipment consist of twelve independent circuits for on-line tritium release and tritium permeation measurements and eight independent circuits for temperature control. The experimental achievements obtained so far contribute to the selection of candidate tritium breeder materials for blanket concepts of near future machines like NET, ITER and DEMO. (orig.)

  16. A rapid and efficient preparation of [{sup 123}I]radiopharmaceuticals using a small HPLC Rocket[reg] column

    Energy Technology Data Exchange (ETDEWEB)

    Katsifis, Andrew [Radiopharmaceuticals Division R and D, Australian Nuclear Science and Technology, Organisation, Menai, NSW 2234, Sydney (Australia)]. E-mail: akx@ansto.gov.au; Papazian, Vahan [Radiopharmaceuticals Division R and D, Australian Nuclear Science and Technology, Organisation, Menai, NSW 2234, Sydney (Australia); Jackson, Timothy [Radiopharmaceuticals Division R and D, Australian Nuclear Science and Technology, Organisation, Menai, NSW 2234, Sydney (Australia); Loc' h, Christian [Radiopharmaceuticals Division R and D, Australian Nuclear Science and Technology, Organisation, Menai, NSW 2234, Sydney (Australia)

    2006-01-01

    A simplified method for the rapid and efficient preparation of [{sup 123}I]radiopharmaceuticals is described. Three radiopharmaceuticals, [{sup 123}I]{beta}-CIT, [{sup 123}I]MIBG and [{sup 123}I]clioquinol, were synthesised and purified as model compounds. The radiotracers were labelled with iodine-123 using electrophilic oxidative conditions and purified by a compact semi-preparative reverse phase column (C-18, 3 {mu}m, 7x53 mm, Alltima Rocket[reg, Alltech] using aqueous-ethanol as HPLC solvents that were directly used for radiopharmaceutical formulation. The radiochemical purity of the radioiodinated tracers as assessed by analytical HPLC was higher than 99% with specific activity higher than 3 GBq/nmol. The total preparation time of a radiotracer ranged from 40 to 60 min and, starting from 3.7 GBq of iodine-123, more than 2.5 GBq of formulated radiopharmaceuticals were available for clinical investigations.

  17. Imaging of tritium implanted into graphite

    International Nuclear Information System (INIS)

    Malinowski, M.E.; Causey, R.A.

    1988-01-01

    The extensive use of graphite in plasma-facing surfaces of tokamaks such as the Tokamak Fusion Test Reactor, which has planned tritium discharges, makes two-dimensional tritium detection techniques important in helping to determine torus tritium inventories. We have performed experiments in which highly oriented pyrolytic graphite (HOPG) samples were first tritium implanted with fluences of ∼10 16 T/cm 2 at energies approx. 0 C resulted in no discernible motion of tritium along the basal plane, but did show that significant desorption of the implanted tritium occurred. The current results indicate that tritium in quantities of 10 12 T/cm 2 in tritiated components could be readily detected by imaging at lower magnifications

  18. JET experiments with tritium and deuterium–tritium mixtures

    Energy Technology Data Exchange (ETDEWEB)

    Horton, Lorne, E-mail: Lorne.Horton@jet.uk [JET Exploitation Unit, Culham Science Centre, Abingdon OX14 3DB (United Kingdom); European Commission, B-1049 Brussels (Belgium); EUROfusion Consortium, JET, Culham Science Centre, Abingdon OX14 3DB (United Kingdom); Batistoni, P. [Unità Tecnica Fusione - ENEA C. R. Frascati - via E. Fermi 45, Frascati (Roma), 00044, Frascati (Italy); EUROfusion Consortium, JET, Culham Science Centre, Abingdon OX14 3DB (United Kingdom); Boyer, H.; Challis, C.; Ćirić, D. [CCFE, Culham Science Centre, Abingdon OX14 3DB, Oxon (United Kingdom); EUROfusion Consortium, JET, Culham Science Centre, Abingdon OX14 3DB (United Kingdom); Donné, A.J.H. [EUROfusion Programme Management Unit, Culham Science Centre, Abingdon OX14 3DB (United Kingdom); FOM Institute DIFFER, PO Box 1207, NL-3430 BE Nieuwegein (Netherlands); EUROfusion Consortium, JET, Culham Science Centre, Abingdon OX14 3DB (United Kingdom); Eriksson, L.-G. [European Commission, B-1049 Brussels (Belgium); EUROfusion Consortium, JET, Culham Science Centre, Abingdon OX14 3DB (United Kingdom); Garcia, J. [CEA, IRFM, F-13108 Saint Paul Lez Durance (France); EUROfusion Consortium, JET, Culham Science Centre, Abingdon OX14 3DB (United Kingdom); Garzotti, L.; Gee, S. [CCFE, Culham Science Centre, Abingdon OX14 3DB, Oxon (United Kingdom); EUROfusion Consortium, JET, Culham Science Centre, Abingdon OX14 3DB (United Kingdom); Hobirk, J. [Max-Planck-Institut für Plasmaphysik, D-85748 Garching (Germany); EUROfusion Consortium, JET, Culham Science Centre, Abingdon OX14 3DB (United Kingdom); Joffrin, E. [CEA, IRFM, F-13108 Saint Paul Lez Durance (France); EUROfusion Consortium, JET, Culham Science Centre, Abingdon OX14 3DB (United Kingdom); and others

    2016-11-01

    Highlights: • JET is preparing for a series of experiments with tritium and deuterium–tritium mixtures. • Physics objectives include integrated demonstration of ITER operating scenarios, isotope and alpha physics. • Technology objectives include neutronics code validation, material studies and safety investigations. • Strong emphasis on gaining experience in operation of a nuclear tokamak and training scientists and engineers for ITER. - Abstract: Extensive preparations are now underway for an experiment in the Joint European Torus (JET) using tritium and deuterium–tritium mixtures. The goals of this experiment are described as well as the progress that has been made in developing plasma operational scenarios and physics reference pulses for use in deuterium–tritium and full tritium plasmas. At present, the high performance plasmas to be tested with tritium are based on either a conventional ELMy H-mode at high plasma current and magnetic field (operation at up to 4 MA and 4 T is being prepared) or the so-called improved H-mode or hybrid regime of operation in which high normalised plasma pressure at somewhat reduced plasma current results in enhanced energy confinement. Both of these regimes are being re-developed in conjunction with JET's ITER-like Wall (ILW) of beryllium and tungsten. The influence of the ILW on plasma operation and performance has been substantial. Considerable progress has been made on optimising performance with the all-metal wall. Indeed, operation at the (normalised) ITER reference confinement and pressure has been re-established in JET albeit not yet at high current. In parallel with the physics development, extensive technical preparations are being made to operate JET with tritium. The state and scope of these preparations is reviewed, including the work being done on the safety case for DT operation and on upgrading machine infrastructure and diagnostics. A specific example of the latter is the planned calibration at

  19. Regulatory aspects of radiopharmaceuticals

    International Nuclear Information System (INIS)

    Kristensen, K.

    1985-01-01

    Regulatory systems in the field of radiopharmaceuticals have two main purposes: efficacy and safety. Efficacy expresses the quality of the diagnostic and therapeutic process for the patient. Safety involves the patient, the staff, and the environment. The world situation regarding regulations for radiopharmaceuticals is reviewed on the basis of a survey in WHO Member States. The main content of such regulations is discussed. The special properties of radiopharmaceuticals compared with ordinary drugs may call for modified regulations. Several countries are preparing such regulations. Close co-operation and good understanding among scientists working in hospital research, industry and regulatory bodies will be of great importance for the fast and safe introduction of new radiopharmaceuticals for the benefit of the patient. Before introducing new legislation in this field, a radiopharmaceutical expert should analyse the situation in the country and the relationship to the existing regulations. It is expected that the most important factor in promoting the fast introduction of new, safe and effective radiopharmaceuticals will be the training of people working within the regulatory bodies. It is foreseen that the IAEA and WHO will have an important role to play by providing expert advice and training in this area. (author)

  20. An improved method for preparing tritium labeled fluoxetine

    Energy Technology Data Exchange (ETDEWEB)

    Hsi, R.S.P.; Stolle, W.T. [Pharmacia and Upjohn Inc., Kalamazoo, MI (United States)

    1996-12-01

    Palladium-on-charcoal catalyzed reduction of N-methyl-3-(3-bromo) phenyl-3-(4-trifluoromethyl)phenoxypropylamine (1) with tritium gas produces a mixture of the debrominated product [{sup 3}H]fluoxetine (2) and N-methyl-3-[3-{sup 3}H]phenylpropylamine (3), which results from cleavage of the benzylic carbon-oxygen bond. Carrying out this reaction in the presence of pyridine eliminates hydrogenolysis and produces [{sup 3}H]fluoxetine as the sole product. (author).

  1. Separation of Tritium from Wastewater

    International Nuclear Information System (INIS)

    JEPPSON, D.W.

    2000-01-01

    A proprietary tritium loading bed developed by Molecular Separations, Inc (MSI) has been shown to selectively load tritiated water as waters of hydration at near ambient temperatures. Tests conducted with a 126 (micro)C 1 tritium/liter water standard mixture showed reductions to 25 (micro)C 1 /L utilizing two, 2-meter long columns in series. Demonstration tests with Hanford Site wastewater samples indicate an approximate tritium concentration reduction from 0.3 (micro)C 1 /L to 0.07 (micro)C 1 /L for a series of two, 2-meter long stationary column beds Further reduction to less than 0.02 (micro)C 1 /L, the current drinking water maximum contaminant level (MCL), is projected with additional bed media in series. Tritium can be removed from the loaded beds with a modest temperature increase and the beds can be reused Results of initial tests are presented and a moving bed process for treating large quantities of wastewaters is proposed. The moving bed separation process appears promising to treat existing large quantities of wastewater at various US Department of Energy (DOE) sites. The enriched tritium stream can be grouted for waste disposition. The separations system has also been shown to reduce tritium concentrations in nuclear reactor cooling water to levels that allow reuse. Energy requirements to reconstitute the loading beds and waste disposal costs for this process appear modest

  2. Harvard-MIT research program in short-lived radiopharmaceuticals. Progress report, March 1, 1985-February 28, 1986

    International Nuclear Information System (INIS)

    1986-03-01

    The Harvard-MIT Research Program in Short-Lived Radiopharmaceuticals was established in 1977 to foster interaction among groups working at Harvard Medical School, the Massachusetts Institute of Technology and the Massachusetts General Hospital in fields related to radiopharmaceutical chemistry. From these collaborations and building upon the special, but different, strengths of the participating individuals, laboratories and institutions, it was hoped that original approaches would be found for the design of new, clinically useful, labeled compounds. We believe that examination of the record demonstrates that this has been a fruitful alliance

  3. Production of the radiopharmaceuticals labelling albumin nano-colloid with 99mTc for scintiscanning studies of the lymphatic system and bone marrow

    International Nuclear Information System (INIS)

    Gonzalez Alvarado, Alba Evelia

    1997-01-01

    The objective of the present work was to carried out the production in Guatemala, of a new radiopharmaceutical in the General Direction of Nuclear Energy for the detection of the cancer, as well as its implementation, the quality control by means of the radiochemical purity, the microbiology control and organoleptic quality , to evaluate the biodistribution in rats and to check its stability. The work was carried out formulating the pharmaco albumin Nano-colloid, then it was labelled with 99m Tc, the radiochemical purity was evaluated, measuring the disintegrations in minutes of the 99m Tc in an scintillation counter type well, being determined the percentage of union from the 99m Tc to the nanocolloid, with a purity bigger than 90%

  4. Iodine and tritium labelling of curarizing and cardiotoxic agents. Study of the conformation of toxic polypeptides extracted from snake venom

    International Nuclear Information System (INIS)

    Menez, Andre.

    1977-01-01

    A short review of present-day knowledge on the action mechanism of toxic snake venom polypeptides is followed by a study of the radioactive labelling of some toxic compounds. Those dealt with more especially are Naja nigricollis α toxin and Laticauda semifasciata b erabutoxin, then (+) tubocurarin, a non-peptidic curarizing alkaloid, and two cardiotoxic polypeptides: cytotoxin II and cardiotoxin γ extracted from the venom of Naja naja and Naja nigricollis respectively. The labelling principle is based on the specific fixation of one or more iodine atoms then tritium substitution of the halogen by catalytic hydrogenolysis. As predicted from titration of the aromatic groups the halogenation process, obtained by addition of iodine monochloride, takes place sometimes on the phenolic nuclei and sometimes on the imidazole nuclei, the position of which targets within each sequence has been identified. From results of the study of reactivity towards iodine combined with those of basic titration, the accessibility of several aromatic nuclei has also been defined. Each iodinated polypeptide is then hydrogenolysed in the presence of tritium gas giving a specific activity between 4 and 27 Ci/mmole according to the compound treated. In all cases the biological potential and physical properties of the radioactive material obtained by the above titration process remained intact. An example of the bonding kinetics of short toxins with the partially purified choligenic receptor is given in the special case of tritiated b erabutoxin. The affinity of this toxin for its receptor target is strong, though slightly less so than that of tritiated Naja nigricollis α toxin [fr

  5. Radiopharmaceuticals for neurotransmitter imaging

    Energy Technology Data Exchange (ETDEWEB)

    Oh, Seung Jun [Asan Medical Center, University of Ulsan College of Medicine, Seoul (Korea, Republic of)

    2007-04-15

    Neurotransmitter imaging with radiopharmaceuticals plays major role for understanding of neurological and psychiatric disorders such as Parkinson's disease and depression. Radiopharmaceuticals for neurotransmitter imaging can be divided to dopamine transporter imaging radiopharmaceuticals and serotonin transporter imaging radiopharmaceuticals. Many kinds of new dopamine transporter imaging radiopharmaceuticals has a tropane ring and they showed different biological properties according to the substituted functional group on tropane ring. After the first clinical trials with [{sup 123}I] {beta} -CIT, alkyl chain substituent introduced to tropane ring amine to decrease time for imaging acquisition and to increase selectivity. From these results, [{sup 123}I]PE2I, [18F]FE-CNT, [{sup 123}I]FP-CIT and [{sup 18}F]FP-CIT were developed and they showed high uptake on the dopamine transporter rich regions and fast peak uptake equilibrium time within 4 hours after injection. [{sup 11}C]McN 5652 was developed for serotonin transporter imaging but this compound showed slow kinetics and high background radioactivity. To overcome these problems, new diarylsulfide backbone derivatives such as ADAM, ODAM, AFM, and DASB were developed. In these candidates, [{sup 11}C]AFM and [{sup 11}C]DASB showed high binding affinity to serotonin transporter and fast in vivo kinetics. This paper gives an overview of current status on dopamine and serotonin transporter imaging radiopharmaceuticals and the development of new lead compounds as potential radiopharmaceuticals by medicinal chemistry.

  6. Software design for the Tritium System Test Assembly

    International Nuclear Information System (INIS)

    Claborn, G.W.; Heaphy, R.T.; Lewis, P.S.; Mann, L.W.; Nielson, C.W.

    1983-01-01

    The control system for the Tritium Systems Test Assembly (TSTA) must execute complicated algorithms for the control of several sophisticated subsystems. It must implement this control with requirements for easy modifiability, for high availability, and provide stringent protection for personnel and the environment. Software techniques used to deal with these requirements are described, including modularization based on the structure of the physical systems, a two-level hierarchy of concurrency, a dynamically modifiable man-machine interface, and a specification and documentation language based on a computerized form of structured flowcharts

  7. Software design for the Tritium Systems Test Assembly

    International Nuclear Information System (INIS)

    Claborn, G.W.; Keaphy, R.T.

    1983-01-01

    The control system for the Tritium Systems Test Assembly (TSTA) must execute complicated algorithms for the control of several sophisticated subsystems. It must implement this control with requirements for easy modifiability, for high availability, and provide stringent protection for personnel and the environment. Software techniques used to deal with these requirements are described, including modularization based on the structure of the physical systems, a two-level hierarchy of concurrency, a dynamically modifiable manmachine interface, and a specification and documentation language based on a computerized form of structured flowcharts

  8. Tritium stripping by a catalytic exchange stripper

    International Nuclear Information System (INIS)

    Heung, L.K.; Gibson, G.W.; Ortman, M.S.

    1991-01-01

    A catalytic exchange process for stripping elemental tritium from gas streams has been demonstrated. The process uses a catalyzed isotopic exchange reaction between tritium in the gas phase and protium or deuterium in the solid phase on alumina. The reaction is catalyzed by platinum deposited on the alumina. The process has been tested with both tritium and deuterium. Decontamination factors (ration of inlet and outlet tritium concentrations) as high as 1000 have been achieved, depending on inlet concentration. The test results and some demonstrated applications are presented

  9. Production of Radioisotopes and Radiopharmaceuticals at the Dalat Nuclear Research Reactor

    International Nuclear Information System (INIS)

    Duong Van Dong; Pham Ngoc Dien; Bui Van Cuong; Mai Phuoc Tho; Nguyen Thi Thu; Vo Thi Cam Hoa

    2014-01-01

    After reconstruction, the Dalat Nuclear Research Reactor (DNRR) was inaugurated on March 20th, 1984 with the nominal power of 500 kW. Since then the production of radioisotopes and labelled compounds for medical use was started. Up to now, DNRR is still the unique one in Vietnam. The reactor has been operated safely and effectively with the total of about 37,800 hrs (approximately 1,300 hours per year). More than 90% of its operation time and over 80% of its irradiation capacity have been exploited for research and production of radioisotopes. This paper gives an outline of the radioisotope production programme using the DNRR. The production laboratory and facilities including the nuclear reactor with its irradiation positions and characteristics, hot cells, production lines and equipment for the production of Kits for labelling with 99m Tc and for quality control, as well as the production rate are mentioned. The methods used for production of 131 I, 99m Tc, 51 Cr, 32 P, etc. and the procedures for preparation of radiopharmaceuticals are described briefly. Status of utilization of domestic radioisotopes and radiopharmaceuticals in Vietnam is also reported. (author)

  10. Radiopharmaceutical development and clinical needs

    International Nuclear Information System (INIS)

    Vieira, M.R.

    1998-01-01

    The use of radionuclides for medical applications has continued to grow at a very rapid pace. The use of radiotracers for nuclear medicine imaging and for radiotherapy of cancer as well as certain benign disorders is firmly established as an important clinical modality. Over the past ten years, nuclear medicine has experienced an evolution towards functional studies and novel therapeutic approaches. New radionuclides are required for these applications. In the developmental stages, each new isotope has to go through a phase of careful scrutiny and evaluation, and practical concerns related to the cost of production and availability must be addressed. The development of 18 F-labeled radiopharmaceuticals has opened a completely new area of investigation. Research on bioconjugates (this term includes radiolabeled antibodies, peptides, receptor-specific and other bioactive molecules) has experienced rapid growth because of the promise of a number of these ''bioactive molecules'' to serve as selective carriers of radionuclides for tumor-associated and other specific antigens/receptors ''in vivo''. The new concept of nuclear medicine, particularly when applied to the field of oncology is directed towards the physiological mechanisms and the study of molecular disfunctions. The search for new radiopharmaceuticals thus aims at studying tumors at a tissue and molecular level. Examples of this new approach are scans utilizing the following substances: -guanethidine and noradrenaline analogues such as meta-iodo-benzyl-guanidine labeled with iodine-131 or iodine-123 aimed at targeting neuroendocrine cells and their secretory granules; -various monoclonal antibodies directed at different tumor types, both for diagnostic and therapeutic purposes. Radioimmunotherapy is considered particularly suited for treatment of tumors not easily amenable to surgery and for the treatment of small disseminated lesions; -somatostatin analogs tagged with indium-111 or more recently with Yttrium

  11. Tritium pellet injection sequences for TFTR

    International Nuclear Information System (INIS)

    Houlberg, W.A.; Milora, S.L.; Attenberger, S.E.; Singer, C.E.; Schmidt, G.L.

    1983-01-01

    Tritium pellet injection into neutral deuterium, beam heated deuterium plasmas in the Tokamak Fusion Test Reactor (TFTR) is shown to be an attractive means of (1) minimizing tritium use per tritium discharge and over a sequence of tritium discharges; (2) greatly reducing the tritium load in the walls, limiters, getters, and cryopanels; (3) maintaining or improving instantaneous neutron production (Q); (4) reducing or eliminating deuterium-tritium (D-T) neutron production in non-optimized discharges; and (5) generally adding flexibility to the experimental sequences leading to optimal Q operation. Transport analyses of both compression and full-bore TFTR plasmas are used to support the above observations and to provide the basis for a proposed eight-pellet gas gun injector for the 1986 tritium experiments

  12. [Mechanism of tritium persistence in porous media like clay minerals].

    Science.gov (United States)

    Wu, Dong-Jie; Wang, Jin-Sheng; Teng, Yan-Guo; Zhang, Ke-Ni

    2011-03-01

    To investigate the mechanisms of tritium persistence in clay minerals, three types of clay soils (montmorillonite, kaolinite and illite) and tritiated water were used in this study to conduct the tritium sorption tests and the other related tests. Firstly, the ingredients, metal elements and heat properties of clay minerals were studied with some instrumental analysis methods, such as ICP and TG. Secondly, with a specially designed fractionation and condensation experiment, the adsorbed water, the interlayer water and the structural water in the clay minerals separated from the tritium sorption tests were fractionated for investigating the tritium distributions in the different types of adsorptive waters. Thirdly, the location and configuration of tritium adsorbed into the structure of clay minerals were studied with infrared spectrometry (IR) tests. And finally, the forces and mechanisms for driving tritium into the clay minerals were analyzed on the basis of the isotope effect of tritium and the above tests. Following conclusions have been reached: (1) The main reason for tritium persistence in clay minerals is the entrance of tritium into the adsorbed water, the interlayer water and the structural water in clay minerals. The percentage of tritium distributed in these three types of adsorptive water are in the range of 13.65% - 38.71%, 0.32% - 5.96%, 1.28% - 4.37% of the total tritium used in the corresponding test, respectively. The percentages are different for different types of clay minerals. (2) Tritium adsorbed onto clay minerals are existed in the forms of the tritiated hydroxyl radical (OT) and the tritiated water molecule (HTO). Tritium mainly exists in tritiated water molecule for adsorbed water and interlayer water, and in tritiated hydroxyl radical for structural water. (3) The forces and effects driving tritium into the clay minerals may include molecular dispersion, electric charge sorption, isotope exchange and tritium isotope effect.

  13. Conceptual design of tritium accountancy system for LLCB TBM

    International Nuclear Information System (INIS)

    Patel, Rudreksh; Sircar, Amit

    2017-01-01

    Lead Lithium Ceramic Breeder (LLCB) Test Blanket Module (TBM) will be tested in ITER for performance evaluation of high grade of heat extraction and tritium breeding. The bred tritium in the breeder materials is extracted and recovered by Tritium Extraction System (TES), whereas tritium permeated from breeder materials to helium coolants, viz., primary coolant and secondary coolant, is recovered by Coolant Purification System (CPS). This recovered tritium has to be accounted before transferring it to tritium plant (i.e., ITER inner fuel). This tritium accountancy is performed by Tritium Accountancy System (TAS). In addition to tritium accountancy, TAS also provides necessary data for the validation of design and modelling tools.In this work, we have presented conceptual design of TAS. It also describes operational philosophy, process parameters, process flow diagram, and interface details with ITER tritium plant. (author)

  14. Tritium in the environment. Knowledge synthesis

    International Nuclear Information System (INIS)

    2009-01-01

    This report first presents the nuclear and physical-chemical properties of tritium and addresses the notions of bioaccumulation, bio-magnification and remanence. It describes and comments the natural and anthropic origins of tritium (natural production, quantities released in the environment in France by nuclear tests, nuclear plants, nuclear fuel processing plants, research centres). It describes how tritium is measured as a free element (sampling, liquid scintillation, proportional counting, enrichment method) or linked to organic matter (combustion, oxidation, helium-3-based measurement). It discusses tritium concentrations noticed in different parts of the environment (soils, continental waters, sea). It describes how tritium is transferred to ecosystems (transfer of atmospheric tritium to ground ecosystems, and to soft water ecosystems). It discusses existing models which describe the behaviour of tritium in ecosystems. It finally describes and comments toxic effects of tritium on living ground and aquatic organisms

  15. Regulatory requirements for radiopharmaceutical radiochemistry and radiation dosimetry

    International Nuclear Information System (INIS)

    Bonnyman, J.

    1985-01-01

    The Australian Department of Health is responsible for ensuring that radiopharmaceuticals are safe and effective and that their use does not result in unnecessary radiation exposure. Section B1 requirements of New Drug Form 4 (NDF4) fall into the following sections - manufacture, product specifications, quality assurance testing, stability studies and expiry dating. It covers ready to inject pharmaceuticals, radioactive formulations used to prepare a radiopharmaceutical, generators and cold kits

  16. Hippuran-123 I: labelling and quality control

    International Nuclear Information System (INIS)

    Barboza, M.F. de; Colturato, M.T.; Herrerias, R.; Muramoto, E.

    1992-01-01

    The o-iodo hippuric acid labelling with radioiodine is a radiopharmaceutical used with more frequently for evaluation the kidney function. Several reactive kits for labelling with 123 I are prepared. Controls of radiochemical purity and biological distribution are made. The reactive kit of hippuran is kept at 4 C during 2 years. (C.G.C.)

  17. The tritium operations experience on TFTR

    International Nuclear Information System (INIS)

    Halle, A. von; Anderson, J.L.; Gentile, C.; Grisham, L.; Hosea, J.; Kamperschroer, J.; LaMarche, P.; Oldaker, M.; Nagy, A.; Raftopoulos, S.; Stevenson, T.

    1995-01-01

    The Tokamak Fusion Test Reactor (TFTR) tritium gas system is administratively limited to 5 grams of tritium and provides the feedstock gas for the neutral beam and torus injection systems. Tritium operations on TFTR began with leak checking of gas handling systems, qualification of the gas injection systems, and high power plasma operations using trace amounts of tritium in deuterium feedstock gas. Full tritium operation commenced with four highly diagnosed neutral beam pulses into a beamline calorimeter to verify planned tritium beam operating routines and to demonstrate the deuterium to tritium beam isotope exchange. Since that time, TFTR has successfully operated each of the twelve neutral beam ion sources in tritium during hundreds of tritium beam pulses and torus gas injections. This paper describes the TFTR tritium gas handling systems and TFTR tritium operations of the gas injection systems and the neutral beam ion sources. Tritium accounting and accountability is discussed, including tritium retention issues of the torus limiters and beam impinged surfaces of the beamline components. Also included is tritium beam velocity analysis that compares the neutral beam extracted ion species composition for deuterium and tritium and that determines the extent of beam isotope exchange on subsequent deuterium and tritium beam pulses. The required modifications to TFTR operating routines to meet the U.S. Department of Energy regulations for a low hazard nuclear facility and the problems encountered during initial tritium operations are described. (orig.)

  18. The tritium operations experience on TFTR

    International Nuclear Information System (INIS)

    von Halle, A.; Gentile, C.

    1994-01-01

    The Tokamak Fusion Test Reactor (TFTR) tritium gas system is administratively limited to 5 grains of tritium and provides the feedstock gas for the neutral beam and torus injection systems. Tritium operations on TFTR began with leak checking of gas handling systems, qualification of the gas injection systems, and high power plasma operations using using trace amounts of tritium in deuterium feedstock gas. Full tritium operation commenced with four highly diagnosed neutral beam pulses into a beamline calorimeter to verify planned tritium beam operating routines and to demonstrate the deuterium to tritium beam isotope exchange. Since that time, TFTR has successfully operated each of the twelve neutral beam ion sources in tritium during hundreds of tritium beam pulses and torus gas injections. This paper describes- the TFTR tritium gas handling systems and TFTR tritium operations of the gas injection systems and the neutral beam ion sources. Tritium accounting and accountability is discussed, including tritium retention issues of the torus limiters and beam impinged surfaces of the beamline components. Also included is tritium beam velocity analysis that compares the neutral beam extracted ion species composition for deuterium and tritium and that determines the extent of beam isotope exchange on subsequent deuterium and tritium beam pulses. The required modifications to TFTR operating routines to meet the US Department of Energy regulations for a low hazard nuclear facility and the problems encountered during initial tritium operations are described

  19. DPRK's 4{sup th} Nuclear Test and its Tritium Production

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Min Soo; Lee, Sang Joon; Chang, Sun Young [Korea Institute of Nuclear Nonproliferation and Control, Daejeon (Korea, Republic of)

    2016-05-15

    On January 6, 2016 at 10:30am, the artificial earthquake in the DPRK was detected by multiple international seismic organizations. After 2 hours, the DPRK announced on state TV that 'The first H-bomb test was successfully conducted in the DPRK at 10:00 am on Wednesday, Juche 105(2016), pursuant to the strategic determination of the ruling communist party.' There has been a doubt about the real nature of the DPRK's 4th nuclear test, since 2 months have been passed after its nuclear test. To analyze the nature of the DPRK's nuclear test, it is necessary to check possible options for production of essential materials. The pathways to produce nuclear fusion material (tritium) and to have a relatively high possibility for the DPRK are described in this article. Tritium is key material for H-bomb. And there are two options for the DPRK which are 1) production and 2) illicit trafficking. And this study is focused on production possibility of DPRK. Determination of the nature of DPRK's nuclear test is very hard issue.

  20. System support software for TSTA [Tritium Systems Test Assembly

    International Nuclear Information System (INIS)

    Claborn, G.W.; Mann, L.W.; Nielson, C.W.

    1987-10-01

    The fact that Tritium Systems Test Assembly (TSTA) is an experimental facility makes it impossible and undesirable to try to forecast the exact software requirements. Thus the software had to be written in a manner that would allow modifications without compromising the safety requirements imposed by the handling of tritium. This suggested a multi-level approach to the software. In this approach (much like the ISO network model) each level is isolated from the level below and above by cleanly defined interfaces. For example, the subsystem support level interfaces with the subsystem hardware through the software support level. Routines in the software support level provide operations like ''OPEN VALVE'' and CLOSE VALVE'' to the subsystem level. This isolates the subsystem level from the actual hardware. This is advantageous because changes can occur in any level without the need for propagating the change to any other level. The TSTA control system consists of the hardware level, the data conversion level, the operator interface level, and the subsystem process level. These levels are described

  1. Verification of tritium production evaluation procedure using Monte Carlo code MCNP for in-pile test of fusion blanket with JMTR

    International Nuclear Information System (INIS)

    Nagao, Y.; Nakamichi, K.; Tsuchiya, M.; Ishitsuka, E.; Kawamura, H.

    2000-01-01

    To evaluate exactly the total amount of tritium production in tritium breeding materials during in-pile test with JMTR, the 'tritium monitor' has been produced and evaluation of total tritium generation was done by using 'tritium monitor' in preliminary in-pile mock-up, and verification of procedure concerning tritium production evaluation was conducted by using Monte Carlo code MCNP and nuclear cross section library of FSXLIBJ3R2. Li-Al alloy (Li 3.4 wt.%, 95.5% enrichment of 6 Li) was selected as tritium monitor material for the evaluation on the total amount of tritium production in high 6 Li enriched materials. From the results of preliminary experiment, calculated amounts of total tritium production at each 'tritium monitor', which was installed in the preliminary in-pile mock-up, were about 50-290% higher than the measured values. Concerning tritium measurement, increase of measurement error in tritium leak form measuring system to measure small amount of tritium (0.2-0.7 mCi in tritium monitor) was found in the results of present experiment. The tendency for overestimation of calculated thermal neutron flux in the range of 1-6x10 13 n cm -2 per s was found in JMTR and the reason may be due to the beryllium cross section data base in JENDL3.2

  2. Verification of tritium production evaluation procedure using Monte Carlo code MCNP for in-pile test of fusion blanket with JMTR

    Energy Technology Data Exchange (ETDEWEB)

    Nagao, Y. E-mail: nagao@jmtr.oarai.jaeri.go.jp; Nakamichi, K.; Tsuchiya, M.; Ishitsuka, E.; Kawamura, H

    2000-11-01

    To evaluate exactly the total amount of tritium production in tritium breeding materials during in-pile test with JMTR, the 'tritium monitor' has been produced and evaluation of total tritium generation was done by using 'tritium monitor' in preliminary in-pile mock-up, and verification of procedure concerning tritium production evaluation was conducted by using Monte Carlo code MCNP and nuclear cross section library of FSXLIBJ3R2. Li-Al alloy (Li 3.4 wt.%, 95.5% enrichment of {sup 6}Li) was selected as tritium monitor material for the evaluation on the total amount of tritium production in high {sup 6}Li enriched materials. From the results of preliminary experiment, calculated amounts of total tritium production at each 'tritium monitor', which was installed in the preliminary in-pile mock-up, were about 50-290% higher than the measured values. Concerning tritium measurement, increase of measurement error in tritium leak form measuring system to measure small amount of tritium (0.2-0.7 mCi in tritium monitor) was found in the results of present experiment. The tendency for overestimation of calculated thermal neutron flux in the range of 1-6x10{sup 13} n cm{sup -2} per s was found in JMTR and the reason may be due to the beryllium cross section data base in JENDL3.2.

  3. [Nuclear cardiology with new radiopharmaceuticals].

    Science.gov (United States)

    Bunko, H

    1994-08-01

    In the field of nuclear cardiology, 99mTc labeled myocardial perfusion agents such as MIBI, Tetrofosmin and Teboroxime, 111In-antimyosin for imaging of myocardial necrosis, 123I-betamethyl-iodophenylpentadecanoic acid (BMIPP) for imaging of myocardial fatty acid metabolism and 123I-metaiodobenzylguanidine (MIBG) for imaging of myocardial adrenergic function are introduced recently in Japan. Improved image quality and simultaneous evaluation of myocardial perfusion, function and wall motion can be obtained with use of 99mTc labeled myocardial perfusion agents. 111In-antimyosin enables specific imaging of myocardial necrosis which leads to the use for wide variety of heart diseases. Discrepancy of the myocardial perfusion and metabolism in case of stunned myocardium or cardiomyopathy can be evaluated by 123I-BMIPP in conjunction with perfusion agent. Recently wide variety of diseases which may have cardiac adrenergic abnormality are targeted for 123I-MIBG imaging. These new radiopharmaceuticals are expected to be powerful tool for evaluation of the pathophysiology including severity and prognosis and evaluation of the etiology of the various heart diseases.

  4. Experiments on tritium behavior in beryllium, (1)

    International Nuclear Information System (INIS)

    Kawamura, Hiroshi; Ishizuka, Etsuo; Matsumoto, Mikio; Inada, Seiji; Sezaki, Katsuji; Saito, Minoru; Kato, Mineo.

    1989-06-01

    In JMTR, it was observed that the tritium concentration of the primary coolant increases with the reactor operation at 50 MW. As one of the tritium generation sources, we paid attention to a neutron reflector made of beryllium because the tritium generation rate in the beryllium is bigger than other components in the reactor core. On the other hand, the irradiation test of blanket materials (i.e. tritium breeding materials and neutron multipling materials) are planned for development of the fusion reactor in JMTR and the beryllium will be also irradiated as a neutron multiplier with tritium breeding materials. Therefore, as the irradiated specimens, we used a hot-pressed beryllium disk fabricated by the same method as the neutron reflector or the neutron multiplier and conducted the irradiation tests in JMTR. The purpose of these tests are to clarify the tritium behavior in the hot-pressed beryllium. In this paper, from a viewpoint of the fabrication of capsules for neutron irradiation, the specifications of the irradiated specimens and capsules are summarized. Additionally, the results on the puncture test of the container of the irradiation specimens are described. (author)

  5. A Study on the Quality Control of 18F-FDG Radiopharmaceutical

    International Nuclear Information System (INIS)

    Kim, Ssang Tae; Yong, Chul Soon; Han, Eun Ok

    2010-01-01

    The types of test items which were recorded in this test report of quality control domestic 18 F-FDG radiopharmaceutical which consisted of 13 different types: appearance, half-life, radioactive heterokaryosis, radiochemical Confirmation (measure of Rf value), radiochemical Purity, Ethanol, Acetonitrile, Kryptofix, Aluminium, pH, Endotoxin, aseptic test, and radioactivity·ml-1. The record was fully recorded in 'appearance', 'radioactive heterokaryosis', 'pH', 'Endotoxin', and 'aseptic test'. In 'half-life', 'radiochemical Confirmation (measure of Rf value), 'radiochemical Purity', 'Ethanol', 'Acetonitrile', 'Kryptofix', 'Aluminium', 'radioactivity·ml-1', there were differences in records of each manufacturing business on radioactive medicine and medical supplies. The result of the test showed all 13 items of quality control test were 100% suitable on the basis of recorded data. There were more radiopharmaceutical made in the laboratory than in hospitals and businesses and in for result of suitability test, the laboratory showed higher suitability than did the hospitals or businesses. Domestically, there are differences of the test report items in the safety of radiopharmaceutical of each facility, and since it is not standardized, supplements are needed. To submit standardized test reports of quality guarantee in radiopharmaceutical, GMP of U.S. and CE Mark of Europe should be referred as well as receiving advice from professionals to standardize as suitable domestic standard

  6. 10 CFR 30.55 - Tritium reports.

    Science.gov (United States)

    2010-01-01

    ... 10 Energy 1 2010-01-01 2010-01-01 false Tritium reports. 30.55 Section 30.55 Energy NUCLEAR..., Inspections, Tests, and Reports § 30.55 Tritium reports. (a)-(b) [Reserved] (c) Except as specified in paragraph (d) of this section, each licensee who is authorized to possess tritium shall report promptly to...

  7. Imaging with 123I labelled fatty acids

    International Nuclear Information System (INIS)

    Dudczak, R.

    1985-01-01

    This report describes the clinical results obtained with radioiodinated aromatic and aliphatic fatty acids. The radiopharmaceuticals were 123 I labelled p-phenylpentadecanoic (p-IPPA) and 123 I labelled heptadecanoic acid (HDA). The possibility to evaluate the myocardial metabolic function in man noninvasively add a complementary diagnostic tool in the clinical follow-up of patients with heart disease. (Auth.)

  8. Tritium concentrations in tree ring cellulose

    International Nuclear Information System (INIS)

    Kaji, Toshio; Momoshima, Noriyuki; Takashima, Yoshimasa.

    1989-01-01

    Measurements of tritium (tissue bound tritium; TBT) concentration in tree rings are presented and discussed. Such measurement is expected to provide a useful means of estimating the tritium level in the environment in the past. The concentration of tritium bound in the tissue (TBT) in a tree ring considered to reflect the environmental tritium level in the area at the time of the formation of the ring, while the concentration of tritium in the free water in the tissue represents the current environmental tritium level. First, tritium concentration in tree ring cellulose sampled from a cedar tree grown in a typical environment in Fukuoka Prefecture is compared with the tritium concentration in precipitation in Tokyo. Results show that the year-to-year variations in the tritium concentration in the tree rings agree well with those in precipitation. The maximum concentration, which occurred in 1963, is attibuted to atmospheric nuclear testing which was performed frequently during the 1961 - 1963 period. Measurement is also made of the tritium concentration in tree ring cellulose sampled from a pine tree grown near the Isotope Center of Kyushu University (Fukuoka). Results indicate that the background level is higher probably due to the release of tritium from the facilities around the pine tree. Thus, measurement of tritium in tree ring cellulose clearly shows the year-to-year variation in the tritium concentration in the atmosphere. (N.K.)

  9. Tritium Management Loop Design Status

    Energy Technology Data Exchange (ETDEWEB)

    Rader, Jordan D. [ORNL; Felde, David K. [ORNL; McFarlane, Joanna [ORNL; Greenwood, Michael Scott [ORNL; Qualls, A L. [ORNL; Calderoni, Pattrick [Idaho National Laboratory (INL)

    2017-12-01

    This report summarizes physical, chemical, and engineering analyses that have been done to support the development of a test loop to study tritium migration in 2LiF-BeF2 salts. The loop will operate under turbulent flow and a schematic of the apparatus has been used to develop a model in Mathcad to suggest flow parameters that should be targeted in loop operation. The introduction of tritium into the loop has been discussed as well as various means to capture or divert the tritium from egress through a test assembly. Permeation was calculated starting with a Modelica model for a transport through a nickel window into a vacuum, and modifying it for a FLiBe system with an argon sweep gas on the downstream side of the permeation interface. Results suggest that tritium removal with a simple tubular permeation device will occur readily. Although this system is idealized, it suggests that rapid measurement capability in the loop may be necessary to study and understand tritium removal from the system.

  10. Production, control and utilization of radioisotopes including radiopharmaceuticals

    International Nuclear Information System (INIS)

    Muenze, R.

    1985-05-01

    From April 29th to May 5th, 1984 27 participants from 21 developing countries stayed within an IAEA Study Tour ('Production, Control and Utilization of Radioisotopes including Radiopharmaceuticals') in the GDR. In the CINR, Rossendorf the reactor, the cyclotron, the technological centre as well as the animal test laboratory were visited. The participants were made familiar by 10 papers with the development, production and control of radiopharmaceuticals in the CINR, Rossendorf. (author)

  11. Modern trends in radiopharmaceuticals for diagnosis and therapy. Proceedings of a symposium

    International Nuclear Information System (INIS)

    1998-08-01

    The IAEA held an International Symposium on Modern Trends in Radiopharmaceuticals for Diagnosis and Therapy in Lisbon, Portugal, from 30 March to 3 April 1998. Two earlier symposia were organized on similar topics in Copenhagen, Denmark in 1973 and in Tokyo, Japan, in 1984. The proceedings of these symposia have been published and widely used as reference sources. To facilitate faster publication and more widespread availability, the IAEA has decided to publish the proceedings of this symposium as a cost-free TECDOC. The symposium was organized into 14 sessions consisting of five on 99m Tc radiopharmaceuticals, two each on therapeutic radiopharmaceuticals and radiohalogens/other isotopes and one each on bioevaluation, radiometric assay, medical isotope production, good radiopharmacy practice and technology transfer. In the proceedings the papers from multiple sessions on the same topic have been grouped together for the convenience of the reader. The papers presented in the symposium reflect current and future developments in diagnostic and therapeutic agents. The largest number of papers presented dealt with 99m Tc, highlighting its continuing importance to nuclear medicine and the role of imaging as an important tool. The emerging interest in therapeutic radiopharmaceuticals based on beta emitting short lived isotopes such as 186 Re and 153 Sm was evident from the papers presented in two sessions devoted to this topic. Also of steady interest was the development of agents labelled with other established isotopes, radioiodine in particular and also 111 In and 67 Ga. Regulation, training and good manufacturing practices are important for ensuring safety in regular use of radiopharmaceuticals and were discussed in a separate session. The production of radiopharmaceuticals has become a regular activity in many developing countries, often facilities were presented at the symposium

  12. Modern trends in radiopharmaceuticals for diagnosis and therapy. Proceedings of a symposium

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1998-08-01

    The IAEA held an International Symposium on Modern Trends in Radiopharmaceuticals for Diagnosis and Therapy in Lisbon, Portugal, from 30 March to 3 April 1998. Two earlier symposia were organized on similar topics in Copenhagen, Denmark in 1973 and in Tokyo, Japan, in 1984. The proceedings of these symposia have been published and widely used as reference sources. To facilitate faster publication and more widespread availability, the IAEA has decided to publish the proceedings of this symposium as a cost-free TECDOC. The symposium was organized into 14 sessions consisting of five on {sup 99m}Tc radiopharmaceuticals, two each on therapeutic radiopharmaceuticals and radiohalogens/other isotopes and one each on bioevaluation, radiometric assay, medical isotope production, good radiopharmacy practice and technology transfer. In the proceedings the papers from multiple sessions on the same topic have been grouped together for the convenience of the reader. The papers presented in the symposium reflect current and future developments in diagnostic and therapeutic agents. The largest number of papers presented dealt with {sup 99m}Tc, highlighting its continuing importance to nuclear medicine and the role of imaging as an important tool. The emerging interest in therapeutic radiopharmaceuticals based on beta emitting short lived isotopes such as {sup 186}Re and {sup 153}Sm was evident from the papers presented in two sessions devoted to this topic. Also of steady interest was the development of agents labelled with other established isotopes, radioiodine in particular and also {sup 111}In and {sup 67}Ga. Regulation, training and good manufacturing practices are important for ensuring safety in regular use of radiopharmaceuticals and were discussed in a separate session. The production of radiopharmaceuticals has become a regular activity in many developing countries, often facilities were presented at the symposium Refs, figs, tabs

  13. 18F based radiopharmaceuticals and automation of synthesis. New 18F radiopharmaceuticals

    International Nuclear Information System (INIS)

    Garg, P.K.; Garg, S.

    2007-01-01

    Fluorine-18 is one of the most commonly used positron emitting isotopes for clinical and research needs with a physical half-life of 110 min. PET isotopes deposit higher radiation absorbed dose than nuclear medicine isotopes. Because of their relatively short half-life, larger quantities of these isotopes are used at the start of synthesis. Therefore, increased shielding and remote automated synthesis are essential for their safe handling. Unlike other radiopharmaceuticals, it is not practical to produce PET radiopharmaceuticals at a central location for subsequent distribution to clinical and research facilities around the country. This limitation compels various academic and research facilities to manufacture their own PET radiopharmaceuticals for in-house use. For multiple reasons, 18 F fluorodeoxyglucose ([ 18 F]FDG) is one of the most commonly used radiopharmaceuticals. The synthesis of [ 18 F]FDG has been optimized and automated, thus allowing independent laboratories to produce this radiopharmaceutical safely. Nonetheless, these laboratories should acquire resources and expertise to fulfil ever increasing regulatory requirements for the safe production and usage of PET radiopharmaceuticals. In addition to [ 18 F]FDG, a wide array of new and novel radiotracers is being developed to explore various biological processes. This paper emphasizes the fact that it is possible to accomplish research and fulfil clinical needs within an academic setting with modest resources. A careful assessment of the need for due diligence in radiation safety issues is very important for the longevity of any PET research endeavour. (author)

  14. Radiation protection with consumer products containing gaseous tritium light sources; Strahlenschutz bei Konsumguetern mit Tritium-Gaslichtquellen

    Energy Technology Data Exchange (ETDEWEB)

    Rahders, Erio; Haeusler, Uwe [Bundesamt fuer Strahlenschutz, Berlin (Germany)

    2017-08-01

    Consumer products containing gaseous tritium light sources (GTLS) were examined with respect to their radiological safety potential regarding leak tightness or accidents. The maximum tritium leakage rate of 2.7 Bq/d determined from experimental testing is well below the criterion for leak tightness of sealed radioactive sources in DIN 25426-4. In order to investigate the incorporation of tritium due to contact with consumer products, 2 scenarios were reviewed; the correct use of a tritium watch and the accident scenario with a keyring.

  15. Quality assessment of radiopharmaceuticals in nuclear medicine services at Northeast states, Brazil; Avaliacao da qualidade de radiofarmacos em servicos de medicina nuclear de estados da regiao nordeste

    Energy Technology Data Exchange (ETDEWEB)

    Andrade, Wellington Gomes de

    2012-07-01

    The radiopharmaceuticals are used in the field nuclear medicine services (NMS) as tracer in the diagnoses and treatment of many diseases. Radiopharmaceuticals used in nuclear medicine and usually have a minimum of pharmacological effect. The procedures for labelling Radiopharmaceuticals should be observed in order to minimize risks to patients, employees and individuals from the public, and to be administered in humans, must be sterile and free of pyrogens and possess elements all measures of quality controls required a conventional drug. The 'Agencia Nacional de Vigilancia Sanitaria (ANVISA)' in its 'Resolucao de Diretoria Colegiada' (RDC) No. 38 of June 4{sup th} 2008, decided that the NMS must perform quality control in the generators eluate and radiopharmaceuticals according to recommendations of manufacturers and scientific evidence accepted by ANVISA. Thus, this study proposes to evaluate the quality of the generator {sup 99M}o-{sup 99m}Tc eluate and radiopharmaceuticals labeled with {sup 99m}Tc used in most NMS of some states in the Northeast, in relation to radionuclide, chemical, radiochemical purity and pH and promote the inclusion of procedure for quality control of radiopharmaceuticals in routine NMS. The results show that 90% radionuclidic purity, 98.2% purity chemical and radiochemical purity of 46% and 100% of the eluates are in agreement with international pharmacopoeias; already radiopharmaceuticals showed 82.6% purity and all radiochemical pH values are also in accordance with international pharmacopoeias. Even with so many positive results, staff the majority of MNS was not able to perform the quality control of the eluates and radiopharmaceuticals. Showing the importance of implementing of quality control programs of the eluates and radiopharmaceuticals in nuclear medicine. (author)

  16. Specific GMP guidelines for radiopharmaceutical products

    International Nuclear Information System (INIS)

    2000-01-01

    These guidelines are intended to complement those provided in ''Good manufacturing practices for pharmaceutical products'', as well as the GMP for sterile pharmaceutical products. The regulatory procedures necessary to control radiopharmaceutical products are in large part determined by the sources of products and methods of manufacture. Manufacturing procedures within the scope of these guidelines include: preparation of radiopharmaceuticals in hospital radiopharmacies, preparation of radiopharmaceuticals in centralized radiopharmacies, production of radiopharmaceuticals in nuclear centres, institutes or industrial manufacturers, preparation and production of radiopharmaceuticals in Positron Emission Tomography (PET) centres

  17. Determination of radiochemical yield of {sup 99m}Tc radiopharmaceutical preparations using gamma counter and linear radiochromatography scanner

    Energy Technology Data Exchange (ETDEWEB)

    Martins, Patricia de A.; Moura, Rebeca G.; Shiki, Andressa M.; Fukumori, Neuza T.O.; Matsuda, Margareth M.N., E-mail: patyosborne@yahoo.com [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil)

    2013-07-01

    The radiochemical purity (RCP) evaluation is a prerequisite for radiopharmaceuticals before the administration in patients. RCP is defined as the proportion of the total radioactivity in the product that is present in the specified chemical form. The most widely used techniques for RCP determination in radiopharmaceutical preparations are thin layer chromatography (TLC-Al), instant thin layer chromatography (ITLC-SG) and paper chromatography (PC). These techniques combined with radioactivity detection are one of the most important tools in the RCP of the radiopharmaceutical compounds. Several methods are used for the determination of the spatial distribution of radioactivity on the strips. The aim of this study was to compare two methods for radioactivity measurement in the determination of RCP in {sup 99m}Tc radiopharmaceuticals using gamma counter and linear radiochromatography scanner. Lyophilized radiopharmaceuticals were labeled with {sup 99m}Tc. The analysis was carried out using TLC-Al and high performance thin layer chromatography (HPTLC-Cellulose) sheets, ITLC-SG and 3MM Whatman PC. The radioactivity distribution was determined by counting each strip during 1 minute in a radiochromatography TLC scanner. For comparison, the strips were cut into small pieces and each one was separately measured in a gamma-counter during 0.20 minutes in 70-210 KeV {sup 99m}Tc window. USP 36 and FDA specify that not less than 90% of the total radioactivity must be in the spot corresponding to {sup 99m}Tc labeled compound. In conclusion, the procedure for RCP determination of ALBUMINA-TEC, DEX500-TEC, ECD-TEC, MACRO-TEC and MIBI-TEC can be faster using radiochromatography. (author)

  18. Effects of tritium in elastomers

    International Nuclear Information System (INIS)

    Zapp, P.E.

    1982-01-01

    Elastomers are used as flange gaskets in the piping system of the Savannah River Plant tritium facilities. A number of elastomers is being examined to identify those compounds more radiation-resistant than the currently specified Buna-N rubber and to study the mechanism of tritium radiation damage. Radiation resistance is evaluated by compression set tests on specimens exposed to about 1 atm tritium for several months. Initial results show that ethylene-propylene rubber and three fluoroelastomers are superior to Buna-N. Off-gassing measurements and autoradiography show that retained surface absorption of tritium varies by more than an order of magnitude among the different elastomer compounds. Therefore, tritium solubility and/or exchange may have a role in addition to that of chemical structure in the damage process. Ongoing studies of the mechanism of radiation damage include: (1) tritium absorption kinetics, (2) mass spectroscopy of radiolytic products, and (3) infrared spectroscopy

  19. Study of the production yields of {sup 18}F, {sup 11}C, {sup 13}N and {sup 15}O positron emitters from plasma-laser proton sources at ELI-Beamlines for labeling of PET radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Amato, Ernesto [Section of Radiological Sciences, Department of Biomedical and Dental Sciences and of Morphologic and Functional Imaging, University of Messina (Italy); Italiano, Antonio, E-mail: italianoa@unime.it [Istituto Nazionale di Fisica Nucleare, Gruppo Collegato di Messina (Italy); Margarone, Daniele [Institute of Physics ASCR, v.v.i. (FZU), ELI-Beamlines Project, 182 21 Prague (Czech Republic); Pagano, Benedetta [Nuclear Medicine Unit, University Hospital “G. Martino”, Messina (Italy); Baldari, Sergio [Section of Radiological Sciences, Department of Biomedical and Dental Sciences and of Morphologic and Functional Imaging, University of Messina (Italy); Nuclear Medicine Unit, University Hospital “G. Martino”, Messina (Italy); Korn, Georg [Institute of Physics ASCR, v.v.i. (FZU), ELI-Beamlines Project, 182 21 Prague (Czech Republic)

    2016-03-01

    The development of novel compact PET radionuclide production systems is of great interest to promote the diffusion of PET diagnostics, especially in view of the continuous development of microfluidics labeling approaches. We studied the feasibility to produce clinically-relevant amounts of PET isotopes by means of laser-accelerated proton sources such that expected at the ELI-Beamlines facility. {sup 18}F, {sup 11}C, {sup 13}N and {sup 15}O production yields were calculated through the TALYS software, by taking into account the broad proton spectra expected. With the hypothesized proton fluencies, clinically-relevant amounts of radionuclides can be obtained, suitable to prepare single doses of {sup 18}F-, {sup 11}C- and {sup 13}N-labeled radiopharmaceuticals exploiting fast and efficient microfluidic labeling systems.

  20. Study of the production yields of "1"8F, "1"1C, "1"3N and "1"5O positron emitters from plasma-laser proton sources at ELI-Beamlines for labeling of PET radiopharmaceuticals

    International Nuclear Information System (INIS)

    Amato, Ernesto; Italiano, Antonio; Margarone, Daniele; Pagano, Benedetta; Baldari, Sergio; Korn, Georg

    2016-01-01

    The development of novel compact PET radionuclide production systems is of great interest to promote the diffusion of PET diagnostics, especially in view of the continuous development of microfluidics labeling approaches. We studied the feasibility to produce clinically-relevant amounts of PET isotopes by means of laser-accelerated proton sources such that expected at the ELI-Beamlines facility. "1"8F, "1"1C, "1"3N and "1"5O production yields were calculated through the TALYS software, by taking into account the broad proton spectra expected. With the hypothesized proton fluencies, clinically-relevant amounts of radionuclides can be obtained, suitable to prepare single doses of "1"8F-, "1"1C- and "1"3N-labeled radiopharmaceuticals exploiting fast and efficient microfluidic labeling systems.